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Antigen-presenting cells play a vital role in the immune system as presentation of antigens via 
cell-surface glycoproteins, such as MHC-I and CD1d, elicits an immune response. Antigen 
loading occurs in the endoplasmic reticulum with the help of chaperone proteins such as 
calreticulin. The natural ligand of calreticulin is an N-linked dodecasaccharide; however, it has 
been shown that a truncated Glc1Man3 tetrasaccharide can also be recognised. A biotinylated 
Glc1Man3 was designed to bind to both calreticulin and streptavidin to allow isolation of the 
calreticulin–tetrasaccharide complex through pull-down experiments. The stereoselective 
synthesis of this biotinylated oligosaccharide is described. CD1d-mediated presentation of 
glycolipids to the T-cell receptor of iNKT cells leads to an immune response. While -
galactosyl ceramide is the prototypical ligand, its activation of iNKT cells produces a mixture 
of TH1 and TH2 cytokines, which limits its therapeutic application.  Analogues that induce a 
biased cytokine response are therefore desirable. Analysis of the crystal structure of the 
CD1d–-GalCer–TCR complex reveals that the 6-OH and ring oxygen are not involved in 
binding. Analogues where these parts of the molecule have been excised, have led to the 
introduction of ThrCer and its cyclitol analogue ThrCer-6.  We report a new and improved 
synthesis of ThrCer-6 and a series of analogues that were designed to elicit biased cytokine 
responses. Studies towards the preparation of ThrCer analogues involving modifications to 
the pseudo-glycosidic linkage are also described. Finally, the synthesis of ceramide analogues 
with the potential for conjugation through a photoreactive group to the CD1d protein are 
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1. General Introduction 
1.1. Immunity 
 
The immune system is the body’s way of fighting the invasion by pathogens, be they viral, 
bacterial, fungal or other external invaders. Vertebrates employ two different types of immunity 
to tackle the problem of attack by opportunistic pathogens; these are termed innate and 
adaptive immunity (Table 1.). Innate immunity is the defence mechanism that is activated 
following immediate exposure to a pathogen. It is non-specific and functions the same 
irrespective of whether or not there has been a previous infection by the same pathogen. In 
contrast, adaptive or acquired immunity is pathogen-specific and is based around the 
recognition of antigens that are specific to a particular pathogen. While innate immunity 
provides a rapid response and is found in all animal- and plant-life, adaptive immunity is a 
slower response and is specific to vertebrates.1 
Table 1.1.  Principal differences between innate and adaptive immunity. 
 Innate Adaptive 
Self/non-self 
discrimination 
Present, reaction is against foreign Present, reaction is against 
foreign 
Lag phase Absent, response is immediate Present, response takes a few 
days 
Specificity Limited, the same response is 
mounted to a wide variety of agents 
High, the response is directed 
only to the agent that initiated it 
Diversity Limited, hence limited specificity Extensive, resulting in a wide 
range of antigen receptors 
Memory Absent, subsequent exposure to an 
agent generates the same response 
Present, subsequent exposure to 
the same agent induces amplified 
responses 




1.2. Innate Immunity 
 
The skin acts as the first physical barrier of the innate immune system with the surface 
epithelial cells physically blocking entry by pathogens. Mucous membranes also trap microbes 
and other particles to prevent their entry.  Other secretions can prevent infection; these include 
tears and saliva, both of which contain lysozyme. This enzyme is able to kill bacterial 
pathogens by breaking up their cell wall. It does this by catalysing the hydrolysis of 1, 4--
glycosyl linkages found in the peptidoglycan component of the cell wall. Stomach acid 
functions similarly by placing the pathogen in a low pH environment, which it may not be able 
to withstand. 
When pathogens get through these external barriers and first lines of defence an internal 
response is required. This internal response will come from phagocytic and Natural Killer (NK) 
cells as well as antimicrobial proteins following an inflammatory response. This response does 
not require any previous exposure to the invading pathogen as no immunological memory is 
required for an innate immune response.  
The internal response is initiated by the recognition of Pathogen-Associated Molecular 
Patterns (PAMPs) by innate cells, such as macrophages and Dendritic Cells (DCs), which 
contain Pattern Recognition Receptors (PRRs) on their cell surfaces.2 PAMPs are conserved 
non-self molecules that are associated with particular pathogens. A large range of PRRs are 
present on innate cells which can identify a similarly large range of different PAMPs.3 PRR-
containing innate cells are present in all tissues to maximise potential exposure. Following 
exposure to a pathogen, phagocytic cells can then be instigated to perform phagocytosis. This 
mechanism works with the cell first engulfing the pathogen to form an endosome within the 
cell. This cell then binds to lysosome, which contains enzymes and acids that digest and kill 
the cell. 4       
 




1.3. Adaptive immunity 
 
Adaptive immunity is unique in that it possesses immunological memory, which was first 
mentioned in history in 430 B.C., when Thucydides, the Greek historian noted that following a 
plague that had swept through Athens, those who had survived were able to tend to the sick 
without being re-infected. However, it wasn’t until Edward Jenner (1749–1823) in the 18th 
century and his experiment with cowpox that we began to understand this side of the immune 
system. Jenner deliberately infected people with cowpox and subsequently showed that they 
were immune to small pox. This observation led to the basis of vaccination whereby antigenic 
material is administered to induce an immune response, developing adaptive immunity to a 
pathogen. Louis Pasteur developed vaccination further along with his proposal of the germ 
theory of disease which stated that microorganisms were the cause of infection. Further study 
has improved our understanding of the immune system much further with the discovery of 
antibodies and the processes about which adaptive immunity and immunological memory take 
place.    
The adaptive immune response relies on the activation of lymphocytes, which are white blood 
cells known as T cells and B cells. B cells are required for the formation of antibodies or 
immunoglobulin (Ig) and are involved in humoral or antibody-mediated immunity. T cells on 
the other hand are involved in cell-mediated immunity, which depend on the activation of 
antigen-specific cytotoxic T-lymphocytes (TC). A special type of T cell known as the helper T 
cell (TH) plays a vital part in both cell-mediated and humoral immunity responses. 
All lymphocytes begin as stem cells in the bone marrow. In humans, stem cells that migrate 
to the thymus for maturation become T cells, whilst stem cells that remain within the bone 
marrow to mature become B cells. Both types of cells are only activated upon recognition by 
an antigen.  
 




1.3.1. Antigen recognition of B cells and T cells 
 
Both B cells and T cells express antigen-specific receptors on their cell surface. The B-cell 
receptor (BCR) is a trans-membrane Y-shaped protein formed from a combination of heavy- 
and light-chain polypeptides linked together by disulfide bonds as shown in Figure 1.1.  
 
 
Figure 1.1. Structure of B-cell receptor. Figure adapted from ref.5 Permission not required. 
 
B-cell receptors have a similar structure to antibodies but are bound to the cell surface. By 
contrast, antibodies are soluble and free-flowing molecules that are secreted from activated B 
cells and found within the blood. T-cell receptors (TCRs) consist of two peptide chains, alpha 
() and beta () linked together by disulfide bonds as shown in Figure 1.2. These molecules 
are also membrane-bound.  





Figure 1.2.  Structure of a T-cell receptor. Adapted from ref.5 Permission not required. 
 
T cells and B cells differ in the way the antigen is presented to their associated receptors. The 
BCR binds to epitopes of its cognate antigen in its native exogenous form. The TCR 
recognises its antigen after it has been processed within an infected antigen-presenting cell 
(APC) and bound to a major histocompatibility complex class 1 (MHC-I) molecule on the 
surface of the infected cell. The resulting antigen–MHC complex is then presented to the TCR, 
an example of which is shown in Figure 1.3.  
 





Figure 1.3. The TCR–antigen–MHC complex. Figure adapted from ref.6 Permission to 




1.3.2. Development of lymphocytes 
 
The development of B- and T cells occurs in two stages, before and after binding to its specific 
antigen. The diversity within the receptors, needed to recognise a large range of potential 
pathogenic proteins and differentiate self from non-self are developed while the cells are 




maturing. Proliferation of activated cells and the formation of immunological memory are 
developed post binding to the specific antigen. 
Diversity among the millions of antigen receptors found on the surface of the millions of cells 
is developed during the synthesis of the proteins within the cell prior to expression. Both BCRs 
and TCRs are made of conserved regions and variable regions. As seen in Figures 1.1. and 
1.2., the constant regions are found at the end of the protein which is embedded within the 
cell membrane. These regions do not change between different receptors and maintain a 
similar function around the cell wall. A variable region is found at the other end, which is 
exposed outwards away from the cell wall.  It is this variable region that recognises pathogenic 
proteins through protein–protein interactions. The mechanism for this is shown in Figure 1.4. 
for the -chain however the -chain has a similar mechanism although it is encoded from 
another part of the DNA. The variable region comes about by the rearranging of the germline 
DNA by a recombinase, which randomly deletes part of the undifferentiated DNA strand for 
the protein which is then transcribed and translated to give a polypeptide of a specific 
sequence, with this sequence being different from the last. These different polypeptides can 
then assemble to form a specific protein with a unique binding site. A large number of potential 
recombinations leads to an even larger number of specific receptors. Before maturation, the 
receptors are tested for self-reactivity as a receptor that reacts with self-antigens will be 
detrimental to the body by causing autoimmunity. Any cell with a receptor shown to be self-
reactive either undergoes apoptosis or is non-functionalised before final maturation.1 





Figure 1.4. Diversity of the TCR from the processing of the germline DNA. Adapted from ref.7 
Permission not required. 
1. Shows the germline DNA for the chain. 
2. Shows the rearrangement of the DNA followed by transcription and translation. 




Proliferation of activated cells is achieved by a process of clonal selection. When a specific 
antigen receptor binds to its epitope the cell undergoes cell divisions to yield a large number 
of clones, each expressing the same desired antigen receptor. These clones will be made into 
memory cells or into effector cells for an immediate immune response. B-cell effector cells are 
known as plasma cells, which secrete antibodies whilst T-cell effector cells are T helper and 
cytotoxic T cells, which go on to react further to kill the invading pathogen. Following the 
primary immune response, which results in the formation of memory cells, any subsequent 








generate a large number of desired clones at a faster rate than was the case at the first 
infection. This is known as immunological memory.    
 
1.3.3. Activation of cells for an immune response 
 
A humoral immune response involves the use of antibodies to fight infection in the blood and 
lymph, while a cell-mediated immune response involves cytotoxic T cells, which kill infected 
cells. Both responses are initiated following the activation of helper T cells (TH) by a dedicatedl 
Antigen-Presenting Cell (APC) presenting the specific antigen bound to a MHC II molecule. 
The accessory protein CD4 found on the surface of the T cell binds as a co-receptor to the 
MHC to stabilise the complex. This complex activates an intracellular pathway that leads to 
the secretion of cytokines which activates T helper cells, causing them to proliferate and form 
clones which can then go on to activate B cells and cytotoxic T cells.  
 
B Cells 
Activation of B Cells occurs following recognition of the BCR with a pathogenic protein with 
the desired epitope. Receptor-mediated endocytosis then takes the antigen into the cell where 
it is broken down by proteases into peptide fragments, which are then bound to a MHC II 
molecule and presented on the cell surface. The antigen–MHC Class II complex then binds to 
a previously activated TH cell via receptors for the same epitope. The newly formed complex 
secretes cytokines that then activate the B cell, which proliferates and multiplies to yield 
plasma cells. These plasma cells no longer produce the membrane-bound receptor but 
instead secrete them as antibodies (Figure 1.5.). 
 
 





Figure 1.5. Production of antibodies via activation of B cells. Adapted from ref.8 Permission 
not required 
 
Antibodies do not kill pathogens themselves but instead mark them for destruction. Following 
recognition of a pathogenic epitope by an antibody there are various ways in which the target 
can be prevented from causing further harm. The first is through neutralisation, which blocks 
off the surface of a virus, preventing it from binding to a host cell. Next is opsonisation, which 
is the process whereby the target is marked for phagocytosis. This is done by the binding of 
opsonins to the target which then attracts macrophages and neutrophils. Finally, through the 




use of a complement system also bound to the antibody, a membrane attack complex is 
formed which forms a pore in the cell wall causing the cell to lyse. 
 
T Cells  
As shown previously, TH cells are vital in both humoral and cell-mediated immunity. As there 
are different cells involved in both processes, TH cells need to be able to signal to a particular 
cell while not signalling to another. This differentiation is achieved through the use of 
cytokines. Cytokines are cell-signalling molecules which are released by one cell to elicit a 
response from another. A range of cytokines can be produced with the cytokine profile being 
important for governing how the body subsequently tackles the infection. Although there are 
many different types of cytokine present in the body, they can be divided into two main groups 
based on their function: those that are pro-inflammatory and those that are essentially anti-
inflammatory but promote allergic responses. TH cells are regarded as being the most prolific 
cytokine producers. They bring about two responses termed TH1 and TH2. TH1-type cytokines 
afford a pro-inflammatory response, responsible for attacking intracellular foreign pathogens 
and for also exacerbating autoimmune responses. Interferon gamma (IFN-γ) is the principal 
Th1 cytokine. The TH2 response is needed to oppose the TH1 response as excessive pro-
inflammatory responses may lead to tissue damage. TH2-type cytokines include interleukins 
(IL) 4, 5, and 13, which are associated with the promotion of IgE (a type of antibody) and also 
interleukin-10, which has more of an anti-inflammatory response.9  
Cell-mediated immunity is so called as it is predicated on the fact that a host cell has become 
infected. The host cell now produces foreign proteins required by the pathogen to survive and 
multiply. Fragments of these proteins are then presented by MHC-I molecules on the cell 
surface. MHC-I and the MHC-II molecules previously seen differ in the type of antigen they 
present.  MHC-II molecules, which are only found on certain APCs, present exogenous 
antigens, which have been taken in from the outside and, by endocytosis or phagocytosis, 




taken into the cell before being processed into fragments that are then presented by the MHC-
II molecule. MHC-I molecules are found on the surface of most cells. They present 
endogenous proteins, which are antigens made within the host cell, be they self-proteins or 
non-self.  
While TH cells which have a CD4 co-receptor and interact with the MHC-II, another T cell, 
known as the Killer T cell interacts with the MHC-I. This killer or cytotoxic T cell (TC) is 
responsible for the apoptosis of infected cells. When an infected cell presents a non-self 
antigen in the context of a MHC-I molecule, it is recognised by the TCR of a cytotoxic T cell, 
with the co-receptor CD8 helping to bind the complex. The TC cell then secretes cytotoxins 
like perforin or granzyme, which effect cell death. Once apoptosis is complete the TC cell is 
released allowing it to search for, and attack, other infected cells.  
 
 
Figure 1.6. Difference between helper T (TH) cells and Killer T (TC) cells. Adapted from ref.5 
Permission not required. 




1.4. Different types of T cells 
 
We have seen that antigen recognition is vitally important in the adaptive immune response 
through the presentation of foreign peptide fragments by the MHC to TCRs located on 
cytotoxic and helper T cells. There are, however, several other types of T cells, which contain 
altered TCRs. Instead of interacting with MHC–peptide complexes, these TCRs recognise 
MHC-like molecules that present alternative small-molecule antigens including glycolipids, 
lipids and vitamin metabolites. These T cells include Natural Killer T (NKT) cells, Mucosal 
Associated Invariant T (MAIT) cells and gamma delta () T cells are of particular interest due 
to their ability to bridge the gap between innate and adaptive immunity through producing / 
reacting to cytokines and chemokines, which can lead to the activation of a range of other 
cells in a resulting immune response.  
1.4.1. -T cells 
Gamma-delta () T cells are so named due to their unique TCR, which is formed like other 
T cells in the thymus. The  TCR is achieved by V(D)J recombination which is mediated by 
the recombination activation gene (RAG).  T cells have not been widely studied and a full 
understanding of their workings is not yet available; however, they have been shown to 
possess a distinct combination of characteristics not seen in other T cells. For example, whilst 
other naive T cells move to the lymph nodes and spleen for maturation,  T cells have been 
shown to migrate to alternative tissues such as the dermis and intestines. V9V2+ T cells are 
the predominant subset of  T cells. These cells recognise phosphoantigens (low molecular-
mass alkyl diphosphates) as their prototypical antigens of which (E)-4-Hydroxy-3-methyl-but-
2-enyl pyrophosphate (HMB-PP) 1 has been shown to be the most potent. HMB-PP is an 
intermediate in the non-mevalonate pathway to the biosynthesis of isopentenyl pyrophosphate 
2 (IPP) and dimethylallyl pyrophosphate 3 (DMAPP) (Scheme 1.1.). These molecules are used 
as starting materials in the biosynthesis of more complex molecules used in cell processes. 
The non-mevalonate pathway is used by many bacterial and pathogenic species but not by 




vertebrate cells, which use the mevalonate pathway. It is not known whether HMB-PP 1 binds 
directly to the TCR or if it is presented following complexation to another molecule.  
 
Scheme 1.1. HMB-PP is a precursor to IPP and DMAPP in the non-mevalonate pathway. 
 
Along with releasing high concentrations of IFN and tumour necrosis factor (TNF),  T cells 
also produce granzymes for lysis of infected cells. Through the release of a range of 
chemokines and cytokines, they can also interact with other important cells. For example, they 
can produce high concentrations of CXC-chemokine ligand 13 (CXCL13), which regulates the 
organisation of B cells.10 
 
1.4.2. MAIT cells and MR1 
Mucosal-Associated Invariant T (MAIT) cells are enriched in mucosal areas and are also found 
in the liver. They make up around 5% of the total T-cell population and are characterised by 
their expression of a semi-invariant  T-cell receptor (V7.2-J33/12/20). This TCR is 
restricted by the MHC-like protein MR1, which is non-polymorphic and highly evolutionarily 
conserved. Until recently it was not known what the natural ligand was for MR1 and activated 
MAIT cells but it has since been discovered that MR1 presents unstable pyrimidine 
intermediates derived from the biosynthesis of riboflavin, which occurs in bacteria but not in 
humans. 





Figure 1.7. Ligands of MR1 which present to MAIT cells. 
 
Kjer-Nielsen et al.11 found that whilst 6-formyl pterin 4 (6-FP) binds to MR1, the resulting 
complex does not activate MAIT cells. Following further studies, it was shown that 5-amino-6-
D-ribitylaminouracil 5 (5-A-RU) was important as an intermediate but that this molecule itself 
was unable to bind MR1 or activate MAIT cells.12 [5-(2-Oxoethylideneamino)-6-D-
ribitylaminouracil] 8 (5-OE-RU) and [5-(2-oxopropylideneamino)-6-D-ribitylaminouracil] 9 (5-
OP-RU), both of which are formed following non-enzymatic condensation of 5-A-RU with either 
glyoxal 6 or methylglyoxal 7, respectively, were shown to bind to MR1 and form reversible 
Schiff base complexes with Lys43 of the human MR1 protein. Glyoxal and methylglyoxal are 
formed during other metabolic pathways. 5-OP-RU is currently believed to be the natural 
ligand of MR1 on the basis of a mass-to-charge ratio (m/z) of 329.11 seen for a ligand bound 
to MR1 which matched 5-OP-RU. This MR1–5-OP-RU complex can also activate MAIT cells.13 




Similarly to  T cells, MAIT cells produce IFN-and TNF following activation and are also 
involved in the granule exocytosis pathway.14, 15  
 
1.4.3. iNKT cells and CD1 
Natural Killer (NK) T cells were first discovered in 198716-18 and so named from their co-
expression of an  TCR along with NK markers, like NK 1.1, which are normally found on 
natural killer cells. It has since been shown that not all NKT cells express this marker and that 
there are in fact three distinct types of NKT cell (see Table 1.2.). 19 
 
Table 1.2. Showing the contrasting features of the different populations of NKT cells. 
Figure adapted from ref.19 Permission to reproduce table was obtained through 
RightsLink® - licence number 4174380942019 . 
 
 Type I Cells (classical 
NKT Cells) 
Type II Cells (non-
classical NKT Cells) 
NKT-like cells (CD1d-









-GalCer reactive Yes No No 
TCR -Chain V14-J18 (mice)       V24-
J18 (humans) 
Diverse, but some V3.2-
J9, V8 (mice) 
Diverse 
TCR -Chain V8.2, V7 and V2 (mice) 
V11 (humans) 
Diverse, but some V 8.2 
(mice) 
Diverse 
NK1.1 (CD161) + (resting mature)               –
/low (immature or post 
activation) 
+/– + 
Subsets CD4+ and DN (mice) CD4+, 
CD8+ and DN (humans) 
CD4+ and DN (mice) CD4+, CD8+ and DN 




Whilst they express the cell-surface marker NK1.1, NKT-like cells are not CD1d-dependent; 
indeed, they may be classical MHC-restricted T cells which also express the NK1.1 marker. 
Type 1 (classical or invariant) and type 2 (non-classical) NKT cells differ in the TCR they 
express on their cell surfaces. There is more diversity in the TCRs found on type 2 NKT cells 
although these are still CD1d-dependent. In contrast, type 1 iNKT cells contain a semi-
invariant TCR in mice and an invariant TCR in humans.  As summarised in Table 2., the  
chain is invariant with one variation possible for both humans (V24-J18) and mice (V14-
J18). The semi-invariance in mice is seen in the composition of the β chains (Vβ8.2, Vβ7 or 
Vβ2) that are predominantly paired with the  chain. In humans, the β chain is composed 
exclusively of Vβ11.  Of the three types of NKT cell, type 1 or invariant (i) NKT cells have been 
the most studied.  In mice, Type I NKT cells represent ~0.5% of the T-cell population in the 
blood and peripheral lymph nodes although they are also found in the spleen and liver at 
higher concentrations. Type I NKT cells in humans display a similar tissue distribution albeit 
at lower concentrations. 
CD1d is a member of the CD1 family of glycoproteins, which are expressed on the surface of 
antigen-presenting cells including dendritic cells or macrophages. These MHC-like proteins 
present glycolipid antigens rather than peptides to the TCR. Although not the natural ligand 
for this protein, alpha-Galactosyl Ceramide 10 (-GalCer) has been used as the prototypical 
model glycolipid in iNKT-cell research since its discovery in 1995.20 
 
 
Figure 1.8. -Galactosyl Ceramide 




Other natural ligands have been shown to bind to CD1d and be presented to the TCR of NKT 
cells. These include the microbial ligands -galacturonylceramide and-glucuronylceramide 
11 (GSL1) found in the cell wall of the gram-negative bacteria sphingomonas and the self-




Figure 1.9. -glucuronylceramide 11 and isoglobotrihexosylceramide 12. 
 
These innate-like T cells secrete a range of cytokines upon activation. While MAIT cells can 
produce high concentrations of IFNwhen activated, NKT cells are of particular interest in that 
they can be activated to produce a cytokine profile involving cytokines such as IFNfor a TH1 
(pro-inflammatory) response as well cytokines, such as interleukin-10 (IL-10) that can lead to 
a TH2 (anti-inflammatory) response. Although these cytokine profiles lead to opposing 
responses, it has been shown that the concentrations of the various cytokines can be altered 
depending on the ligand–CD1d complex that is activating the T cell. In this way, by changing 
the ligand it is possible to modulate the immune response in different ways. 
 




1.5. Aims and objectives 
 
The immune system contains a complex array of diverse cells, which have differing roles to 
ensure that invading pathogens are discovered and killed before they can do damage to the 
host. The aim of my Ph.D. will be to use chemical synthesis to help further understand the 
mechanisms and workings of these biological processes.  Specifically, we will focus on two 
aspects of the immune response. The first part will discuss the synthesis of biotinylated 
Glc1Man3 tetrasaccharide 13 and its role in binding to calreticulin, an ER resident protein 
involved in the folding of proteins, including the cell surface proteins MHC-I and CD1d.  
 
Figure 1.10. Tetrasaccharide 13. 
The second part of this project will focus on the development of glycolipid and non-glycolipid 
molecules, which activate iNKT cells. Non-glycosidic analogues ThrCer 14 and and ThrCer-6 
16, which were developed from -GalCer 10 have previously been synthesised within the 
group. This project involves synthesis of the second generation of these compounds which 
contain modifications of the acyl chain as well as at the pseudo-glycosidic linkage. These 
molecules would then be tested for their ability to induce an immune response from iNKT 
cells and in particular measure their TH1/TH2 cytokine response. 


























2. Synthesis of biotinylated Glc1Man3 tetrasaccharide 
 
Introduction 
The Major Histocompatibility Complex (MHC) and Human Leukocyte Antigen (HLA) as it is 
known in humans comprise a set of cell-surface proteins that are required for the adaptive 
immune response. They function by binding peptides. The resulting MHCpeptide–complex 
can then be recognised by T-cell receptors located on the surface of different T cells. If the 
peptide is not recognised as being from the host then an immune response is initiated. 
2.1. MHC-II 
 
There are two major sub-classes of MHC molecules, class I and class II. MHC class II 
molecules are normally only expressed on the surface of Antigen-Presenting Cells (APC) such 
as Dendritic Cells (DC). These molecules bind exogenous peptides, i.e. peptides from non-
self proteins that have been degraded in the endocytic pathway. As seen in Figure 2.1. the 
MHC-II molecule is comprised of an and a chain that are assembled in the endoplasmic 
reticulum (ER) where they form a complex with the so-called Invariant chain (li). The Invariant 
chain blocks the peptide antigen binding site thereby preventing peptides present in the ER 
from binding prematurely. Following transport of the IiMHC-II complex to the MHC class II 
compartment (MIIC), the Invariant chain is digested by cathepsin proteases. A class-II 
associated Ii peptide (CLIP) remains in the MHC binding site after this digestion. A late 
endosome, containing digested exogenous protein, fuses with the MIIC bringing these foreign 
peptides into contact with the MHC molecule. An MHC-like molecule, HLA-DM facilitates the 
removal of CLIP enabling exogenous protein peptide to bind to the MHC-II. The length of the 
peptide can extend up to 12 amino acids due to the binding groove being open-ended. The 
peptide-bound MHC complex is then transported from the MIIC to the cell surface where it is 
presented to CD4+ T cells. 







Figure 2.1. The mechanism for presentation of an MHC IIpeptide complex to a TCR. 
Figure adapted from ref.22 Permission to reproduce figure was obtained through 




While both MHC class I and class II molecules present peptides on the cell surface, the types 
of peptides, the synthesis of the loaded antigen complex and the type of TCR that recognises 
the MHCpeptide complex are different. Peptides presented by class I molecules are 
endogenous, i.e., they are derived from proteins that have been synthesised within the cell 




before being digested by proteasomes. Healthy cells will generate peptides that when 
presented on the cell surface, are not recognised as TCRs do not recognise self-antigens. 
However, when a foreign pathogen like a virus enters the cell and hijacks cell function, 
peptides arising from the pathogen are recognised as non-self and will therefore initiate an 
immune response. 
 
Figure 2.2.  Difference between the structure of MHC-I and MHC-II molecules. Adapted 
from ref.23 Permission not required 
 
Figure 2.3. shows the processes involved in the presentation of an MHC-I–peptide complex. 
Following transcription and translation of proteins in the nucleus of a cell some are broken 
down into smaller peptide units. The bulk of peptides that are loaded on to MHC molecules 
are generated by the 26S proteasome, which consists of a 20S core barrel and two 19S caps 
(Item 1). This multi-domain protein produces peptides in the cytosol. The transporter 
associated with antigen-processing (TAP) then pumps these peptides from the cytosol into 
the ER lumen (Item 2). Meanwhile the MHC class I molecule is already within the ER and 
being assembled and folded in readiness for peptide loading (Item 3). Unlike the MHC class 
II molecule, which has two homogenous and chains, the MHC-I molecule consists of one 
heavy chain and a 2-microglobulin (2m), which is non-covalently bonded to the 3 domain 
(Figure 2.2). Two other common chaperones, ERp57 and calreticulin help to fold and stabilise 




the MHC-I molecule. Calreticulin is a carbohydrate binding protein known as a lectin which 
binds N-glycosylated MHC-I molecules to help form a stable interaction between the MHC-I 
molecule and tapasin. Tapasin itself is required to stabilise the interaction between TAP and 
the MHC-I molecule. Together, the complex of the unloaded MHC-I, TAP, tapasin, calreticulin 
and ERp57 is known as the peptide loading complex (PLC) (Item 4). Together, the molecules 
of the PLC stabilise the peptide binding groove of the MHC molecule in a configuration for 
optimum loading of a peptide (Item 5). The ER aminopeptidase associated with antigen 
presentation (ERAAP) will trim the peptides if required before loading and release of the 
loaded MHC-I complexes from the PLC (Item 6). The Golgi apparatus then helps to transport 
the complex to the cell surface to allow presentation (Item 7–8). This complex is recognised 
CD8+ cytotoxic T-cells with the 3 domain interacting with CD8 (Item 9). 
 
Figure 2.3. The mechanism for presentation of an MHC Ipeptide complex to a TCR. 
Figure adapted from ref.24 Permission to reproduce figure was obtained through 
RightsLink® - licence number 4106420255336. 




2.3. Calreticulin  
 
Calreticulin has two major functions. It acts as a chaperone for the folding of glycopeptides 
into functional proteins. It is this function that makes it vital in MHC-I synthesis. However, it is 
named for its other function, which is to regulate calcium levels within the ER. As shown 
schematically in Figure 2.3., the protein is divided into three domains. The C-domain contains 
a high concentration of acidic amino acids, which allows for high-capacity, low-affinity calcium 
binding. The terminal KDEL sequence prevents calreticulin from leaving the ER as it is 
retrieved from the Golgi apparatus by retrograde transport using the COPI protein complex. 
The P-domain is proline-rich forming a long, arm-like domain that contains the ERp57 binding 
site. Finally, the N-domain is a globular domain containing the glycan binding site. This domain 
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Figure 2.5.  Structure of the oligosaccharide Glc3Man9GlcNAc2 donor used for post-








N-Glycosylation is an important post-translational modification that occurs on nascent 
peptides in the ER. The enzyme oligosaccharyltransferase catalyses the transfer of the 
oligosaccharide Glc3Man9GlcNAc2 (Figure 2.4.) from dolicholdiphosphate to an asparagine 
(Asn) residue in a sequence of Asn-X-Ser/Thr, where X is any amino acid except proline. 
Processing of the resulting glycoprotein then occurs with -glucosidase I/II removing the two 
terminal glucose units (Glc-3 then Glc-2) to yield the dodecasaccharide within the blue box of 
Figure 2.4. At this stage the glycan can now bind to calreticulin and protein folding can occur. 
Once correct folding has been achieved, removal of the final terminal glucose (Glc-1) by -






















Figure 2.6.  Structural basis of recognition by calreticulin of tetrasaccharide Glc1Man3. 
Figure adapted from ref. 27 Permission not required. 
A. An omit map showing the binding cavity for tetrasaccharide binding; B. 
Surface representation of calreticulin showing the residues in contact with the 
tetrasaccharide; C. Dotted lines show hydrogen bonds between the 
tetrasaccharide and the protein including ordered water molecules; D. Close 
up detail of hydrogen bonds formed between Glc(3) and protein residues with 
a water molecule. 
 
 




Figure 2.6. shows the crystal structure of the tetrasaccharide Glc1Man3 (the tetrasaccharide 
found in red of Figure 2.5.) bound at the lectin binding site of a mutant calreticulin in which the 
P-domain has been deleted and replaced with a short linker and the C-terminus has been 
removed by cleavage at Lys368. These modifications kept the globular domain of the protein 
intact but allowed the tetrasaccharideprotein complex to be crystallised. The sugars of the 
tetrasaccharide will be referred to according to the numbering of the natural ligand, i.e. Glc(3)-
Man(D1)-Man(C)-Man(4) (Figure 2.5.).27 
The Glc1Man3 tetrasaccharide has been used as a model for studying the mode of action of 
calreticulin and has been shown to be an effective competitor for binding versus the natural 
ligand.28 This means effective study can be done using the tetrasaccharide in place of the 
structurally more complex and significantly less accessible complete natural oligosaccharide. 
The crystal structure of the tetrasaccharide bound to calreticulin shows how the methyl 
glycosyl linkage of Man(4) of the tetrasaccharide is directed away from the protein, which has 
been interpreted as suggesting that only this tetrasaccharide portion of the natural 
oligosaccharide is involved in binding at the lectin site.  
 
Sugar atom Hydrogen bonds 
Glc(3)  
1-O Asp125 via H2O molecule 
2-O Asp125 via H2O molecule; Lys111 (side-chain);  
Gly124 (backbone carbonyl) 
3-O Tyr128 (side-chain); Asn154 (side-chain) 
4-O Asn154 (backbone carbonyl) via H2O molecule 
6-O Asp135 via H2O molecule; Tyr109 (side-chain) 
Table 2.1.  Hydrogen-bond interactions between calreticulin and Glc(3) residue of the 
Glc1Man3 tetrasaccharide. 




Table 2.1 lists the hydrogen bonds (both direct and indirect) between the glucose terminus 
(Glc-3) of the tetrasaccharide and amino-acid residues in the calreticulin binding site as shown 
in Figure 2.5., Panel C. From these extensive contacts, it can be seen why this glucose residue 
is necessary for effective binding as all of the hydroxyl groups are involved in binding to the 
protein. The structure also shows why binding is selective to the mono-glucosylated glycan 
[Glc(3)-Man(D1)-Man(C)-Man(4)] rather than the di-glucosylated tetrasaccharide glycan 
[Glc(2)-Glc(3)-Man(D1)-Man(C)] which does not fully bind due to the glycosidic bond of the 
second sugar being at the 3-O position rather than the 2-O position [-Glc-(1→3)--Glc-
(1→3)--Man-(1→2)--Man-(1→2)] vs [-Glc-(1→3)--Man-(1→2)--Man-(1→2)--Man-
(1→2)] . 
Sugar atom Hydrogen bonding 
Man(D1)  
2-O Asp125 via H2O molecule 
4-O Tyr109 (side chain); Asp317 (backbone carbonyl & side chain) 
6-O Asp317 (side chain) 
Man(C)  
3-O Tyr109 via H2O molecule; Asp135 via H2O molecule 
4-O Asp135 (side chain) 
6-O Asp135 (side chain); Tyr109 via H2O molecule; 
Trp319 (backbone amide) via H2O molecule 
Table 2.2.  Hydrogen-bond interactions between calreticulin and Man(D1) and Man(C) 
residues of the Glc1Man3 tetrasaccharide. 
 
Man(D1) and Man(C) also form key hydrogen bonds with calreticulin as summarised in Table 
2.2. Finally Man(4) is also necessary for effective binding. Kapoor et al. 29 showed that the 
binding constant is doubled between the tri- and tetrasaccharide (from 112.0 ± 5.18 × 10–4 M–




1 to 230.0 ± 5.6 × 10–4 M–1 measured at 279 K), as a consequence of the partial wrapping of 
the C(1)-O(1) bond of Man(4) with the disulfide bond between Cys105 and Cys137.  
 




Owing to the problems related to the isolation of the complete oligosaccharide and its 
challenging synthesis and knowing that only the Glc1Man3 tetrasaccharide is involved in 
binding at the lectin site, the tetrasaccharide has been used as a model for studying the mode 
of action of calreticulin. There have been four syntheses of the tetrasaccharide methyl -D-
glucopyranosyl-(1→3)--D-mannopyranosyl-(1→2)--D-mannopyranosyl-(1→2)--D-
mannopyranoside 35 published to date. One further synthesis has also been achieved in 
which a fluorescent label has been incorporated at the reducing end of the tetrasaccharide. 
The tetrasaccharide has been synthesised using both linear and convergent strategies, with 
the key challenges, as with all oligosaccharide syntheses, being the controlling of 
thestereoselectivity of the glycosylation reactions.  
The synthesis of tetrasaccharide 35 requires the formation of four glycosidic linkages, three 
-mannosides and one -glucoside. The synthesis of an -mannoside linkage is 
straightforward due to mannose having an axial hydroxyl at the C-2 position, which can be 
functionalised to increase the  selectivity of the glycosylation reaction. Steric bulk from a 
large C-2 protecting group (e.g. benzyl) can be used to cover the top face slowing reactivity. 
Alternatively, an ester protecting group can engage in the glycosylation by neighbouring group 
participation, which serves to block the face even more effectively. Both of these -
mannosylation strategies are highlighted in Scheme 2.1. 





Scheme 2.1. Participating and bulky groups on the 2-O position in mannose can lead to -
selectivity. 
 
The stereoselective formation of -glucosides is however, more problematic. Glucose is the 
C-2 epimer of mannose with its hydroxyl in an equatorial position in its low energy 4C1 
conformation. This means it is more challenging to achieve -selective glycosylation. The 
anomeric effect can be used advantageously to increase the -stereoselectivity of 
glycosylations, as can the use of non-participating groups to prevent neighbouring group 
participation.  The type of glycosyl donor used in particular the protecting groups employed, 
the solvent, the pressure and temperature can all have an effect on the stereoselectivity of the 
glycosylation. 30 In this regard there has been good reason to investigate both linear and 
convergent strategies to tetrasaccharide 35.  
 
Tetrasaccharide 35 was first synthesised by Jain et al. in 1995.31 The key glycosylation 
reactions involved in this linear strategy are summarised in Scheme 2.2.  





Scheme 2.2.  Linear synthesis of Glc1Man3 tetrasaccharide by Jain et al.
31 
 
Mannosyl acceptor 26 and thiomannoside 27 were both synthesised from mannose in four 
steps. The first glycosylation reaction between these two reactants was performed using N-
iodosuccinimide and triflic acid to activate the thiosugar donor 27 and yielded disaccharide 28 




in 78% yield. The high selectivity for the product was ensured by using an acetate protecting 
group at the 2-O in the donor. Following uneventful removal of the acetate in 28 using Zemplén 
conditions, disaccharide 29 was used as the glycosyl acceptor in a glycosylation with O-
pentenyl mannosyl donor 30, which was synthesised from mannose in five steps. Although a 
different donor, glycosylation was performed using NIS and triflic acid under the same 
conditions as the first glycosylation to provide trisaccharide 31 in 65% yield. In this instance 
the large benzyl protecting group on 2-O of the mannosyl donor was sufficient to achieve the 
desired  selectivity. The acetate at the 3-O position of the newly added mannose was then 
saponified to yield the trisaccharide acceptor 32 in excellent yield. The final glycosylation was 
performed with donor 33 and acceptor 32 in the presence of tetrabutylammonium bromide and 
copper(I) bromide, yielding tetrasaccharide 34 in 39% yield. Although no stereoselectivity is 
mentioned in the paper and the mass balance is not accounted for, the procedure used is 
adapted from a paper by Sato et al. who mention complete -selectivity when using this donor 
under these conditions admittedly to form a different disaccharide product.32 Finally, 
hydrogenolysis of the benzyl protecting groups using 10% palladium on carbon afforded the 
desired tetrasaccharide 35 in 42% yield. 
The problems related to a linear synthesis of tetrasaccharide 35 can be seen in this example. 
The preparation of acceptor 26 and donors 27 and 30 each requires 4-5 steps and an extra 
step to remove a protecting group to be able to proceed to the next reaction. The yield of the 
glycosylation reactions is often lower when employing larger oligosaccharides and may also 
have contributed to the poor yield in the final glycosylation reaction. 
Convergent syntheses are often more efficient and the first convergent synthesis of 
tetrasaccharide 35 was reported by Cherif et al. in 2002 and is summarised in Scheme 2.3. 33 
 




Scheme 2.3. Cherif et al. synthesis of tetrasaccharide 35. 
 
This convergent “2+2” synthesis involved the preparation of two disaccharides 38 and 42 
which were then coupled to provide the tetrasaccharide 43 and subsequently target 35  after 
global deprotection. All of the mannosyl residues employed a benzylidene acetal to protect 




the 4-O and 6-O positions. The glucosyl donor in this instance was per-benzylated 
trichloroacetimidate 36. Activation of 36 using trimethylsilyl triflate in the presence of mannosyl 
acceptor 37 yielded disaccharide 38 in 49% yield. Whilst no ratio was reported, this 
reaction is believed to be -selective. The group had previously published the -selective 
synthesis of disaccharide 38 using acceptor 37 with the phenyl thioglycoside rather than the 
ethyl thioglycoside used in the present study.34 The previous synthesis yielded the 
disaccharide at 85% yield with an ratio of 93:7. As a thiosugar, disaccharide 38 was primed 
to act as a donor in the next glycosylation reaction. The synthesis of the mannobiose coupling 
partner 42 was achieved using phenyl thiomannoside 40 and mannosyl acceptor 39. Activation 
of the thioglycoside was achieved using dimethyl(thiomethyl)sulfonium triflate (DMTST) and 
2,6-di-tert-butyl-4-methylpyridine and reaction with the acceptor yielded disaccharide 41 in 
48% yield. This reaction is also presumed to be  although there was no mention of selectivity 
in the paper. The poor yield of this glycosylation might be attributed to the inefficient activation 
of the phenyl thioglycoside which is less reactive than its methyl or ethyl counterparts. 
Zemplén deacetylation provided the desired disaccharide acceptor 42. Disaccharide donor 38 
and acceptor 42 reacted under activation of the donor using NIS and silver(I) triflate to yield 
the desired tetrasaccharide 43 in 47% yield. This reaction was also probably -selective, 
although the stereoselectivity of this final glycosylation was not reported. In glycosylation 
reactions, as the size of the coupling partners increases they typically become less reactive 
and substrate effects can become more important leading to an erosion (or improvement) of 
stereoselectivity. Global deprotection of tetrasaccharide 43 using hydrogen gas and palladium 
on carbon in methanol yielded the final tetrasaccharide 35 in 93% yield. 
One of the benefits of a convergent synthesis is that there are fewer steps which often allows 
the synthesis of the intermediates in larger quantities and often higher overall yields. However, 
in this case Kapoor’s linear strategy which employed similarly protected glycosides was more 
efficient principally owing to the improved yields of the glycosylation reactions. Yields may 




have been sacrificed by Cherif et al. so as to achieve high levels of selectivity in the 
glycosylation steps. 
The last published synthesis of the O-methyl tetrasaccharide 35 was accomplished by Gemma 
et al. who also employed a convergent strategy.35 Scheme 2.4. outlines shows the synthesis 
of the mannobiose acceptor from benzyl-protected orthoester 44, which was adapted from a 
previous paper by Ogawa et al. 36 Conveniently, both acceptor and donor were synthesised in 
one step from this starting material; thus, conversion to chloride donor 45 was achieved using 
chlorotrimethylsilane in CH2Cl2 while in situ ring-opening of the orthoester and deacetylation, 
using acetyl chloride in methanol yielded acceptor 46. Activation of donor 45 using silver(I) 
triflate in the presence of acceptor 46 yielded disaccharide 47 in 82% yield. The high 
selectivity can again be attributed to the acetyl protecting group at the 2-O position. 
 
 
Scheme 2.4.   Synthesis of mannobiose disaccharide 48 from orthoester 44.   
 
The second disaccharide of this synthesis was once again the more difficult due to the control 
of the stereoselectivity. Gemma et al. chose a glycosyl iodide as their donor which could be 
activated in the presence of a thioglycoside. Iodide 49 (which was formed from the reaction of 
the corresponding glycosyl acetate with trimethylsilyl iodide) and thioglycoside 50 were stirred 
together for 72 h in CH2Cl2 in the presence of triphenylphosphine oxide to yield disaccharide 




51 in 70% yield. While there is no mention of the ratio in the paper, Kobashi et al. who 
published the original work on the use of glycosyl phosphonium iodide donors achieved  
ratios from 95:5 to 99:1.37 The coupling of both disaccharides proceeded uneventfully with the 
tetrasaccharide formed selectively  in 88% yield using NIS with silver(I) triflate in CH2Cl2. 
Global deprotection of the benzyl groups was achieved using H2 gas in the presence of Pd/C 
to yield tetrasaccharide 35 in 90% yield. 
 
 
Scheme 2.5.   Synthesis of disaccharide donor 51.  
 
Finally, Iwamoto et al. recently published a synthesis of the tetrasaccharide which incorporates 
a fluorescent label at the reducing end.38 Tetrasaccharide 54 was synthesised using a linear 
strategy similar to that reported by Jain et al. although interestingly the same mannosyl donor 
was used in all of the glycosylation reactions, thereby taking advantage of the high levels of 
-selectivity associated with mannosylations.  





Scheme 2.6.  Orthoester 44 was used as the building block for the three residues shown in 
red with the remaining residue of Man (D1) using thioglycoside 53. 
 
Orthoester 44 (shown in red, Scheme 2.6.) was a key building block in the synthesis with N-
protected 3-aminopropanol used as the first acceptor. Thioglycoside 53 was used as the third 
residue (shown in blue) in the synthesis, which allowed selective deprotection of the 3-O 
position. Following this deprotection, glycosylation using chloride 45 yielded mannotetraose 
55 in 90% yield. Scheme 2.7. shows the conversion of mannotetraose 55 to the desired 
tetrasaccharide 58 via an oxidation/reduction sequence which was needed to epimerise the 
2-O position and convert the fourth mannose to a glucose residue. Deacetylation of 55 yielded 
tetrasaccharide 56 in excellent yield. Activated DMSO oxidation of the resulting alcohol using 
Alrbight-Goldman conditions yielded ulosyl 57 which underwent direct reduction using sodium 
triacetoxyborohydride in THF to yield tetrasaccharide 58 in 63% yield over the two steps The 
selectivity of the reduction of the ulosyl product to a glucosyl residue as the major product was 
first shown by Lemieux et al. in 1968.39 Steric hindrance forces hydride attack at the opposite 
face to the trisaccharide in the -position drives formation of the desired glucose residue 
(Figure 2.7.). Previously they had shown that the use of more sterically hindered reducing 
agents yielded a higher Glc:Man ratio NaBH4 gave a ratio of 4:1, while the use of L-selectride 




gave a ratio of 57:1 (as measures by HPLC).40 Global deprotection and reaction of the amine 
with dansyl chloride yielded the desired target tetrasaccharide 27.  
The benefits of using mannosyl residues for all glycosylations can be seen in the yields 
achieved in these reactions, however, this route introduces more steps and a new 
stereocentre in which the desired compound will need to be separated from its epimer. 
 
 
Scheme 2.7.  Conversion of Man4 tetrasaccharide 55 to Glc1Man3 tetrasaccharide 58 via 














Biotin is a water-soluble B vitamin and essential for cell growth. It also has a use for biological 
studies. Both streptavidin and avidin bind the biotin moiety with very high affinity, with a Kd of 
10-14 M making it one of the strongest non-covalent binding coefficients observed in nature. 
This feature can be exploited to extract a protein target for a ligand. Biotinylation of a molecule 
of interest can be used to extract the moleculeprotein through the use of streptavidin-coated 
beads and subsequent isolation of the desired complex. To be succussful the biotinylated 
compound must behave similarly to the unlabelled molecule under study in how it interacts 
with the protein. Judicious positioning of the biotin group and inclusion of a linker to separate 
the two parts of the molecule may therefore be required.41 
The process is illustrated in Scheme 2.8. Starting with the biotinylated molecule of interest, 
step 1 shows the addition of the protein under study which yields the bound moleculeprotein 




complex in the presence of unbound protein. Step 2 introduces streptavidin which is bound to 
a surface e.g. on beads. Providing the binding of biotin to streptavidin does not interfere with 
the complex of interest, in Step 3 the complex of interest can then be isolated from unbound 
protein allowing study of the bound complex.  
 
 
Scheme 2.8. Schematic showing biotinylated product being pulled down using streptavidin 
to isolate the desired ligand–protein complex.  
  
 




2.6. Aims and objectives. 
 
The aim of this project is to synthesise a biotinylated Glc1Man3 tetrasaccharide which retains 
its ability to bind at the lectin binding site of calreticulin, with the goal of developing a strategy 
from more efficiently isolating the calreticulin–tetrasaccharide complex. With this in mind, we 
elected to incorporate the biotin group at the reducing end of the tetrasaccharide via a five-
carbon spacer. As seen in the crystal structure of the complex between calreticulin and 
tetrasaccharide 13, the glycosidic bond at the reducing end points away from the protein. 
Moreover as Iwamoto et al. have previously incorporated a dansyl group at this position we 
postulated that incorporation of the biotin group into this site would have minimal impact on 
binding.  
With all of this information, tetrasaccharide 13 was our synthetic target. As seen below it 
contains the Glc1Man3 tetrasaccharide shown in blue. The presence of the biotin group shown 
in red will allow for selective pull down of the proteintetrasaccharide complex and a five-















Our target tetrasaccharide 13 seen above can be separated into three parts, shown by the 
different colours. The blue shows the Glc1Man3 tetrasaccharide all with -glycosidic linkages 
as required for binding to calreticulin. An aminopentyl chain is shown in green and acts as 
both a linker and spacer between the tetrasaccharide and the biotin group shown in red. 
Incorporation of a fluorescent label at the reducing end of the tetrasaccharide had previously 
been shown by Iwamoto et al. to not impede on protein binding therefore we postulated that 












The retrosynthesis of 5-biotinamido-pentanyl -D-Glcp-(1→3)--D-Manp-(1→2)--D-Manp-
(1→2)--D-Manp 13 is summarised in Scheme 2.9. Owing to the unit cost of the biotin label 
along with a desire to minimise potential side-reactions and handling issues, we decided to 
incorporate the biotin in the final step of the synthesis. Through formation of an amide bond 
via the coupling of amine 64 with commercially available (+)-biotin N-hydroxysuccinimide ester 
65. The tetrasaccharide would be assembled using a convergent “2+2” synthesis, which both 
Cherif et al. and Gemma et al. had used successfully. Also, installing the glucose residue on 
to the 3-O hydroxyl of the Man(D1) residue would minimise the number of 
protection/deprotection steps. Cleavage of the glycosyl bond connecting Man(D1) and Man(C) 
would yield two disaccharides, GlcMan disaccharide 66 and ManMan disaccharide 67. It was 
decided that the GlcMan disaccharide donor would be a thioglycoside, which is stable to a 
range of glycosylation conditions, allowing alternative reactions conditions to be investigated 
for the most challenging coupling of the glucosyl donor with the suitably protected mannose 
thioglycoside acceptor. Tetra-O-protected glucose 68 can be synthesised from glucose or 
purchased commercially, while mannose thioglycoside 69 can be synthesised from D-
mannose 70. The synthesis of ManMan disaccharide 66 would utilise a suitably protected 
mannose orthoester 71 for both residues as shown by Gemma and Iwamoto separately. The 
linker 72, which can be synthesised from azide displacement of a pentanol halide 73, would 
provide the acceptor for the first glycosylation reaction.  













2.7.2. Synthesis of Mannose orthoester (44) 
 
Starting with D-mannose, peracetylation using acetic anhydride in pyridine led to the 
peracetylated mannose 76 in quantitative yield with an ratio of 77:23. Selective 
bromination at the anomeric position was achieved using 33% HBr in acetic acid solution. Due 
to the potential for hydrolysis of the bromide, bromide 74 was used directly in the next step 
and while no :ratio was measured, bromide 74 has been shown to exist as the -
steroisomer exclusively.42  Orthoester 77 was synthesised from bromide 74 using 2,6-lutidine 
in CH2Cl2 and methanol in 67% yield over two steps. The acetate at the 2-O position displaces 
the bromide to form the corresponding acetoxonium ion which is trapped by methanol at the 
carbonyl carbon to yield the orthoester 77 (Scheme 2.10.).  
 
 
Scheme 2.10.  Synthesis of benzyl orthoester 44. 
 
2,6-Lutidine being a non-nucleophilic base, acts as an acid scavenger but will not itself take 
part in the reaction. The methanol has the potential to attack from both sides, it was shown 




that the major isomer was achieved in a 93:7 ratio and subsequent analysis by X-ray diffraction 
confirmed exo-77 as the major product (Scheme 2.11).42   
 
Scheme 2.11. Formation of Orthoester leads to two products depending on face of 
attack of methanol.   
 
Having differentiated the 2-O position from the other sites, the remaining acetates were 
exchanged for benzyl ethers in a one-pot reaction. Thus, in-situ deacetylation using potassium 
hydroxide provided the corresponding alkoxides, which reacted with benzyl bromide to yield 
the target intermediate orthoester 44 in 76% yield. Orthoester 44 could be stored until required 
at which point it was converted to chloride 45 using TMSCl in CH2Cl2, to act as a mannosyl 
donor in a Koenigs–Knorr glycosylation. 
 
2.7.3. Synthesis of ManMan disaccharide (83) 
 
Scheme 2.12. outlines the synthesis of mannobiose 83 starting with acceptor 79 and using 
mannosyl chloride 45 as the donor in both glycosylation reactions. Azido-pentan-1-ol 79 was 
synthesised in quantitative yield from bromo-pentan-1-ol 78 via bromide displacement using 
sodium azide in DMF. Care had to be taken during the work-up to ensure the DMF was 
partitioned efficiently into the aqueous phase as the high temperature/ low pressure needed 




to remove residual DMF from the organic phase led to some loss of the product. In 
glycosylation reactions, it is common to stir the acceptor and activator together in the presence 
of activated molecular sieves for up to a half an hour prior to adding the donor as a solution 
(which may also have been dried similarly with sieves). Our first attempt at the Koenigs–Knorr 
reaction using azido alcohol 79 as the acceptor and chloride 45 as the donor, we followed this 
general drying procedure. Alcohol 79, 4 Å M.S., and silver(I) triflate were stirred together for 
30 minutes prior to adding chloride 45. However, the reaction did not proceed as expected 
and gave a complicated mixture of products as observed by TLC with no discernible major 
product. On repeating the reaction, TLC analysis of the mixture of sieves, activator and 
acceptor prior to addition of the donor revealed degradation of the acceptor which appeared 
to be the cause of the previous failed reaction. Precedent was found for the acid-catalysed 
decomposition of azide with a range of Lewis acids.43 Under our conditions, the stoichiometric 
amount of AgOTf may have acted as a Lewis acid, leading to the decomposition products. To 
counter this problem the silver(I) triflate activator was stirred alone with molecular sieves, 
followed by simultaneous addition of both acceptor and donor as a solution in 
dichloromethane. This modification led to the desired -mannoside 80 in 56% yield. Adding 
both acceptor and donor simultaneously presumably allows preferential activation of the 
chloride donor over competing degradation pathways with the azide. The benefits of using 
chloride 45 as the donor were next shown as selective deprotection of the acetate at the 2-O 
position was achieved using sodium methoxide in methanol to yield alcohol 81 in 92% yield. 
With our next acceptor, alcohol 81, in hand, this was coupled with chloride donor 45 using the 
same conditions that had worked previously. The target disaccharide 82 was isolated in 48% 
yield and only the -product was observed. Finally, removal of the acetate in 82 under 
Zémplen conditions yielded our first target disaccharide 83 which would serve as the acceptor 
in the key ‘2+2’ glycosylation reaction.  





Scheme 2.12.   Synthesis of ManMan disaccharide 83. 
 
2.7.4. Synthesis of 4,6-O benzylidene mannose thioglycoside (86) 
 
With mannobiose disaccharide 83 in hand attention turned to the synthesis of the GlcMan 
disaccharide donor. We decided to investigate the phenyl thioglycoside rather than the ethyl 
thioglycoside. Although the ethyl thioglycoside is more reactive the synthesis of the phenyl 
thioglycoside employs thiophenol which is less toxic (and has a lower stench than ethanethiol).  




Previously synthesised mannose pentaacetate 76, was converted into phenyl thioglycoside 
84 using thiophenol and boron trifluoride diethyl etherate in dichloromethane and 1H NMR 
analysis confirmed the major product as the -thioglycoside. Global deacetylation using 
sodium methoxide in methanol yielded phenylthioglycoside 85. In order to isolate the 3-O 
hydroxyl we chose to protect the 4-O and 6-O positions as a benzylidene acetal and then 
explore methods for regioselectively protecting the 2-O position.  
 
 
 Scheme 2.13  Synthesis of  Phenyl 4,6-O-benzylidene-1-thio--D-mannopyranose 86. 
 
Under thermodynamic conditions, benzylidene acetals favour the protection of 1,3-diols over 
1,2-diols, while isopropylidene acetals favour the protection of 1,2-diols over 1,3-diols. As 
highlighted in Figure 2.8., formation of a six-membered ring in the protection of the 4-O and 6-
O positions using benzaldehyde provides an acetal in which the large phenyl group can adapt 
an equatorial position leaving the hydrogen atom to assume axial position. In contrast, the 




analogous isopropylidene acetal formed from using acetone would introduce significant 1,3-
diaxial interactions as one of the methyl is forced into an axial position. A first attempt at the 
formation of thioglycoside 86 using benzylidene dimethylacetal in DMF with camphorsulfonic 
acid yielded a mixture of mono 4,6-O and bis 2,3:4,6-O benzylidene-protected thioglycosides 
86 and 87 shown (Scheme 2.13). As the 2-O and 3-O hydroxyls in mannose are cis to one 
another, the formation of this bis-protected product is perhaps not unexpected. Purification of 
this mixture proved difficult. Although based on TLC the products should have been easily 
separated, their poor solubility caused complications when preparing a column for flash 
chromatography. Large volumes of solvent were required and the product also precipitated 
from solution on the column.  
 
Figure 2.8. 1,3 Diaxial interactions of 4,6 protected mannose with benzylidene 
acetal and isopropylidene acetal. 
 
It transpires that this is a known problem for the synthesis of benzylidene thioglycoside 86. 
Previous methods to synthesise benzylidene 86 have used alternative Lewis acids and 
solvents.44 More recently, Sanapala et al. published a synthesis of benzylidene thioglycoside 
86, achieving the desired compound in 94% yield with no presence of the bis-benzylidene 
product observed.45 The key modification to the method involved the use of acetonitrile as the 




solvent. We were able to replicate this reaction. While the starting material is not fully soluble 
in acetonitrile, following addition of the benzylidene dimethylacetal and camphorsulfonic acid 
the mixture became briefly homogenous before a white solid (the desired product) began to 
precipitate out. The reaction was quenched with triethylamine. The product was recovered in 
pure form in 85% yield by filtration after washing with petroleum ether (b.p. 40–60 °C). The 
choice of solvent was key here as desired product precipitates outs before further reaction 
can take place. 
 
 
2.7.5. First synthesis of GlcMan disaccharide  
 
The next step following the formation of benzylidene thioglycoside 86 was the selective 
protection of the 2-O position leaving the free 3-OH to act as an acceptor for the next 
glycosylation reaction. The target thioglycoside 92 has been previously synthesised via 
different routes from mannose thioglycoside 85. Szurmai et al. found that chemoselective 
reductive ring opening of the dioxolane in bis 2,3:4,6-O benzylidene-protected thioglycoside 
endo-87 and was possible using LiAlH4–AlCl3.46 Interestingly, the regioselectivity of the 
reaction was determined by the endo/exo nature of the dioxolane benzylidene; thus, exo-87 
afforded the 3-O-Bn product 91 at a 20:1 ratio with the 2-O-Bn product 92, whereas endo-87 
provided its 2-O-benzyl regioisomer at a 10:1 ratio with the 3-O-Bn product.  





Scheme 2.14. Reductive ring opening of the dioxolane in bis 2,3:4,6-O benzylidene-
protected thioglycoside. 
 
Scheme 2.14 shows the formation of the 2-O-Bn and 3-O-Bn products from mannose 
thioglycoside 85. While the reaction with benzylidene dimethyl acetal yielded a 1:1 mixture of 
endo:exo products, fractional crystalisation was then used to isolate both exo and endo 
isomers, at 41.8% and 22.4% respectively and only a moderate–good yield was obtained for 
the reductive ring openings of the dioxolane benzylidene in bis-acetals exo-87 and endo-87. 
As we had previously encountered problems purifying bis 2,3:4,6-O benzylidene 87, we chose 
to investigate alternative methods.  
Another method for selectively differentiating the 2- and 3-O-positions of thioglycoside 86 
involved the use of tin acetal chemistry, which Cherif et al. used to selectively protect the 3-O 
position as a p-methoxybenzyl ether (Scheme 2.15).34 Benzyl protection of the 2-O position 
followed by selective removal of the PMB group with DDQ yielded the desired thioglycoside 
92 in 63% yield over the three steps. While this approach offered a more efficient route to our 
target acceptor, it still required an inelegant protection–deprotection sequence. 
 





Scheme 2.15  Synthesis of alcohol 92 via initial 3-O protection.  
Phase transfer-catalysed reactions have been studied on carbohydrate diols and in some 
cases shown to provide high yields of selectively mono-protected products.47, 48 Of relevance 
to our target, Crich et al. described the regioselective phase transfer-catalysed benzylation of 
the 2-OH of the desired thioglycoside 92 in 75% yield.49 Applying the same conditions to our 




Scheme 2.16   Selective 2-O protection using a phase transfer catalyst. 
 
The next key step of the synthesis involved incorporation of the -glucose residue, which had 
been the most challenging in all of the previous syntheses of tetrasaccharide 13. A range of 
-selective glycosylation methods were explored; thus, glucosyl iodide, trichloroacetamide 




and bromide donors were all tested for their reactivity and stereoselectivity in their reaction 
with acceptor 92. 
Within the group, the synthesis of GalCer 10 is typically achieved via the coupling of per-
TMS-protected galactosyl iodide 95 and protected sphingosine 96 using conditions that were 
developed by Gervay-Hague (Scheme 2.17).52-55  The product glycolipid 97 is typically isolated 
in excellent yield and selectively as the -product.  -Selectivity is achieved by establishing 
conditions that allow rapid anomerisation of the intermediate - and -iodides through the 
inclusion of TBAI in the reaction mixture.  Selective SN2 substitution is acheived on the more 
reactive -iodide.  Since equilibration of the intermediate - and -iodides proceeds much 
faster than glycosylation, high -selectivity can be achieved (Curtin-Hammett conditions).  
 
 
 Scheme 2.17  -selective glycosylation of glycolipid 97 as a precursor of -GalCer. 
 
Whilst there are no examples of glycosylations using TMS-protected galactosyl iodide donor 
95 with a sugar acceptor, Davis et al. have performed a glycosylation using per-TMS glucosyl 
and galactosyl iodides and cholesterol (Scheme 2.18).56  





Scheme 2.18  Glycosylation of iodide 95 with cholesterol acceptor.  
 
While the acceptor in our synthesis of -GalCer is a primary alcohol we expected our 
glycosylation would proceed with similar -stereoselectivity albeit with a less reactive 
secondary alcohol sugar acceptor.  Per-TMS protection of glucose was achieved in 94% yield 
using TMSCl in pyridine with HMDS acting as a co-solvent (Scheme 2.19.).  TMS-glucose 102 
was then treated with TMSI in CH2Cl2.  After 30 min, the reaction mixture was co-evaporated 
with anhydrous toluene to remove any unreacted TMSI and the crude glucosyl iodide product 
was used directly without purification in the glycosylation reaction. Thus, a solution of iodide 
95 in anhydrous dichloromethane was added to a dichloromethane solution of thioglycoside 
92, TBAI and Hünig's base, which had been previously stirred over activated 4 Å molecular 
sieves for 30 min. Unfortunately, no glycosylation product was observed; the acceptor proved 
unreactive and was recovered intact.   
 





Scheme 2.19 Failed attempt at GlcMan disaccharide synthesis using per-TMS 
glucosyl donor. 
 
Gemma et al. were also unable to effect glycosylation between donor 49 and acceptor 50 
under Gervay-Hague conditions (Scheme 2.20); however, they had more success using 
conditions developed by Mukaiyama and Kobashi,37 which employ a phosphine oxide activator 
(Scheme 2.4, p38).  
 
 
Scheme 2.20. Failed attempt at glycoyl iodide glycosylation by Gemma et al. using 
Gervay-Hague conditions. 




In our syntheses of -GalCer analogues, we have also observed that small changes to the 
lipid acceptor or glycosyl donor can affect the success of Gervay-Hague glycosylations.52 In 
these instances, we too have often had more success with perbenzylated glycosyl halide 
donors. 
Based on these observations, we decided to move away from glycosyl iodides and focus 
instead on alternative, more stable donors that had been previously established within the 
group. 
 
Scheme 2.21 Synthesis of GlcMan disaccharide 105 using a trichloroacetamidate 
donor. 
 
Trichloroacetimidate 36 was synthesised from commercially available 2,3,4,6 tetra-O-benzyl 
glucose in one step from trichloroacetonitrile and solid potassium carbonate. The product was 
used directly without further purification in a glycosylation with acceptor 92 under TMSOTf 
activation. Full consumption of the donor 92 was observed after 1 h and disaccharide 105 was 
successfully isolated in a 3:1 ratio and combined yield of 45%. Unfortunately, the two 
anomers proved inseparable by flash column chromatography.  




A second method that had been previously used within the group to synthesise -GalCer was 
through the use of 2,3,4,6-tetra-O-benzyl glucose as the donor in a dehydrative 
glycosylation.57 The method developed by Nishida uses the Appel reagents, 
triphenylphosphine and carbon tetrabromide, to prepare the active glycosyl bromide in situ as 
summarised in Scheme 2.22.58-60  
 
Scheme 2.22.  Conversion of hydroxyl group to bromide using Appel reagents. 
  

The first step involves reaction of triphenylphosphine and carbon tetrabromide to yield the 
phosphonium salt 108. The carbanion acts as a base to deprotonate the alcohol and form 
bromoform. The resulting alkoxide reacts with the phosphonium  cation to yield phosphonium 
intermediate 111, which undergoes substitution with bromide anion to form the glycosyl 
bromide and triphenylphosphine oxide, which provides a strong driving force for the reaction. 
Scheme 2.23 summarises the -selective glycosylation. Under the reaction conditions, the 
more stable -glycosyl bromide is in equilibrium with its highly reactive β-anomer. The 
inclusion of N,N-tetramethylurea (TMU) and presence of bromide anions facilitate the rapid 
equilibration; which crucially, proceeds at a much faster rate than does any reaction with the 
acceptor. The acceptor alcohol (R-OH) then reacts preferentially with the more reactive -




glycosyl bromide in an SN2 fashion to provide the -glycoside product. The use of an excess 
of the Appel reagents ensures any glycosyl bromide that is hydrolysed by adventitious water 
is recycled. The use of non-participating groups is also vital, especially at the 2-O position 
prevent neighbouring group participation. While this was beneficial during the syntheses of -
linked mannose residues, neighbouring group participation at the equatorial 2-O position of a 
glucsoyl donor serves to block the -face, leading to attack from the -face. 
 
Scheme 2.23 Summarising the -selectivity of the Koenig Knorr reaction using Appel 
reageants. 
Using three equivalents of the Appel reagents to one equivalent of the hydroxyl sugar 114 in 
dichloromethane, the mixture was stirred for 3 h at room temperature until TLC analysis 




showed full conversion of the starting material1. N,N-Tetramethylurea along with acceptor 92 
were then added and the reaction mixture was stirred for four days, after which time, TLC 
analysis showed full consumption of the bromide to yield disaccharide 105 in 51% yield as a 
10:1  mixture. The reaction was also attempted with the addition of tetrabutylammonium 
iodide and tetrabutylammonium bromide to facilitate equilibration; however, these additives 




Scheme 2.24   Synthesis of GlcMan disaccharide 105.  
 
Nishida reported that an acetyl protecting group at the 6-O position of the sugar donor 
increased the -stereoselectivity of the reaction, proposing long-range group participation and 
formation of an acetoxonium intermediate on the -stereoface.58 Hydroxy sugar  was therefore 
synthesised in two steps from 2,3,4,6-tetra-O-benzylglucopyranose via acetylation of the 
anomeric and 6-O position and selective deprotection of the anomeric acetate (Scheme 
2.25).62, 63 While the glycosylation reaction was now completely -stereoselective, 
disaccharide 118 was only isolated in 26% yield as its separation from the starting acceptor, 
                                               
1 The bromide can be visualised by TLC 




which was used in excess, proved problematic. As a consequence, we decided to continue 
the synthesis with disaccharide 105, which could be prepared on the larger scales needed to 
complete the synthesis of the tetrasaccharide target.  
 
 
Scheme 2.25.  Synthesis of GlcMan disaccharide 118.  
 
 
2.7.6. Synthesis of Glc1Man3 tetrasaccharide (119) 
 
With both disaccharides in hand, the next step was the ‘2+2’ coupling of acceptor 83 with 
donor 105. Activation of the thioglycoside using (freshly recrystallised) N-iodosuccinimide 
(NIS) and trifluoromethanesulfonic acid followed by addition of the acceptor afforded a mixture 
of tetrasaccharide products in 22% yield. The presence of the -isomer from the previous 
reaction to form the GlcMan disaccharide 105 along with any -isomer formed in '2+2' coupling 
reaction meant that up to four diastereomers were possible. NMR analysis of the product 
confirmed the presence of a mixture. As we could not separate the diastereomers at this stage, 
and the next step in the synthesis was a global deprotection of the benzyl ethers and 




hydrogenolysis of the azide, separating a mixture of highly polar products would be very 
challenging. We therefore investigated an ester protecting group at the 2-OH position of the 
mannose residue of the GlcMan disaccharide. During the synthesis of the ManMan 
disaccharide 83, following both glycosylations, deacetylation had caused a change in polarity 
which usefully allowed the - and - diastereomers to be separated. We postulated that a 
similar deprotection strategy might allow for separation of the major, desired isomer from other 
tetrasaccharide products.  
 
 
Scheme 2.25 a.  Synthesis of tetrasaccharide 119.  
 
2.7.7. Synthesis of alternative GlcMan disaccharide (125)  
 
We decided to protect the the 2-O position of the acceptor as a benzoate as there was 
literature precedent for the synthesis of thioglycoside acceptor 120 using the phase transfer 
catalyst method described previously (see p56).64 Unlike the benzylation reaction, which 
required heating under reflux overnight for the reaction to reach completion, the analogous 




benzoylation proceeded at 0 °C and was complete in 30 min (Scheme 2.26). The desired 
product 120 was isolated in 48% yield. Bis-benzoate 121 was also isolated in 26% yield with 
the potential for this product to be recycled back to alcohol 86 under Zemplén conditions. 
  
Scheme 2.26 Model glycosylation using thioglycoside 121 and mannosyl acceptor 
123. 
 
We decided to investigate the reactivity of the thioglycoside 121, which is a further disarmed 
donor compared with disaccharide 120,65, 66 with methyl 3,4,6-tri-O-benzyl mannopyrannoside 
123. Acceptor 123 was synthesised from orthoester 44 in two steps; thus, TMSOTf-mediated 
ring opening of the orthoester provided acetate 122, which underwent Zemplen deacetylation 
to yield model acceptor 123 in 96% yield. With both model donor 121 and acceptor 123 in 
hand, we attempted the glycosylation using NIS / triflic acid to activate the donor. Pleasingly, 
the reaction proceeded uneventfully, affording the desired disaccharide 124 in 74% yield as a 
single -anomer. 
 




2.7.8. Second synthesis of GlcMan disaccharide 
 
Having shown that thioglycoside 121 was a competent donor, we next targeted the GlcMan 
disaccharide containing a benzoate ester at the 2-O position of the mannose residue. Under 
Nishida's dehydrative glycosylation conditions, donor 114 reacted with acceptor 120 to yield 
the desired disaccharide 125 in 57% yield, an improved yield from the reaction using the 2-O 
benzyl acceptor although again as a 10:1 ratio.  
 
 
Scheme 2.27  Synthesis of disaccharide 125 using acceptor 120. 
 
2.7.9. Second synthesis of tetrasaccharide 
 
Using our newly synthesised donor 125, activation of the thioglycoside, once again with NIS / 
triflic acid and reaction with acceptor 83 yielded a new product which was confirmed as the 
tetrasaccharide 126 by mass spectrometry. As before, the product was isolated as an 
inseparable mixture of diastereomers; however, these were separable after debenzoylation 
under Zémplen conditions, allowing isolation of the desired target tetrasaccharide 127 in 35% 
yield over two steps from thioglycoside 125. 





Scheme 2.29 Synthesis of tetrasaccharide 127 followed by global deprotection to 128 
using hydrogenation conditions.  
 
Our attention turned to confirming that all of the glycoside linkages in tetrasaccharide 127 were 
indeed -linkages. To do this, we would use NMR spectroscopy. Figure 2.9. shows the angular 
relationship between the H-1 and H-2 substituents of - and -glucosides and - and -
mannosides.  In the case of glucose, there is a large difference in the dihedral angle between 
the H1 and H2 substituents in the two anomers, which makes it possible to differentiate them 




by determining the magnitude of the vicinal coupling constant.  In accord with the Karplus 
relationship, axial-axial coupling (dihedral angle ~ 180°) observed in a -glucoside gives a J1,2 
value of 8–12 Hz whereas in the case of -glucosides, a smaller J1,2 value of 2–5 Hz (dihedral 
angle ~ 60°) is observed for this equatorial-axial coupling.  Differentiating - and -mannosides 
by measuring the analogous vicinal J1,2 coupling constants is more difficult as the dihedral 
angle between the two protons is around 60° for both - and -linkages. However, 
experimentally the Jeq-ax value in -mannosides is typically slightly larger than the Jax-ax value 
for -mannosides (Figure 2.9.).67, 68  
 
 
Figure 2.9. J-coupling values of anomeric position H-1 and H-2 of mannosyl and glucosyl 
residues 
 
The NMR spectra of tetrasccharide 127 were recorded on the 900 MHz Varian spectrometer, 
housed in the Henry Wellcome Building NMR facility, by Sara Whittaker (NMR Operations 
Manager).  Recording the NMR spectra on such a sensitive, high-field instrument provided the 
best opportunity to separate the resonances in the spectrum and to obtain the best possible 
resolution to confirm that only one diastereomer was present.  







Figure 2.10. Expansion of 1H NMR spectrum of tetrasaccharide 127 
 
Pendant 13C, COSY, HSQC and HMBC experiments allowed near complete2 full assignment 
of the proton and carbon resonances for the tetrasaccharide. Figure 2.10 shows a 
magnification of the region of the 1H-NMR spectrum containing the four resonances arising 
from the anomeric hydrogens. The measured J1,2 value of 3.9 Hz for the glucose residue is 
consistent with an -glycosidic linkage.  As expected, the measured J1,2 values for the three 
mannose were residues small. The 1.7 Hz coupling constant obtained for Man-C and Man-4 
was in agreement with the value reported in of a previous synthesis of the tetrasaccharide.31 
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The lower value of J1,2 for Man-D1 can be attributed to the presence of the benzylidene group, 
which restricts the conformational flexibility and increases torsional strain of this particular 
mannoside residue. Similar observations were observed by Cherif et al.33 and Despras et al.69, 
whose measured values for J1,2 of -mannosides containing benzylidene protecting groups 
are in agreement with ours.  
 
Having confirmed that all of the glycosidic linkages were of the correct stereochemistry, the 
next step was the global deprotection of the molecule with removal of the benzyl and 
benzylidene protecting groups, and reduction of the azide. Hydrogenation was done using 
Pd(OH)2 catalyst with H2 gas in methanol. Pd(OH)2 is a more active catalyst than Pd/C and 
the addition of acetic acid has a dual purpose in that it facilitates the removal of the benzylidene 
group under hydrogenolysis conditions as well as protonate the amine to help reduce 
poisoning of the catalyst. The reaction mixture was stirred over an atmosphere of H2 for 2 
days, with the reaction being worked up and restarted with fresh catalyst after 24 h. The fully 
deprotected product 128, as determined by mass spectrometry, was isolated in 45% yield 
following flash chromatography using a H2O:methanol eluent. 
 
 
2.7.10. Biotinylation of tetrasaccharide 
 
The final step of the synthesis involved the coupling of the biotin to the amine via an amide 
linkage. Reaction of amine 128 with commercially available (+)-biotin N-hydroxysuccinimide 
ester proceeded uneventfully to provide biotinylated tetrasaccharide 13 in 68% yield (Scheme 
2.30.). Conversion of the amine to the amide also facilitated purification of the final compound 
as CHCl3:MeOH could now be used as the eluent without having to include water. However, 




we were unable to isolate pure product; TLC analysis showed the presence of another 
compound with a similar Rf value. NMR spectroscopic analysis confirmed that the impurity was 
neither a carbohydrate nor did it contain biotin. As the biotin group was prerequisite for the 














2.8. Binding studies of Calreticulin and its mutants to oligosaccharide 
substrates 
  
Calreticulin (CRT) is an ER-resident lectin chaperone involved in the folding of various 
glycoproteins. The natural ligand for CRT is the mono-glucosylated oligosaccharide 
Glc1Man9GlcNAc2, which is found on the surface of glycoproteins in the ER. Whilst the terminal 
glucose is essential for CRT binding, this residue is only transiently present on the 
oligosaccharide substrate, as this undergoes further processing in the cell. The development 
of CRT mutants that are able to recognise the non-glucosylated substrate, Man9GlcNAc2, are 
desirable as these will interact with a larger number of glycoproteins, which will facilitate the 
isolation of chaperone-substrate complexes. It has been shown previously that a truncated 
oligosaccharide containing the terminal Glc1Man3 tetrasaccharide can be recognised by CRT 
and that modifications at the reducing end do not interfere with binding.38 To this end, 
biotinylated tri-mannose trisaccharide 129 and biotinylated tetrasaccharide 13 are being used 
as surrogate substrates to detect functional mutants in the sugar-binding domain, which alter 
the specificity of the lectin such that it can bind to non-glucosylated glycoproteins. 
 
 
The biotinylated sugars can be bound to streptavidin-coated agarose beads and used in a 
pull-down assay with purified mutant CRTs.  Alternatively, they can be bound to streptavidin-
coated plates and employed in a high-throughput ELISA-based assay. Tetrasaccharide 13 
serves as both a positive control in these experiments to ensure the assay is functioning, and 




to test whether or not any CRT mutant, which is pulled down, has retained the binding 
specificity of the wildtype (WT)-CRT.  
Tetrasaccharide 13 was submitted for biological testing, which was carried out by Dr Najla 
Arshad, a member of Prof. Peter Cresswell’s group at the Department of Immunobiology at 
Yale University School of Medicine, US.  Initial experiments used GST-fusion proteins of i) 
WT-CRT, ii) a known CRT mutant (Y92A) which is unable to bind to any oligosaccharides, and 
iii) a test CRT mutant (K111A) which was recombinantly expressed in E. coli and purified from 
the bacteria by affinity purification using GSH-agarose beads. The biotinylated 
oligosaccharides were incubated with streptavidin beads to allow attachment. The beads were 
then dispensed into tubes, protein was added to each tube and the mixture was incubated for 
1.5 h at 4 °C. The recovered beads were then boiled in sample-loading buffer and subjected 
to SDS PAGE, to remove unbound protein, followed by Coomassie staining. 10% of the protein 
used in each experiment was run on the gel.  
The results of these experiments are summarised in Figure 2.11. As expected, the calreticulin 
wildtype binds to tetrasaccharide 13 but not to trisaccharide 129, which is in accordance with 
the known specificity requirement of the terminal Glc residue.  This result supports our design 
strategy: the biotin label does not compromise the ability of CRT-WT to recognise the 
tetrasaccharide unit in 13 nor does the tetrasaccharide unit compromise the ability of the biotin 
label to attach to the streptavidin-coated beads. The mutant CRT-Y92A does not interact with 
either of the sugars, as expected, but neither does CRT- K111A. These initial results suggest 
that this mutation (of lysine to alanine) at position 111 has rendered CRT incapable of binding 
sugars. However, further studies are needed since the amount of CRT-WT used in the assay 
was more than the other two proteins, which may confound the result. New mutants are 
currently being isolated, which may prove to successfully bind to the trisaccharide.  
 




















2.9. Conclusions and future work 
 
Successful synthesis of biotinylated Glc1Man3 13 has been achieved using a convergent 2+2 
method. Successful binding was seen between WT-CRT and the tetrasaccharide, however, 
thus far, no functional mutant that can bind to non-glucosylated trisaccharide has been 
isolated. Future work may involve the development of a cleavable linker between the 
tetrasaccharide and the biotin group. The conditions required to separate the biotin–
streptavidin complex are harsh and would also separate the tetrasaccharide–calreticulin 
complex in the process. An enzymatic cleavable linker in particular would be beneficial as the 
conditions required are highly selective. Development of the cleavable linker would allow 
isolation of the tetrasaccharide–calreticulin complex in the absence of the biotin–streptavidin 
complex. This may be of benefit when calreticulin mutants are discovered that bind both 
tetrasaccharide 13 and trisaccharide 129 and it is necessary to develop a crystal structure to 








Synthesis of analogues of ThrCer-6 and ThrCer 




















The Cluster of Differentiation 1 (CD1) family of antigen-presenting proteins are highly 
conserved. They have a similar function to MHC molecules. However, in contrast to MHC 
molecules, which present peptide antigens to T-cell receptors (TCR), CD1 molecules bind and 
present a range of lipids and glycolipids to the TCR of CD1-restricted T cells. There are five 
different isoforms of CD1. Based on their nucleotide and amino acid sequence homology, they 
can be divided into three groups. Group 1 comprises CD1a, CD1b, and CD1c, which are 
expressed by humans, but not present in mice. Group 2 consists of CD1d, which is present in 
both humans and mice. CD1e is the sole representative of group 3 and has received little 
study.70-72  
CD1 molecules are structurally similar to MHC class I molecules in that they comprise a heavy 
trans-membrane chain, which is folded into three domains (1, 2 and 3). This heavy chain 
is non-covalently associated with 2 -microglobulin (2m). The structure of CD1 molecules 
allows for the binding of antigens of amphipathic nature which contain a hydrophilic head 
group and a hydrophobic tail. The antigen binding site of CD1 molecules is generated by the 
1 and 2 domains, which fold to form deep, narrow pockets that are lined with mostly non-
polar amino acids. The hydrophobic nature of these pockets allows for the binding of lipids 
through stabilisation by hydrophobic interactions. The polar, hydrophilic head group is then 
exposed on the surface of the protein molecule, where it is stabilised by hydrogen-bonding 
interactions and available for TCR recognition.  
CD1 molecules have almost invariant binding grooves; however, they can still bind a range of 
antigens, including both intracellular and extracellular lipids of endogenous or foreign origin. 




CD1a presents glycolipids such as the sphingolipid sulfatide 130 (which has also been shown 
to bind to CD1b, CD1c and CD1d) and mycobacterial lipopeptides including 
didehydroxymycobactin (DDM) 131 (Figure 3.1.). CD1b is able to bind lipids with very long 
lipid tails such as mycolic acids 132 (Figure 3.1.) because the molecule has two extra pockets 
which provide the necessary space to accommodate these longer lipids.CD1c binds and 
presents polyketides like mannosyl-1-phosphomycoketide 133 which contain branched lipid 
tails. 
CD1e is different from the other members of the CD1 family. It is not involved in surface 
antigen presentation. Instead, it is converted into a soluble lysosomal form and found in late 
endosomes. It is still immunologically relevant and is involved in intracellular lipid transport 
and antigen processing. It is also involved in the conversion of PIM6 to PIM2 by -
mannosidase.  
 
Figure 3.1.  Examples of lipid antigens presented by CD1 molecules 




CD1d is recognised exclusively by the semi-invariant TCR of iNKT cells. It is assembled in the 
endoplasmic reticulum, where it is loaded with an endogenous lipid and binds to chaperones 
including calreticulin, calnexin, ERp57 and 2m, which facilitates its transport first through the 
Golgi apparatus and then to the plasma membrane via the secretory pathway (Figure 3.2, a–
b). Nascent CD1d molecules on the surface are then internalised via a clathrin-coated pit into 
the early or sorting endosome, with the help of adapter protein (AP) 2 (Figure 3.2, c). AP3 
allows murine CD1d to traffic from early endosomes to late endosomes before being re-
exported to the cell membrane (Figure 3.2, e). Human CD1d cannot interact with AP3 so gets 
re-exported to the cell membrane after only being in the early endosome. The trafficking into 
endosomes is important in allowing CD1d to encounter and bind to lipids for subsequent 
presentation to T-cells.73 
 
Figure 3.2. Intracellular trafficking of CD1d. Figure adapted from ref.73 Permission to 
reproduce figure was obtained through RightsLink® - licence number 
4106400518435. 





3.2. iNKT cells  
 
As previously mentioned (paragraph 1.4.3.) NKT cells are so named because of their co-
expression of an  TCR along with NK markers, which are normally found on natural killer 
cells. The most studied of these are Type 1 or invariant (i) NKT cells, which are CD1d-
restricted in that their activity is dependent on the presentation of a glycolipid-bound CD1d 
molecule to the invariant TCR. 
Like conventional T cells, the development of iNKT cells begins in the thymus. The TCR is 
formed on a precursor thymocyte at the double positive (DP) stage. Positive selection of the 
iTCR occurs through the recognition of CD1d-expressing DP thymocytes (Figure 3.3). The 
endogenous glycolipid bound to the CD1d in the thymus is still unknown. Isoglobotrihexosyl 
ceramide (iGb3) has been suggested as the self ligand but this view has challenged.74 More 
recent research has shown that both synthetic and purified sources of mammalian -
glycolipids contain a small percentage of the -anomer (0.5–1%).3 While this has not been 
tested regarding positive selection within the thymus, even a low abundance of the -anomer 
would likely be sufficient to bind and activate the invariant TCR.75 Following positive selection 
of immature NK 1.1- CD4+CD8+ NKT cells, downregulation of the CD8 receptor leaves CD4+ 
cells. These NK1.1- cells are then transported to the periphery of the spleen or liver where 




                                               
3 While it had previously been thought that mammals are unable to synthesise -anomeric sugars 





Figure 3.3 Development of Vα14i T cells in the thymus. TCR with random αβ 
rearrangement is first expressed by an uncommitted precursor thymocyte at 
the DP stage. CD1d-expressing DP thymocytes then positively select DP cells 
with a CD1d-specific Vα14i α-chain (Vα14–Jα18). After maturing into DN and 
CD4+ T cells they are exported to peripheral organs where a hypothetical 
second signal is required for the expression of mature iNKT cells. Positive 




selection of T cells with TCRs that are specific for MHC–peptide complexes 
leads to maturation of mainstream CD4+ and CD8+ T cells. Figure adapted 
from ref.76 Permission to reproduce figure was obtained through RightsLink® - 





Upon activation iNKT cells have the ability to induce the expression of various cytokines, which 
can in turn activate other cells such as NK cells, conventional T cells and B cells. Cytokines 
are cell-signalling protein molecules that are secreted by numerous cells. These messenger 
molecules allow cells to communicate with each other and are responsible for most of the 
biological effects in the immune system, such as cell-mediated immunity and 
allergicresponses. Although there are many different cytokines present in the body, they can 
be divided into two main groups based on their function: those that are pro-inflammatory and 
those that are essentially anti-inflammatory but promote allergic responses. 
T lymphocytes are the major source of cytokines. Those T lymphocytes that express the cell-
surface molecule CD4 are also called mature helper T cells, and these are regarded as being 
the most prolific cytokine producers. CD4+ T cells can give two responses, termed TH1 and 
TH2 (T helper) depending on the cytokine profile they induce. TH1-type cytokines afford a pro-
inflammatory response, responsible for attacking intracellular foreign pathogens and also for 
exacerbating autoimmune responses. Interferon gamma (IFN-γ) is the main TH1 cytokine. The 
TH2 response is needed to oppose the TH1 response as excessive pro-inflammatory 
responses may lead to tissue damage.77 TH2-type cytokines include interleukins (IL) 4, 5, and 
13, which are associated with the promotion of IgE (a type of antibody) and also interleukin-
10, which has more of an anti-inflammatory response.9 iNKT cells have been shown to be able 
to induce both TH1 and TH2 cytokines following activation. As both processes lead to separate 




outcomes the potential to use iNKT cells to induce a biased response make them a great 





Figure 3.4.  Cytokines produced by TH1 and TH2 responses along with the overall effect. 
Figure adapted from ref.78 Permission to reproduce figure was obtained through 




3.4. -Galactosyl Ceramide (-GalCer)  
 
Of the glycolipids that bind to CD1d and activate iNKT cells, the most studied is -Galactosyl 
Ceramide (-GalCer) 10. In 1993, novel glycosphingolipids were isolated by Natori et al. from 
the marine sponge Agelas mauritianus in the Okinawa Sea.79 Four agelasphins (AGLs) were 
isolated from the sponge all possessing an -galactosylceramide structure. -




Galactosylceramides were already known these but -galactosylceramides were novel and 
the first cerebrosides to have an -galactosyl linkage (Figure 3.5). 
 
Figure 3.5 Structure of four agelaspins isolated from Agelas mauritianus 
The AGLs showed potent in vivo antitumor activity against a murine B16 melanoma cell line. 
Using AGL-9a and AGL-9b (shown to be most active) as the starting point, a range of synthetic 
AGLs were developed for further experimental studies. Morita et al. showed that the hydroxyl 
group alpha to the amide carbonyl was not necessary for activity nor was the terminally 
branched methyl group; the structurally simplified analogue, -GalCer also known as 




Figure 3.6 Structure of -GalCer  
  




-GalCer is comprised of a D-galactopyranose sugar alpha linked to a phytosphingosine 
backbone which is N-acylated with hexacosanoic acid (Figure 3.6). It binds strongly to CD1d-
with a kinetic dissociation constant (Kd) of 1.29 ± 0.08 M.  
While -GalCer has been shown to have therapeutic effects against autoimmune diseases 
including type I diabetes, experimental allergic encephalomyelitis, arthritis and systemic lupus 
erythematosus80 and been shown to be effective in antitumour therapy,81, 82 it has certain 
properties that have prevented its application as a therapeutic agent: 
 
1. It over-stimulates iNKT cells resulting in cytokine storm, DC lysis and iNKT cell 
anergy.  
2. It possesses glycosidic and amide bonds, which can potentially be hydrolysed in 
vivo by glycosidases and amidases, respectively.  
3. Activation of iNKT cells leads to the production of both TH1 and TH2 cytokines, 
which can lead to a mixed immune response, which limits its therapeutic 
application. 
 
Anergy is a tolerance mechanism in which a lymphocyte is intrinsically functionally inactivated 
following an encounter with an antigen, meaning that after stimulation by the antigen the cell 
is unable to be activated upon further stimulus. 
 
3.5. Crystal Structure CD1d Protein–GalCer  
 
. The Crystal structure of the complex of -GalCer glycolipid and human (h)CD1d complex 
has been determined and shows the binding interactions between the molecules and the 
structure of the -GalCer glycolipid (Figure 3.7.–3.9.)83. Structures are also available for 
mouse and other organisms are also available in PDB.84 







Figure 3.7  Ribbon representation of the CD1d–-GalCer complex. PDB ID:1ZT4. Figure 
adapted from ref.83 Permission to reproduce figure was obtained through 









Figure 3.8.  Ribbon representation of the CD1d–-GalCer complex showing the binding 
groove from above. Figure adapted from ref.83 Permission to reproduce figure 
was obtained through RightsLink® - licence number 4106420868745. 
 
   
Figure 3.9. Space-filling representation of CD1d–-GalCer complex. Figure adapted from 
ref.85 Permission to reproduce figure was obtained through RightsLink® - 
licence number 4111590202719. 
 
 




CD1d is a heterodimeric protein consisting of a heavy chain made up of three domains, 1, 
 and . The antigen binding groove is made up of the 1 and 2 domains and consists of 
two anti-parallel -helices sitting on top of a β-pleated sheet. This groove superficially 
resembles the binding pocket of MHC class I molecules but is deeper and larger in volume. It 
is also narrower and divides into two channels, generating the so-called A’ and F’ pockets. 
MHC molecules characteristically have a number of small pockets in the wall of the binding 
groove to accommodate peptide side-chains. In CD1 molecules these pockets have fused 
together to form the two pockets A’ and F’, which are lined with amino acids such as 
phenylalanine and tryptophan imparting the hydrophobic nature of these binding sites. 
 
The acyl chain (26 carbons) of -GalCer fits in the A’ pocket while the sphingosine chain (18 
carbons) fits in the less voluminous F’ pocket. Both hydrocarbon chains fully occupy these two 
pockets and so are indicative of the maximum chain length which can be tolerated in the 
antigen-binding groove of human CD1d.83 This finding explains why CD1d exhibits much 
higher binding affinity than glycolipids possessing truncated chains. Figure 3.9. shows how 
the glycolipid is anchored in the CD1d binding groove via hydrophobic interactions between 
the lipid chains and the hydrophobic amino acids lining the binding pockets, leaving the sugar 
head-group exposed on the surface of the protein for recognition by the iNKT cell TCR. The 
hydrogen bond interactions between Asp151 and the 2-O hydroxy of the sugar as well as 
Thr154 and the anomeric oxygen are vitally important as they not only stabilise the glycolipid 












Figure 3.10.  Ribbon representation showing key H-bonding interactions between -GalCer 
and the CD1d molecule. Figure adapted from ref.83 Permission to reproduce 




Figure 3.11.  Key Hydrogen bonding interactions between hCD1d and -GalCer.  
 





Position on –GalCer Human CD1d Mouse CD1d 
1’-O  Thr154 on 2-helix of CD1d Thr156 on 2-helix of CD1d 
2’-OH  Asp151 on 2-helix of CD1d Asp153 on 2-helix of CD1d 
3-OH  Asp80 on 2-helix of CD1d Asp80 on 2-helix of CD1d 
NH Thr154 on 2-helix of CD1d Thr156 on 2-helix of CD1d 
C=O  Ile69* on 1-helix of CD1d Met69* on 1-helix of CD1d 
 
Table 3.1  Key hydrogen bonds between -GalCer and the CD1d molecule. 
 *This hydrogen bond involves a bridging H2O molecule. 
 
Table 3.1. summarises the key hydrogen bonding interactions between -GalCer and the 
CD1d molecule. These interactions between the protein and the polar group on the -GalCer 
molecule ensure the sugar head group is oriented parallel to the plane of the -helices. 86-87  
Thus positioning is vital for effective recognition by the iNKT cell TCR.  
 




3.6. CD1d–Glycolipid–iNKT-cell TCR Ternary complex 
 
Figure 3.12  Shows the TCR–-GalCer–CD1d complex. Figure adapted from ref.88 
Permission to reproduce figure was obtained through RightsLink® - 
licence number 4173120438296. 
 




The iNKT-cell TCR comprises an invariant V24-J18 -chain and a restricted V11-
containing -chain. A co-crystal structure of the human NKT-cell TCR-GalCerCD1d 
complex has also been described at 3.2 Å resolution. It shows that the TCR binds almost 
parallel to the antigen binding site, positioned above the F′ pocket and at the extreme enB of 
AB1d. The crystal structure also shows that the -chain contributes more interactions with 
CD1d-GalCer than does the -chain (approximately 82 compared to 32 respectively). The 
total buried surface area (BSA) of the TCR-GalCerCD1d interface is around 910 Å2 with 
the -chain again contributing more to the BSA than does the -chain (65.5% vs 34.5%, 
respectively).  
 
Figure 3.13  Hydrogen bonding interactions between the sugar head-group and 
amino-acid residues in the TCR. Figure adapted from ref.88 Permission 
to reproduce figure was obtained through RightsLink® - licence number 
4173120438296. 





The majority of the Van der Waals, electrostatic and hydrogen bonding interactions are 
between the CD1d molecule and the TCR. For the V-chain, the major contact is between the 
CDR2 loop to the 1-helix of CD1d. Contacts are found between the CDR3loop of the V-
chain and the 1- and 2-helix of CD1d. However, a glycolipid is required for activity meaning 
the interactions between the polar head group and the TCR are vital. The galactose ring is 
positioned underneath the CDR1 loop, which only interacts with the ligand and next to the 
CDR3loop. Figure 3.13 shows the numerous hydrogen bonds that stabilise the TCR-–
GalCer interaction: the 3-OH of the sphingosine chain hydrogen bonds to the side-chain of 
Arg95. The sugar 2′- and 4′-OH groups hydrogen bond with the main chain of Gly96 and 
Phe29, respectively, and the 3’-OH forms a hydrogen bond to the side-chain hydroxyl residue 
of Ser30 (Table 2) 
These interactions are important for recognition of the TCR and are also stereospecific as -
ManCer does not activate iNKT cells. Mannose differs from galactose in the orientation of the 
OHs groups at C-2′ and C-4′, which result in the loss of two key hydrogen-bond interactions 
and no activation of the TCR even though -ManCer does still bind to CD1d.  
The -linkage is also important for TCR recognition and activation; while -GalCer is able to 
activate iNKT cells, it is a much less potent agonist than its -anomer. It is predicted that -
GalCer adopts a more perpendicular orientation due to the altered position of the head group. 










3.7. Analogues of α-GalCer    
 
As iNKT cells can induce both TH1 and TH2 cytokines the potential for use in therapeutic 
application are great if a biased response can be induced. This highlights the importance of 
the synthesis glycolipid targets that activate iNKT cells. Production of the key TH2 cytokine, 
IL-4 is rapid after initial iNKT-cell stimulation, typically showing its highest concentration when 
assayed after 2 hours. Production of key TH1 cytokine, IFN- requires prolonged stimulation 
and is typically assayed 18 to 24 h after administration of the agonists.89 While there are other 
factors that affect biaising, these observations led to the proposal that analogues of -GalCer 
that dissociate from the ternary complex after a short period of time may elicit a TH2-biased 
(more IL-4, less IFN-) response. Conversely, glycolipids and analogues that result in a more 




3.7.1. Analogues with modifications to the sphingosine chain 
 
 
Modifications that can be made to the sphingosine chain include altering the length, using 
alternative stereoisomers and functionalising the chain. OCH 138, first synthesised by 
Yamamura et al., is a truncated analogue of -GalCer. The phytosphingosine chain is 
shortened to nine carbons instead of the eighteen found in -GalCer.90 The acyl chain is also 
truncated by two carbons compared with that in -GalCer. OCH has been shown to be a less 
potent agonist than -GalCer but elicits a TH2-biasing immune response by producing more 
IL-4 and less IFN- in vitro, compared to -GalCer, leading to its potential application in treating 
autoimmune diseases. The TH2-bias is believed to be due to the fact that OCH–CD1d complex 
is less stable as the alkyl chain does not fill the binding groove resulting in faster dissociation. 








It has been shown independently by Iijima et al.91 and Brossay et al.92 that when the 3-OH and 
the 4-OH of the phytosphingosine unit are removed, the molecule loses the ability to proliferate 
spleen cells in mice. These observations have been rationalised by a loss of key H-bonding 
interactions between the 3-OH to the CD1d Asp80 as well as to Arg 95 of the CDR3-loop of 
the TCR, leading to a differently bound confirmation which is no longer recognised by the TCR. 
However, if only the 4-OH is removed, the analogue 139 still initiates a strong biological 
response in mice. 4-Deoxy-4, 4-difluoro--GalCer 140, was synthesised by Leung et al. to 
investigate the effect of removing the hydrogen-bond donating capacity and minimising  the 
ability to accept a hydrogen bond.93  Following only minimal loss of activity, it was argued that 









Analogues which contain an aromatic group at the end of a truncated phytosphingosine chain 
such as 141 have also been shown to provide be a potent iNKT cell activator that induces a 
more TH1-biased cytokine response. It is suggested that the ligand binds to CD1d with a higher 
binding affinity due to the extra aromatic interaction caused by the aromatic group of the 
antigen and aromatic residues of the CD1d protein which prolongs the lifetime of bound 
complex leading to increased levels of IFN- 
 
 
3.7.2. Modifications to the Acyl chain 
 
-GalCer analogues containing a truncated acyl chain such as C10:0 142 display a TH2 
biasing cytokine response whereas appending an aromatic group to the end of the acyl chains 
has provided analogue 143, which has similarly been shown to induce a TH1 cytokine bias, 
believed to be due to the increased stability of the CD1d––GalCer complex and enhancing 
IFN- secretion, which requires longer stimulation time to be released.89 This increased 
stability of the glycolipidCD1d complex is due to – stacking with aromatic residues lining 
the binding pockets.94 
 
 






Another acyl chain analogue is C20:2 145 which contains an unsaturated acyl chain with two 
cis double bonds at C11 and C14, this compound skews the response towards TH2, with a 
diminished IFN-γ production.95 However, in contrary to -GalCer, it does not require 
endosomal localisation of CD1d for efficient loading and presentation.96  
7DW8-5 144, developed by Wu et al.97 which contains a terminal para-fluoro phenyl group and 
has also been shown to be a highly potent iNKT cell activator. It has also been shown to induce 
a higher level of IFN-γ compared to the unfluorinated analogue.98 7DW8-5 144 shows higher 
affinity towards CD1d which is due to the fluorine forming of a neutral hydrogen bond within 
the binding pocket.99 
 
3.7.3. Modifications to the amide bond 
 
The amide N-H in -GalCer is perfectly aligned to form a hydrogen bond with the OH group 
of Thr154 as shown in the crystal structure of the hCD1d–GalCer complex.100 It was 
postulated that the gem-difluoro analogue 146 would increase the H-bond capability by 
increasing the acidity of the N-H. A stronger interaction between the amide N-H and Thr154 
should stabilise the complex and lead to a TH1 bias. However, this compound proved to be 




less potent than -GalCer, inducing less IFN-.  In light of these experimental results, it was 
suggested that the H-bonding involving the amide N–H formed a network with the 2’OH of the 
sugar and Thr154 and Asp151 of CD1d which contributed to the correct orientation of the 
sugar head.101, 102 It was postulated that introducing the fluorine substitution changed this H-
bonding network which negatively impacted on the polar group stabilisation, consistent with 
the lower affinity with the TCR and resulting TH2 cytokine bias. Replacing of the amide with 
sulfonamides, both aliphatic 147 and aromatic 148103 and a triazole 149104 have been shown 
to impart a TH2 cytokine bias.  
 
 
More recently, substitutions with thioamides 151 and 15287 and urea 153105 have been 
developed and shown to elicit a TH1 response. Thioamides have increased polarity and N–H 
acidity versus amides making them better hydrogen bond donors, while the sulfur atom 
functions as a weaker hydrogen bond acceptor. It was postulated that the thioamide would 
form a strong hydrogen bond with Thr156. It was subsequently shown however that while it 
induced a TH1 biased response, TCR binding affinity was actually weaker than the parent 
amide. This has shown that the correlation between TCR binding affinity for a CD1d−glycolipid 
complex and the measured cytokine profile is not the sole factor involved in determining a 
cytokine profile.106, 107 Researchers have attributed differences in cytokine response profiles 




to other factors, that have been attributed to altered cytokine profiles include different 
pharmacokinetics properties and ability to transactivate NK cells downstream of iNKT cell 
activation. For the latter however, thioamide 152 was shown to not transactivate NK cells, with 
the further studies needed to identify the factors involved in thioamide binding and activation.87      
 
 
3.7.4. Modifications to the glycosidic bond 
 
The glycosidic bond in -GalCer is susceptible to hydrolysis in vivo by glycosidases.-C–
GalCer 154, an analogue where the glycosidic oxygen is substituted with a methylene group, 
gives a TH1 cytokine bias. It has been proposed that this increase in concentration of IFN- 
compared to -GalCer is possibly due to prolonged stimulation times due to the increased 









3.7.5. Modifications to the Sugar head group 
 
As the sugar head group provides the most interactions with the TCR, modifications to this 
part of the glycolipid have been careful not to disrupt the H-bonding interactions formed by  
the hydroxyls at the 2, 3 and 4 positions of the ring.  Based on crystallographic information of 
the CD1d–-GalCer–TCR complex, (Figure 3.13. p 92) the 6’-OH is the only hydroxyl group, 
along with the ring oxygen, that is not involved in H-bonding to the TCR. Tashiro et al.109 
showed that a methoxy group at the 6 position 155 gives a TH1 response. This has been 
postulated to be due to the fact that the 6 position can no longer act as a H-bond donor, 





Nitrogen–substituted compounds at the 6 position with aryl amide 156 and urea 157 moieties 
have also been shown to give a TH1 biased response. – Stacking of the aromatic ring with 
the indole of Trp153 is postulated to contribute to the stability of these compounds in the 
CD1d–ligand–TCR complex.110  
 






3.7.6. Non-glycosidic –GalCer analogues   
 
As crystallographic information of the TCR–-GalCer–CD1d complex has shown, the ring 
oxygen or the 6′-OH is not involved in H-bonding to the TCR nor CD1d while the glycosidic 
oxygen is involved in H-bonding (to Thr154 on the 2 helix of hCD1d) it was envisioned that 
excising both groups would retain key interactions with the TCR and CD1d molecules but at 
the same time also exhibit increased metabolic stability. Threitol ceramide (ThrCer) 14 
contains an ether bond and is an acyclic analogue of -GalCer as it retains the key alcohols 
in the correct relative and absolute configuration that are required for the formation of the 
CD1d–Glycolipid–TCR complex. 14 should be similarly resistant to hydrolysis by -
galactosidases (as the molecule now contains an ether bond) as -C-GalCer 154. Due to the 
increase in entropic loss of the acyclic chain when bound in the ternary complex compared to 
–GalCer it was postulated that this analogue would not overstimulate iNKT cells, which leads 
to cell anergy, but also retain activity. This analogue has also been developed further by 
substituting a urea, thioamide and carbamate  at the amide position.87 These analogues were 
shown to have an IFN- bias although at a lower activity to that of -GalCer, although ThrCer 
was also seen to be less potent.111    
Due to the conformational flexibility of the ThrCer acyclic analogue further work within the 
group was done to develop carbocycles that contained the ʟ-threitol configuration within six-, 




seven- and eight- membered rings 158. The six and seven ring structures showed similar 
cytokine response profiles as -GalCer, thus incorporating ThrCer into a ring recovers 




3.8. Development of ThrCer-6 analogues 
 
The lead compound of our target analogues was ThrCer-6 16 which was previously developed 
within the group. Scheme 3.1. shows the development of ThrCer-6 from -GalCer progressing 
via ThrCer. Starting with -GalCer, removal of the ring oxygen, C-5 and C-6(OH) yields a polar 
head group based on tetrose L-threitol, which retains the same absolute and relative 
configuration at C-2 and C-3 as D-galactose. Previous studies had shown that ThrCer does 
not show any cytokine bias and is less biologically active than -GalCer but was still of 
potential therapeutic interest as it was shown to overcome the iNKT cell activation-induced 
anergy associated with α-GalCer.114 It was postulated that constraining the threitol sugar unit 
into a carbocycle would recover activity whilst retaining some of the attractive features of 
ThrCer.To this end, the sugar was incorporated into a carbocycle by the addition of two carbon 
atoms to yield ThrCer-6.  
In the case of -GalCer the galactose residue adopts a 4C1 chair conformation as a 
consequence of the anomeric effect and minimisation of unfavourable 1,3-diaxial interactions. 
As ThrCer-6 is not a sugar there is no anomeric stabilisation. Moreover, loss of the 




hydroxymethyl group further reduces the 1,3-diaxial interactions in the pseudo “1C4” chair 
conformation.  
It was therefore not obvious at the outset whether or not this molecule would adopt the pseudo 
“4C1” chair conformation required for effective TCR recognition and iNKT simulation. However, 
it was postulated that the two chair conformational isomers of ThrCer-6 would have similar 
energies. Providing the barrier to their interconversion was low, it was postulated that the low 
energy conformation was not important and binding to CD1d would ensure the required 
pseudo “1C4” conformation is adopted through an induced fit. Whilst these proposals have not 
been confirmed, ThrCer-6 exhibited greatly increased potency similar to and in some 
experiments, better than -GalCer. Moreover, it also led to a TH1 cytokine bias, similar to other 
carbocycles which restored biological activity and caused a TH1 bias similar to other 
carbocycles previously synthesised.113 













3.8.1. First Generation Synthesis of ThrCer-6 
 
The first-generation synthesis of ThrCer-6 involved the use of protected sulfamidate 162 as 
the electrophilic coupling partner. Alcohol 160 (which could itself be synthesised from 
phytosphingosine in four steps) was reacted with thionyl chloride in the presence of imidazole 
and Et3N in CH2Cl2 to form intermediate sulfamidite 161 which was further oxidised using 
ruthenium chloride and sodium periodate to sulfamidate 162 in 58% yield over the two steps 
(Scheme 3.2.). 
 
Scheme 3.2.  First generation of electrophilic phytosphingosine coupling partner 
 
Conduritol E based alcohol 163 was reacted with NaH in DMF at 0 °C followed by addition of 
sulfamidate 162 to yield the intermediate sodium salt 164. This was subsequently hydrolysed 
using 20% H2SO4 in Et2O to yield benzylamine 165 in 43% over two steps. Global deprotection 
under hydrogenation and acidic conditions followed by acylation with hexacosanoyl chloride 
in NaOAc (aq)/THF yielded ThrCer-6 16 in 33% yield over the three steps.  
The main problems associated with this route involved the protecting group on the nitrogen. 
Harsh conditions were required in the deprotection step when a benzyl group was used. Other 
groups on the nitrogen also proved problematic. When a boc protected sulfamidate was used 
using similar conditions to ring open the sulfamidate only loss of the Boc group was observed 
and a PMB group was similarly difficult to remove following ring-opening.  





Scheme 3.3.  First generation synthesis of ThrCer-6 16 
 
3.8.2. Target ThrCer-6 analogues 
 
As the first-generation synthesis of ThrCer-6 had previously involved a hydrogenolysis step to 
deprotect the benzylamine hydrogenation of the double bond was also effected. Compound 
166 which retains the double bond was of interest as structurally the inclusion of an alkene 
into the carbocycle increases rigidity of the ring along with forcing all the hydroxyl groups into 
a different in space. Testing of this molecule could be important in further elucidating new 
binding potentials of the next generation of glycolipids to the TCR.  
 While the factors that lead to TH1/TH2 biases (in either direction) are not fully understood, 
certain structural features, for whatever reason have been shown to lead to particular 
responses as seen by the range of analogues discussed in the introduction. Further skewing 
of the TH1/TH2 cytokine bias of ThrCer-6 was hoped through the use of alternative acyl chains 
which are known to elicit a more biased response. Thioamide analogues of -GalCer and 
ThrCer have previously been shown to elicit a more TH1 response, which we hoped might 
translate to compound 167.87 An -GalCer analogue possessing a truncated chain terminating 




with a para-fluorobenzyl group has also shown a more TH1 biased response; thus, compound 
169 was of interest.115 Finally compounds with a Z,Z eicosa-11,14-dienoic (C20:2) acyl chain 
have been shown to provide a skewed TH2 cytokine bias, leading to compound 168 as another 
target.96 
 




The retrosynthetic analysis for targets 16, 166, 167, 168 and 169 are summarised in Scheme 
3.4. Cleavage of the amide bond yields amine 171 and acid 173. Leaving the acylation to the 
final step is attractive as it allows late-stage incorporation of a range alternative acyl chains 
using a common advanced intermediate. Cleavage of amine 171 at the ether linkage 
separates the polar head group from the phytosphingosine-derived chain, yielding alcohol 
174, which is based on conduritol E, to act as the nucleophile and an electrophilic 
phytosphingosine coupling partner 175, in this case an activated aziridine. Ring opening of 
protected conduritol E 174 yields diene 176 which itself can be synthesised from commercially 
available (2R, 3R)-dimethyl 2,3-O-isopropylidene tartrate 177. The electrophilic 




phytosphingosine coupling partner 175, would be accessed from commercially available 
phytosphingosine 179 via standard functional group manipulations. 
 
Scheme 3.4.  Retrosynthetic analysis of ThrCer-6 analogues 
 
3.8.4. Aziridine Synthesis 
 
The first step in the synthesis of our target molecules involved the development of an 
electrophilic phytosphingosine coupling partner. It was postulated that an activated aziridine 
might prove more attractive. Whilst soft nucleophiles are more commonly used to ring-open 
aziridines, there is precedent for the use of oxygen nucleophiles.116-120 Indeed Tsunoda et al.121  
successfully reacted tosyl aziridine 180 with the sodium alkoxide of 114  to provide glycoside 
181 in 60% yield (Scheme 3.5.).  





Scheme 3.5.  Tsunoda et al. Ts-aziridine ring-opening using an oxygen nucleophile 
 
The cleavage of the tosyl amides generally requires harsh acidic conditions or reductive 
conditions.122-126 It was therefore proposed to synthesise the more reactive 4-
nitrobenzenesulfonyl 187 and 2-nitrobenzenesulfonyl 188 aziridines which would allow more 
facile deprotection.118  Using the acyl chain as an activating group in acyl aziridine 192 would 
allow direct incorporation of the desired acyl chain and reduce the number of steps to the final 
target.  
 
Scheme 3.6.  Synthesis of phytosphingosine based aziridine 186. 
 
Scheme 3.6. shows the synthesis of the unprotected aziridine 186 from phytosphingosine 179. 
Imidazole-1-sulfonyl azide hydrochloride 182 was used to convert the phytosphingosine 179 




to azide 183.127 Trifluoromethanesulfonyl azide (TfN3) had been used previously as the diazo 
donor; however, imidazole-1-sulfonyl azide hydrochloride is less explosive, shelf stable (as its 
crystalline hydrochloride salt) and therefore more attractive than TfN3 which needs to be 
prepared immediately before use.128, 129 The internal 1,2-diol of azide 183 was next protected 
as an 1,2-isopropylidene using acetone under acid catalysis. Acetonide 184 was obtained in 
63% yield following stirring of the reaction mixture for 2 days to promote the formation of the 
thermodynamic product. The remaining primary alcohol of acetonide 184 was then converted 
to the mesylate in quantitative yield.130 
  
Trimethylphosphosine is frequently used in the group for Staudinger reactions in place of 
triphenylphosphine which is most commonly used. Increased volatility of the phosphine and 
phosphine oxide by-product often removes the need for purification via column 
chromatography. For this reason, Me3P was first used to reduce the azide 185 to the 
intermediate amine which would undergo intramolecular substitution to afford aziridine 186. 
However, this reaction led to a complex mixture of products, which may have arose as a 
consequence of the elevated temperature which was required to effect aziridine formation. 
The same problems were not encountered with Ph3P. Trituration of the majority of the 
phosphine oxide with neat hexane, follow by purification by column chromatography provided 
aziridine 186 in 77% yield. While not isolated the uncyclized amine 187 was also observed. 
Reduction of the azide to the amine occurred rapidly with the rate limiting step being the 
intramolecular substitution. However, leaving the reaction longer or increasing the 
temperature did not increase the yield. Amine 187 proved difficult to separate from the 
aziridine at this stage but could be easily purified following reaction with the activating group. 
 





Scheme 3.7.  Synthesis of activated aziridines 
 
Acyl aziridine 190 was formed by reaction of aziridine 186 with the NHS ester of hexacosanoic 
acid 188, which was prepared from using EDCI.HCl and NHS in CH2Cl2 in excellent yield 
(Scheme 3.7.). Usefully NHS ester 188 could be stored in the fridge and used when required. 
Sulfonyl aziridines 191, 192 and 193 were synthesised in moderate to great yields using their 
respective sulfonyl chlorides in the presence of Et3N in THF (Scheme 3.7.).  
 
3.8.5. Ring opening- Trial studies with cyclohexanol 
 
With a series of activated aziridines in hand the next step was to study the ring opening using 
cyclohexanol as a model secondary alcohol (Scheme 3.8.). Starting with acyl aziridine 190, 
treatment of 2 equivalents of sodium cyclohexanoate failed to yield any of the desired ring 
opened product, instead yielding ester 195 and the recovery of aziridine 186 with the amide 




carbonyl group evidently proving to be more electrophilic than the aziridine resulting in 
transacylation. 
 Next, ring-opening was attempted on both nosyl aziridines 191 and 192 to examine the effect 
of the position of the nitro group on reactivity. Once again, however, the desired ring-opened 
product was not obtained. This time, the major products arose from SNAr reaction of 
cyclohexanoate at the nitro carbon and the sulfone carbon leading to aryl ether products 196 
and 197 respectively. Loudon and Shulman reported SNAr substitution of the nitro and a 
sulfone can be achieved using a sodium alkoxide.131 Varying the reaction temperature, 
reaction stoichiometry and solvent led to no improvement. A similar distribution of products 
was observed when two and 1.25 equiv. of the sodium alkoxide were used at rt and at 40 °C. 
Use of THF at rt afforded aryl ether 196 as the major product, whilst in DMF, no reaction was 
observed at 0 °C even in the presence of four equiv. of the sodium alkoxide. Finally, tosyl 
aziridine 198 did provide the desired product in quantitative yield.  
 
Scheme 3.8. Attempts at ring-opening Nosyl, Acyl, and Tosyl aziridine with cyclohexanol as 
a model cyclitol 
 




3.8.6. Attempts at detosylation of sulfonamide (198)  
 
Following successful ring-opening of aziridine 193 by sodium cyclohexanoate, different 
reaction conditions were examined to effect detosylation. While the use of HBr led to complex 
mixture of products, sodium naphthelanide proved more promising. The desired amine was 
observed; however, the large excess of naphthalene hampered purification and amine was 
isolated in only poor yield. This reaction also proved difficult to replicate. Finally, successful 
removal of the tosyl group was achieved by conversion to the boc carbamate 200. Nyasse et 
al. showed that detosylation proceeded readily using solid magnesium powder in methanol 
with sonication to provide the corresponding Boc amides.132 Gratifyingly, carbamate 200 was 
isolated in quantitative yield over the two steps. Boc protection was not deemed a problem as 
it was envisaged this group would be removed in the global deprotection step. 
 
Scheme 3.9. Detosylation of sulfonamide 198  
 
3.8.7. Synthesis of TBDMS conduritol E (163)  
 
The cyclohexanol coupling partner 163, was synthesised using a modified route to what had 
been developed previously in the group (Scheme 3.12). Previously, DIBALH reduction of 




tartrate-derived di-ester 177, followed by in-situ reaction of the bis-aldehyde intermediate with 
vinyl magnesium bromide provided diene 176 as an inseparable 3:1 mixture of 
diastereoisomers (desired product was major diastereoisomer). Competing-reduction of the 
intermediate aldehyde was a problem in this reaction. Seeking to improve on this reaction, 
divinylzinc was used as Jørgensen et al. had reported enhanced diastereoselectivity.133 
Though not commercially available, divinyl zinc can be synthesised by reaction of vinyl 
magnesium bromide with ZnCl2 via transmetallation.134 Due to the hygroscopic nature of ZnCl2, 
care had to be taken when fusing under vacuum, a Schlenk flask allowed the addition of THF 
to be made in an Argon atmosphere to give a solution of ZnCl2 in THF which was then heated 
with vinyl magnesium bromide for 4 h. Cooling of the reaction mixture led to precipitation of 
Mg salts which were allowed to settle and the supernatant containing the newly formed divinyl 
zinc was filter cannulated directly into the reaction mixture of the DIBALH reduction. Indeed, 
the diastereoselectivity was improved to 5:1 and less over-reduction was observed (Scheme 
3.12.).  
 
Scheme 3.10.   Synthesis of TBDMS-protected conduritol E 
 
Scheme 3.11 shows the potential products of the Barbier reaction, both diol 176 and diol 204 
are symmetrical and diol 206 and diol 208 are equivalent. While the products were inseparable 




at the vinyl alcohol stage, following ring-closing metathesis the major product was isolated 
pure. Confirmation that the major product was the desired was done using both NMR and 
optical rotation. As the 1H NMR confirmed a symmetric molecule, conduritol F 207 as the major 
product was eliminated. Elimination of (–) conduritol B 205 was done by comparison of 
previously published NMR shift values and further confirmed following a positively signed 
optical rotation measurement4 was obtained indicating (+) conduritol E.135, 136 
 
 
Scheme 3.11. Potential for synthesis of a range of diols following Barbier reaction 
leading to different conduritols after ring-closing metathesis 
 
While no difference could be measured for the J coupling values, the difference in shift values 
for key atoms can be used to identify the correct isomer. Tables 3.2 and 3.3 compare the 1H 
and 13C spectra of (–) conduritol B 205 and (+) conduritol E 202 along with the data obtained 
from my synthesis of (+) conduritol E 202. While (–) conduritol B 205 has only been 
                                               
4 []D20 = +304.0 (c = 1.0, CHCl3) obtained, lit.133 (+) conduritol E []D25 = +338.6 (c = 0.7, CHCl3). 




synthesised by Yong-Uk Kwon et. al.137  (+) conduritol E has been synthesised by three groups 
whose data is similar and confirms the chemical shift differences.136, 138, 139  
1H 
(–) conduritol B 205 
(Published) 
(+) conduritol E 202 
(Published) 
(+) conduritol E 202 (Mine) 
1.47 (6H, s) 1.48 (6H, s) 1.48 (6H, s) 
2.74 (2H, br ,s) 2.63 (2H, br s) 2.70 (2H, br s) 
3.55 (2H, dd, J 5.6, 2.3) 3.94 (2H, dd, J 1.9, 1.3) 3.88–3.95 (2H, m) 
4.50 (2H, dd, J 5.6, 2.3) 4.49 (2H, br d) 4.53 (2H, app. s) 
5.69 (2H, s) 5.98 (2H, dd, J 3.2, 1.5) 5.98 (2H, m) 
 
Table 3.2  Compares the 1H spectra highlighting a key difference, data shown for 
published (+) conduritol E from ref 139 
13C 
(–) conduritol B 205 
(Published) 
(+) conduritol E 202 
(Published) 
(+) conduritol E 202 (Mine) 
27.4 (CH3) 25.9 (CH3) 26.9 (CH3) 
71.1 (CH) 63.7 (CH) 64.8(CH) 
81.1 (CH) 72.4 (CH) 73.4 (CH) 
111.7 (C) 109.5 (C) 110.5 (C) 
130.9 (CH) 129.4 (CH) 130.4 (CH) 
 
Table 3.3  Comparing the 13C spectra, higlighting the key differences, data shown for 
published (+) conduritol E from ref 139 
The stereochemical outcome can be rationalised under the predictions of the Felkin-Anh 
model (Scheme 3.12.).133, 140  





Scheme 3.12.   Felkin-Anh model predicts formation of diol 176 
 
Next, ring-closing metathesis of diene 176 using Grubbs’ second-generation catalyst yielded 
the corresponding cyclohexene as a mixture of diastereoisomers, which were now readily 
separable. Monosilyletherification of diol 202 using TBDMSCl in the presence of Et3N provided 
silyl ether 163 in 58%.  The bis-silylated and unreacted starting were both readily isolated and 
could be recycled (Scheme 3.12.).  
 
3.8.8. Synthesis of carbamate intermediate (211) via Ts-aziridine ring-opening 
as a precursor to target (166) 
 
Turning our attention to alcohol 163, we found that it was not necessary to employ a two-fold 
excess of substrate as had previously been used during the model ring-opening experiements, 
when following the conditions used by Tsunoda et al.121 ; thus, regioselective ring-opening of 
aziridine 193 with equimolar quantities of the sodium alkoxide of 163 yielded sulfonamide 209 
in 58%. Detosylation of sulfonamide 209 to carbamate 211 was achieved in 86% yield by 
employing the two-step method developed by Nyasse et al. Initial Boc protection proceeded 
in quantitative yield using Boc2O in the presence of DMAP to yield intermediate carbamate 
210 which was next reacted with magnesium metal in methanol under sonication for 30 min 
to yield carbamate 211 in 86% yield. Treatment of 211 with TFA effected global deprotection 
of the protecting groups in a single step to provide amine 212, which, without purification, 




underwent acylation using the NHS ester of hexacosanoic acid 189 to yield our first target 166 
in 62% yield over two steps (Scheme 3.13.).   
 
Scheme 3.13.  Synthesis of target alkene 166. 
 
3.8.9. Synthesis of ThrCer-6 (16) and C20:2 (168) compounds 
 
In order to complete the synthesis of the three remaining target molecules, 167, 168 and 169, 
the cyclohexene needed to be reduced. Hydrogenation of alkene 211 was effected using H2 
and Pd/C in the presence of a stoichiometric amount of Hünig’s base, which prevented the 
premature acid-catalysed hydrolysis of the acetonide protecting groups. Subsequent global 
deprotection of the protecting groups provided ammonium trfilate 214, from which amides 16 




and 168 were accessed uneventfully by acylation with the corresponding NHS esters of (Z, 
Z)-eicosa-11, 14-dienoic acid 215 and hexacosanoic acid 189, respectively.  
 
Scheme 3.14.  Synthesis of ThrCer-6 (16) and C20:2 (168)  
 
3.8.10. Synthesis of thioamide (167) 
 
Formation of thioamide 167 was accomplished in a three-step sequence from amide 16. Thus, 
peracetylation with acetic anhydride in pyridine afforded pentacetate 216, which reacted 
selectively with Lawesson’s reagent to provide thioamide 217 in 94% yield. Deacetylation 
under Zemplén conditions afforded, thioamide 167 in 74% yield.  
 





Scheme 3.15.  Synthesis of thioamide 167 
 
 
3.8.11. Synthesis of amide target (169) via acylation with acid (221) 
 
Synthesis of our final target, namely amide 169, required acylation of ammonium 214 with an 
appropriate activated acid.  Previously within the group, aryl acid 221 was synthesised using 
a cross-metathesis between 1-allyl-4-fluorobenzene and dec-9-enoic acid using Grubbs’ 
second-generation catalyst. However, competing homo-coupling of the allyl benzene (the 
homodimer was not a substrate for desired cross-metathesis) led to a poor yield of the desired 
acid.  Moreover, separating the cross-metathesis acid product from the starting alkenyl acid 
proved difficult and compounded the problem. An alternative route summarised in Scheme 
3.16. was more successful.  





Scheme 3.16.   Synthesis of amide 169 via acylation with acid 221 
 
 Acid 221 was synthesised in two steps via a Sonagashira cross-coupling reaction between 
alkyne 218 and 4-fluoroiodobenzene 219. Alkyne 220 was obtained in 79% yield with full 
conversion of the acid starting material 218 (facilitating purification). Subsequent 
hydrogenation of the alkyne using H2/Pd/C in methanol furnished the acid in quantitative yield.  
Reaction of the corresponding acid chloride generated using oxalyl chloride with ammonium 









3.9. Biological evalutation of target ThrCer-6 analogues 
 
iNKT cells are activated to induce an immunological response following binding with CD1d 
cell-surface protein in the presence of a suitable glycolipid, which is necessary for formation 
of the CD1d–ligand–TCR interaction. While -GalCer 10 has been used as the prototypical 
model glycolipid due to its potency, it induces a mixed TH1/TH2 cytokine response; however, 
it has been shown that altering the ligand can bias the cytokine profile to produce a potentially 
more therapeutically useful immune response. Using ThrCer-6 16 as the starting point and 
reference, four analogues were synthesised, three (167, 168 and 169) containing 
modifications of the acyl chain, which are known to induce a biased cytokine response and 
one (166) with a conduritol polar head group. 
A first set of experiments were performed by Dr Hemza Ghadbane, a member of Prof. 
Vincenzo Cerundolo’s group at the Weatherall Institute of Molecular Medicine in Oxford, UK. 
The compounds were tested for in vivo activation of iNKT cells using C57 BL/6 WT and 
CD1d−/− mice. The mice were injected intravenously with lipids at concentrations ranging from 
0.06 ng/ml to 1000 ng/ml (n=3 at each concentration for each compound tested) and after 48 
h, blood serum was taken. The presence of IFN- was then determined by enzyme-linked 
immunosorbent assay (ELISA).114 The results of these experiments are summarised in Figure 
3.15. Starting with the conduritol analogue 166, at lower concentrations of 0.2, 1.1, 4 and 15 
ng/ml a greater IFN- response is produced compared to that stimulated by the parent -
GalCer, compound 10 (P<0.05 at each concentration). An increase in IFN- was also produced 
by compound 166 at 15 ng/ml compared to parent compound ThrCer-6, compound 16 
(P<0.05). However, at higher concentrations, 1000 ng/ml and 250 ng/ml, both ThrCer-6 16 
and -GalCer 10 produce a stronger IFN- response compared to all other compounds, 166, 
167, 168 and 169 (P<0.05). Further study is needed to determine the mode of binding. The 
three other analogues, 167, 168 and 169, produced a weaker IFN- response than both 
ThrCer-6 16 and -GalCer 10 at all concentrations. The C20:2 analogue 168 in particular 




showed a weaker response at higher concentrations, 1000ng/ml and 250/ng/ml compared to 
-GalCer 10 (P<0.05 at each concentration) and at all concentrations compared to ThrCer-6 
16 (P<0.05 at each concentration). This may be due to the known ability of glycolipids 
incorporating a C20:2 acyl chain to induce a TH2 response, however, it would be necessary to 
measure the IL-4 response to confirm any TH2 cytokine bias. Data were analysed by two-way 
ANOVA to compare treatment groups, followed by a Dunnett’s multiple comparison test to 
identify differences compared to untreated controls. Differences were considered statistically 
significant at P<0.05.  The fact that no activity is seen when CD1d-deficient mice were used 
confirms that the observed bioactivity of the glycolipids is CD1d-dependent.  
 
 





Figure 3.15. IFN- response of synthesised compounds in splenocytes of (A) C57 
BL/6 WT mice (n=3 for each compound at each concentration) (B) 
CD1d-/- mice (n=3 for each compound at each concentration). Data 
presented as mean  S.E.M (error bars). (C) Structures of glycolipids 
tested.  
 
In a further set of experiments,141 which were carried out by Shalu Sharma, a member of Prof 
Steven A. Porcelli’s group at the Albert Einstein College of Medicine in New York, US, the 




same set of compounds were incubated with human HeLa cells transfected with human CD1d 
in concentrations ranging from 1–100 nM.  After 18 hours, the cells were washed and exposed 
to cultured iNKT cells (human clone HDD3).  Supernatants were collected after 24 hours, and 
the levels of IFN- were measured by ELISA.  All five compounds were highly stimulatory to 
iNKT cells.5 The results of these experiments are summarised in Figure 3.16. At all 
concentrations, a stronger IFN- response is seen from all of the cyclitol-based glycolipids 
compared to that of the galactose-based control compounds. At concentrations of 100, 10 and 
1 nM, compounds 166 and 167 resulted in an increase in IFN- (P<0.005, Figure 3.16). 
Treatment with compound 168 increased concentration of IFN- at 10 and 1 nM (P<0.05, 
Figure 3.16).  Treatment with compound 169 increased IFN- at 100 and 10 nM (P<0.05, 
Figure 3.16). There was no change in IFN- concentration from treatment with compounds 
169, KRN7000 and 7DW85.  Data were analysed by two-way ANOVA to compare treatment 
groups, followed by a Dunnett’s multiple comparison test to identify differences compared to 
untreated controls. Differences were considered statistically significant at P<0.05.  The 
conduritol analogue 166 once again proved to be the most active, showing a two-fold stronger 
cytokine response over -GalCer 10 (KRN7000) at 100 nM concentration.  
                                               
5 The positive controls for comparison are KRN7000 (-GalCer 10), and another potent analogue 
7DW8-5 (C11 p-fluoro analogue of -GalCer 144).  





Figure 3.16. IFN- response of synthesised compounds using hCD1d and HDD3   
human clone iNKT cells (in vitro study). For each compound tested at 
each concentration n=5.  Data presented as mean concentration ± 
S.E.M (error bars). *, p<0.05. (2way ANOVA with multiple comparison 
tests).  
 
To determine the cytokine bias, the ratio of IFN-:IL-4 now needs to be measured; however, 
these preliminary experiments reveal that this set of compounds activate iNKT cells in a CD1d-
dependent manner, producing varying levels of IFN- and in some cases, a stronger response 








































































3.10. Synthesis of ThrCer analogues at the pseudo-anomeric linkage 
 
Following on with the development of analogues with a TH1/TH2 skewing bias, we decided to 
develop analogues with alternative atoms at the pseudo-glycosidic linkage of ThrCer. The 
potential to generate ThrCer analogues that not only induce a biased response but also a 
more potent response was desirable.  
Previously synthesised analogues of -GalCer which contain alternative atoms at the 
glycosidic linkage have shown to have varying cytokine profiles (Figure 3.17). Of these -C-
GalCer 154 is the most studied, it has shown to be more potent than -GalCer in some tests 
and induces a TH1 biased cytokine profile.142, 143 The thio analogue of -GalCer, -S-GalCer 
223 has also been synthesised with more studied needed on its mode of binding as it has 
been shown to not activate the murine iNKT cells both in vitro and in vivo, but stimulated 
human iNKT cells in vitro.144 Finally, only one synthesis of the amino analogue -N-GalCer 
224 has been published but there has been no biological testing data published on the 
molecule145 However, the non-glycosidic amino analogue 225 has been shown to induce a 
TH1 biased respone.146, 147  
 
 
Figure 3.17 Analogues of -GalCer with alternative atoms at the glycosidic linkage 
 




Through the use of the previously developed activated aziridines as electrophilic 
phytosphingosine coupling partners we targeted ThrCer 14 and three analogues N-ThrCer 
227, S-ThrCer 226 and C-ThrCer 228.  
 
 
Figure 3.18  ThrCer and three analogues S-ThrCer, N-ThrCer and C-ThrCer 
 
 
3.10.1.   Retrosynthesis 
 
A retrosynthetic analysis of these molecules is shown in Scheme 3.17 and follows a similar 
pattern to that of the ThrCer-6 analogues. Cleavage of the amide bond yields amine 231 and 
activated carboxylic acid 232. Further disconnection of amine 231 would yield the activated 
aziridine 175, which can be synthesised from phytosphingosine 179, and a threitol-based 
nucleophile 233, which can be synthesised from commercially available (+)-2,3-O-
Isopropylidene-L-threitol 234. 
 





Scheme 3.17.   Retrosynthetic analysis of ThrCer and its analogues. 
 
3.10.2. Synthesis of ThrCer via aziridine ring-opening 
 
The synthesis of the parent molecule, ThrCer 14, began with (+)-2,3-O-Isopropylidene-L-
threitol 234 which was protected as its monobenzyl ether 235 in 76% yield following reaction 
with NaH and BnBr. The small amount of debenzylated product was readily separated from 
the desired product by column chromatography. Next, ring-opening of tosyl aziridine 193 by 
the sodium alkoxide of benzyl ether 235 was achieved using the same conditions as had been 
developed for the protected conduritol E analogue 163, in the synthesis sulfonamide 209.  In 
this instance tosyl amide 236 was achieved in 64% yield. Conversion of the resulting tosyl 
amide 236 to its Boc carbamate 238 was achieved in 65% over two steps: sulfonamide 236 
was first reacted with Boc2O to yield the sulfonamide carbamate 237, which underwent facile 
detosylation by reaction with magnesium metal in MeOH under sonication to yield Boc 
carbamate 238. Global deprotection was then achieved by first removing the benzyl group 




using by hydrogenolysis, which afforded alcohol 239 in 79%. Alcohol 239 was then treated 
with neat TFA to remove the Boc carbamate and acetal protecting groups. The resulting 
ammonium salt 240 was treated directly with C26 NHS ester 189 in the presence of Et3N to 
yield the first target ThrCer 14 in 62% over two steps (Scheme 3.18.).  
 
 
Scheme 3.18.  Synthesis of ThrCer via  aziridine ring-opening 
 




A published syntheses of ThrCer has previously been done within the group.148 Alcohol 241 
was used as a nucleophilic phytosphingosine coupling partner in reaction with threitol triflate 
242 in a Williamson etherification. Our synthesis is comparable in overall yield at 15% over 7 
steps in comparison to 16% over 6 steps. However, our aziridine synthesis is much more 
amenable to scale up, especially with regards the coupling reaction as no large by-products 
such as the triflate are formed. With regards the synthesis of the other targets, an electrophilic 
phytosphingosine coupling partner is much more desirable due to shorter synthetic sequences 
required for the threitol analogues 
 
 
Scheme 3.19.  Key coupling step of published synthesis of ThrCer 
 
3.10.3. Attempted synthesis of N-ThrCer  
 
To access the next target, amino-substituted N-ThrCer, it was necessary to introduce an 
amine into the threitol nucleophilic coupling partner. Starting with alcohol 235, tosylation under 
standard conditions, followed by azide displacement yielded azide 245 in 63% yield over the 
two steps. Selective reduction of the azide using hydrogenation conditions, afforded amine 
246 in 67% yield. Potential hydrogenolysis of the benzyl ether was avoided by conducting the 
hydrogenolysis for a short reaction time. Using hydrogenation rather than a Staudinger 
reaction to reduce the azide facilitated the work up and purification of the amine product 
(Scheme 3.20). 






Scheme 3.20.   Conversion of alcohol 235 to amine 246 
 
Llebaria had reported that amines could be used to effect the ring opening of a 
phytosphingosine-based acyl aziridine in the presence of lithium perchlorate.149 However in 
our hands were unable  to replicate their results, and instead isolated amide 248, resulting 
from transamidation, as the major product (Scheme 3.21). The length of the acyl chain may 
have been a factor as the acyl aziridine used by Alcaide and Llebaria was only 8 carbons in 
length versus our 26 carbon chain and we have previously seen the effects of the 
hexacosanoyl chain on solubility in organic solvents. Reaction of the LiClO4 and acyl aziridine 
190 was required for 30 min prior to addition of the amine. The poor solubility may have 
affected the reaction of the Lewis acid with the aziridine. The amine then reacted with the 
unactivated acyl aziridine at the carbonyl carbon as the most electrophilic site to give amide 
248 as the desired product 
 





Scheme 3.21.   Attempted ring opening of aziridine 190 with amine 246 
 
Harrak et al. have previously shown that nosyl aziridines can be ring-opened by both primary 
and secondary amines substrates.130, 146 Using their conditions, we were able to successfully 
ring-open nosyl aziridine 192 in 65% yield following stirring with nosyl amide 249 in MeCN. 
Next removal of the nosyl group was achieved in excellent yield of 86% using PhSH and 
CsCO3.  
With amine 250 in hand we next attempted to selectively acylate at the primary amine, for 
which there was precedent from the work of Harrak et al.146 The benefit of the attempted use 
of the acyl aziridine can be seen here with the route being more efficient, if ring-opening had 
been successful the acyl chain would be previously installed. With limited material available, 
a small scale reaction of diamine 250 with NHS ester 189 afforded a less polar product, which 
was fully deprotected using TFA followed by hydrogenolysis of the benzyl ether to yield a final 
product. 
Mass spectrometry data of this product revealed that monoacylation had occurred. However 
owing to the small quantities of material we were working with, we were unable to confirm the 
selectivity of the acylation step (Scheme 3.22.). 
 





Scheme 3.22.   Attempted synthesis of N-ThrCer 227 
 
3.10.4. Attempted synthesis of S-ThrCer  
 
Using the previously synthesised tosylate 244, nucleophilic substitution using thioacetic acid 
in the presence of Cs2CO3 yielded thioacetate 253 in excellent yield. Due to the potential for 
thiols to undergo oxidative dimerisation we elected not to isolate the thiol but rather to 
deprotect the thioacetate 253 using 2 equivalents of NaOMe and use the thiolate directly in a 
ring-opening of aziridine 193. This strategy proved successful and sulfide 255 was isolated in 
68%. While these conditions were not extended to nosyl aziridine 191 or 192, an attempt at 
ring-opening the acyl aziridine 190 was made; however, this reaction proved unsuccessful 
even with a longer reaction time and increased temperature. Boc protection of tosyl amide 255 




followed by detosylation using Mg metal with sonication, afforded carbamate 256 in 70% yield 
over two steps (Scheme 3.23). 
 
 
Scheme 3.23.   Synthesis of carbamate 256  
 
After removal of the acetal and Boc protecting groups using neat TFA, acylation using NHS 
ester 189 in the presence of Et3N yielded amide 258 in 47% over the two steps. All that 
remained was removal of the benzyl ether protecting group. Since sulphides are known to act 
as poisons for the Pd and Pt catalysts that are commonly used to effect hydrogenolysis of 
benzyl ethers, we chose to employ a Birch reduction instead. Unfortunately, and despite 
literature precedent, dissolving metal reduction led to complex mixture of products from which 
we were unable to isolate the desired product.150, 151 Time prevented us from exploring 
alternative conditions (Scheme 3.24).   
 
 





Scheme 3.24 Attempted synthesis of S-ThrCer 
 
3.10.5. Studies towards the synthesis of C-ThrCer 
 
The synthesis of C-ThrCer required a carbon nucleophile analogue of threitol. Using a 1,3 
dithiane would allow us to introduce one carbon, while the umpolung nature would allow us to 
deprotonate the carbon to act as a nucluophile. We postulated that a double alkylation of 1,3 
dithiane would allow us to unite the threitol and phytosphingosine units.1,3 Dithianes have 
been shown to react with epoxides, sulfamidates and carbonyls, fortunately they have also 
been shown to react with aziridines.152, 153 Precedent was also found for the synthesis of 
protected threitol 1,3 dithiane 261 via displacement of an iodide.154 This approach would also 
potentially allow us to access other analogues. Whilst Ra-Ni would be used to effect 
desulfurisation to provide our target molecule, C-ThrCer 228, dithioacetal hydrolysis would 
provide a keto analogue 263, which could undergo difluorination using DAST to provide a CF2 
analogue 264, which is arguable even more attractive.  





Scheme 3.25.  Retrosynthesis of C-ThrCer  
 
 Conversion of alcohol 235 to iodide 265 was achieved using PPh3 and imidazole in the 
presence of I2, to yield the desired product in 97%. This primary alkyl iodide 265 proved to be 
stable and could be stored at –4 °C for at least 6 months without noticing (significant) 
decomposition. Following conditions used by Enders et al., reaction of iodide 265 with 2-lithio-
2-TMS-1,3 dithiane in the presence of HMPA in THF yielded a mixture of dithiane products, 
TMS-dithiane 266 in 52% yield and dithiane 267 in 18% yield. TMS-dithiane 266 was 
deprotected to afford dithiane 267 in quantitative yield using TBAF. 2-Lithio-1,3 dithiane was 
also used as the nucleophile in a reaction with iodide 265 but provided lower yield (39%) of 
the desired dithiane 267. Thus a solution of dithiane 267 in THF:HMPA at – 78 °C was treated 
with t-BuLi. After 15 min, aziridine 193 was added, however no reaction was seen and both 
starting materials were recovered in quantitative yield. The reaction was repeated using n-
BuLi as the base and by performing the reaction at higher temperatures (up to –30 °C) but still 
no reaction was observed (Scheme 3.26.). 





Scheme 3.26. Attempted synthesis of dithiane 268 via ring-opening of aziridine 193 
with dithian 267. 
 
To investigate whether unreactivity of the aziridine or the nucleophilicity of the alkyl dithiane 
were the problem with the lack of product formation, we tested the ring opening of Ts-aziridine 
193 with 2-lithio-2-TMS-1,3-dithiane. The desired ring-opened product, phytosphingosine 
TMS-dithiane 269 was isolated in 56% yield; however, the reaction was noticeably sluggish, 
even at –30 °C, required an excess of 2-lithio-2-TMS-1,3-dithiane and the reaction mixture still 
contained starting material after reacting for 24 h. The reaction was also performed in the 
presence of HMPA as a co-solvent; however, whilst this change led to full consumption of 
starting material, a complex mixture of products was observed. These observations suggest 
inclusion of HMPA is detrimental for the ring-opening of the aziridine coupling partner. 
Deprotection of TMS-dithiane 269 was achieved using TBAF to yield dithiane 270 in 87% yield 
(Scheme 3.27.).  
 





Scheme 3.27.  Ring-opening of aziridine 193 with 2-lithio-2-TMS-1,3-dithiane. 
 
 
3.10.6. Future Work 
 
These studies were performed on small quantities of material and time constraints prevented 
further optimisation. Future work on the synthesis of N-ThrCer 227 would involve repeating 
the synthetic sequence in order to bring through enough material to elucidate the position of 
the C26 acyl chain in the final molecule. If it transpired that the acyl chain has reacted on the 
secondary amine, an alternative approach will be required. Another potential route to N-ThrCer 
could be to first convert amine 246 to a secondary amine such as a PMB amine, providing this 
amine is able to ring-open the Ns-aziridine 192, the selective acylation should not present a 
problem. Moreover, PMB group might also undergo deprotection along with the acetal groups 
under acidic conditions, if not a dimethoxy benzyl protecting group could be used (Scheme 
3.28.). 
 





Scheme 3.28.  Potential alternative route to N-ThrCer. 
 
Due to the difficulty in removing the benzyl group in the final step of the S-ThrCer synthesis 
the use of an alternative protecting group such as a TBDPS group could be used. Removal of 
the silyl ether could then be achieved using TBAF (Scheme 3.29.). A previous co-worker has 
investigated the use of a TBDPS-protected threitol 275 in the ring-opening of Ts-aziridine 193. 
In this case, the reaction led to a complex mix of products. However, this may not be an issue 
under the milder conditions needed for the ring-opening reaction using the thiolate.  
 
 
Scheme 3.29. Using a silyl protecting group on S-ThrCer precursor would allow for 
selective deprotection conditions to the desired thioether product 226. 
 
As HMPA has proven detrimental when used as a co-solvent in the ring-opening reaction with 
our Ts-aziridine 193, attempts to retry the ring-opening with threitol dithiane 267 without HMPA 




present. If the reaction still does not proceed, we can turn our attention to phytosphingosine 
dithiane 270 as we have seen the efficacy of iodide 265 to displacement by a lithio-dithiane  
 
 
Scheme 3.30. Potential route to dithiane 268 using an electrophilic threitol coupling 
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4. Synthesis of glycolipid and ceramide analogues incorporating a 
novel acyl chain with a terminal photoreactive group 
4.1. Introduction 
 
Incorporating covalent ligands such as fluorophores and cross-linkers into biological systems 
has been key to furthering our understanding of key processes and pathways. Singh et al. first 
introduced the concept of photoaffinity labelling (PAL) in 1962.155 PAL involves the use of a 
ligand which has been modified to contain a photoreactive group (PhG). Following irradiation 
of the photoreactive group at a certain wavelength, a reactive species is formed which reacts 
with molecules in close proximity. In this way, a ligand can be covalently bound to a protein or 
other biomolecule with which it is interacting. There are three major types of PhG that have 
been used in photoaffinity labelling. These include benzophenones 277, arylazides 278, and 
diazirines 279 (Figure 4.1.). The use of a particular PhG is based on certain criteria. Following 
introduction of the PhG, the modified ligand should still structurally resemble and behave like 
the starting ligand in order that it binds similarly. The PhG should have an activation 
wavelength which does not affect other parts of the system under study. While arylazides can 
be prepared easily, the short wavelength (250–350 nm) needed to effect photo-activation can 
cause significant damage to the protein. Diazirines are the smallest PhG and are activated 
upon irradiation at a wavelength of 350–380 nm, which is generally not harmful for biological 
systems. They are however more difficult to synthesise. Benzophenones are also activated 
with light of a wavelength around 350–360 nm. Moreover, they are a relatively robust 
functionality, stable in most organic solvents and can be incorporated readily into a synthetic 
sequence. However, the benzophenone group is sterically bulky compared to arylazides and 
diazirines and the need for longer irradiation times can lead to non-specific binding and 
potentially damage to the biomolecules under study.156-159 
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Figure 4.1. Benzophenones, arylazides, and diazirines as photoreactive functional 
groups  
 
Following irradiation, the benzophenone group generates a reactive triplet carbonyl state 280 
This is achieved by intersystem crossing from an n→* singlet excited state to an energetically 
similar  →* triplet state which quickly decays to the lower energy n→* triplet excited state. 
The oxygen, which now has an unpaired electron acts as a radical and can abstract a proton 
from the neighbouring receptor, to yield a receptor radical 282 and alcohol radical 283 which 
can form a covalent bond to yield the crosslinked compound 284 (Scheme 4.1.)160  
 
 
Scheme 4.1. Bioconjugation of the benzophenone functional group 
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Previous work within the group involved the synthesis of a series of -GalCer analogues 285–
292 (Figure 4.2.) which contained an acyl chain of differing lengths, terminating with a 
benzophenone group. As the hydrophobic tails of the glycolipid bind in the A′ and F′ pockets 
of CD1d, it was postulated that the benzophenone acyl chains would fit in the A′ pocket with 
the potential of the benzophenone group to cross-link with the protein to form a 
glycolipid/protein covalent complex. Because of the non-covalent nature of the interaction 
between the glycolipid and the CD1d protein, the glycolipid–protein complex is not stable and 
dissociation of the latter as well as displacement of the glycolipid by natural inhibitors in vivo, 
is very likely and results in loss of activity. A covalent interaction between the two is desired 
in order to create a long-lived CD1d protein/ glycolipid complex, hence increasing its stability 
and maintaining potent iNKT-cell activating properties 
All compounds were shown to activate iNKT cells in a CD1d-dependent manner and of these 
compound 290 (C11:BP) showed the highest potency as the free molecule. 
 
 
Figure 4.2.  Range of benzophenone containing -GalCer analogues 
 
 
The benzophenone containing series has been shown to form stable covalent adducts. Figure 
4.3. shows the difference in optical density before and after a wash both pre- and post 
exposure to the activating wavelength. As seen using optical density (OD), prior to activation 
of the benzophenone, the compounds are bound until a wash is done. However, post-
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irradiation there is no reduction in OD, indicating formation of a covalent bond (n=3). Work is 
currently ongoing to determine the exact site of formation of the covalent bond.  
 
Figure 4.3. Following UV irradiation, no change in OD after wash. Both non-covalent and 
covalent complexes of the galactosyl ceramides with CD1d were coated on 
high binding plates and washed intermittently to allow dissociation of the lipids. 
Complexes bound to the plate were detected using L363 anitbody 
 
Using C11:BP 290 as the model we envisioned the synthesis of its analogue 293 which did 
not contain an oxygen atom in the acyl chain and to test whether the substitution of the oxygen 
to a carbon had an effect on activity. While the ether linkage was initially chosen due to the 
synthetic ease, introducing an oxygen to the chain decreases hydrophobicity, which may alter 
binding within the hydrophobic pocket of CD1d. Formation of a more hydrophobic tether which 
should more closely resembles the all carbon acyl chain in -GalCer would therefore be a 
better model. To this end, reaction of acid 294 with amine 295 would deliver our target 
molecule, glycolipid 293 
 
Figure 4.4.  Glycolipid 293 formed by reaction of acid 294 with amine 295 
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4.2. Retrosynthesis of acid (294) 
 
Retrosynthetic analysis of acid 294 alongside a comparison with the original acid 296 used in 
the synthesis of glycolipid 290 is shown in Scheme 4.2. The original acid can be cleaved at 
the benzylic ether to give 11-bromo undecanoic acid 297, which is commercially available, 
alcohol 298 which was synthesised from commercially available 3-methylbenzophenone in 
two steps. The acid 294 used for the new compound would need to be thirteen carbons in 
length to match the thirteen-atom chain of acid 296. Introduction of an alkyne (300) would 
open up a disconnection to provide alkyne 301 and a 3-halobenzophenone 302, which could 
be coupled under Sonagashira conditions. While 3-iodobenzophenone would be likely the 
more reactive starting material we chose to use 3-bromobenzophenone which is cheaper and 
commercially available. Alkyne 301 would be synthesised from 11-bromoundecanoic acid 303 
via an alkynylation.  
        
Scheme 4.2.  Retrosynthetic analysis of acid 294 and acid 296. 
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4.3. Synthesis of carboxylic acid (294) 
 
Reaction of lithium (TMS)acetylide with 11-bromoundecanoic acid at –30 °C in THF:HMPA 
yielded TMS-alkyne 304 in 88% yield and terminal alkyne 301 after treatment with TBAF. 
Attempts to form alkyne 301 directly using 2.5 equivalents lithium acetylide ethylenediamine 
complex, were unsuccessful and just led to recovery of the starting bromo acid. For primarily 
practical reasons, acid 301 was converted into the corresponding methyl ester 305 by 
treatment with methanol in the presence of H2SO4.  
 
 
Scheme 4.3.  Synthesis of acid 294 
Following Sonagashira coupling conditions used by Queseda et al. on similar reactants,161, 162 
coupling of alkyne 305 with 3-bromobenzophenone 306 in the presence of 
bis(triphenylphosphine)palladium chloride and copper(I) iodide afforded alkyne 307 in 66% 
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yield. Deoxygenation of the diethylamine solvent was important to prevent formation of the 
Glaser homocoupling diyne product 308. Next, hydrogenation of the alkyne using Pd/C 
provided ester 309 in 85% yield (Scheme 4.3.). 
The short reaction time for the alkyne reduction was critical to avoid reduction of the 
benzophenone, which we had observed in an alternative approach in which the carboxylic 
acid/ ester was replaced with a benzyl-protected alcohol (Scheme 4.4.). Whilst benzyl ether 
314 was prepared uneventfully, attempted debenzylation and alkyne reduction led to a range 
of reduction products 316–318, none of which was the desired alcohol 315. Whilst 
hydrogenation of the alkyne proved to be rapid, the longer reaction time required to effect 
hydrogenolysis of the benzyl ether also led to reduction of the benzophenone to alcohol 317 
and methylene derivative 318 as evidenced by resonances in the 1H NMR due to the presence 
of CHOH and CHOH in 317 and CH2 in 318 (Scheme 4.4.).6  
 
Scheme 4.4. Attempted synthesis of alcohol 315 
                                               
6 Selected resonance: 317 [2.25 (1H, d, J 3.0, CHOH), 5.82 (1H, d, J 3.0, CHOH)], 318 [3.96 (2H, s, 
CH2)] 
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With ester 309 in hand, saponification NaOH (aq) in MeOH:THF provided Acid 294 which was 
converted to NHS ester 310 in 96% yield. This activated ester could be stored at – 4 °C for at 
least six months without any evidence of decomposition (Scheme 4.3.). 
4.4. Synthesis of ether-linked carboxylic acid (296) 
 
Ether-linked carboxylic acid 296 was also synthesised. Starting with 3-methylbenzophenone 
299, radical bromination using N-bromosuccinimde in the presence of benzoyl peroxide as the 
initiator yielded bromide 319, which was immediately hydrolysed without purification using 
CaCO3 in a H2O:dioxane mixture to yield alcohol 298 in 53% yield over two steps. Reaction of 
11-bromo undecanoic acid 303 with three equivalents of the sodium alkoxide of alcohol 298 
effected etherification to provide acid 296. It was necessary to perform this reaction under 
dilute concentration (0.05 M) as the reaction mixture was too viscous at higher concentrations. 
An excess of the alcohol was also important to ensure complete consumption of 11-bromo 
undecanoic acid 303 which otherwise was difficult to separate from the product. Acid 296 was 
then converted to NHS ester 320 under the standard conditions. Separation of the desired 
NHS ester 320 from any NHS ester of the unreacted bromo acid which had been carried 
through from the previous reaction was readily achieved by flash column chromatography 
(Scheme 4.5.). 
 
Scheme 4.5.  Synthesis of acid 296 
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4.5. Synthesis of glycolipid amine coupling partner (295) 
 
With both acids in hand the next step was to synthesise the glycolipid amine coupling partner 
295. A route to a protected analogue (97) of glycolipid 295 was already available in the group,52 
however, we decided upon the synthesis of glycoside 321 in which an isopropylidene acetal 
was used to protect the vicinal diol in the phytosphingosine fragment. Previous experience 
had revealed that removal of the TBDMS protecting groups from ThrCer-6 analogue 213 was 
often sluggish under the TFA global deprotection conditions on similar substrates. 
Trimethylsilyl ethers were used as the protecting group for the galactose sugar head group 
due to their ease of protection/deprotection as well as the ‘arming’ effect that silyl ethers impart 
on the donor during glycosylation reactions. A Boc protecting group was chosen for the 
phytosphingosine nitrogen due to its potential for deprotection under acidic conditions. The 









Chapter 4  Synthesis of glycolipid and ceramide analogues incorporating a novel acyl chain with a   






4.5.1. Synthesis of protected phytosphingosine acceptor (321) 
 
Starting with phytosphingosine 179, chemoselective Boc protection of the amine was achieved 
using Boc2O in the presence of Et3N to obtain carbamate 322 in 96% yield. This compound 
can be recrystallised from hot EtOAc avoiding the need for purification by column 
chromatography. Next, selective protection of the primary alcohol using TBDPSCl in pyridine 
gave silyl ether 323 in 92% yield. While acceptor alcohol 325 can be synthesised from 
carbamate 322 in one step without the need for protection of the primary alcohol, we found 
that silyletherification of the primary alcohol reduced the number of side-products in the acetal 
forming step and an improved yield of the final acceptor target.7 From a practical standpoint, 
incorporating a TBDPS ether also imparted some U.V. activity on the product which allowed 
for easier monitoring of the product by TLC. Silyl ether 323 was reacted with acetone under 
acidic conditions to yield acetal 324 in 84% yield. Fluoride mediated deprotection of the silyl 
ether provided target acceptor 325 in 88% yield.     
                                               
7 While the potential for the formation of the 1,3-acetonide product 326 (and in some cases the 1,4-
acetonide 327) can be reduced through longer reaction times to give the 1,2-acetonide as the 
thermodynamic product, this also drives the formation the bis acetal hemiaminal product 328 
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Scheme 4.6. Synthesis of target acceptor 325 
 
4.5.2. Synthesis of Benzophenone-derivatised -GalCer analogues 
 
TMS protection of galactose 329 using TMSCl in pyridine and HMDS as co-solvent gave per-
TMS galactose 330 in excellent yield. Following the work developed by Gervay-Hague, 
conversion of the per-TMS sugar to glycosyl iodide 95 was achieved using TMSI in CH2Cl2. 
This product was used directly in the key glycosylation reaction. Acceptor 325, TBAI and 
Hünig’s base were stirred over activated 3 Å molecular sieves for 30 minutes prior to addition 
of glycosyl iodide 95. Use of an excess of iodide 95 ensured full consumption of the starting 
acceptor and formation of a new product based on TLC analysis of the reaction mixture. Work-
up involved trituration of the ammonium salts with Et2O which yielded a mixture of 
phytosphingosine glycosylation product 321 and excess sugar. This mixture was then treated 
with acid using CHCl3:MeOH:HCl (40 mL total volume, 10:10:3) which formed a homogenous 
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solution. After 15 minutes, CHCl3 (17.5 mL) and H2O (7.5 mL) were added and the solution 
separated into two layers, with the organic compounds in the organic layer. Following 
concentration of the organic layer under reduced pressure, the residue was purified to afford 
glycoside 331 in 48% yield and glycoside 332 in 28% yield. Both products were isolated as 
the -anomer; the -anomer was not observed by analysis of these products by NMR 
spectroscopy. Deprotecting the glycosylation product using the 10:10:3 method allowed 
separation of the majority of the excess galactose sugar which was water soluble and 
therefore partitioned into the aqueous layer.  
Glycoside 332 was treated with TFA for 30 minutes to afford glycoside  as its ammonium 
trifluoroacetate salt. As both acid coupling partners were very similar we investigated the 
acylation under two different conditions. For the synthesis of target glycoside 333, glycoside 
295 was treated with NHS ester 320 in the presence of Et3N in THF to give amide 333 in 48% 
yield. Acylation of the ammonium salt of 295 using NHS ester 310 was performed in a solution 
of pyridine:H2O (9:1); to provide a similar yield of 50% of the desired glycoside 334. However, 
the purification was much easier using the pyridine:H2O method. Et3N was difficult to remove 
under reduced pressure and purification using column chromatography also proved difficult 
as Et3N co-eluted with the product. 
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4.6. Conclusions and Future Work 
 
These compounds have been submitted to Prof. Steven A. Porcelli to comparatively study 
their biological properties and to determine whether the replacement of the oxygen atom with 
a methylene group in the acyl chain effects binding and activity towards iNKT cells. If the 
effects of the new compound are beneficial then the new acyl chain will be used going forward 
in the synthesis of the next generation of analogues including analogues containing the cyclic 
threitol polar head group. Further studies involving the development of a crystal structure of 
the ligand–CD1d covalent complex would also help elucidate the area of binding, and mode 
of conjugation of the ceramide to the CD1d 
 
4.7. Synthesis of alkyne and azide benzophenone ceramides to for use in 
development of high throughput 
 
Alkyne–azide [3+2] dipolar cycloaddition reactions have previously been used in the synthesis 
of analogues of -GalCer, including substituting the amide bond with a triazole 149.163  Another 
synthesis involved the substitution of the 6-O position of the galactose sugar with an azide 
335, which was subsequently used to “click” with a range of alkynes.164 
       
          
More recently however, and more appropriate for our needs, two syntheses have been 
published which have used Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC)  in the 
synthesis of glycolipid analogues which contain triazole groups at the pseudo-anomeric 
position (Scheme 4.8). Gorantla et al. reacted an azido-based phytosphingosine 337 with N-
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propargyl-2-pyrrolidinone 336 using CuI and Hünig's base in MeCN to give triazole 338 in the 
key coupling step (Scheme 4.8, A).165 McDonagh et al also used CuI and Hünig's base in 
MeCN in their reaction however, they also required MW conditions to drive the reaction as 
they used a less reactive -glycosyl azide 339 and an alkyne based phytosphingosine 340 
(Scheme 4.8, B)  
 
 
Scheme 4.8. Published reactions using “click” chemistry to form a triazole at the 
anomeric position of -GalCer analogues 
 
Using the previously developed benzophenone containing analogues, which covalently bond 
to CD1d, we aimed to develop a high-throughput method for the synthesis and evaluation of 
potentially iNKT cell activating, triazole containing compounds using azide 342 and alkyne 344 
as the base molecules (Figure 4.6.). 
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Figure 4.6. Azide 342 and alkyne 344 as precursors towards a novel library of 
triazole containing ceramides 
 
Scheme 4.9. shows how azide 342 and alkyne 344 can be used in a high-throughput screening 
method. Starting with a 96 well plate, CD1d protein is bound to each well followed by addition 
of azide 342 or alkyne 344. At this stage the ligand is only bound by electrostatic and hydrogen 
bonding interactions and can be washed away. However, activation using U.V. at around 350 
nm will yield the covalently bound molecule. At this stage, a range of alkyne and azide 
containing compounds, with the potential for hydrogen bonding, can be reacted using Alkyne–
azide [3+2] dipolar cycloaddition reaction conditions, to give the target triazole containing 
compounds. The high selectivity nature of the cycloaddition reaction, along with the fact that 
azides and alkynes are not found in proteins has led to the use of “click” chemistry being used 
to further functionalise biomolecules.166 The triazole containing, CD1d derived compound can 
then be measured for its activity towards iNKT cells. Whilst the newly synthesised compounds 
won’t overlap and have the same hydrogen bonding interactions formed between the TCR 
and the galactosyl polar head group, the potential to yield a large library of compounds could 
help to find another area of the TCR to bind with and induce an immune response. 
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Scheme 4.9.  Schematic view of the potential for high-throughput development of a large 
library of iNKT cells activating compounds 
 
4.7.1. Retrosynthetic analysis 
 
Starting with triazoles 343 and 345, “retro”  click of these molecules provides azide 342 and 
alkyne 344 along with a range of azides and alkynes. Disconnection of the amide bond of 
azide 342 and alkyne 344 gives amine 346 and amine 347, respectively, and the previously 
synthesised benzophenone acid 294. Both amine 346 and amine 347 can be synthesised from 
activated aziridine 175 which can be accessed in five steps from phytosphingosine 179. 
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4.7.2. Synthesis of azido ceramide (342) via Ns-aziridine ring-opening 
 
Ring opening of nosyl aziridine 192 using NaN3 in MeCN:H2O proceeded uneventfully to give 
azide 348 in 72% yield. These conditions were developed by Bisai et al. for a range of Ts-
aziridines; we have shown they extend to Ns-aziridines.167 Harrak et al. also showed the 
successful ring opening of Ns-aziridine 192 using NaN3 to give azide 348 in 85% yield.130 They 
used a 9:1 mixture of MeOH:H2O which led to an extended reaction time, taking 16 h rather 
than the 2 h needed using MeCN:H2O. Denosylation using thiophenol in the presence of 
Cs2CO3 provided amine 349 in 83% yield. Cesium thiophenolate which is formed in situ reacts 
at the ipso position of the nosyl ring via a SNAr reaction to give the desired amine 349 and a 
bis-aryl thioether bi-product which are easily separable. Next, acylation using NHS ester 310 
afforded amide 350 in 76% yield. Having the molecule fully protected meant it was much easier 
to handle following the acylation and probably reflects the increased yield of this reaction. 
Finally, removal of the acetonide was achieved using TFA in CH2Cl2 to give target azide 342 
in 56% yield. With target azide 342 in hand a test cycloaddition reaction was attempted using 
4-pentyn-ol as a model alkyne. While the previously published syntheses of anomeric triazole 
containing compounds employed the used of CuI, DIPEA and MeCN, we chose to use 
conditions that would potentially be more suitable for reaction on biomolecules. Initial attempts 
employed conditions used previously in the group for Huisgen cycloaddition reactions with -
GalCer analogues which used a 1:1 t-BuOH:H2O solvent mixture.164, 168 No reaction was seen 
however, which we believe is due to solubility issues. The -GalCer analogues used 
previously would be much more soluble in butanol than our azide. However, when the solvent 
mixture was changed to 2:1 H2O:THF the reaction proceeded to give the desired triazole 351 
in an excellent 90% yield.169-171 
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Scheme 4.11.   Synthesis of triazole 351 via azido-ceramide 342 
 
As well as sodium azide, sodium cyanide was also used to ring open Ns-aziridine 192. This 
afforded nitrile 352 in 64% yield using a MeCN:H2O solution. The nosyl group was also 
removed from the nitrogen using cesium carbonate and thiophenol to give amine 353 in 92% 
yield (Scheme 4.12.). Future work on this project involves the development of tetrazole ring 
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Scheme 4.12. Ring opening of nosyl aziridine using sodium cyanide followed by 
deprotection 
 
4.7.3. Synthesis of alkynyl benzophenone ceramide (357) via Ns-
Aziridine ring-opening  
 
The synthesis of alkyne 344 was similarly achieved using Ns-aziridine 192. While there is little 
literature precedent for the ring-opening of sulfonyl aziridines with lithium acetylides,172, 173 
reaction of Ns-aziridine 192 with the lithium acetylide of TMS-acetylene in THF:HMPA (10:1) 
at –78 °C alkyne 354 in 79% yield. The silyl group was removed using TBAF in THF to give 
alkyne 355 in quantitative yield. Denosylation under standard conditions afforded amine 356 
in 77% yield. Acylation of amine 356 using NHS ester 310 provided amide 357 under the 
pyridine:H2O conditions to afford the desired product in 77% yield. Acetal hydrolysis using TFA 
in wet CH2Cl2 yielded alkyne 344 in 85% yield. With the target alkyne in hand a test click 
reaction was performed: using the same conditions previously used for the synthesis of 
triazole 351, 3-azidopentan-1-ol as the model azide reacted with alkyne 344 to give the desired 
triazole 358 in 90% yield (Scheme 4.13.). 
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4.7.4. Conclusions and Future Work 
 
Nosyl aziridine 192 have been successfully ring-opened with sodium azide, sodium cyanide 
and TMS-lithio acetylide with the azido and alkynyl compounds being subsequently acylated 
with acid 310 to give the target azide 342 and alkyne 344. These compounds were then shown 
to be acceptable reactants towards CuAAc chemistry with successful coupling to yield 
triazoles 351 and 358. The next step is the development of the covalent bonding of azide 342 
and alkyne 344 with the CD1d molecule using U.V. irradiation and to test whether both the 
azide and alkyne functional groups are unaffected by the cross-coupling procedure. Following 
successful cross-coupling, design and optimisation of the “click” reaction will be necessary. 
Due to the potential for the copper source to interact with the biomolecule being tested, ligands 
such as TBTA 359 are used to coordinate and stabilise the copper and as we have seen 




























Infra-red spectra were recorded neat as thin films on Varian 660-IR FT-IR spectrometer. The 
intensity of each band is described as s (strong), m (medium) or w (weak) and with the prefix 
v (very) and suffix br (broad) where appropriate. 1H-NMR, 19F-NMR and proton-decoupled 13C-
NMR spectra were recorded in CDCl3 at ambient temperature unless specified otherwise. 1H-
NMR spectra are reported as follows: H (frequency of spectrometer, solvent) chemical shift 
(number of protons, multiplicity, coupling constant(s) J (Hz), assignment) at 400 or 300 MHz. 
Multiplicities of 1H-NMR resonances are reported as follows: s – singlet, d – doublet, t – triplet, 
q – quartet, qn – quintet, m – multiplet, v – very, br – broad signal, stack and apparent (app.). 
The term ′stack′ is used to describe a region in the spectrum where resonances arising from 
non-equivalent nuclei are coincident while multiplet, m, is used to describe a resonance arising 
from a single nucleus (or equivalent nuclei) in which coupling constants cannot be readily 
assigned.  Chemical shifts are reported as  values (ppm) referenced to the following solvent 
signals: CDCl3, H 7.26; CDCl3, C 77.0, CD3OD, H 3.31; CD3OD c 49.0.  In analysing ABX 
(and similar) systems, where the resonance pattern forms two, clearly separated groups of 
lines (two sets of four lines for an ABX system), these are reported as “A of ABX” and “B of 
ABX”, along with JA–B, which can be directly measured from the spectra.  Whilst JA–X cannot 
strictly be measured directly from the spectrum, the value obtained from the spectrum is 
sufficiently close to the actual value for it still to be useful; however it is acknowledged that the 
value quoted for JA–X is not the true value. The chemical shift reported for A of AB (or AX of 
ABX etc.) is the measured midpoint between the lines making up the resonance. It is 
acknowledged that this figure is not the true chemical shift for the resonance, which needs to 
be calculated. Proton-decoupled 13C-NMR spectra were recorded at 100 MHz and are 
reported as follows: chemical shift F ppm [multiplicity (CH3, CH2, CH or C), assignment].  




Connectivities were deduced from COSY90, HSQC and HMBC experiments. Proton-coupled 
19F-NMR spectra were recorded at 282 MHz and are reported as follows: F (frequency of 
spectrometer) chemical shift ppm [multiplicity, coupling constant(s) J (Hz), assignment] and 
all spectra were recorded relative to chlorotrifluoromethane as the internal standard. Optical 
rotations were measured in CHCl3 at a concentration of 10 mg /1 mL (unless specified 
otherwise) using a PolAAR 2001 automatic polarimeter (Optical Activity Ltd., Huntingdon, 
Cambridgeshire, United Kingdom), using a 5 cm cell, at a wavelength of 589 nm (sodium D 
line), and are quoted as DTemp. EI (electron impact) mass spectra and TOF ES+ (time of 
flight electrospray) mass spectra were recorded on and are reported as (m/z (%)) usinga Xevo 
G2-XS TOF with Waters e2695 separation module, a Synapt G2-S with Waters e2695 
separation module, an LCT Premier with Waters 600 controller, a GCT Premier with Agilent 




Reactions were monitored by thin layer chromatography using pre-coated glass-backed silica 
plates (60A F254, Merck) and visualised by UV detection (at 254 nm) and with 
phosphomolybdic acid (lipid stain) staining dip or -naphthol with H2SO4 (sugar stain) staining 
dip or vanillin staining dip or KMnO4 staining dip. Column chromatography was performed usin 
silica gel (40–60 m mesh) and on pre-packed column cartridges (Mega Bond Elut Si 5 g – 
20 mL and 2 g – 12 mL). 
 
All reactions were conducted with magnetic stirring in oven-dried (140 °C) or flame-dried 
glassware under an argon atmosphere and at ambient temperature (20 to 25 °C) unless 
specified otherwise.  Volumes of 1 mL or less were measured and dispensed with gastight 
syringes. Evaporation of volatiles and concentration of solutions under reduced pressure were 




performed at 50–700 mbar at 40 °C.  Residual solvent was removed under high vacuum (<1 
mbar). 
 
5.1.2. Chemicals and Reagents 
 
All reagents were obtained from commercial sources and used without further purification 
unless specified otherwise. All solutions are aqueous and saturated unless specified 
otherwise. 
5.1.3. General procedure for activation of molecular sieves 
Powdered molecular sieves were weighed into a round-bottom flask (or the reaction vessel 
whenever possible) and then heated with a Bunsen flame under high vacuum for 5 min. The 




















Ac2O (61 mL, 0.55 mol) was added to a solution of D-mannose (5.0 g, 0.028 mol) in pyridine 
(100 mL).  After stirring the resulting solution for 16 h at rt, the solvent was removed by co-
evaporation with toluene (2 × 50 mL). The residue was redissolved in CH2Cl2 (50 mL) and 
washed sequentially with H2O (2 × 50 mL), 1 M HCl (2 × 30 mL), NaHCO3 solution (2 × 40 
mL) and brine (1 x 50 mL) and dried using Na2SO4. The product was then filtered and 
concentrated under reduced pressure to yield pentaacetate 76 as a viscous oil and a mixture 
of anomers [α:β, 1.0 : 0.3 (as determined by 1H-NMR), 9.95 g, 92%]: Data for mixture unless 
specified otherwise: Rf = 0.42 (50% EtOAc in hexane); max(film)/cm–1 2955 vw, 1743 vs (C=O), 
1433 w, 1368 m, 1209 vs, 1148 s, 1087 m, 1051 s, 1025 s, 973 s, 913 w, 732 w; H(400 MHz, 
-anomer) [2.00, 2.05, 2.09, 2.16, 2.17 (15H, 5 × s, C(O)CH3)], 4.02–4.07 (1H, m), 4.10 (1H, 
dd, J 12.4, 2.3), 4.28 (1H, dd, J 12.4, 4.9), 5.26 (1H, app t, J 2.2), 5.33–5.35 (2H, stack), 6.08 
(1H, d, J 1.9, H-1); C(100 MHz,-anomer) [20.5, 20.6, 20.7, 20.8 (5 × CH3, C(O)CH3, 
resonance overlap), 62.1 (CH2, C-6), [65.5, 68.3, 68.7, 70.6 (CH, C-2, C-3, C-4, C-5)], 90.6 
(CH, C-1), [168.0, 169.5, 169.7, 170.0, 170.6 (5 × C, C=O)]; visible resonances for minor -
anomer: H(400 MHz) 2.10, 2.21 (2 × 3H, s, C(O)CH3), 3.80 (1H, ddd, J 9.9, 5.3, 2.3, H-5), 
5.13 (1H, dd, J 10.0, 3.3, H-3), 5.48 (1H, dd, J 3.3, 1.0, H-2), 5.86 (1H, d, J 1.0, H-1); H(100 
MHz) 65.4 (CH), 68.2 (CH), 73.3 (CH), 90.4 (CH); m/z (TOF ES+) 413.1 ([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.42 
 
 







33% HBr in AcOH (50 mL, 0.20 mol) was added to a solution of pentaacetate 76 (5.0 g, 0.013 
mol) in CH2Cl2 (50 mL) at rt.  After 2 h, the solvent was co-evaporated with toluene (3 × 50 
mL) to leave bromide 74, which was used directly without further purification. Assuming full 
conversion to the bromide, the flask was charged with MeOH (50 mL), CH2Cl2 (50 mL) and 
2,6-lutidine (10 mL, 0.086 mol) and the resulting solution stirred overnight at rt. The reaction 
mixture was then concentrated under reduced pressure and the residue was co-evaporated 
with toluene (2 × 30 mL).  The residue was re-dissolved in CHCl3 (50 mL) and washed 
sequentially with H2O (3 × 50 mL) and brine (1 × 50 mL).  The organic layer was dried using 
Na2SO4, filtered and concentrated under reduced pressure.  The residue was purified by flash 
column chromatography (20% EtOAc in hexanes) to yield orthoester 77 as an off white solid 
and a 7.5:1 exo:endo mixture of diastereomers (as measured by 1H NMR) (3.15 g, 67%): Data 
for mixture unless specified otherwise : Rf = 0.43 (50% EtOAc in hexanes); m.p. 101–106 °C 
(Et2O), lit.42 110–111 °C (MeOH, Et2O); []D21 = –22.8 (c = 1.0, CHCl3), lit.42 []D25 = –26.8 (c 
= 1.0, CHCl3); max(neat)/cm–1 1741 s (C=O), 1432 w, 1385 m, 1371 m, 1257 m, 1210 vs, 1137 
m, 1115 m, 1053 vs, 1029 s, 958 m, 891s; H(400 MHz, exo anomer) 1.73 (3H, s, 
C(OCH3)CH3), [2.04, 2.06, 2.11 (9H, 3 × s, C(O)CH3)], 3.27 (3H, s, OCH3), 3.67 (1H, ddd, J 
9.5, 4.9, 2.7, H-5), 4.13 (1H, dd, J 12.1, 2.7, H-6A), 4.22 (1H, dd, J 12.1, 4.9, H-6B), 4.60 (1H, 
dd, J 4.0, 2.6, H-2), 5.14 (1H, dd, J 9.9, 4.0, H-3), 5.29 (1H, app. t, J 9.8, H-4), 5.48 (1H, d, J 




2.5, H-1); C(100 MHz, exo anomer) [20.68, 20.72, 20.8 (CH3, 3 × C(O)CH3)], 24.3 (CH3, 
C(OCH3)CH3), 49.9 (CH3, OCH3), 62.3 (CH2, C-6), 65.4 (CH, C-4), 71.3 (CH, C-3), 70.6 (CH, 
C-5), 76.5 (CH, C-2), 97.3 (CH, C-1), 124.5 (C, C(OCH3)CH3), [169.4, 170.3, 170.6 (C, 3 × 
C=O)]; visible resonances for minor endo anomer; H(400 MHz) 1.51 (3H, s, C(OCH3)CH3), 
2.01 (3H, s, C(O)CH3), 3.48 (3H, s, OCH3), 4.37 (1H, dd, J 4.2, 2.4), 5.19 (1H, dd, J 10.0, 4.2), 
5.38 (1H, app. t, J 9.9); C(100 MHz) 24.0 (C(OCH3)CH3), 50.1 (OCH3), 61.9 (CH2, C-6), 65.3 
(CH), 70.8 (CH), 75.4 (CH), 94.8 (CH); m/z (TOF ES+) 385.1 ([M + Na]+, 100%). 




BnBr (5.00 mL, 42.1 mmol) and solid KOH (4.60 g, 82.8 mmol) were added to a solution of 
orthoester 77 (3.00 g, 8.28 mmol) in THF (30 mL). After heating at reflux, H2O (50 mL) was 
added and the reaction mixture was diluted with CH2Cl2 (100 mL). The organic layer was 
separated, washed sequentially with NaHCO3 solution (50 mL) and brine (50 mL), dried 
(Na2SO4), filtered and the filtrate concentrated under reduced pressure. The residue was 
purified by flash column chromatography (20% EtOAc in hexanes) to yield exo-orthoester 44 
as a white solid (3.2 g, 76%)8: Rf = 0.6 (50% EtOAc in hexanes); m.p. 74 –76 °C (Et2O), lit.42 
76–78 °C (Et2O-pentane);  []D21  = +27.6 (c = 1.0, CHCl3), lit.42 []D19 +34.4 (c = 6.0, CHCl3); 
max(film)/cm–1 2954 w, 2906 w, 2867 w, 1454 m, 1383 m, 1355 m, 1260 w, 1239 m, 1207 m, 
1155 m, 1130 m, 1099 vs, 1066 s, 1049 vs, 1036 vs, 1026 vs, 987 m, 969 m, 931 m, 893 s, 
877 m, 839 w, 822 w, 793 w, 735 s, 696 vs, 673 m, 655 m; H(400 MHz) 1.66 (3H, s, 
                                               
8 No sign of endo anomer from 1H NMR following purification. 




C(OCH3)CH3), 3.21 (3H, s, OCH3), 3.34 (1H, ddd, J 9.4, 4.4, 2.4, H-5), 3.61–3.70 (3H, stack, 
H-3, H-6A, H-6B), 3.85 (1H, app. t, J 9.4, H-4), 4.32 (1H, dd, J 3.9, 2.6, H-2), 4.45–4.55 (3H, 
stack, PhCH2), 4.69 (1H, A of AB, J 12.3, PhCHAHB), 4.73 (1H, B of AB, J 12.3, PhCHAHB), 
4.82 (1H, d, J 10.8, PhCH2), 5.27 (1H, d, J 2.6, H-1), 7.15–7.34 (15H, stack, Ar CH); C(100 
MHz) 24.4 (CH3, C(OCH3)CH3), 49.7 (CH3, OCH3), 69.0 (CH2, C-6), 72.4 (CH2, PhCH2), 73.3 
(CH2, PhCH2), 74.1 (CH, C-4), 74.2 (CH, C-5), 75.2 (CH2, PhCH2), 77.1 (CH, C-3), 79.0 (CH, 
C-2), 97.5 (CH, C-1), 124.0 (C, C(OCH3)CH3), [127.5, 127.8, 128.0, 128.3, 128.4, 128.5 (CH, 
Ar CH, resonance overlap)], [137.8, 138.2 (C, Ar C, resonance overlap)]; m/z (TOF ES+) 529.2 
([M + Na]+, 100%). 




A solution of 5-bromo-1-pentanol (2.00 g, 12.0 mmol) and NaN3 (2.34 g, 36.0 mmol) in DMF 
(15 mL) was heated at 80 °C for 12 h. After cooling to rt, H2O (100 mL) was added and the 
resulting mixture was extracted with EtOAc (5 × 80 mL). The combined organic layers were 
washed sequentially with H2O (200 mL) and brine (200 mL), and dried over Na2SO4, filtered 
and concentrated under reduced pressure to yield azide 79 as a pale yellow oil (1.47 g, 94%), 
which was used immediately without further purification: Rf = 0.6 (20% EtOAc in hexanes);  
max(film)/cm–1 3337 br m (O–H), 2936 m, 2865 m, 2090 vs (N3), 1455 m, 1349 m, 1255 m, 
1165 w, 1071 w, 1052 m, 1018 w, 877 w, 835 w; H(400 MHz) 1.40–1.46 (2H, m, H-3), 1.54–
1.65 (4H, stack, H-2, H-4), 2.36 (1H, br s, OH), 3.26 (2H, t, J 6.9, H-5), 3.62 (2H, t, J 6.5, H-
1); C(100 MHz) 22.9 (CH2, C-3), [28.5, 32.0 (CH2, C-2, C-4)], 51.3 (CH2, C-5), 62.4 (CH2, C-
1); m/z (TOF ES+) 130.1 ([M + H]+, 15%), 132.1 (100). 
Data were in agreement with those reported in the literature.174 




5′-Azidopentyl 2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranoside (80) 
 
TMSCl (2.5 mL, 19.7 mmol) was added to a solution of orthoester 44 (1.00 g, 1.97 mmol) in 
CH2Cl2 (20 mL) at 0 °C. After 1 h, the reaction mixture was concentrated under reduced 
pressure to yield the glycosyl chloride 45 as a syrup that was used directly without further 
purification. In a separate flask, AgOTf (0.557 g, 2.17 mmol) and activated 4 Å MS (1 g) in 
CH2Cl2 (10 mL) were stirred at rt for 30 min. The flask was then cooled to –30 °C.  A solution 
of alcohol 79 (0.517 g, 3.72 mmol) in CH2Cl2 (10 mL) was added, followed immediately by a 
solution of the glycosyl chloride 45 in CH2Cl2 (10 mL). The reaction mixture warmed to rt and 
then stirred for 16 h before filtering through Celite and concentrating the filtrate under reduced 
pressure. Purification of the residue by flash column chromatography (20% EtOAc in hexanes) 
yielded -mannoside 80 as a colourless syrup (0.666 g, 56%): Rf = 0.5 (20% EtOAc in 
hexane); []D21 = +24.0 (c = 1.0, CHCl3); max(film)/cm–1 3031 vw, 2935 w, 2867 w, 2093 s (N3), 
1743 s (C=O), 1496 w, 1453 m, 1367 m, 1234 vs, 1137 s, 1076 vs, 1060 vs, 1027 s, 977 s, 
911 w, 845 w, 798 w, 735 vs, 696 vs, 678 m; H(300 MHz) 1.26–1.39 (2H, stack, H-3′), 1.45–
1.57 (4H, stack, H-2′, H-4′), 2.07 (3H, s, C(O)CH3), 3.18 (2H, app. t, J 6.9, H-5′), 3.33 (1H, 
app. dt, J 9.7, 6.3, H-1′A), 3.56–3.66 (2H, stack, H-6A, H-1′B), 3.66–3.76 (2H, stack, H-5, H-6B), 
3.80 (1H, app. t, J 9.3, H-4), 3.90 (1H, dd, J 9.1, 3.3, H-3), 4.40 (1H, A of AB, J 10.7, PhCHAHB), 
4.44 (1H, A of AB, J 12.1, PhCHCHD), 4.47 (1H, A of AB, J 11.1, PhCHEHF), 4.61 (1H, B of AB, 
J 12.1, PhCHCHD), 4.64 (1H, B of AB, J 11.1, PhCHEHF), 4.75 (1H, d, J 1.7, H-1), 4.78 (1H, B 
of AB, J 10.7, PhCH2), 5.28 (1H, dd, J 3.3, 1.7, H-2), 7.05–7.11 (2H, stack, Ar CH), 7.16–7.31 
(13H, stack, Ar CH); C(100 MHz) 21.1 (CH3, C(O)CH3), 23.3 (CH2, C-3′), [28.6, 28.9 (CH2, C-
2′, C-4′)], 51.2 (CH2, C-5′), 67.5 (CH2, C-1′), 68.8 (CH, C-2), 68.8 (CH2, C-6), 71.3 (CH, C-5), 




71.7 (CH2, PhCH2), 73.4 (CH2, PhCH2), 74.3 (CH, C-4), 75.2 (CH2, PhCH2), 78.2 (CH, C-3), 
97.7 (CH, C-1), [127.6, 127.7, 127.9, 128.0, 128.3 (CH, Ar CH, resonance overlap)], [137.9, 
138.1, 138.2 (C, Ar C)] 170.5 (C, C=O); m/z (TOF ES+) 626.3 ([M + Na]+, 100%); HRMS m/z 
(TOF ES+) 626.2838 [M + Na]+, C34H41N3O7Na requires 626.2842. 
 
5′-Azidopentyl 3,4,6-tri-O-benzyl--D-mannopyranoside (81) 
 
NaOMe (5 mL of a 0.5 M soln. in MeOH, 2.5 mmol) was added to a solution of acetate 80 
(0.504 g, 0.835 mmol) in MeOH (30 mL). After 3 h, the reaction mixture was neutralised by 
the addition of acidic ion-exchange resin [Dowex H CR-S, pre-washed sequentially with MeOH 
(100 mL) and CHCl3 (50 mL)]. The solution was filtered and the resin washed sequentially with 
MeOH (2 × 20 mL) and CHCl3 (2 × 20 mL). The filtrate was concentrated under reduced 
pressure and the residue purified by flash column chromatography (25% EtOAc in hexanes) 
to provide alcohol 81 as a clear oil (0.427 g, 92%): Rf = 0.2 (20% EtOAc in hexanes); []D21 = 
+43.6 (c = 1.0, CHCl3); max(film)/cm–1 3435 br vw (O–H), 3030 vw, 2920 m, 2865 m, 2094 s 
(N3), 1626 m, 1577 w, 1496 w, 1454 s, 1386 m, 1339 s, 1249 m, 1212 m, 1190 m, 1152 m, 
1099 vs, 1055 vs, 1028 vs, 980 m, 749 s, 699 vs; H(400 MHz) 1.28–1.37 (2H, stack, H-3′), 
1.46–1.56 (4H, stack, H-2′, H-4′), 2.45 (1H, br s, OH), 3.17 (2H, app. t, J 6.9, H-5′), 3.34 (1H, 
app. dt, J 9.7, 6.4, H-1′A), 3.58–3.71 (4H, stack, including H-1′B, H-6A, H-6B), 3.72–3.82 (2H, 
stack, including H-3), 3.95 (1H, app s, H-2), 4.40–4.49 (2H, stack, PhCH2), 4.52–4.63 (3H, 
stack, PhCH2), 4.75 (1H, B of AB, J 10.8, PhCH2), 4.81 (1H, d, J 1.4, H-1), 7.07–7.11 (2H, 
stack, Ar CH), 7.16–7.32 (13H, stack, Ar CH); C(100 MHz) 23.4 (CH2, C-3′), [28.6, 28.9 (CH2, 
C-2′, C-4′)], 51.2 (CH2, C-5′), 67.3 (CH2, C-1′), 68.4 (CH, C-2), 68.9 (CH2, C-6), 71.0 (CH), 




71.9 (CH2, PhCH2), 73.4 (CH2, PhCH2), 74.3 (CH), 75.1 (CH2, PhCH2),  80.2 (CH), 99.1 (CH, 
C-1), [127.5, 127.7, 127.8, 128.0, 128.3 (CH, Ar CH, resonance overlap)], [138.0, 138.2 (C, 
Ar C, resonance overlap)]; m/z (TOF ES+) 584.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 





TMSCl (2.0 mL, 15.8 mmol) was added to a solution of orthoester 44 (0.302 g, 0.596 mmol) 
in CH2Cl2 (15 mL) at 0 °C. After 1 h, the reaction mixture was concentrated under reduced 
pressure to yield the glycosyl chloride 45 as a syrup, which was directly used without further 
purification. In a separate flask, a mixture of AgOTf (0.168 g, 0.656 mmol) and activated 4 Å 
MS (0.6 g) in CH2Cl2 (10 mL) was stirred at rt for 30 min. The flask was then cooled to –30 °C 
before a solution of alcohol 81 (0.402 g, 0.715 mmol) in CH2Cl2 (10 mL), followed immediately 
by a solution of glycosyl chloride 45 in CH2Cl2 (10 mL) were added. The reaction mixture was 
warmed to rt.  After 16 h, the reaction mixture was filtered through Celite and the filtrate 
concentrated under reduced pressure. Purification of the residue by flash column 
chromatography (20% EtOAc in hexanes) yielded disaccharide 82 as a colourless syrup 
(0.296 g, 48%): Rf = 0.5 (20% EtOAc in hexane); []D21 = +24.0 (c = 1.0, CHCl3); max(film)/cm–
1 3030 vw, 2914 m, 2865 m, 2096 s (N3), 1743 s (C=O), 1605 vw, 1497 m, 1454 s, 1366 s, 
1236 vs, 1138 vs, 1101 vs, 1059 vs, 1028 s, 980 m, 912 w, 846 vw, 741 vs, 699 vs; H(400 
MHz) 1.21–1.30 (2H, stack, H-3′′), 1.40–1.51 (4H, stack, H-2′′, H-4′′), 2.05 (3H, s, C(O)CH3), 




3.11–3.21 (3H, stack, H-1′′A, H-5′′), 3.51 (1H, app. dt, J 9.6, 6.5, H-1′′B), 3.60–3.78 (7H, stack, 
including H-6A, H-6B, H-6′A, H-6′B), 3.82 (1H, dd, J 9.2, 2.9), 3.86–3.93 (3H, stack, including H-
2, H-3′), 4.33 (1H, A of AB, J 10.9, PhCHAHB), 4.36–4.43 (2H, stack, PhCH2), 4.44–4.50 (2H, 
stack, PhCH2), 4.55–4.63 (5H, stack, PhCH2), 4.74–4.80 (3H, stack, H-1, PhCH2), 5.00 (1H, 
d, J 1.6, H-1′), 5.46 (1H, dd, J 3.2, 1.9, H-2′), 7.06–7.10 (2H, stack, Ar CH), 7.10–7.14 (3H, 
stack, Ar CH), 7.15–7.30 (25H, stack, Ar CH); C(100 MHz) 21.1 (CH3, C(O)CH3), 23.3 (CH2, 
C-3′′), [28.6, 28.9 (CH2, C-2′′, C-4′′)], 51.2 (CH2, C-5′′), 67.3 (CH2, C-1′′), 68.7 (CH, C-2′), [69.1, 
69.3 (CH2, C-6, C-6′)], 71.7 (CH), 71.8 (CH), [71.9, 72.0, 73.3, 73.3 (CH2, PhCH2)], 74.3 (CH), 
74.6 (CH), 74.9 (CH), [75.0, 75.2 (CH2, PhCH2)], 78.1 (CH), 79.6 (CH), 98.6 (CH, C-1), 99.5 
(CH, C-1′), [127.4, 127.5, 127.6, 127.7, 128.1, 128.3 (CH, Ar CH, resonance overlap)], [138.0, 
138.2, 138.3, 138.3, 138.4, 138.5 (C, Ar C)], 170.1 (C, C=O); m/z (TOF ES+) 1058.5 [M + 





NaOMe (1.0 mL of a 0.5 M soln. in MeOH, 0.5 mmol) was added to a solution of acetate 82 
(0.25 g, 0.24 mmol) in MeOH (20 mL) at rt. After 3 h, the reaction mixture was neutralised by 
the addition of acidic ion-exchange resin [Dowex H CR-S, pre-washed sequentially with MeOH 
(100 mL) and CHCl3 (50 mL)]. The solution was filtered and the resin washed sequentially with 
MeOH (2 × 20 mL) and CHCl3 (2 × 20 mL). The filtrate was concentrated under reduced 
pressure and the residue purified by flash column chromatography (25% EtOAc in hexanes) 




to afford alcohol 83 as a colourless oil (0.215 g, 90%): Rf = 0.2 (20% EtOAc in hexanes); []D21 
= +29.6 (c = 1.0, CHCl3); max(film)/cm–1 3372 br vw (O–H), 3030 vw, 2913 m, 2865 m, 2095 s 
(N3), 1496 m, 1454 s, 1362 m, 1309 m, 1279 m, 1209 m, 1103 vs, 1058 vs, 1029 vs, 910 w, 
738 vs, 699 vs; H(400 MHz) 1.22–1.30 (2H, stack, H-3′′), 1.37–1.51 (4H, stack, H-2′′, H-4′′), 
2.37 (1H, br s, OH), 3.12–3.21 (3H, stack, H-1′′A, H-5′′), 3.51 (1H, app. dt, J 9.6, 6.5, H-1′′B), 
3.61–3.68 (4H, stack including H-4′, H-6A, H-6′A and H-6B or H-6′B), 3.69–3.78 (3H, stack, H-
4, H-6B or H-6′B and H-5 or H-5′), 3.80 (1H, dd, J 9.1, 3.2, H-3′), 3.83 (1H, dd, J 9.1, 3.2, H-3), 
3.80 (1H, ddd, J 9.7, 4.2, 2.7, H-5 or H-5′), 3.93–3.95 (1H, m, H-2), 4.04–4.07 (1H, m, H-2′), 
4.40–4.64 (10H, stack, PhCH2), 4.72–4.78 (2H, stack, PhCH2), 4.82 (1H, d, J 1.7, H-1), 5.07 
(1H, d, J 1.4, H-1′), 7.08–7.30 (30H, stack, Ar CH); C(100 MHz) 23.4 (CH2, C-3′′), [28.6, 29.0 
(CH2, C-2′′, C-4′′)], 51.3 (CH2, C-5′′), 67.3 (CH2, C-1′′), 68.5 (CH, C-2′), [69.3, 69.4 (CH2, C-6, 
C-6′)], 71.5 (CH), 71.9 (CH, C-4′), [72.2, 72.3, 73.3, 73.4 (CH2, PhCH2)], 74.4 (CH), 74.8 (CH), 
75.0 (CH, C-2), [75.1, 75.2 (CH2, PhCH2)], 79.8 (CH, C-3), 80.0 (CH, C-3′), 98.8 (CH, C-1), 
101.1 (CH, C-1′), [127.4, 127.5, 127.6, 127.7, 127.8, 127.9, 128.0, 128.3, 128.4, 128.5 (CH, 
Ar CH, resonance overlap)], [138.0, 138.2, 138.3, 138.36, 138.41, 138.6 (C, Ar C)]; m/z (TOF 
ES+) 1016.5 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 1016.4670 [M + Na]+, C59H67N3O11Na 
requires 1016.4673.  
 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio--D-mannopyranose (84) 
 
PhSH (2.00 mL, 19.6 mmol) was added to a solution of pentaacetate 76 (5.00 g, 12.8 mmol) 
in CH2Cl2 (50 mL) and the mixture was cooled to 0 °C. BF3·Et2O (2.0 mL, 32 mmol) was added 
dropwise over 5 min and the reaction mixture was warmed to rt. After 3 h, CH2Cl2 (50 mL) was 
added and the mixture was washed sequentially with 2 M NaOH solution (2 × 50 mL) and H2O 
(2 × 50 mL).  The organic phase was dried (Na2SO4), filtered and concentrated under reduced 




pressure. Purification of the residue by flash column chromatography (20% EtOAc in hexanes) 
yielded thiosugar 84 as an off-white solid (5.6 g, quant.). Rf = 0.4 (30% EtOAc in hexanes); 
m.p. 79–81 °C, lit.175 83-85 °C; []D21 =  +96.4 (c = 1.0, CHCl3), lit.176 []D24 = +85.6 (c = 2.0, 
CH2Cl2); max(film)/cm–1 1739 vs (C=O), 1481 vw, 1439 w, 1366 s, 1242 vs, 1217 vs, 1100 s, 
1061 s, 1046 vs, 979 s, 752 s, 739 s; H(400 MHz) 2.01 (3H, s, C(O)CH3), 2.05 (3H, s, 
C(O)CH3), 2.07 (3H, s, C(O)CH3), 2.15 (3H, s, C(O)CH3), 4.10 (1H, dd, J 12.2, 2.3, H-6A), 4.30 
(1H, dd, J 12.2, 5.9, H-6B), 4.54 (1H, ddd, J 9.8, 5.9, 2.3, H-5), 5.28–5.37 (2H, stack, H-3, H-
4), 5.47–5.52 (2H, stack, H-1, H-2), 7.27–7.34 (3H, stack, Ph), 7.46–7.51 (2H, stack, Ph); 
C(100 MHz) [20.6, 20.7, 20.9 (CH3, C(O)CH3, resonance overlap)], 62.4 (CH2, C-6), [66.3, 
69.4 (CH, C-3, C-4)], 69.5 (CH, C-5), 70.9 (CH, C-2), 85.7 (CH, C-1), [128.1, 129.2, 132.1 
(CH, Ar CH)], 132.6 (C, Ar C), [169.7, 169.8, 169.9, 170.6 (C, C=O)]; m/z (TOF ES+) 463.1 
([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.176 
 
 
Phenyl 1-thio--D-mannopyranose (85) 
 
NaOMe (100 mL of a 0.5 M soln. in MeOH, 0.5 mmol) was added to a solution of tetraacetate 
84 (5.00 g, 11.4 mmol) in MeOH (50 mL). After 16 h, the reaction mixture was neutralised by 
the addition of acidic ion-exchange resin [Dowex H CR-S, pre-washed sequentially with MeOH 
(100 mL) and CHCl3 (50 mL)]. The solution was filtered and the resin washed sequentially with 
MeOH (2 × 50 mL) and CHCl3 (2 × 20 mL). The filtrate was concentrated under reduced 
pressure. Purification of the residue by flash column chromatography (10% MeOH in CHCl3) 
provided thiosugar 85 as a white solid (3.0 g, quant.): Rf = 0.54 (30% MeOH in CHCl3); m.p. 
130–134 °C; solubility issues prevented an optical rotation measurement; max(film)/cm–1 3314 




br s (O–H), 2878 br w, 1583 w, 1478 m, 1455 m, 1439 m, 1411 m, 1388 m, 1329 m, 1255 m, 
1215 m, 1095 vs, 1062 vs, 1040 vs, 1023 vs, 968 s, 913 s, 876 m, 849 m, 796 s, 770 s, 738 
vs, 688 vs, 670 vs, 664 vs; H(300 MHz) 3.69–3.85 (4H, stack, H-3, H-4, H-6A, H-6B), 4.01 (1H, 
app. dt, J 9.6, 3.2, H-5), 4.10 (1H, dd, J 3.2, 1.4, H-2), 5.44 (1H, d, J 1.4, H-1), 7.21–7.30 (3H, 
stack, Ar CH), 7.41–7.46 (2H, stack, Ar CH); C(100 MHz) 61.4 (CH2, C-6), [67.3, 72.1 (CH, 
C-3, C-4)], 72.4 (CH, C-2), 73.6 (CH, C-5), 88.8 (CH, C-1), [127.6, 129.2, 131.8 (CH, Ar CH)], 
134.3 (C, Ar C); m/z (TOF ES+) 295.1  ([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.177 
 
 
Phenyl 4,6-O-benzylidene-1-thio--D-mannopyranose (86) 
 
(1S)-(+)-10-Camphorsulfonic acid (0.681 g, 2.94 mmol) and benzaldehyde dimethyl acetal 
(1.90 mL, 12.2 mmol) were added to a suspension of thioglycoside 85 (3.20 g, 11.8 mmol) in 
CH3CN (32 mL) at rt.  After 15 min, the product had precipitated and the reaction was 
quenched with Et3N (2 mL). The reaction mixture was partitioned between EtOAc (200 mL) 
and H2O (150 mL).  The aqueous phase was extracted with EtOAc (2  100 mL).  The 
combined organic fractions were washed with brine (100 mL) and then dried (Na2SO4) and 
filtered. Removal of the solvent under reduced pressure afforded a white solid, which was 
washed with petroleum ether (b.p. 40–60 °C) (3  30 mL) to provide benzylidene 86 as a white, 
fluffy solid (3.62 g, 85%): Rf = 0.5 (50% MeOH in CHCl3); m.p. 198–202 °C, lit.49 202–204 °C; 
solubility issues prevented an optical rotation measurement; max(film)/cm–1 3318 br w (O–H), 
3197 br m, 2896 w, 1451 m, 1473 m, 1441 m, 1401 m, 1370 s, 1352 w, 1338 w, 1287 m, 1253 
w, 1216 m, 1162 w, 1078 vs, 1032 s, 1007 vs, 979 s, 974 s, 860 s, 742 vs, 700 vs, 688 vs; 
H(DMSO-d6, 400 MHz) 3.72–3.82 (2H, stack, H-3, H-6A), 3.97 (1H, app. t, J 9.3, H-4 or H-5), 




4.02 (1H, app. t, J 3.1, H-2), 4.04–4.12 (2H, stack, H-6B, H-5 or H-4), 5.24 (1H, d, J 6.0, 3-
OH), 5.48 (1H, app. s, H-1), 5.57 (1H, d, J 4.1, 2-OH), 5.64 (1H, s, benzylidene CH), 7.34–
7.42 (5H, stack, Ph), 7.45–7.51 (5H, stack, Ph); C(DMSO-d6,100 MHz) 65.2 (CH, C-4 or C-
5), 67.5 (CH2, C-6), 68.0 (CH, C-3), 72.3 (CH, C-2), 78.4 (CH, C-5 or C-4), 89.2 (CH, C-1), 
101.1 (CH, benzylidene CH), [126.3, 127.3, 127.9, 128.8, 129.2, 131.2 (CH, Ph)], [133.6, 
137.8 (C, Ph, ipso C)]; m/z (TOF ES+) 743.2 ([2M + Na]+, 100%), 383.1 (75, [M + Na]+).  
Data were in agreement with those reported in the literature.49 
 
 
Phenyl 2-O-benzyl-4,6-O-benzylidene-1-thio--D-mannopyranose (92) 
 
1 M NaOH solution (7 mL) was added to a mixture of diol 86 (500 mg, 1.39 mmol), Bu4NHSO4 
(94 mg, 0.28 mmol) and BnBr (0.2 mL, 1.66 mmol) in CH2Cl2 (20 mL).  The reaction mixture 
was heated under reflux for 20 h, then cooled to rt, and diluted with CH2Cl2 (10 mL). The 
phases were separated. The aqueous phase was extracted with CH2Cl2 (2  10 mL). The 
combined organic fractions were washed sequentially with NaHCO3 solution (30 mL) and brine 
(30 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (10% EtOAc in hexanes)  to afford monobenzyl ether 
92 as a white solid (506 mg, 81%): Rf = 0.5 (30% EtOAc in hexanes); m.p. 147–150 °C, lit.49 
144−146 °C; []D21 = +117.6 (c = 1.0, CHCl3), lit.49 []D26 = +144.4 (c = 1.3, CHCl3); 
max(film)/cm–1 3505 br w (O–H), 3029 w, 2902 m, 2863 m, 1582 m, 1476 m, 1455 s, 1387 m, 
1360 m, 1272 w, 1214 m, 1153 m, 1080 vs, 1041 s, 1025 vs, 1003 s, 970 s, 916 m, 856 m, 
774 m, 743 s, 697 vs, 674 m; H(400 MHz) 2.23 (1H, br s, OH), 3.84 (1H, app. t, J 10.2, H-6A), 
4.00 (1H, app. t, J 9.3, H-4), 4.10–4.15 (2H, stack, H-2, H-3), 4.23 (1H, dd, J 10.2, 4.9, H-6B), 




4.32 (1H, app. dt, J 9.8, 4.9, H-5), 4.56 (1H, A of AB, J 11.6, PhCHAHB), 4.66 (1H, B of AB, J 
11.6, PhCHAHB), 5.58–5.61 (2H, stack, H-1, benzylidene CH), 7.29–7.40 (11H, stack, Ar CH), 
7.41–7.45 (2H, stack, Ar CH), 7.50–7.54 (2H, stack, Ar CH); C(100 MHz) 64.7 (CH, C-5), 68.4 
(CH2, C-6),  69.0 (CH, C-2 or C-3), 73.1 (CH2, PhCH2), 79.5 (CH, C-4), 80.0 (CH, C-3 or C-2), 
86.2 (CH, C-1), 102.1 (CH, benzylidene CH), [126.3, 127.8, 128.1, 128.26, 128.34, 128.7, 
129.2, 131.8 (CH, Ar CH, resonance overlap)] [133.6, 137.2 (C, Ar C, resonance overlap)]; 
m/z (TOF ES+) 473.1 ([M + Na]+, 100%). 




HMDS (10 mL, 0.048 mol) and TMSCl (5 mL, 0.039 mol) were added sequentially to a solution 
of D-glucose (1.0 g, 5.55 mmol) in pyridine (30 mL). The solution was heated at 75 ºC for 1 h 
under an Ar atmosphere and then cooled to rt. The mixture was poured into ice-H2O (100 mL) 
and extracted with hexane (3 × 150 mL). The combined organic extracts were washed with 
H2O (3 × 150 mL), dried (MgSO4) and concentrated under reduced pressure to afford per-
silylated glucose 102 as a colourless oil (2.82 g, 94%, -only): Rf = 0.25 (4% EtOc in hexane); 
[]D22 +65.6 (c 1.0, CHCl3), lit.179 []D20 +62.5 (c 0.2, CHCl3); max(film)/cm−1 2956 m, 2904 w, 
1386 w, 1248 s, 1153 m, 1102 m, 1070 s, 1051 m, 967 m, 891 m, 864 s, 821 vs, 746 s, 682 
m; H(400 MHz) 0.10 (9H, s, Si(CH3)3), 0.12 (9H, s, Si(CH3)3), 0.140 (9H, s, Si(CH3)3), 0.144 
(9H, s, Si(CH3)3), 0.17 (9H, s, Si(CH3)3), 3.33 (1H, dd, J 9.1, 3.10, H-2), 3.37–3.43 (1H, m, H-
4), 3.63–3.74 (3H, stack, H-5, H-6), 3.77 (1H, app. t, J 8.9, H-3), 5.00 (1H, d, J 3.1, H-1); 
C(100 MHz) [–0.2, 0.2, 0.5, 1.0, 1.3 CH3, Si(CH3)3], 62.3, (CH2, C-6), 72.3 (CH, C-4), 72.5 




(CH, C-5), 74.0 (CH, C-3), 74.2 (CH, C-2), 93.9 (CH, C-1); m/z (TOF ES+) 563.25 ([M + Na]+, 
100%). 
 
Data were in agreement with those reported in the literature.52 
 
Trichloroacetimidate 2,3,4,6-tetra-O-benzyl--D-glucopyranoside (36) 
 
CCl3CN (0.5 mL, 4.81 mmol) and K2CO3 (0.25 g, 1.85 mmol) were added to a solution of 
2,3,4,6-tetra-O-benzyl--D-glucopyranose (200 mg, 0.37 mmol) in CH2Cl2 (5 mL) was stirred 
vigorously with for 12 h at rt. The reaction mixture was then filtered through Celite and the 
filtrate was concentrated under reduced pressure to give trichloroacetimidate 36 as a 
colourless syrup (, 1 : 2.5, 221 mg 87%): Data for mixture unless specified otherwise: Rf = 
0.5 (20% EtOAc in hexanes); max(film)/cm–1 3337 br w (N–H), 3030 w, 2914 m, 2867 m, 1671 
s, 1496 m, 1453 s, 1359 m, 1287 s, 1209 m, 1149 m, 1055 vs, 1027 vs, 909 s, 833 s, 794 vs, 
732 vs, 690 vs, 645 s; H(400 MHz) 3.66–3.74 (1H, m, H-5), 3.76–3.87 (5H, stack, H-2, H-3, 
H-4, H-6), 4.50–5.00 (8H, stack, PhCH2), 5.86 (1H, d, J 5.4, H-1), 7.27–7.40 (20H, stack, Ar 
CH), 8.75 (1H, br s, C=NH); C(100 MHz, -anomer) 68.2 (CH2, C-6), 73.3 (CH2, PhCH2), 74.8 
(CH2, PhCH2), 74.9 (CH2, PhCH2), 75.5 (CH2, PhCH2), 75.8 (CH, C-5), [77.2, 80.9, 84.5 (CH, 
C-2, C-3, C-4), 90.9 (C, CCl3), 98.3 (CH, C-1), [127.6, 127.7, 127.8, 127.9, 128.0, 128.3 (CH, 
Ar CH, resonance overlap)], [137.9, 138.0, 138.1, 138.4 (C, Ar C), 161.1 (C, C=NH);  visible 
resonances for minor -anomer: H(400 MHz) 4.00–4.20 (2H, stack, H-3, H-5), 6.58 (1H, d, J 
3.1, H-1), 8.63 (1H, s, C=NH); C(100 MHz) 68.0 (CH2, C-6), 72.8 (CH2, PhCH2), 73.1 (CH, C-




5), 73.4 (CH2, PhCH2), 75.3 (CH2, PhCH2), 76.8 (CH), 79.3 (CH), 81.3 (CH), 94.4 (CH, C-1), 
161.3 (C, C=NH); m/z (TOF ES+) 706.2 ([M + Na]+, 10%), 577.3 (100). 





CBr4 (0.88 g, 2.66 mmol) and Ph3P (0.7 g, 2.66 mmol) were added sequentially to a 
solution of 2,3,4,6-tetra-O-benzyl-D-glucose 114 (437 mg, 0.81 mmol) in CH2Cl2 (5 mL) at 
rt. The reaction mixture was stirred for 3 h. In a separate flask, a solution of tetramethyl 
urea (TMU) (0.5 mL), Bu4NBr (0.86 g, 2.66 mmol) and acceptor 92 (400 mg, 0.89 mmol) 
in CH2Cl2 (5 mL), were stirred over activated 3 Å MS for 30 min, after which time, this 
solution was added dropwise (5 min) via syringe to the solution containing the glycosyl 
donor. The reaction mixture was stirred at r.t. for 3 d until the donor was no longer being 
consumed (as judged by TLC). The reaction mixture was then filtered through a silica plug, 
washed with CH2Cl2 (50 mL) and concentrated under reduced pressure to provide the 
crude product. Purification of the residue by flash column chromatography (10% EtOAc in 
hexane) afforded glycoside 105 as a colourless oil oil and a mixture of anomers [α:β, 10 : 1 
(as determined by 1H-NMR), 402 mg, 51%]: Data for mixture unless specified otherwise: Rf = 
0.6  (25% EtOAc in hexanes); []D21 = + 127.2 (c = 1.0, CHCl3),(-anomer); max(film)/cm–1 
2955 vw, 1743 vs, 1433 w, 1368 m, 1209 vs, 1148 s, 1087 m, 1051 s, 1025 s, 973 s, 913 w, 
732 w; H(400 MHz) 3.45 (1H, dd, J 9.7, 3.6, H-2′), 3.46–3.52 (1H, m, H-4′), 3.56–3.62 (2H, 




stack, H-6′A, H-6′B), 3.66–3.72 (1H, m, H-5′), 3.79 (1H, app. t, J 10.0, H-6A), 3.90 (1H, app. t, 
J 9.3, H-3′), 4.01 (1H, app. s, H-2), 4.12 (1H, dd, J 10.3, 4.5, H-6B), 4.21–4.43 (6H, stack, H-
3, H-4, H-5, three PhCH2 hydrogens), 4.45–4.56, (2H, stack, PhCH2), 4.65–4.80 (4H, stack, 
PhCH2), 4.90 (1H, d, J 10.9, PhCH2), 5.42 (1H, s, benzylidene CH), 5.45 (1H, d, J 3.5, H-1′), 
5.49 (1H, d, J 1.1, H-1), 6.89–6.92 (2H, stack, Ph), 7.02–7.48 (33H, stack, Ph); C(100 MHz) 
65.3 (CH, C-5), 68.6 (CH2, C-6, C-6′, resonance overlap), 70.6 (CH2, PhCH2), 70.9 (CH, C-5′), 
72.8 (CH, C-3), 73.3 (CH2, PhCH2), 73.4 (CH2, PhCH2), 75.0 (CH2, PhCH2), 75.5 (CH2, 
PhCH2), 77.4 (CH, C-4′), 78.8 (CH, C-2′), 79.1 (CH, C-2), 79.5 (CH, C-4), 81.3 (CH, C-3′), 87.2 
(CH, C-1), 97.0 (CH, C-1′), 102.4 (CH, benzylidene CH), [126.4, 127.2, 127.5, 127.6, 127.8, 
127.9, 128.0, 128.1, 128.3, 128.5, 129.1, 129.3, 128.5 (CH, Ph, resonance overlap)], 133.8 
(C, SPh ipso C), [137.3, 137.6, 137.9, 138.1, 138.4, 138.7 (C, Ph ipso C)]; m/z (TOF ES+) 
995.4 ([M + Na]+, 75%), 473.1 (100, [thioglycoside fragment + Na]+); HRMS m/z (TOF ES+) 




Concentrated H2SO4 (4 drops) was added to a solution of 2,3,4,6-Tetra-O-benzyl-D-
glucopyranose (200 mg, 0.37 mmol) in acetic anhydride (1.5 mL) and acetic acid (0.5 mL). 
After 30 min at rt the reaction mixture was poured into ice-water (20 mL). The aqueous phase 
was extracted with CH2Cl2 (3 × 30 mL). The combined organic extracts were washed with 
brine (50 mL) and then dried (Na2SO4). The solvent was removed under reduced pressure 
and the residue purified by flash column chromatography (30% EtOAc in hexane) to yield the 
acetate 115 as a colourless syrup and as a mixture of anomers [α:β, 1.0 : 0.2 (as determined 
by 1H-NMR), 162 mg, 82%]; Data for mixture unless specified otherwise: Rf = 0.5 (50% EtOAc 
in hexanes); H(400 MHz, -anomer) 2.03 (3H, s, C(O)CH3), 2.16 (3H, s, C(O)CH3), 3.54–3.60 




(1H, m, H-4), 3.67 (1H, dd, J 9.6, 3.6, H-2), 3.91–4.01 (2H, stack, H-3, H-5), 4.23 (1H, dd, J 
12.2, 2.6, H-6A), 4.29 (1H, dd, J 12.2, 3.9, H-6B), 4.57 (1H, A of AB, J 10.7, PhCHAHB), 4.64 
(1H, A of AB, J 11.5, PhCHCHD), 4.71 (1H, B of AB, J 11.5, PhCHCHD), 4.83 (1H, A of AB, J 
10.8, PhCHEHF), 4.89 (1H, B of AB, J 10.7, PhCHAHB), 4.99 (1H, B of AB, J 10.8, PhCHEHF), 
6.32 (1H, d, J 3.5, H-1), 7.27–7.37 (15H, stack, Ph); C(100 MHz, -anomer) 20.8 (CH3, 
C(O)CH3), 21.1 (CH3, C(O)CH3), 62.7 (CH2, C-6), 71.1 (CH, C-5), 73.2 (CH2, PhCH2), 75.3 
(CH2, PhCH2), 75.8 (CH2, PhCH2), 76.6 (CH, C-4), 78.9 (CH, C-2), 81.6 (CH, C-3), 89.7 (CH, 
C-1), [127.8, 127.9, 128.10, 128.14, 128.2, 128.5, 128.6 (CH, Ar CH, resonance overlap)], 
[137.4, 137.6, 138.4 (C, Ar C)], [169.4, 170.4 (C, C=O)]; visible resonances for minor -
anomer: H(400 MHz) 2.06 (3H, s, C(O)CH3), 5.62 (1H, d, J 8.2, H-1); C(100 MHz) 62.7 (CH2, 
C-6), 73.7 (CH, C-5), 75.1 (CH2, PhCH2), 84.8 (CH, C-3), 93.8 (CH, C-1); m/z (TOF ES+) 
557.2  ([M + Na]+, 100%). 




AcOH (15 L, 0.27 mmol) and ethylenediamine (15 L, 0.23 mmol) were added to a solution 
of diactate 115 (100 mg, 0.19 mmol) in THF (2 mL). After 24 h the THF was removed under 
reduced pressure and the crude residue was dissolved in CH2Cl2 (20 mL), washed with 2M 
HCl (20 mL), saturated sodium bicarbonate (20 mL) and then H2O (3 × 50 mL). The organic 
layer was dried (Na2SO4), filtered and the filtrate was concentrated under reduced pressure. 
The crude residue was purified using flash column chromatography (30% EtOAc in hexanes) 
to give glucosyl 116 as a colourless syrup and a mixture of anomers [α:β, 1.0 : 0.64 (as 
determined by 1H-NMR), 62 mg, 66%]; Data for mixture unless specified otherwise: Rf = 0.4 




(50% EtOAc in hexanes); max(film)/cm–1 3031 w, 2873 w, 1739 s (C=O), 1496 m, 1454 m, 
1363 m, 1235 s, 1147 m, 1067 vs, 1029 vs, 912 m, 748 s, 698 s; H(400 MHz, -anomer) 2.03 
(3H, s, C(O)CH3), 3.23 (1H, br s, OH), 3.48–3.60 (2H, stack, H-2, H-4), 4.02 (1H, spp. t, J 9.2, 
H-3), 4.08–4.12 (1H, m, H-5), 4.24–4.32 (2H, stack, H-6), 5.20 (1H, d, J 3.4, H-1), 4.58 (1H, A 
of AB, J 10.9, PhCHAHB), 4.70 (1H, A of AB, J 11.8, PhCHCHD), 4.78 (1H, B of AB, J 11.8, 
PhCHCHD), 4.84–4.91 (2H, stack, PhCH2), 4.99 (1H, B of AB, J 10.8, PhCHEHF), 7.27–7.39 
(15H, stack, Ar CH); C(100 MHz, -anomer) 20.9 (CH3, C(O)CH3), 63.0 (CH2, C-6), 68.8 (CH, 
C-5), 73.3 (CH2, PhCH2), 75.0 (CH2, PhCH2), 75.7 (CH2, PhCH2), 77.16 (CH, C-4), 80.0 (CH, 
C-2), 81.6 (CH, C-3), 91.1 (CH, C-1), [127.7, 127.77, 127.84, 127.9, 128.01, 128.05, 128.1, 
128.4, 128.5 (CH, Ar CH, resonance overlap)], 137.6, 137.67, 137.73, 138.2, 138.3, 138.4 (C, 
Ar C, ) 170.8 (C, C=O); visible resonances for minor -anomer: H(400 MHz) 2.04 (3H, s, 
C(O)CH3), 3.42 (1H, dd, J 9.1, 7.8, H-2), 3.67–3.72 (1H, m, H-3) C(100 MHz) 21.0 (CH3, 
C(O)CH3), 63.1 (CH2, C-6), 73.0 (CH, C-5), 74.8 (CH2, PhCH2), 77.20 (CH, C-4), 83.0 (CH, C-
2), 84.5 (CH, C-3), 97.4 (CH, C-1); m/z (TOF ES+) 515.2 ([M + Na]+, 100%); HRMS m/z (TOF 
ES+) 515.2044 [M + Na]+, C29H32O7Na requires 515.2046. 

















CBr4 (101 mg, 0.30 mmol) and Ph3P (80 mg, 0.30 mmol) were added sequentially to a 
solution of glucosyl 116 (50 mg, 0.10 mmol) in CH2Cl2 (3 mL) at rt. The reaction mixture 
was stirred for 3 h. In a separate flask, a solution of tetramethyl urea (TMU) (0.3 mL), 
Bu4NBr (97 mg, 0.30 mmol) and acceptor 92 (45 mg, 0.10 mmol) CH2Cl2 (2 mL), were 
stirred over activated 3 Å MS for 30 min, after which time, this solution was added dropwise 
(2 min) via syringe to the solution containing the glycosyl donor. The reaction mixture was 
stirred at r.t. for 2 d until the donor was no longer being consumed (as judged by TLC). 
The reaction mixture was then filtered through a silica plug, washed with CH2Cl2 (30 mL) 
and concentrated under reduced pressure to provide the crude product. Purification of the 
residue by flash column chromatography (10% EtOAc in hexane) afforded glycoside 118 
as a colourless oil (24 mg, 26%): Rf = 0.5 (25% EtOAc in hexanes); []D22 = +109.3 (c = 1.0, 
CHCl3); max(film)/cm–1 2910 vw, 1740 m (C=O), 1454 m, 1365 w, 1234 m, 1092 vs, 1039 vs, 
1027 vs, 1004 s, 967 m, 907 m, 741 vs, 696 vs; H(400 MHz) 2.00 (3H, s, CH3), 3.30 (1H, app. 
t, J 9.4, H-4′), 3.41 (1H, dd, J 9.6, 3.6, H-2′), 3.71–3.83 (2H, stack, H-6A, H-5′), 3.91 (1H, app. 
t, J 9.2, H-3′), 3.99–4.02 (1H, m, H-2), 4.08–4.19 (3H, stack, H-6B, H-6′A, H-6′B), 4.22 (1H, d, J 
12.3, PhCH2), 4.25–4.39 (3H, stack, H-3, H-4, H-5), 4.45 (1H, d, J 11.0, PhCH2), 4.49 (1H, d, 
J 12.3, PhCH2), 4.67 (1H, d, J 10.9, PhCH2), 4.72 (1H, A of AB, J 11.9, PhCHAHB), 4.76 (1H, 
B of AB, J 11.9, PhCHAHB), 4.80 (1H, d, J 11.0, PhCH2), 4.92 (1H, d, J 10.9, PhCH2), 5.39 
(1H, d, J 3.6, H-1′), 5.42 (1H, s, benzylidene CH), 5.51 (1H, d, J 0.9, H-1), 6.88–6.91 (2H, 
stack, Ph), 7.05–7.40 (28H, stack, Ph);  C(100 MHz) 21.0 (CH3), 63.5 (CH2, C-6′), 65.3 (CH), 




68.6 (CH2, C-6), 69.4 (CH, C-5′), 70.6 (CH2, PhCH2), 73.0 (CH), 73.4 (CH2, PhCH2), 75.1 (CH2, 
PhCH2), 75.6 (CH2, PhCH2), 77.3 (CH, C-4′), 78.7 (CH, C-2′), 79.2 (CH, C-2), 79.5 (CH), 81.3 
(CH, C-3′), 87.2 (CH, C-1), 96.9 (CH, C-1′), 102.6 (CH, benzylidene CH), [126.5 ,127.28 
,127.34 ,127.6 ,127.8 ,128.09 ,128.18 ,128.23 ,128.37 ,128.43 ,128.6 ,129.2 ,129.4 ,131.5 
(CH, Ph, resonance overlap)], [133.7 ,137.3 ,137.5 ,137.99 ,138.03, 138.6 (C, Ph, ipso C)] 
,170.9 (C, C=O); m/z (TOF ES+) 947.3 ([M + Na]+, 100%; HRMS m/z (TOF ES+) 947.3462 [M 







A solution of thioglycoside 105 (65 mg, 0.066 mmol) and acceptor 83 (65 mg, 0.066 mmol) in 
CH2Cl2 (2 mL) was stirred over activated 4 Å molecular sieves (70 mg) for 30 mins. NIS (30 
mg, 0.132 mmol) was added and the mixture stirred for a further 10 min before cooling to –20 
°C. TfOH (2 L, 0.02 mmol) was added and after 2 h the reaction was quenched by addition 
of Et3N (0.5 mL). The solution was diluted with CH2Cl2 (20 mL) before being filtered through a 
Celite pad. The filtrate was washed sequentially with Na2S2O3 solution (20 mL), H2O (20 mL) 
and brine (20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (10% EtOAc in hexanes) to afford 




tetrasaccharide 119 as a colourless oil and as a mixture of anomers (27 mg, 22%): Data for 
mixture unless specified otherwise: Rf = 0.5 (25% EtOAc in hexanes); max(film)/cm–1 2923 m, 
2862 m, 2094 m (N3), 1495 m, 1453 m, 1361 m, 1279 m, 1209 m, 1052 br vs, 913 m, 814 m, 
736 vs, 696 vs; H(400 MHz) 1.20–1.27 (2H, stack), 1.35–1.50 (4H, stack), 3.07–3.18 (3H, 
stack), 3.37–3.47 (3H, stack), 3.45–3.66 (7H, stack), 3.71–3.77 (3H, stack), 3.78–3.88 (5H, 
stack), 3.89–3.96 (3H, stack), 4.02 (1H, dd, J 10.0, 4.8), 4.09–4.14 (2H, stack), 4.22 (1H, A of 
AB, J 12.3, PhCHAHB), 4.26–4.32 (2H, stack), 4.35–4.40 (2H, stack), 4.41–4.43 (2H, stack), 
4.45–4.54 (7H, stack), 4.59–4.67 (5H, stack), 4.70–4.79 (3H, stack), 4.85–4.89 (2H, stack), 
5.08 (1H, d, J 1.3), 5.10 (1H, d, J 1.1), 5.37 (1H, s, benzylidene CH), 5.47 (1H, d, J 3.5), 7.00–
7.30 (60H, stack, Ar CH); C(100 MHz) 23.3 (CH2), 28.6 (CH2), 29.0 (CH2), 51.3 (CH2), 64.6 
(CH), 67.4 (CH2), 68.1 (CH2), 68.8 (CH2), 69.4 (CH2), 69.7 (CH2), 70.7 (CH2), 70.8 (CH), 71.9 
(CH), 72.1 (CH), 73.3 (CH2), 73.5 (CH2), 74.9 (CH), 75.1 (CH2), 75.1 (CH2), 75.2 (CH2), 75.3 
(CH), 75.5 (CH2), 76.0 (CH), 77.1 (CH), 77.7 (CH), 79.0 (CH), 79.2 (CH), 79.7 (CH), 81.4 (CH), 
96.8, (CH), 98.7 (CH), 100.8 (CH), 101.1 (CH), 102.4 (CH, benzylidene CH), [126.5, 127.2, 
127.3, 127.4, 127.5, 127.6, 127.7, 127.8, 128.0, 128.1, 128.23, 128.29, 128.34, 128.5, 128.6, 
129.2 (CH, Ar CH, resonance overlap)], [137.5, 137.9, 138.0, 138.2, 138.3, 138.4, 138.6, 



















5% NaOH solution (7 mL) was added to solution of diol 86 (1.00 g, 2.77 mmol) and Bu4HSO4 
(190 mg, 0.55 mmol) in CH2Cl2 (80 mL) at –3 °C. A solution of BzCl (0.35 mL, 3.05 mmol) in 
CH2Cl2 (5 mL) was added to the biphasic mixture over 5 min. After 35 min, the phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2  10 mL). The combined 
organic fractions were washed sequentially with NaHCO3 solution (50 mL) and brine (50 mL), 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified 
by flash column chromatography (10% EtOAc in hexanes) to afford in order of elution , bis-
benzoate 121 as a white solid (410 mg, 26%): Rf = 0.5 (20% EtOAc in hexanes); m.p. 145–
148 °C, lit.64 141-143 °C; []D21 = +6.0 (c = 1.0, CHCl3), lit.64 []D27 = +4.3 (c = 1.0, CHCl3); 
max(film)/cm–1 1731 s (C=O), 1709 s (C=O), 1478 w, 1451 w, 1378 w, 1364 w, 1277 s, 1249 
s, 1177 m, 1086 vs, 1066 vs, 1026 s, 1011 s, 1002 s, 964 s, 744 s, 713 vs, 697 vs, 689 vs; 
H(400 MHz) 3.99 (1H, app. t, J 10.3, H-6A), 4.35 (1H, dd, J 10.4, 4.9, H-6B), 4.43 (1H, app. t, 
J 9.9, H-4), 4.65 (1H, app. td, J 9.9, 4.6, H-5), 5.69 (1H, d, J 1.3, H-1), 5.70 (1H, s, benzylidene 
CH), 5.84 (1H, dd, J 10.3, 3.4, H-3), 5.98 (1H, dd, J 3.4 1.3, H-2), 7.31–7.39 (8H, stack, Ph), 
7.47–7.53 (5H, stack, Ph), 7.54–7.58 (2H, stack, Ph), 7.60–7.66 (1H, m, Ph), 7.92–7.97 (2H, 
stack, Ph), 8.06–8.11 (2H, stack , Ph); C(100 MHz) 65.3 (CH, C-5), 68.6 (CH2, C-6), 69.2 (CH, 
C-3), 72.5 (CH, C-2), 76.9 (CH, C-4), 87.0 (CH, C-1), 102.0 (CH, benzylidene CH), [126.2, 
128.2, 128.3, 128.6, 129.1, 129.3 (CH, Ph)], [129.4, 129.5 (C, Ph ipso C)], [129.8, 129.9, 132.4 
(CH, Ph)], 132.9 (C, Ph ipso C), [133.2, 133.6 (CH, Ph)], 137.0 (C, Ph ipso C), [165.3, 165.4 
(C, C=O)]; m/z (TOF ES+) 591.1 ([M + Na]+, 100%), followed by monobenzoate 120 (0.62 g, 




48%): Rf = 0.29 (20% EtOAc in hexanes); m.p. 131–136 °C, lit.64 150–151 °C; []D21 = +85.6 
(c = 1.0, CHCl3), lit.64 []D27 = +131.3 (c = 1.0, CHCl3); max(film)/cm–1 3477 br w, 3061 w, 2868 
w, 1721 s (C=O), 1382 m, 1266 s, 1091 vs, 1025 s, 1001 s, 965 s, 740 s, 710 s, 699 s; H(400 
MHz) 2.53 (1H, br s, OH), 3.82 (1H, app. t, J 10.3, H-6A), 4.04 (1H, app. t, J 9.7, H-4), 4.21 
(1H, dd, J 10.3, 4.9, H-6B), 4.27 (1H, dd, J 9.9, 3.5, H-3), 4.37 (1H, app. dt, J 9.9, 4.9, H-5), 
5.55 (1H, d, J 1.1, H-1), 5.59 (1H, s, benzylidene CH), 5.65 (1H, dd, J 3.5, 1.1, H-2), 7.20–
7.55 (13H, stack, Ph), 7.99–8.03 (2H, stack, Ph); C(100 MHz); 64.6 (CH, C-5), 68.0 (CH, C-
3), 68.5 (CH2, C-6), 74.1 (CH, C-2), 79.5 (CH, C-4), 87.0 (CH, C-1), 102.3 (CH, benzylidene 
CH), [126.3, 128.0, 128.4, 128.5, 129.2, 129.4, 129.9, 132.1 (CH, Ph)], 133.1 (C, Ph ipso C), 
133.5 (CH, Ph) 137.0 (C, Ph ipso C, resonance overlap), 165.9 (C, C=O); m/z (TOF ES+) 
487.1 ([M + Na]+, 100%). 
 
Data were in agreement with those reported in the literature.64 
 
Methyl 2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranose (122) 
 
A solution of orthoester 44 (0.3 g, 0.59 mmol) in CH2Cl2 (2 mL) was stirred over activated 
powdered 4 Å molecular sieves (100 mg) for 30 min. The solution was then cooled to 0 °C and 
TMSOTf (11 µL, 0.061 mmol, 10 mol%) was added dropwise over 0.5 min. The reaction 
mixture was stirred for 1 h and then diluted with CH2Cl2 (10 mL) and filtered. The filtrate was 
washed with NaHCO3 solution (3 × 10 mL). The aqueous phase was extracted with CH2Cl2 (2 
× 50 mL). The combined organic extracts were washed with brine (100 mL) and then dried 
(Na2SO4). The solvent was removed under reduced pressure and the residue purified by flash 
column chromatography (15% EtOAc in hexane) to yield the acetate 122 as a colourless syrup 




(0.26 g, 87%): Rf = 0.40 (30% EtOAc in hexanes); []D21 = +432.8 (c = 1.0, CHCl3), lit.42 []D19 
= +29.2 (c = 5.8, CHCl3); max(film)/cm–1 2910 w, 1744 s (C=O), 1496 w, 1453 m, 1366 m, 
1286 w, 1233 vs, 1138 s, 1076 vs, 1059 vs, 1027 s, 971 s, 913 w, 847 w, 735 vs, 696 vs; 
H(400 MHz) 2.08 (3H, s, acetyl CH3), 3.28 (3H, s, OCH3), 3.61–3.75 (3H, stack, H-5, H-6A, H-
6B), 3.80 (1H, app. t, J 9.3, H-4), 3.89 (1H, dd, J 9.2, 3.2, H-3), 4.40 (1H, d, J 10.8, PhCH2), 
4.42–4.47 (2H, stack, PhCH2), 4.58–4.67 (2H, stack, PhCH2), 4.66 (1H, d, J 1.4, H-1), 4.78 
(1H, d, J 10.8, PhCH2), 5.29 (1H, dd, J 3.2, 1.6, H-2), 7.08–7.10 (2H, stack, Ph), 7.16–7.30 
(13H, stack, Ph);C(100 MHz) 21.2 (CH3, acetyl CH3), 55.0 (CH3, OCH3), 68.7 (CH, C-2), 68.9 
(CH2, C-6), 71.3 (CH, C-5), 71.8 (CH2, PhCH2), 73.5 (CH2, PhCH2), 74.3 (CH, C-4), 75.2 (CH2, 
PhCH2), 78.2 (CH, C-3), 98.8 (CH, C-1), [127.6, 127.77, 127.82, 128.1, 128.3, 128.4 (CH, Ph, 
resonance overlap)], [138.0, 138.2, 138.4 (C, Ph, ipso C)], 170.5 (C, C=O); m/z (TOF ES+) 
([M + Na]+, 100%).  
Data were in agreement with those reported in the literature.42 
 
Methyl 3,4,6-tri-O-benzyl--D-mannopyranose (123) 
 
NaOMe (1.0 mL of a 0.5 M soln. in MeOH, 0.5 mmol) was added to a solution of acetate 122 
(0.2 g, 0.39 mmol) in MeOH (10 mL). After stirring at rt for 3 h, the reaction mixture was 
neutralised by the addition of acidic ion-exchange resin [Dowex H CR-S, pre-washed 
sequentially with MeOH (100 mL) and CHCl3 (50 mL)]. The solution was filtered and the resin 
washed sequentially with MeOH (2 × 20 mL) and CHCl3 (2 × 20 mL). The filtrate was 
concentrated under reduced pressure and the residue purified by column chromatography 
(25% EtOAc in hexanes) to provide alcohol 123 as a colourless oil (0.176 g, 96%): Rf = 0.25 
(30% EtOAc in hexanes); []D21 = + 448.2 (c = 1.0, CHCl3), lit.42 []D19 = +50.7 (c = 6.7, CHCl3); 




max(film)/cm–1 3368 br m (OH), 2910 w, 1637 m, 1453 m, 1363 w, 1209 w, 1098 s, 1055 s, 
1025 m, 970 m, 907 w, 734 s, 696 s; H(400 MHz) 3.38 (3H, s, OCH3), 3.70–3.80 (3H, stack, 
H-6A, H-6B, H-5), 3.83–3.91 (2H, stack, H-3, H-4), 4.05 (1H, dd, J 2.6, 1.8, H-2), 4.52 (1H, d, J 
10.9, PhCH2), 4.56 (1H, d, J 12.2, PhCH2), 4.67 (1H, d, J 12.2, PhCH2), 4.70 (2H, AB quartet 
J 11.5, PhCH2), 4.58 (1H, A of AB, J 11.6, PhCHAHB), 4.62 (1H, B of AB, J 11.6, PhCHAHB),  
4.82 (1H, d, J 1.8, H-1), 4.84 (1H, d, J 10.9, PhCH2), 7.16–7.21 (2H, stack, Ph), 7.25–7.40 
(13H, stack, Ph); C(100 MHz) 54.8 (CH3, OMe) 68.2 (CH, C-2), 68.9 (CH2, C-6), 70.9 (CH, C-
5), 71.9 (CH2, PhCH2), 73.4 (CH2, PhCH2), 74.2 (CH, C-4), 75.0 (CH2, PhCH2), 80.1 (CH, C-
3), 100.2 (CH, C-1), [127.5, 127.6, 127.8, 128.1, 128.3, 128.5, (CH, Ph, resonance overlap)], 
[137.9, 138.2, 138.3 (C, Ph, ipso C)]; m/z (TOF ES+) 487.2 ([M + Na]+, 100%). 






A solution of thioglycoside 121 (100 mg, 0.176 mmol) and acceptor 123 (100 mg, 0.215 mmol) 
in CH2Cl2 (2 mL) was stirred over activated 4 Å molecular sieves (150 mg) for 30 mins. NIS 
(79 mg, 0.352 mmol) was added and the mixture stirred for a further 10 min before cooling to 
–20 °C. TfOH (5 L, 0.053 mmol) was added and after 2 h the reaction was quenched by 
addition of Et3N (0.5 mL). The solution was diluted with CH2Cl2 (25 mL) before being filtered 
through a Celite pad. The filtrate was washed sequentially with Na2S2O3 solution (20 mL), H2O 




(20 mL) and brine (20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. 
The residue was purified by flash column chromatography (10% EtOAc in hexanes) to afford 
disaccharde 124 as a colourless oil (120 mg, 74%): Rf = 0.5 (25% EtOAc in hexanes); []D21 
= +359.2 (c = 1.0, CHCl3); max(film)/cm–1 2911 w, 1729 s (C=O), 1452 m, 1364 w, 1314 w, 
1272 s, 1218 w, 1176 w, 1135 m, 1093 vs, 1068 vs, 1058 vs, 1026 s, 969 m, 916 w, 751 m, 
712 s, 698 s, 667 m; H(400 MHz) 3.29 (3H, s, OCH3), 3.67–3.74 (3H, stack, H-6, H-5), 3.81–
3.89 (3H, stack, H-3, H-4, H-6′A), 3.95–3.97 (1H, m, H-2), 4.12–4.24 (2H, stack, H-4′ and H-
5′), 4.27 (1H, dd, J 10.2, 4.4, H-6′B), 4.49 (1H, d, J 10.9, PhCH2), 4.52–4.66 (4H, stack, 2 × 
PhCH2), 4.74 (1H, d, J 1.7, H-1), 4.78 (1H, d, J 10.9, PhCH2), 5.14 (1H, d, J 1.3, H-1′), 5.55 
(1H, s, benzylidene CH), 5.80 (1H, dd, J 9.5, 3.5, H-3′), 5.84 (1H, dd, J 3.5, 1.3, H-2′), 6.96–
7.02 (1H, m, Ph), 7.03–7.28 (17H, stack, Ph), 7.30–7.44 (7H, stack, Ph), 7.50–7.54 (1H, m, 
Ph), 7.80–7.84 (2H, stack, Ph), 7.96–8.00 (2H, stack, Ph); C(100 MHz) 54.8 (CH3, OCH3), 
64.3 (CH, C-4′), 68.9 (CH2, C-6′), 69.0 (CH, C-3′), 69.4 (CH2, C-6), 70.8 (CH, C-2′), 72.0 (CH, 
C-5), 72.6 (CH2, PhCH2), 73.5 (CH2, PhCH2), 75.0 (CH, C-4), 75.3 (CH2, PhCH2), 75.4 (CH, 
C-2), 77.0 (CH, C-5′), 80.0 (CH, C-3), 99.8 (CH, C-1), 100.2 (CH, C-1′), 102.0 (CH, 
benzylidene CH), [126.3, 127.5, 127.6, 127.8, 128.2, 128.3, 128.4, 128.6, 129.1, (CH, Ph, 
resonance overlap)],129.7 (C, Ph, ipso C), [129.8, 129.9, 133.0, 133.5 (CH, Ph)], [137.2, 
138.3, 138.4, 138.6 (C, Ph, ipso C)], [165.1, 165.3 (C, C=O)]; m/z (TOF ES+) 945.3 ([M + Na]+, 














CBr4 (430 mg, 1.29 mmol) and Ph3P (338 mg, 1.29 mmol) were added sequentially to a 
solution of 2,3,4,6-tetra-O-benzyl-D-galactose 114 (227 mg, 0.42 mmol) in CH2Cl2 (5 mL) 
at rt. The reaction mixture was stirred for 3 h. In a separate flask, a solution of tetramethyl 
urea (TMU) (0.3 mL), Bu4NBr (415 mg, 1.29 mmol) and acceptor 120 (200 mg, 0.43 mmol) 
in CH2Cl2 (5 mL), were stirred over activated 3 Å MS for 30 min, after which time, this 
solution was added dropwise (5 min) via syringe to the solution containing the glycosyl 
donor. The reaction mixture was stirred at r.t. for 3 d until the donor was no longer being 
consumed (as judged by TLC). The reaction mixture was then filtered through a silica plug, 
washed with CH2Cl2 (50 mL) and concentrated under reduced pressure to provide the 
crude product. Purification of the residue by flash column chromatography (10% EtOAc in 
hexane) afforded glycoside 125 as a colourless oil (236 mg, 57%): Rf = 0.6 (25% EtOAc in 
hexanes); []D21 = +67.2 (c = 1.0, CHCl3); max(film)/cm–1 3030 w, 3865 w, 1730 m (C=O), 1454 
m, 1242 s, 1215 m, 1165 m, 1093 vs, 1059 vs, 1027 vs, 736 vs, 695 vs; H(400 MHz) 3.39 
(1H, dd, J 9.7, 3.7, H-2′), 3.48 (1H, app. t, J 9.5, H-4′), 3.58–3.64 (2H, stack, H-6′A, H-6′B), 3.68 
(1H, app. t, J 9.3, H-3′), 3.76–3.84 (2H, stack, H-5′, H-6A), 4.17 (1H, dd, J 10.3 4.8, H-6B), 
4.23–4.37 (3H, stack, H-4, PhCH2), 4.38–4.46 (5H, stack, H-3, H-5, three Bn hydrogens), 
4.54–4.70 (3H, stack, 3 × Bn hydrogens), 5.38 (1H, d, J 3.7, H-1′), 5.42 (1H, s, benzylidene 
CH), 5.59 (1H, d, J 1.2, H-1), 5.66 (1H, dd, J 3.4, 1.2, H-2), 6.87–6.91 (2H, stack, Ph), 6.99–
7.44 (30H, stack, Ph), 7.47–7.52 (1H, m, Ph), 8.04–8.08 (2H, stack, Ph);C(100 MHz) 65.0 




(CH, C-5), 68.4 (CH2, C-6′), 68.6 (CH2, C-6), 70.8 (CH2, PhCH2), 70.9 (CH, C-5′), 71.7 (CH, 
C-3), 73.5 (CH2, PhCH2) 74.3 (CH, C-2), 74.5 (CH2, PhCH2 protecting 4′-O), 75.4 (CH2, PhCH2 
protecting 3′-O), 77.2 (CH, C-4′), 79.0 (CH, C-2′), 79.7 (CH, C-4), 81.1 (CH, C-3′), 87.1 (CH, 
C-1), 97.5 (CH, C-1′), 102.4 (CH, benzylidene CH), [126.4, 127.0, 127.2, 127.4, 127.6, 128.0, 
128.1, 128.2, 128.4, 128.5, 129.2, 129.4 (CH, Ph)], 129.8 (C, Ph ipso C), [130.0, 132.0 (CH, 
Ph)], 133.1 (C, Ph ipso C), 133.4 (CH, Ph), [137.1, 138.0, 138.4, 138.6, 138.8 (C, Ph ipso C)], 
165.9 (C, C=O); m/z (TOF ES+) 1009.4 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 1009.3602 






















A solution of thioglycoside 125 (180 mg, 0.182 mmol) and acceptor 83 (180 mg, 0.182 mmol) 
in CH2Cl2 (2 mL) was stirred over activated 4 Å molecular sieves (200 mg) for 30 mins. NIS 
(82 mg, 0.364 mmol) was added and the mixture stirred for a further 10 min before cooling to 
–20 °C. TfOH (5 L, 0.55 mmol) was added and after 2 h the reaction was quenched by 
addition of Et3N (0.5 mL). The solution was diluted with CH2Cl2 (25 mL) before being filtered 
through a Celite pad. The filtrate was washed sequentially with Na2S2O3 solution (20 mL), H2O 
(20 mL) and brine (20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. 
The residue was purified by flash column chromatography (10% EtOAc in hexanes) to afford 
tetrasaccharide 126 as a colourless oil and as a mixture of anomers (148 mg, 43%). Data for 
mixture unless specified otherwise: Rf = 0.5 (25% EtOAc in hexanes); max(film)/cm–1 2923 m, 




2855 m, 2096 m (N3), 1726 m (C=O), 1493 m, 1453 m, 1362 m, 1264 s, 1095 br vs, 737 s, 
698 s; H(400 MHz) 1.20–1.27 (2H, stack), 1.35–1.50 (4H, stack), 3.10–3.16 (3H, stack), 3.35 
(1H, dd, J 9.6, 3.6), 3.43–3.57 (5H, stack), 3.60–3.83 (12H, stack), 3.85–4.10 (7H, stack), 
4.13–4.24 (4H, stack), 4.31 (1H, A of AB, J 11.3, PhCHAHB), 4.37–4.60 (16H, stack), 4.67 (1H, 
B of AB, J 11.3, PhCH2), 4.74 (1H, B of AB, J 10.7, PhCH2), 4.78 (1H, B of AB, J 10.9), 4.83 
(1H, d, J 1.55), 5.09 (1H, d, J 1.3), 5.13 (1H, d, J 1.5), 5.36 (1H, s, benzylidene CH), 5.39 (1H, 
d, J 3.5, H-2′′′′), 5.56 (1H, dd, J 3.6, 1.44, H-1′′′′), 7.00–7.30 (60H, stack, Ar CH); m/z (TOF 
ES+) 1893.7 ([M + Na]+, 100%); NaOMe (0.5 mL of a 0.5 M soln. in MeOH, 0.25 mmol) was 
added to a solution of benzoate 126 (148 mg, mmol) in MeOH (3 mL). After stirring at rt for 3 
h, the reaction mixture was neutralised by the addition of acidic ion-exchange resin [Dowex H 
CR-S, pre-washed sequentially with MeOH (20 mL) and CHCl3 (20 mL)]. The solution was 
filtered and the resin washed sequentially with MeOH (2 × 20 mL) and CHCl3 (2 × 20 mL). The 
filtrate was concentrated under reduced pressure and the residue purified by column 
chromatography (10% EtOAc in hexanes) to provide alcohol 127 as a colourless oil (0.111 g, 
35% over two steps): Rf = 0.3 (25% EtOAC in hexanes); max(film)/cm–1 3398 br m (O–H), 3031 
w, 2914 m, 2096 (N3), 1496 m, 1453 m, 1361 m, 1280 w, 1210 w, 1134 s, 1093 vs, 1053 vs, 
1027 vs, 913 m, 812 m, 736 vs, 696 vs; H(900 MHz) 1.35–1.39 (2H, stack, H-3), 1.51–1.55 
(2H, stack, H-2), 1.57–1.61 (2H, stack, H-4), 3.25–3.28 (3H, stack, H-1A, H-5), 3.59–3.62 (2H, 
stack, H-1B, H-2′′′′), 3.64–3.71 (3H, stack, H-4′′′′, H-6′′′′) 3.75–3.78 (2H, stack, H-5′, H-6′A), 
3.79–3.82 (2H, stack, H-6′′), 3.83–3.87 (4H, stack, H-4′, H-4′′ H-6′B, H-6′′′A) 3.94 (1H, ddd, J 
10.1, 3.5, 2.2, H-5′′′′), 3.96 (1H, dd, J 9.4, 3.0, H-3′), 3.99–4.01 (2H, stack, H-2′, H-3′′), 4.04 
(1H, app. t, J 9.3, H-3′′′′), 4.06 (1H, ddd, J 9.8, 4.6, 3.3, H-5′′), 4.11 (1H, app. dt, J 9.8, 5.0, H-
5′′′), 4.18 (1H, dd, J 10.3, 5.0, H-6′′′B), 4.21–4.22 (1H, m, H-2′′), 4.28 (1H, dd, J 3.1, 1.4, H-2′′′), 
4.30 (1H, app. t, J 9.6, H-4′′′), 4.36 (1H, A of AB, J 12.2, PhCHAHB), 4.38 (1H, dd, J 9.8, 3.2, 
H-3′′′), 4.45 (1H, A of AB, J 12.0, PhCHCHD), 4.47 (1H, A of AB, J 10.7, PhCHEHF), 4.54 (1H, 
A of AB, J 10.8, PhCHKHL), 4.58 (1H, B of AB, J 12.2, PhCHAHB), 4.60–4.65 (6H, stack, 
PhCH2), 4.71–4.76 (4H, stack, PhCH2), 4.85–4.90 (4H, stack, PhCH2), 4.98 (1H, d, J 1.6, H-




1′), 5.03 (1H, A of AB, J 10.9, PhCHPHQ), 5.20 (1H, d, J 1.1, H-1′′′), 5.24 (1H, d, J 1.5, H-1′′), 
5.52 (1H, d, J 3.8, H-1′′′′), 5.57 (1H, s, benzylidene CH), 7.06–7.08 (2H, stack, Ar CH), 7.16–
7.17 (2H, stack, Ar CH), 7.19–7.22 (4H, stack, Ar CH), 7.23–7.40 (43H, stack, Ar CH), (2H, 
stack, Ar CH), 7.42–7.44 (4H, stack, Ar CH);  C(100 MHz) 23.4 (CH2, C-3), 28.6 (CH2, C-4), 
29.0 (CH2, C-2), 51.3 (CH2, C-5), 64.1 (CH, C-5′′′), 67.3 (CH2, C-1), 68.2 (CH2, C-6′′′′), 68.8 
(CH2, C-6′′′), 69.4 (CH2, C-6′), 69.6 (CH2, C-6′′), 70.7 (CH, C-5′′′′), 71.1 (CH, C-2′′′), 71.2 (CH2, 
PhCH2), 71.9 (CH, C-5′), 72.10 (CH2, PhCH2), 72.14 (CH, C-5′′), 72.6 (CH2, PhCH2), [73.3, 
73.4 (CH2, 3 × PhCH2 and CH, C-3′′′, resonance overlap)], 74.9 (CH, C-4′), [75.1, 75.2 (CH2, 
3 × PhCH2 and CH, C-2′, C-4′′, resonance overlap)], 75.3 (CH, C-2′′), 75.6 (CH2, PhCH2), 75.9 
(CH, C-4′′), 77.3 (CH, C-4′′′′), 78.7 (CH, C-4′′′), 79.0 (CH, C-2′′′′), 79.1 (CH, C-3′), 79.6 (CH, C-
3′′), 81.4 (CH, C-3′′′′), 97.0, (CH, C-1′′′′), 98.7 (CH, C-1′), 101.1 (CH, C-1′′), 101.8 (CH, C-1′′′), 
102.3 (CH, benzylidene CH), [126.3, 127.4, 127.6, 127.68, 127.71, 127.8, 127.9, 128.0, 128.2, 
128.3, 128.5, 129.0 (CH, Ar CH, resonance overlap)], [137.3, 137.6, 138.0, 138.2, 138.3, 
138.7 (C, Ar C, resonance overlap)]; m/z (TOF ES+) 1789.8 ([M + Na]+, 70%), 906.4 ([M + 




















A flask containing a solution of tetrasaccharide 127 (110 mg, 0.062 mmol) in MeOH:AcOH 
(9:1, 10 mL) was purged with H2 gas for 10 min.  Pd(OH)2 (2 mg, cat.) was then added and 
the mixture was stirred under a flow of H2 for 24 h, after which time, the mixture was filtered 
through Celite, washing with MeOH (40 mL) and the filtrate was concentrated under reduced 
pressure. This procedure was repeated for another 24 h, until all of the protecting groups had 
been removed as evidenced by mass spectrometry analysis. Amine 128 was afforded as a 
white solid (21 mg, 45%): Selected data for amine 128: m/z (TOF ES+) 752.8 ([M + H]+, 50%), 
774.7 ([M  + Na]+, 50%). Biotin NHS ester 65 (12 mg, 0.034 mmol) was added to a solution of 
amine 128 (21 mg, 0.028 mmol) in pyridine:H2O (2 mL, 9:1). After 14 h at 60 °C, the reaction 
mixture was co-evaporated with toluene under reduced pressure and purified by flash column 




chromatography (30% MeOH in EtOAC) to afford amide 13 (18 mg, 68%) as an off white foam: 
Rf = 0.3 (4:2:1, EtOAc:MeOH:H2O); max(film)/cm–1 3300 br m (O–H), 2919 s, 2853 m, 1680 vs 
(C=O), 1635 s (C=O), 1591 m, 1457 m, 1400 m, 1360 m, 1246 m, 1206 m, 1128 s, 1090 vs, 
1052 vs, 1029 vs, 919 m, 819 m, 700 m; H(400 MHz,1:1 CDCl3:CD3OD) 1.33–176 (12H, 
stack), 2.01 (2H, t, J 7.3, H-1′′′′′), 2.67–2.74 (1H, m, H-8′′′′′A), 2.94 (1H, dd, J 12.8, 4.9, H-8′′′′′B), 
3.15–3.25 (4H, stack), 3.37–3.90 (23H, stack), 4.01 (1H, m), 4.22–4.24 (1H, m), 4.31 (1H, dd, 
J 7.9, 4.4, H-6′′′′′), 4.50 (1H, dd, J 7.9, 4.3, H-7′′′′′), 4.97 (1H, d, J 1.7), 5.05–5.06 (1H, m), 5.15 
(1H, d, J 3.9, H-1′′′), 5.29 (1H, d, J 1.3) exchangeable hydrogens not observed; C(100 MHz) 
24.8, 27.0, 29.6, 29.8, 30.2, 30.3, 33.5, 36.9, 37.9, 40.3, 41.1, 57.1, 61.7, 63.0, 63.1, 63.2, 
63.5, 67.8, 68.5, 69.2, 69.3, 71.1, 72.0, 72.1, 72.3, 74.1, 74.2, 74.7, 75.0, 75.1, 75.3, 80.5, 
81.0, 81.5, 99.8, 101.8, 102.5, 104.2, 166.2, 176.1; m/z (TOF ES+) 1000.4 ([M + Na]+, 100%); 
















5.3. Chapter 3  
 
Imidazole-1-sulfonyl azide hydrochloride (182) 
 
SO2Cl2 (16.1 mL, 200 mmol) was added dropwise over 30 min to an ice-cooled suspension of 
NaN3 (13.0 g, 200 mmol) in dry CH3CN (200 mL). The reaction mixture was stirred overnight 
at rt. Imidazole (25.9 g, 380 mmol) was then added portionwise over 1 h to the ice-cooled 
mixture and the resulting slurry was stirred for 3 h at rt. The mixture was then diluted with 
EtOAc (400 mL), washed sequentially with H2O (2 × 400 mL) and NaHCO3 solution (2 × 400 
mL), dried over Na2SO4 and filtered. A solution of HCl in EtOH [obtained by dropwise addition 
of AcCl (21.2 mL, 300 mmol) to ice-cooled dry EtOH (75 mL)] was added dropwise over 10 
min to the filtrate with stirring. The mixture was chilled in an ice bath, filtered and the filter cake 
washed with EtOAc (3 × 100 mL) to give azide 182 as a white solid (29.3 g, 70%): m.p. 103–
104 °C, lit.127 100–102 °C; H(400 MHz, D2O) 7.64 (1H, app. s), 8.06 (1H, app. s), 7.43 (1H, 
app. s); C(100 MHz, D2O) 120.1 (CH), 123.1 (CH), 137.7 (CH); m/z (ASAP) 174.1 ([M – Cl]+, 
100%), 146.1 ([M – Cl – N2]+, 70%); HRMS m/z (ASAP) 174.0083 [M – Cl]+, C3H4N5O2S 
requires 174.0086. 
 











(2S, 3S, 4R)-2-Azido-3, 4-O-isopropylidene-1, 3, 4-octadecanetriol (184) 
 
 
A solution of imidazole-1-sulfonyl azide hydrochloride 182 (6.60 g, 31.5 mmol) in CH2Cl2 (50 
mL) was added to a vigorously stirred solution of phytosphingosine 179 (6.00 g, 15.6 mmol), 
CuSO4 (40 mg, 0.16 mmol) and K2CO3 (3.23 g, 23.4 mmol) in H2O (47 mL).  MeOH (157 mL) 
was added dropwise over 10 min and the mixture was stirred vigorously at rt for 18 h. The 
solution was then diluted with CH2Cl2 (400 mL) and washed sequentially with NaHCO3 solution 
(100 mL), H2O (70 mL) and brine (70 mL). The organic layer was dried over Na2SO4, filtered 
and the filtrate concentrated under reduced pressure. The crude azide 183 was isolated as a 
white solid and used directly in the next step without further purification (6.49 g, quant.): Rf = 
0.7 (100% EtOAc); m.p. 91–94 °C (lit.111  92–94 °C); solubility issues prevented an optical 
rotation measurement data; max(film)/cm–1  3261 br w (O–H), 2916 s, 2847 s, 2096 s (N3), 
1590 w, 1461 m, 1248 m, 1098 w, 1058 s, 1008 m, 922 w, 857 m, 723 s; H(300 MHz, 
(CD3)2SO) 0.85 (3H, t, J 6.8, CH3), 1.21–1.30 (23H, stack, alkyl chain), 1.36–1.64 (3H, stack, 
alkyl chain), 3.23–3.38 (2H, stack), 3.48–3.65 (2H, stack), 3.71–3.79 (1H, m), 4.55 (1H, d, J 
6.4, OH), 4.91 (1H, app t, J 4.9, OH), 5.04 (1H, d, J 5.7, OH); C(100 MHz, (CD3)2SO) 14.0 
(CH3, CH3), 22.1 (CH2, alkyl chain), 25.1 (CH2, alkyl chain),  [28.7, 29.1, 29.2 (CH2, alkyl chain, 
significant resonance overlap)], 31.3 (CH2, alkyl chain), 33.0 (CH2, alkyl chain), 60.0 (CH2, 
CH2OH), 65.4 (CH, CHN3), [70.7, 74.5 (CH, 2 × CHOH)]; m/z (TOF ES+) 366.3 ([M + Na]+, 
100%); HRMS m/z (TOF ES+) 366.2727 [M + Na]+, C18H37N3O3Na requires 366.2733. Data 
were in agreement with those reported in the literature.111  Concentrated H2SO4 (4 drops) was 
added to a solution of azide 183 (6.40 g, 18.6 mmol) in dry acetone (50 mL) at 0 °C.  After 
stirring for 20 h, the reaction mixture was quenched by the addition of solid NaHCO3 and then 




concentrated under reduced pressure. The residue was partitioned between EtOAc (35 mL) 
and H2O (30 mL). The layers were separated and the aqueous phase was extracted with 
EtOAc (3 × 20 mL).  The combined organic layers were washed with brine (20 mL), then dried 
over Na2SO4, filtered and the filtrate concentrated under reduced pressure. The crude product 
was purified by column chromatography (20% EtOAc in hexanes) to give acetonide 184 as a 
white, low-melting point, amorphous solid (4.47 g, 63%): Rf = 0.6 (20% EtOAc in hexanes); 
[]D20  = +26.8 (c = 1.0, CHCl3), lit. 111 []D22  = + 23 (c = 1.0, CHCl3); max(film)/cm–1 3435 br w 
(O–H), 2920 s, 2851 s, 2136 m, 2116 m, 2095 s (N3), 1471 m, 1426 vw, 1382 w, 1370 w, 1317 
w, 1261 m, 1208 s, 1165 m, 1102 m, 1065 m, 1019 s, 970 w, 883 m, 857 w, 826 w, 719 m; 
H(300 MHz) 0.90 (3H, t, J 6.5, CH2CH3), 1.25–1.33 (23H, stack, alkyl chain), 1.35 [3H, s, 
C(CH3)A(CH3)B], 1.45 [3H, s, C(CH3)A(CH3)B], 1.53–1.67 (3H, stack, alkyl chain), 2.18 (1H, br 
s, OH), 3.45–3.53 (1H, m), 3.83–3.94 (1H, m), 3.95–4.06 (2H, stack), 4.16–4.24 (1H, m); 
C(100 MHz) 14.4 (CH3, CH2CH3), 22.9 (CH2, alkyl chain), 25.8 [CH3, C(CH3)A(CH3)B], 26.5 
(CH2, alkyl chain), 28.3 [CH3, C(CH3)A(CH3)B], [29.6, 29.8, 29.9 (CH2, alkyl chain, significant 
resonance overlap)], 32.2 (CH2, alkyl chain), 61.4 (CH, C-2), 64.2 (CH2, C-1), [76.9, 77.9 (CH, 
C-3, C-4)], 108.7 [C, C(CH3)2]; m/z (TOF ES+) 406.3 ([M + Na]+, 30%), 356.3 (100, [M – N2 + 
H]+); HRMS m/z (TOF ES+) 406.3050 [M + Na]+, C21H41N3O3Na requires 406.3046, and then 
triol 183 (2.0 g, 31 %).  Data were in agreement with those reported in the literature.111  
 
(2S, 3S, 4R)-2-Azido-3, 4-O-isopropylidene-1-O-methanesulfonyl-1, 3, 4-octadecanetriol 
(185) 
 
Et3N (1.09 mL, 7.82 mmol) and MsCl (0.31 mL, 5.21 mmol) were added sequentially to a 
solution of alcohol 184 (1.00 g, 2.61 mmol) in THF (30 mL) at rt. The reaction mixture was 




stirred for 3 h and then quenched with NaHCO3 solution (20 mL). The phases were separated 
and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic layers 
were washed with brine (25 mL), dried over Na2SO4, filtered and the filtrate was concentrated 
under reduced pressure to yield mesylate 185 as a low-melting point, amorphous solid, which 
was used without further purification (1.13 g, 94%): Rf = 0.4 (15% EtOAc in hexanes); []D20  
= +6.0 (c = 1.0, CHCl3) lit.182 []D21 +8.9 (c 0.45, CHCl3); max(film)/cm–1 2995 w, 2944 m, 2918 
vs, 2850 s, 2127 m, 2096 s (N3), 1471 m, 1455 w, 1377 w, 1340 vs, 1324 s, 1280 w, 1252 m, 
1224 s, 1167 s, 1109 m, 1067 m, 1032 m, 988 s, 967 vs, 951 s, 922 w, 879 m, 868 m, 856 m, 
824 s, 799 w, 782 w, 737 m, 717 m, 653 w; H(300 MHz) 0.87 (3H, t, J 6.7, CH2CH3), 1.23–
1.30 (20H, stack, alkyl chain), 1.31 [3H, s, C(CH3)A(CH3)B], 1.33–1.39 (3H, stack, alkyl chain), 
1.42 [3H, s, C(CH3)A(CH3)B], 1.51–1.66 (3H, stack, alkyl chain), 3.09 (3H, s, SO2CH3), 3.67–
3.75 (1H, m), 3.85 (1H, dd, J 9.4, 5.5), 4.14–4.22 (1H, m), 4.30 (1H, dd, J 10.8, 7.6), 4.67 (1H, 
dd, J 10.8, 2.6); C(100 MHz) 14.5 (CH3, CH2CH3), 23.0 (CH2, alkyl chain), 25.8 [CH3, 
C(CH3)A(CH3)B], 26.9 (CH2, alkyl chain), 28.4 [CH3, C(CH3)A(CH3)B], [29.5, 29.7, 29.8, 29.9, 
30.0 (CH2, alkyl chain, significant resonance overlap)], 32.3 (CH2, alkyl chain), 38.0 (CH3, 
SO2CH3), 59.7 (CH, C-2), 70.3 (CH2, C-1), [75.7, 77.9 (CH, C-3, C-4)], 109.0 [C, C(CH3)2]; m/z 
(TOF ES+) 484.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 484.2829 [M + Na]+, 
C22H43N3O5SNa requires 484.2821. 
Data were in agreement with those reported in the literature.182  
 
(2S, 3S, 4R)-1, 2-Imino-3, 4-O-isopropylidene-octadecane-3, 4-diol (186) 
 
i-Pr2NEt (2.35 mL, 13.5 mmol) and Ph3P (3.07 g, 11.7 mmol) were added to a solution of 
mesylate 185 (4.15 g, 9.0 mmol) in THF–H2O (90 mL, 8:1). The reaction mixture was heated 




at 60 °C for 3 h and then cooled to rt. The mixture was washed with brine (60 mL) and the 
aqueous phase was extracted with Et2O (2 × 80 mL). The organic layers were combined, dried 
with Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The crude 
residue was purified first by trituration with hexane, which allowed the removal of the 
phosphine oxide by-product by filtration, then by column chromatography (30% EtOAc in 
hexanes) to yield aziridine 186 as a colourless oil (2.37 g, 77%): Rf = 0.2 (5% MeOH in CHCl3); 
[]D20 = +6.0 (c = 1.0, CHCl3) lit. 130 []D20  = +7 (c = 1.0, CHCl3); max(film)/cm–1 3308 vw (N-
H), 2987 w, 2922 vs, 2853 s, 1466 m, 1378 m, 1368 m, 1245 m, 1214 s, 1165 m, 1090 m, 
1049 s, 859 m, 721 w; H(300 MHz) 0.87 (3H, t, J 6.9, CH2CH3), 1.22–1.31 (24H, stack, alkyl 
chain), 1.33 [3H, s, C(CH3)A(CH3)B], 1.46 [3H, s, C(CH3)A(CH3)B], 1.50–1.57 (1H, m), 1.59 (1H, 
d, J 3.6), 1.64–1.73 (2H, stack), 1.88 (1H, d, J 5.7), 2.07–2.14 (1H, m), 3.58 (1H, dd, J 7.5, 
6.2), 4.20 (1H, app dt, J 7.5, 5.6); C(100 MHz) 14.5 (CH3, CH2CH3), 23.0 (CH2, alkyl chain), 
25.6 [CH3, C(CH3)A(CH3)B], 27.0 (CH2, alkyl chain), 28.2 [CH3, C(CH3)A(CH3)B], 29.4 (CH, C-
2), 29.7 (CH2, alkyl chain), [29.9, 30.0, 30.1 (CH2, alkyl chain and C-1, significant resonance 
overlap)], 30.3 (CH2, alkyl chain), 32.3 (CH2, alkyl chain), [78.3, 80.4 (CH, C-3, C-4)], 108.2 
[C, C(CH3)2]; m/z (TOF ES+) 340.3 ([M + H]+, 100%); HRMS m/z (TOF ES+) 340.3224 [M + 
H]+, C21H42NO2 requires 340.3216. 












Hexacosanoic acid-2, 5-dioxo-1-pyrrolidinyl ester (189) 
 
EDCI.HCl (450 mg, 2.72 mmol) and N-hydroxysuccinimide (348 mg, 3.02 mmol) were added 
sequentially to a solution of hexacosanoic acid (0.84 g, 2.12 mmol) in CH2Cl2 (30 mL). The 
reaction mixture was heated at 40 °C for 3 h, and then the mixture was poured into H2O (20 
mL) and extracted with Et2O (60 mL). The organic layer was washed with brine (20 mL), dried 
over Na2SO4, and filtered. The solvent was removed under reduced pressure to give NHS 
ester 189 as a white foam (963 mg, 92%): Rf = 0.4 (25% EtOAc in hexanes); max(film)/cm–1 
2956 w, 2917 vs, 2849 vs, 1819 m, 1787 m, 1740 vs (C=O), 1724 vs (C=O), 1463 m, 1430 w, 
1409 w, 1296 w, 1255 w, 1208 vs, 1147 w, 1123 w, 1069 vs, 1061 vs, 1019 m, 1003 m, 993 
m, 865 s, 811 m, 770 w, 722 m, 668 m, 654 s; H(400 MHz) 0.88 (3H, t, J 6.9, CH2CH3), 1.22–
1.35 (44H, stack, alkyl chain) 1.36–1.44 (2H, stack, H-4), 1.70–1.78 (2H, stack, J 7.5, H-3), 
2.60 (2H, t, J 7.5, H-2), 2.81–2.86 (4H, stack, NHS CH); C(100 MHz) 14.1 (CH3, CH2CH3), 
[22.7, 24.6, 25.6, 28.8, 29.1, 29.4, 29.6, 29.7, 30.0, 30.1, 30.9, 31.9 (CH2, alkyl chain, 
resonance overlap)], 168.7 (C, C=O, ester) 169.2(C, C=O, imide). 











(2S, 3S, 4R)-1, 2-(Hexacosanoyl)imino-3,4-O-isopropylidene-octadecane-3, 4-diol (190) 
 
NHS ester 189 (290 mg, 0.589 mmol) and Et3N (160 L, 1.17 mmol) were added to a solution 
of aziridine 186 (200 mg, 0.589 mmol) in dry THF (10 mL). After stirring the reaction mixture 
for 12 h, the solvent was removed under reduced pressure. The crude mixture was purified by 
column chromatography (10% EtOAc in hexanes) to yield aziridine 190 as a white solid (313 
mg, 74%): Rf = 0.5 (10% EtOAc in hexanes); m.p. 63–65 °C; []D20 = –15.6 (c = 1.0, CHCl3); 
max(film)/cm–1 2956 m, 2916 vs, 2848 vs, 1684 s (C=O), 1474 m, 1463 s, 1381 m, 1366 m, 
1345 m, 1285 w, 1275 w, 1253 s, 1216 m, 1181 m, 1161 m, 1134 w, 1090 m, 1067 m, 1037 
s, 979 w, 913 w, 875 m, 866 m, 846 w, 789 w, 728 m, 718 m, 668 m, 656 m; H(400 MHz) 
0.88 (6H, app. t, J 6.8, 2 × CH2CH3), 1.22–1.32 (68H, stack, alkyl chain), 1.34 (3H, s, 
C(CH3)A(CH3)B), 1.46 (3H, s, C(CH3)A(CH3)B), 1.60–1.66 (2H, stack, alkyl chain), 1.71–1.85 
(2H, stack, alkyl chain), 2.22 (1H, dd, J 3.2, 0.6, H-1A),  2.28 (1H, dd, J 6.0, 0.6, H-1B), 2.30–
2.47 (2H, stack, 2 × H-2′),  2.64 (1H, ddd, J 6.8, 6.0, 3.2, H-2), 3.78 (1H, app. t, J 6.4, H-3), 
4.20 (1H, app. dt, J 8.6, 5.5, H-4); C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 
24.9 (CH2, C-3′), 25.4 (CH3, C(CH3)A(CH3)B), 26.6 (CH2, alkyl chain), 27.9 (CH3, 
C(CH3)A(CH3)B), 28.4 (CH2, C-1), [29.4, 29.5, 29.7, 31.9 (CH2, alkyl chain, resonance overlap)], 
35.1 (CH, C-2), 36.7 (CH2, C-2′), 77.8 (CH, C-4), 78.5 (CH, C-3), 108.1 (C, C(CH3)2), 185.7 
(C, C=O); m/z (TOF ES+) 740.7 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 740.6898 [M + 
Na]+, C47H91NO3Na requires 740.6897 
 
 




(2S, 3S, 4R)-3,4-O-Isopropylidene-1, 2-(para-nitrobenzenesulfonyl)imino-octadecane-3, 
4-diol (191) 
. 
para-Nosyl chloride (109 mg, 0.59 mmol) was added to a solution of Et3N (0.5 mL, 3.53 mmol) 
and aziridine 186 (168 mg, 0.59 mmol) in THF (5 mL). The reaction mixture was stirred at rt 
for 3 h, then quenched with NaHCO3 solution (30 mL). The phases were separated and the 
aqueous phase was extracted with EtOAc (3 × 40 mL). The combined organic layers were 
dried (Na2SO4), filtered and the solvent removed under reduced pressure to give the crude 
product which was purified by column chromatography (10% EtOAc in hexanes) to yield 
sulfonamide 192 as a white solid yellow oil (143 mg, 55%): Rf = 0.5 (25% EtOAc in hexanes); 
[]D22 = –10.8 (c = 1.0, CHCl3); max(film)/cm–1 2923 vs, 2853 s, 1606 w, 1533 s, 1465 m, 1369 
m, 1348 s, 1312 m, 1217 m, 1161 s, 1090 m, 1061 m, 982 w, 855 m, 741 m, 686 w, 618 w; 
H(400 MHz) 0.87 (3H, t, J 6.8, CH2CH3), 1.23–1.30 (23H, stack, alkyl chain), 1.32 [3H, s, 
C(CH3)A(CH3)B], 1.45 [3H, s, C(CH3)A(CH3)B], 1.47–1.67 (3H, stack, alkyl chain), 2.29 (1H, d, 
J 4.5, H-1A), 2.70 (1H, d, J 7.0, H-1B), 3.08 (1H, app. td, J 7.0, 4.5, H-2), 3.73 (1H, dd, J 6.7, 
6.0, H-3), 4.15 (1H, ddd, J 9.6, 5.7, 4.0, H-4), 8.13–8.17 (2H, m, Ar CH), 8.37–8.41 (2H, m, Ar 
CH), C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.2 [CH3, C(CH3)A(CH3)B], 
26.8 (CH2, alkyl chain), 27.9 [CH3, C(CH3)A(CH3)B], [29.4, 29.5, 29.6, 29.7, 31.9 (CH2, alkyl 
chain, significant resonance overlap)], 32.1 (CH2, C-1), 38.6 (CH, C-2), 77.5 (CH, C-4), 77.7 
(CH, C-3), 108.6 [C, C(CH3)2], [124.4, 129.4, (CH, Ar CH)], [143.9, 150.7 (C, Ar C)]; m/z (TOF 
ES+) 547.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 547.2817 [M + Na]+, C27H44N2O6SNa 
requires 547.2818. 





(2S, 3S, 4R)-3,4-O-Isopropylidene-1, 2-(ortho-nitrobenzenesulfonyl)imino-octadecane-
3, 4-diol (192) 
 
ortho-Nosyl chloride (208 mg, 1.18 mmol) was added to a solution of Et3N (0.5 mL, 3.53 mmol) 
and aziridine 186 (320 mg, 1.18 mmol) in THF (10 mL). The reaction mixture was stirred at rt 
for 3 h, then quenched with NaHCO3 solution (30 mL). The phases were separated and the 
aqueous phase was extracted with EtOAc (3 × 40 mL). The combined organic layers were 
dried (Na2SO4), filtered and the solvent removed under reduced pressure to give the crude 
product which was purified by column chromatography (10% EtOAc in hexanes) to yield 
sulfonamide 192 as a white solid yellow oil (321 mg, 65%): Rf = 0.4 (25% EtOAc in hexanes); 
[]D22 = –30.0 (c = 1.0, CHCl3), lit.130 []D = –47 (c = 1.0, CHCl3); max(film)/cm–1 3100 vw br, 
2917 vs, 2849 s, 1594 vw, 1539 vs, 1473 m, 1461 m, 1441 w, 1407 vw, 1377 m, 1350 s, 1327 
vs, 1310 m, 1244 m, 1215 m, 1162 vs , 1146 s, 1103 s, 1090 m, 1080 s, 1072 m, 1045 s, 1013 
w, 999 m, 985 m, 952 m, 897 m, 882 s, 856 s, 787 s, 774 m, 744 s, 736 s, 717 m, 688 m, 672 
m; H(300 MHz) 0.87 (3H, t, J 6.8, CH2CH3), 1.23–1.30 (24H, stack, alkyl chain), 1.32 [3H, s, 
C(CH3)A(CH3)B], 1.44 [3H, s, C(CH3)A(CH3)B], 1.59–1.69 (2H, stack, alkyl chain), 2.50 (1H, d, 
J 4.7, H-1A), 2.91 (1H, d, J 7.0, H-1B), 3.16 (1H, ddd, J 7.0, 6.0, 4.7, H-2), 3.94 (1H, app t, J 
6.0, H-3), 4.18–4.23 (1H, m, H-4), 7.71–7.79 (3H, stack, Ar CH), 8.17–8.21 (1H, m, Ar CH); 
C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.2 [CH3, C(CH3)A(CH3)B], 26.7 
(CH2, alkyl chain), 27.8 [CH3, C(CH3)A(CH3)B], [29.4, 29.5, 29.6, 29.7, 31.9 (CH2, alkyl chain, 
significant resonance overlap)], 33.3 (CH2, C-1), 39.9 (CH, C-2), 77.0 (CH, C-3), 78.3 (CH, C-




4), 108.5 [C, C(CH3)2], [124.4, 131.3, (CH, Ar CH)], 132.1 (C, Ar C), [132.2, 134.5 (CH, Ar CH), 
148.5 (C, Ar C); m/z (TOF ES+) 547.3 ([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.130 
 
(2S, 3S, 4R)-3,4-O-Isopropylidene-1, 2-[para-(cyclohexyloxy)-benzenesulfonyl]imino-
octadecane-3, 4-diol (196) 
 
NaH (11 mg of a 60% dispersion in mineral oil, 0.23 mmol) was added to a solution of 
cyclohexanol (23 mg, 0.23 mmol) in DMF (1 mL) at 0 °C. After stirring for 1 h, a solution of 
aziridine 191 (100 mg, 0.19 mmol) in DMF (1 mL) was added.  After 20 min at 0 °C, the reaction 
mixture was warmed to rt and stirred for a further 15 h. The reaction was then quenched with 
H2O (25 mL) and extracted with EtOAc (5 × 30 mL). The combined organic layers were washed 
with brine (70 mL), dried using Na2SO4, filtered and the filtrate was concentrated under 
reduced pressure. The crude residue was purified using column chromatography (10% 
EtOAc) to yield aryl ether 196 as a colourless oil (63 mg, 58%.): Rf = 0.6 (20% EtOAc in 
hexanes); []D22 = –14.8 (c = 1.0, CHCl3); max(film)/cm–1 2923 vs, 2853 vs, 1593 s, 1495 m, 
1458 m, 1370 m, 1256 s, 1217 m, 1158 vs, 1093 m, 1045 m, 926 w, 732 w; H(400 MHz) 0.88 
(3H, t, J 6.8, CH2CH3), 1.23–1.29 (23H, stack, alkyl chain), 1.31 [3H, s, C(CH3)A(CH3)B], 1.33–
1.43 (3H, stack, alkyl chain and cyclohexyl ring), 1.45 [3H, s, C(CH3)A(CH3)B], 1.47–1.61 (6H, 
stack, alkyl chain and cyclohexyl ring), 1.76–1.85 (2H, stack, cyclohexyl ring), 1.95–2.02 (2H, 




stack, cyclohexyl ring),  2.19 (1H, d, J 4.3, H-1A), 2.58 (1H, d, J 7.0, H-1B), 2.89 (1H, app. td, 
J 7.3, 4.6, H-2), 3.66 (1H, dd, J 7.3, 5.8, H-3), 4.11 (1H, ddd, J 9.6, 5.7, 4.0, H-4), 4.31–4.38 
(1H, m, H-1′′), 6.94–6.98 (2H, stack, Ar CH, H-3′), 7.80–7.84 (2H, m, Ar CH, H-2′); C(100 
MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 23.5 (CH2, cyclohexyl) 25.3 [CH3, 
C(CH3)A(CH3)B], 25.4 (CH2, cyclohexyl), 26.8 (CH2, alkyl chain), 28.0 [CH3, C(CH3)A(CH3)B], 
[29.4, 29.5, 29.6, 29.7 (CH2, alkyl chain, significant resonance overlap)], 31.1 (CH2, C-1), 
[31.45, 31.49, 31.9 (CH2, cyclohexyl resonance overlap)], 37.9 (CH, C-2), 75.8 (CH, C-1′′), 
77.6 (CH, C-4), 78.3 (CH, C-3), 108.4 [C, C(CH3)2], 115.7 (CH, C-3′), 128.5 (C, C-1′), 130.3 
(CH, C-2′), 162.3 (C, C-4′); m/z (TOF ES+) 600.4 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 
600.3696 [M + Na]+, C33H55 NO5SNa requires 600.3699. 
 
(2S, 3S, 4R)-3,4-O-Isopropylidene-1, 2-(para-toluenesulfonyl)imino-octadecane-3, 4-diol 
(193) 
 
p-Tosyl chloride (1.37 g, 7.16 mmol) was added to a solution of Et3N (1.36 mL, 9.72 mmol) 
and aziridine 186 (2.21 g, 6.51 mmol) in THF (65 mL). The reaction mixture was stirred at rt 
for 3 h and then quenched with NaHCO3 solution (100 mL). The phases were separated and 
the aqueous phase was extracted with EtOAc (3 × 100 mL). The combined organic layers 
were dried (Na2SO4), filtered and the solvent removed under reduced pressure to give the 
crude product which was purified by column chromatography (10% EtOAc in hexanes) to yield 
sulfonamide 193 as a white solid (3.18 g, 85%): Rf = 0.5 (20% EtOAc in hexane); []D20  = 
−22.0 (c = 1.0, CHCl3); m.p. 43–44 °C; max(film)/cm–1 2920 s, 2851 s, 1597 vw, 1469 w, 1369 




w, 1317 s, 1305 m, 1290 m, 1246 m, 1216 m, 1183 vw, 1156 vs, 1117 w, 1090 s, 1054 w, 
1020 vw, 999 m, 933 m, 897 m, 878 m, 854 w, 830 w, 813 s, 724 s, 715 s, 700 s, 671 m, 653 
s;  H(300 MHz) 0.88 (3H, t, J 6.7, CH2CH3), 1.21–1.29 (24H, stack, alkyl chain), 1.31 [3H, s, 
C(CH3)A(CH3)B], 1.44 [3H, s, C(CH3)A(CH3)B], 1.46–1.58 (2H, stack, alkyl chain), 2.20 (1H, d, 
J 4.4, H-1A), 2.44 (3H, s, tosyl CH3), 2.61 (1H, d, J 7.0, H-1B), 2.92 (1H, app. td, J 7.0, 4.4, H-
2), 3.66 (1H, dd, J 7.4, 5.7, H-3), 4.11 (1H, ddd, J 9.5, 5.7, 3.7, H-4), 7.31–7.36 (2H, ArH), 
7.80–7.84 (2H, m, ArH); C(100 MHz) 14.1 (CH3, CH2CH3), 21.7 (CH3, tosyl CH3), 22.7 (CH2, 
alkyl chain), 25.3 [CH3, C(CH3)A(CH3)B], 26.8 (CH2, alkyl chain), 28.0 [CH3, C(CH3)A(CH3)B], 
[29.4, 29.5, 29.7 (CH2, alkyl chain, significant resonance overlap)], 31.2 (C-1), 31.9 (CH2, alkyl 
chain), 37.9 (CH, C-2), 77.6 (CH, C-4), 78.3 (CH, C-3), 108.4 [C, C(CH3)2], 128.2 (CH, Ar), 
129.7 (CH, Ar), 134.9 (C, Ar), 144.7 (C, Ar); m/z (TOF ES+) 494.3 ([M + H]+, 100%); HRMS 
m/z (TOF ES+) 494.3298 [M + Na]+, C28H47NO4SNa requires 494.3304. 
 
(2S, 3S, 4R)-1-O-Cyclohexyl-3, 4-O-isopropylidene-2-toluenesulfonamido-1, 3, 4-
octadecanetriol (198) 
 
NaH (30 mg of a 60% dispersion in mineral oil, 1.21 mmol) was added to a solution of 
cyclohexanol (83 L, 0.8 mmol) in DMF (1 mL) at 0 °C. After stirring for 1 h, a solution of 
aziridine 193 (100 mg, 0.2 mmol) in DMF (1 mL) was added.  After 20 min at 0 °C, the reaction 
mixture was warmed to rt and stirred for a further 15 h. The reaction was then quenched with 
H2O (25 mL) and extracted with EtOAc (5 × 30 mL). The combined organic layers were washed 
with brine (70 mL), dried using Na2SO4, filtered and the filtrate was concentrated under 
reduced pressure to yield ether 198 as a white non-amorphous solid (115 mg, quant.): Rf = 
0.7 (25% EtOAc in hexanes); m.p. 79–81 °C; []D22 = +29.2 (c = 1.0, CHCl3); max(film)/cm–1 
3308 br m (N–H), 2920 vs, 2850 s, 1598 w, 1468 m, 1438 m, 1329 s, 1244 s, 1220 m, 1158 




s, 1086 s, 1061 s, 962 w, 816 m, 723 w, 670 s; H(400 MHz) 0.87 (3H, t, J 6.8, CH2CH3), 1.09–
1.21 (7H, stack, alkyl CH2), 1.22–1.28 (23H, stack, CH2 of alkyl chain), 1.28 [3H, s, 
C(CH3)A(CH3)B], 1.36 [3H, s, C(CH3)A(CH3)B], 1.40–1.50 (2H, stack), 1.52–1.70 (4H, stack), 
2.42 (3H, s, tosyl CH3), 2.89–2.96 (1H, m, H-1′), 3.00 (1H, dd, J 9.2, 3.0, H-1A), 3.45–3.52 (2H, 
stack, H-1B, H-2), 4.03–4.10 (2H, stack, H-3,H-4), 4.98 (1H, d, J 9.6, N-H), 7.28 (2H, AA′ of 
AA′ BB′, J 8.2, Ar CH), 7.75 (2H, BB′ of AA′ BB′,  J 8.2, Ar CH); C(100 MHz) 14.1 (CH3, 
CH2CH3), 21.5 (CH3, tosyl CH3), 22.3 (CH2), 22.7 (CH2), 23.5 (CH2), 23.7 (CH2), 25.7 (CH2),  
25.8 [CH3, C(CH3)A(CH3)B], 26.2 (CH2), 28.1 [CH3, C(CH3)A(CH3)B], [29.0, 29.4, 29.5, 29.7 
(CH2, alkyl chain, significant resonance overlap)], 31.6 (CH2), 31.9 (CH2), 53.1 (CH, C-2), 64.9 
(CH2, C-1), 75.9 (CH, C-3 or C-4), 77.3 (CH, C-1′), 77.7 (CH, C-4 or C-3), 107.6 [C, C(CH3)2], 
[127.1, 129.6 (CH, Ar CH)], [138.6, 143.5 (C, Ar C)]; m/z (TOF ES+) 614.4 ([M + Na]+, 100%); 
HRMS m/z (TOF ES+) 614.3859 [M + Na]+, C34H57NO5SNa requires 614.3855. 
 
(3S, 4S, 5S, 6S)-4, 5-O-Isopropylidene-octa-1, 7-dien-3, 4, 5, 6-tetraol (176) 
 
Preparation of ZnCl2 solution:184 Solid ZnCl2 (4.0 g, 29.3 mmol) contained in a flame-dried 
Schlenk flask was fused by heating with a Bunsen burner under reduced pressure and then 
allowed to cool to rt. Dry THF (20 mL) was added under an argon atmosphere and the resulting 
mixture was sonicated until the ZnCl2 had completely dissolved to yield a 1.4 M solution of 
ZnCl2. 
 
Preparation of divinylzinc:185 Vinyl magnesium bromide (1.0 M in THF, 60 mL) and dry THF 
(20 mL) were added to a flask containing ZnCl2 solution (1.4 M in THF, 20 mL, 29.3 mmol).  
The solution was heated under reflux for 4 h, after which time, the solution was cooled to rt. 




The precipitated salts were allowed to settle and then the supernatant solution was transferred 
into a dry flask by filter cannula to yield a solution of divinylzinc (0.3 M in THF, 100 mL). 
 
A solution of (2R, 3R)-dimethyl 2,3-O-isopropylidene tartrate 177 (2.0 g, 9.17 mmol) in toluene 
(25 mL) was degassed by bubbling argon through the solution for 10 min while sonicating. 
DIBALH (1.0 M in toluene, 18.3 mL, 18.3 mmol) was then added dropwise over 10 min to the 
solution at −78 °C.  After 2.5 h, a solution of divinylzinc (0.3 M in THF, 100 mL, 29.3 mmol) 
was added. The reaction mixture was stirred for 2 h at −78 °C and then warmed to rt over 4 h.  
The reaction mixture was then cooled to 0 °C and the reaction carefully quenched by the 
dropwise addition of H2O (30 mL) over 30 min. The mixture was filtered through Celite and the 
resulting solution was concentrated under reduced pressure. The crude product was re-
dissolved with EtOAc (50 mL) and washed with H2O (3 × 30 mL). The organic layer was 
washed with brine (20 mL), dried over Na2SO4, filtered and the filtrate concentrated under 
reduced pressure. The crude product was purified by column chromatography (25% EtOAc in 
hexanes) to give diene 176 (d.r: 5:1, major stereoisomer desired product) as a colourless oil 
(1.01 g, 55%): data on diastereoisomeric mixture unless specified otherwise: Rf = 0.2 (25% 
EtOAc in hexanes); max(film)/cm–1 3456 w (OH), 3081 vw, 2939 w, 2874 w, 1640 w, 1426 w, 
1381 s, 1372 s, 1315 w, 1239 s, 1213 m, 1165 m, 1136 m, 1082 m, 1040 m, 993 s, 925 s, 877 
s, 811 m, 736 s, 698 s; H(300 MHz) [1.40 (6H, s, C(CH3)2, major), 1.43 (6H, app s, C(CH3)2, 
minor)], [2.44–2.62 (2H, stack, OH, minor), 2.97 (2H, br s, OH, major)], [3.83–3.92 (2H, stack, 
2 × CHO, major), 3.99–4.04 (2H, stack, 2 × CHO, minor)], [4.12–4.21 (2H, stack, 2 × CHO, 
major), 4.25–4.31 (2H, stack, 2 × CHO, minor)], 5.23–5.44 (4H, stack, 2 × CH=CH2), 5.86–
6.05 (2H, stack, 2 × CH=CH2);  C(100 MHz) [26.9 (CH3, acetal CH3, major), 27.2 (CH3, acetal 
CH3, minor)], [71.6 (CH, CHO, minor), 72.6 (CH, CHO, minor), 73.6 (CH, CHO, major)], [79.0 
(CH, CHO, minor), 80.2 (CH, CHO, minor), 81.7 (CH, CHOH, major)], 109.5 (C, acetal C, 
major), (acetal C for minor stereoisomer not observed), [116.5 (CH2, CH=CH2, minor), 117.2 
(CH2, CH=CH2, major)], [136.1 (CH, CH=CH2, minor), 136.9 (CH, CH=CH2, major), 137.2 (CH, 




CH=CH2, minor)]; m/z (TOF ES+) 215.1 ([M + H]+, 100%); HRMS m/z (TOF ES+) 215.1292 
[M + H]+, C11H19O4Na requires 215.1283. 
 
Data were in agreement with those reported in the literature.139-186 
 
 
(1S, 2S, 3S, 4S)-2, 3-O-Isopropylidene-cyclohex-5-en-1, 2, 3, 4-tetraol (202)  
 
A solution of diene 176 (0.48 g, 2.2 mmol, 5:1 mixture of diastereoisomers) in CH2Cl2 (500 
mL) was degassed by bubbling argon through the solution for 10 min while sonicating. Grubbs 
2nd generation Ru metathesis catalyst (46 mg, 0.054 mmol) was then added and the solution 
was heated under reflux.  After 2 h, the solution was concentrated under reduced pressure 
and the crude product purified by column chromatography (5% MeOH in CHCl3) to give diol 
202 as a colourless oil (0.32 g, 78%):  Rf = 0.2 (5% MeOH in CHCl3); []D20 = +304.0 (c = 1.0, 
CHCl3)  lit.136 []D25 = +338.6 (c = 0.7, CHCl3); max(film)/cm–1 3312 br m (O–H), 3043 vw, 2988 
w, 2934 vw, 2902 w, 1449 w, 1368 m, 1335 w, 1279 w, 1247 m, 1230 m , 1210 m , 1171 m, 
1148 s, 1129, s, 1116 s, 1091 vs, 1068 w, 1048 m, 1017 s, 992 w, 977 w, 967 m, 931 s, 839 
vs, 795 m, 766 w, 732 m; H(300 MHz) 1.48 [6H, s, C(CH3)2], 2.70 (2H, s, OH), 3.88–3.95 (2H, 
m, CHO), 4.53 (2H, app s, CHOH), 5.92–5.99 (2H, m, CH=CH); C(100 MHz) 26.9 [CH3, 
C(CH3)2], 64.8 (CH, CHO), 73.4 (CH, CHO), 110.5 [C, C(CH3)2], 130.4 (CH, =CH); m/z (TOF 
ES+) 209.1 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 209.0795 [M + Na]+, C9H14O4Na requires 
209.0790. 
Data were in agreement with those reported in the literature.139, 186  
 




(1S, 2S, 3S, 4S)-4-O-tert-Butyldimethylsilyl-2, 3-O-isopropylidene-cyclohex-5-en-1, 2, 3, 
4-tetraol (163) and (1S, 2S, 3S, 4S)-1, 4-di-O-tert-butyldimethylsilyl-2, 3-O-
isopropylidene-cyclohex-5-en-1, 2, 3, 4-tetraol (203) 
 
 
      
Imidazole (0.23 g, 3.31 mmol) and TBDMSCl (0.39 g, 1.61 mmol) were added sequentially to 
a solution of diol 202 (0.41 g, 2.22 mmol) in DMF (5 mL).  After stirring overnight, the reaction 
mixture was diluted with EtOAc (30 mL) and washed sequentially with H2O (10 mL) and NH4Cl 
solution (10 mL). The organic layer was dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (20% EtOAc in hexanes) to give, in order of elution, bis-silyl ether 203 as a 
colourless oil (0.21 g, 23%): Rf = 0.9 (20% EtOAc in hexanes); []D20 = +192.0 (c = 1.3, CHCl3); 
max(film)/cm–1 3031 vw, 2987 vw, 2954 w, 2930 w, 2897 w, 2857 w, 1472 w, 1463 w, 1378 m, 
1368 w, 1252 m, 1232 m, 1210 w, 1172 w, 1148 m, 1131 s, 1093 m, 1058 s, 1036 s, 1005 w, 
971 m, 939 w, 919 w, 886 s, 854 m, 831 vs, 803 m, 775 vs, 712 w, 700 w, 681 w; H(300 MHz) 
0.08 [6H, s, 2 × Si(CH3)A(CH3)B], 0.09 [6H, s, 2 × Si(CH3)A(CH3)B], 0.88 [18H, s, C(CH3)3], 1.42 
[6H, s, C(CH3)2], 3.92–3.96 (2H, stack, CHO), 4.43–4.47 (2H, stack, CHO), 5.75 (2H, dd, J 
3.1, 1.6, CH=CH); C(100 MHz) −4.8 [CH3, Si(CaH3)(CbH3)], −4.5 [CH3, Si(CaH3)(CbH3)], 18.3 
[C, SiC(CH3)3], 25.8 [CH3, SiC(CH3)3], 27.1 [CH3, C(CH3)2], 66.1 (CH, CHO), 73.5 (CH, CHO), 
109.8 [C, C(CH3)2], 130.2 (CH, =CH) and then silyl ether 163 as a colourless oil (0.38 g, 58%): 
Rf = 0.3 (20% EtOAc in hexanes); []D20 = +19.6 (c = 1.0, CHCl3); max(film)/cm–1 3431 w (O–
H), 2987 w, 2953 w, 2930 m, 2892 w, 2856 m, 1472 w, 1462 w, 1371 m 1249 m, 1231 m, 
1170 m, 1144 s, 1127 vs, 1090 vs, 1051 m, 1027 vs, 1006 w, 963 s, 935 m, 898 m, 832 vs, 




777 vs; H(400 MHz) 0.08 [3H, s, Si(CH3)A(CH3)B], 0.09 [3H, s, Si(CH3)A(CH3)B], 0.87 [9H, s, 
C(CH3)3], 1.437 [3H, s, C(CH3)A(CH3)B], 1.442 [3H, s, C(CH3)A(CH3)B], 2.29 (1H, br s, OH), 
3.86 (1H, dd, J = 10.0, 3.4, H-3), 4.01 (1H, dd, J = 10.0, 3.7, H-2), 4.44–4.47 (1H, m, H-4), 
4.48–4.51 (1H, m, H-1), 5.85–5.91 (2H, stack, CH=CH); C(100 MHz) −4.8 [CH3, 
Si(CH3)A(CH3)B], −4.6 [CH3, Si(CH3)A(CH3)B], 18.4 [C, SiC(CH3)3], 25.9 [CH3, C(CH3)3], 27.1 
[CH3, C(CH3)2], 65.2 (CH, C-1), 65.9 (CH, C-4), 73.2 (CH, C-2), 73.8 (CH, C-3), 110.3 [C, 
C(CH3)2], 128.5 (CH, CH=CH), 132.4 (CH, CH=CH); m/z (TOF ES+) 323.2 ([M + Na]+, 100%); 
HRMS m/z (TOF ES+) 323.1656 [M + Na]+, C15H28O4SiNa requires 323.1655. 
 
(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-1-O-[4′-O-tert-Butyldimethylsilyl-2′, 3′-O-isopropylidene-
2′, 3′, 4′-trihydroxycyclohex-5′-enyl]-3, 4-O-isopropylidene-2-toluenesulfonamido-1, 3, 
4-octadecanetriol (209) 
 
NaH (30 mg of a 60% dispersion in mineral oil, 1.21 mmol,) was added to a solution of 
cyclohexenol 163 (84 mg, 0.33 mmol) in DMF (0.37 mL) at 0 °C. After 1 h, a solution of 
aziridine 190 (150 mg, 0.303 mmol) in DMF (0.7 mL) was added.  After 20 min at 0 °C, the 
reaction mixture was warmed to rt and stirred for a further 15 h. The reaction was quenched 
with H2O (25 mL) and extracted with EtOAc (5 × 30 mL). The combined organic layers were 
washed with brine (70 mL), dried using Na2SO4, filtered and the filtrate was concentrated 
under reduced pressure. The crude mixture was purified by column chromatography (10% 
EtOAc in hexanes) to yield ether 209 as a colourless oil (115 mg, 58%): Rf = 0.7 (20% EtOAc 
in hexanes); []D20  = +107.6 (c = 1.0, CHCl3); max(film)/cm–1 3271 br vw (N–H), 2985 vw, 2925 
m, 2854 m, 2216 m, 1695 w, 1589 w, 1491 w, 1459 w, 1438 w, 1378 m, 1334 w, 1268 w, 1246 
w, 1221 w, 1189 m, 1168 m, 1148 w, 1129 w, 1091 w, 1065 m, 1025 w, 975 m, 923 w, 902 w, 




834 m, 816 w, 800 w, 778 m, 760 s, 734 w, 706 w, 666 m; H(500 MHz) 0.08–0.09 (6H, stack, 
Si(CH3)2), 0.86–0.89 (12H, stack, CH2CH3, C(CH3)3), 1.22–1.26 (22H, stack, CH2 of alkyl 
chain), 1.27 (3H, s, C(CH3)A(CH3)B), 1.35 (3H, s, C(CH3)A(CH3)B), 1.38 (3H, s, C(CH3)C(CH3)D), 
1.41–1.51 (2H, stack), 1.45 (3H, s, C(CH3)C(CH3)D), 1.57–1.65 (2H, stack), 2.45 (3H, s, tosyl 
CH3), 3.02 (1H, dd, J 9.9, 3.3, H-1A), 3.47–3.53 (1H, m, H-2), 3.70 (1H, dd, J 5.2, 3.5, H-1′), 
3.76 (1H, dd, J 10.0, 3.6, H-3′), 3.92 (1H, dd, J 10.0, 3.5, H-2′), 4.01–4.10 (3H, stack, H-1B, H-
3, H-4), 4.40 (1H, dd, J 5.1, 3.6, H-4′), 5.00 (1H, d, J 9.8, NH), 5.64 (1H, dd, J 9.7, 5.2, 6′-H), 
5.79 (1H, dd, J 9.7, 5.1, 5′-H), 7.29 (2H, AA′ of AA′ BB′,  J 8.2, ArH), 7.74 (2H, BB′ of AA′ BB′,  
J 8.2, ArH); C(100 MHz) −4.8 (CH3, Si(CH3)A(CH3)B), −4.6 (CH3, Si(CH3)A(CH3)B), 14.1 (CH3, 
CH2CH3), 18.3 (C, SiC(CH3)3), 21.6 (CH3, tosyl CH3), 22.7 (CH2), 25.8 (CH3, SiC(CH3)3), 25.9 
(CH3, C(CH3)A(CH3)B), 26.8 (CH3, (CH3)C(CH3)D), 26.9 (CH3, C(CH3)C(CH3)D), 28.1 (CH3, 
C(CH3)A(CH3)B), 26.3 (CH2), [29.0, 29.4, 29.7 (CH2, alkyl chain, significant resonance 
overlap)], 31.9 (CH2), 53.2 (CH, C-2), 65.8 (CH, C-4′), 68.9 (CH2, C-1), 73.5 (CH, C-1′), 73.85 
(CH, C-3′), 73.94 (CH, C-2′), [75.8, 77.8 (CH, C-3, C-4)], 107.7 [C, chain acetal, 
C(CH3)A(CH3)B], 110.1 [C, cyclitol acetal, C(CH3)C(CH3)D], 126.9 (CH, Ar), 127.1 (CH, C-6′), 
129.7 (CH, Ar), 131.9 (CH, C-5′), 138.7 (C, Ar), 143.6 (C, Ar); m/z (TOF ES+) 816.5 ([M + 












(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-2-[(N-tert-Butoxycarbonyl)amino]-1-O-[4′-O-tert-
butyldimethylsilyl-2′, 3′-O-isopropylidene-2′, 3′, 4′-trihydroxycyclohex-5′-enyl]-3, 4-O-




Boc2O (38 mg, 0.18 mmol) and DMAP (5 mg, 10 weight %) were added to a solution of 
sulfonamide 209 (70 mg, 0.088 mmol) in CH2Cl2 (1 mL). The solution was stirred for 4 h and 
then the solvent was removed under reduced pressure to provide the crude product 210, which 
was used directly in the next reaction without further purification: MeOH [1.1 mL (dried over 
activated 3 Å molecular sieves)] was charged to the flask containing the intermediate 
sulfonamide 210 (78 mg, 0.088 mmol).  Mg powder (12 mg, 0.48 mmol) was added and the 
reaction mixture was sonicated in an ultrasound bath.  After 30 min, the mixture was poured 
into hydrochloric acid (10 mL, 1.0 M) and extracted with Et2O (3 × 15 mL).  The combined 
organic phases were washed sequentially with NaHCO3 solution (20 mL) and brine (20 mL), 
and dried with Na2SO4. The solvent was removed under pressure and the residue purified by 
flash column chromatography (20% EtOAc in hexanes) to give Boc amide 211 as a colourless 
oil (42 mg, 98% from 209): Rf = 0.5 (10% EtOAc in hexanes); []D20  = +108.0 (c = 1.0, CHCl3); 
max(film)/cm–1 2926 vs, 2855 s, 1719 s (C=O), 1502 m, 1461 m, 1368 m, 1249 m, 1172 s, 
1149 m, 1129 s, 1092 m, 1067 s, 1045 m, 1025 m, 985 w, 968 w, 922 vw, 834 m, 802 w, 705 
w, 665 w; H(400 MHz) 0.08–0.09 (6H, stack, Si(CH3)2), 0.85–0.89 (12H, stack, CH2CH3, 
SiC(CH3)3), 1.22–1.26 (23H, stack, CH2 of alkyl chain), 1.30 (3H, s, C(CH3)A(CH3)B), 1.39 (3H, 
s, C(CH3)A(CH3)B), 1.40–1.43 (12H, stack, O(CH3)3), C(CH3)C(CH3)D), 1.50 (3H, s, 
C(CH3)C(CH3)D), 1.54–1.60 (3H, stack), 3.67 (1H, app d, J 9.0, H-1A), 3.76–3.84 (1H, m, H-2), 




3.90 (1H, dd, J 9.9, 3.5, 2′-H or 3′-H), 3.97–4.05 (2H, stack, H-1B, H-2 or H-3), 4.06–4.13 (2H, 
stack, H-3, H-4), 4.20 (1H, app t, J 3.8, H-1′), 4.43 (1H, app t, J 4.0, H-4′), 4.88 (1H, d, J 9.1, 
NH), 5.79–5.86 (2H, stack, H-5′, H-6′); C(100 MHz) −4.8 [CH3, Si(CH3)A(CH3)B], −4.6 [CH3, 
Si(CH3)A(CH3)B], 14.1 (CH3, CH2CH3), 18.3 [C, SiC(CH3)3], 22.7 (CH2), 25.7 (CH3, 
C(CH3)A(CH3)B), 25.8 [CH3, SiC(CH3)3], 26.6 (CH2), 26.9 (CH3, C(CH3)C(CH3)D), 27.1 (CH3, 
C(CH3)C(CH3)D), 27.9 (CH3, C(CH3)A(CH3)B), 28.4 [CH3, OC(CH3)3], [28.9, 29.4, 29.5, 29.7 
(CH2, alkyl chain, significant resonance overlap)], 31.9 (CH2), 50.3 (CH, C-2), 65.8 (CH, C-4′), 
71.1 (CH2, C-1), 73.0 (CH, C-1′), 73.8 (CH, C-3′), 74.0 (CH, C-2′), [76.6, 77.9 (CH, C-3, C-4)], 
79.3 [C, OC(CH3)3] 107.7 [C, chain acetal C(CH3)2], 110.0 [C, cyclitol acetal C(CH3)2], 127.8 
(CH, C-6′), 131.4 (CH, C-5′), 155.2 (C, C=O); m/z (TOF ES+) 762.5 ([M + Na]+, 100%); HRMS 
m/z (TOF ES+) 762.5336 [M + Na]+ C41H77NO8NaSi requires 762.5316. 
 
(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-2-Hexacosanoylamino-1-O-[2′, 3′, 4′-trihydroxycyclohex-




TFA (2 mL) was added to ether 211 (30 mg, 0.041 mmol).  The mixture was stirred for 15 min 
before removing the TFA by bubbling argon through the mixture.  Residual TFA was removed 
under reduced pressure. This procedure was repeated if necessary until all of the protecting 
groups had been removed as evidenced by TLC.  The crude aminopolyol 212 was isolated, 
presumably as its TFA salt, as a yellow solid. [Rf = 0.3 (30% MeOH in CHCl3)] and used without 
further purification in the next step:  NHS ester 189 (20 mg, 0.041 mmol) and Et3N (10 L, 
0.072 mmol) were added to a solution of aminopolyol 12 in dry THF (2 mL). After 12 h, the 




solvent was removed under reduced pressure. The residue was purified by column 
chromatography (gradient: CHCl3  5% MeOH in CHCl3) to yield amide 166 as a white solid 
(17 mg, 52%): Rf = 0.3 (10% MeOH in CHCl3); m.p. 80–83 °C; solubility issues prevented an 
optical rotation measurement; max(film)/cm–1 3303 br w (O–H, N–H), 2955 w, 2916 s, 2849 s, 
1630 m (C=O), 1543 w, 1467 m, 1259 w, 1066 s, 926 w, 856 w, 801 w, 719 m; H(400 MHz, 
2:1 CDCl3:CD3OD) 0.84 (6H, t, J 6.8, 2 × CH2CH3), 1.12–1.27 (69H, stack, alkyl chain), 1.45–
1.59 (3H, stack, alkyl chain), 2.12 (2H, app t, J 7.6, H-2′′), 3.46–3.59 (2H, stack, H-3, H-4), 
3.67 (1H, dd, J 9.6, 4.0, H-1A), 3.76 (1H, dd, J 9.6, 3.6, H-1B), 3.85 (1H, dd, J 8.2, 4.2, H-2′ or 
H-3′), 3.94–3.99 (2H, stack, H-3′ or H-2′, H-1′ or H-4′), 4.11–4.16 (1H, m, H-2), 4.24–4.27 (1H, 
m, H-4′ or H-1′), 5.79–5.84 (2H, stack, H-5′, H-6′), exchangeable hydrogens not observed; 
C(100 MHz, 2:1 CDCl3:CD3OD) 14.3 (CH3), 23.1 (CH2), 26.3 (CH2), [29.7, 29.8, 29.9, 30.0, 
30.1, (CH2, significant resonance overlap)], 32.4 (CH2), 32.8 (CH2), 36.9 (CH2, C-2′′), 50.6 
(CH, C-2), 66.7 (CH, C-1′ or C-4′), 69.1 (CH, CHOH), 69.4 (CH2, C-1), 70.1 (CH, C-2′ or C-3′), 
[72.7,  75.3 (CH, C-3, C-4)], 75.5 (CH, CHOH), [127.8, 130.7 (CH, C-5′, C-6′)], 174.8 (C, C=O); 
m/z (TOF ES+) 847.7 ([M + Na]+, 70%), 489.1 (100); HRMS m/z (TOF ES+) 847.7240 [M + 














(2S, 3S, 4R, 1′S, 2′S, 3′R, 4′S)-2-[(N-tert-Butoxycarbonyl)amino]-1-O-[4′-O-tert-
butyldimethylsilyl-2′, 3′-O-isopropylidene-2′, 3′, 4′-trihydroxycyclohexyl]-3, 4-O-
isopropylidene-1, 3, 4-octadecanetriol (213) 
 
A flask containing a solution of alkene 211 (90 mg, 0.122 mmol) in MeOH (15 mL) was purged 
with H2 gas for 10 min.  Pd/C (0.01 g, 30 mol %) was then added and the mixture was stirred 
under a flow of H2 for 12 h, after which time, the mixture was filtered through Celite, washing 
with MeOH (40 mL).  The filtrate was concentrated under reduced pressure and the residue 
was purified by column chromatography (5% EtOAc in hexanes) to afford cyclohexane 213 as 
a colourless oil (78 mg, 86%): Rf = 0.5 (10% EtOAc in hexanes); []D20 = +46.8 (c = 1.0, CHCl3); 
H(400 MHz) 0.05 (3H, s, Si(CH3)A(CH3)B), 0.07 (3H, s, Si(CH3)A(CH3)B), 0.85–0.89 (12H, 
stack, CH2CH3, SiC(CH3)3), 1.22–1.26 (22H, stack, alkyl chain), 1.30 (3H, s, C(CH3)A(CH3)B), 
1.36 (3H, s, C(CH3)C(CH3)D), 1.39 (3H, s, C(CH3)A(CH3)B), 1.42 (9H, s, O(CH3)3), 1.44 (3H, s, 
C(CH3)C(CH3)D), 1.49–1.58 (4H, stack), 1.66–1.72 (4H, stack),  3.57 (1H, app d, J 8.3, H-1A), 
3.77–3.84 (1H, m, H-2), 3.87 (1H, dd, J 9.8, 2.1, H-2′ or H-3′), 3.94–4.10 (5H, stack), 4.29–
4.32 (1H, m), 4.80 (1H, d, J 9.7, NH); C(100 MHz) −5.1 [CH3, Si(CH3)A(CH3)B], −4.7 [CH3, 
Si(CH3)A(CH3)B], 14.1 (CH3, CH2CH3), 18.1 [C, SiC(CH3)3], 22.7 (CH2), 24.9 (CH2), 25.7 [CH3, 
SiC(CH3)3, C(CH3)A(CH3)B, resonance overlap], 26.4 (CH2), 26.8 [CH3, C(CH3)C(CH3)D], 26.9 
(CH3, C(CH3)C(CH3)D), 27.9 (CH2), 28.1 (CH3, C(CH3)A(CH3)B), 28.3 (CH3, OC(CH3)3), [28.9, 
29.3, 29.5, 29.7 (CH2, alkyl chain, significant resonance overlap)], 31.9 (CH2), 50.1 (CH, C-2), 
67.4 (CH, CHO), 70.1 (CH2, C-1), [74.5, 75.6, 75.7, 76.5, 77.9 (CH, CHO)], 79.4 (C, 
OC(CH3)3), 107.7 [C, chain acetal C(CH3)2], 108.6 [C, cyclitol acetal C(CH3)2], 155.1 (C, C=O). 
 
 





(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-2-Hexacosanoylamino-1-O-[2′, 3′, 4′-
trihydroxycyclohexyl]-1, 3, 4-octadecanetriol (16) 
 
TFA (2 mL) was added to ether 213 (30 mg, 0.041 mmol).  After 15 min, the TFA was removed 
by bubbling argon through the mixture. Any residual TFA was removed under reduced 
pressure.  This procedure was repeated if necessary until all of the protecting groups had 
been removed as evidenced by TLC.  The crude aminopolyol 214 was isolated, presumably 
as its TFA salt, as a yellow solid [Rf = 0.3 (30% MeOH in CHCl3)] and used without further 
purification in the next step:  NHS ester 19 (20 mg, 0.041 mmol) and Et3N (10 L, 0.072 mmol) 
were added to a solution of aminopolyol 214 in dry THF (2 mL).  After 12 h the solvent was 
removed under reduced pressure. The crude mixture was purified by column chromatography 
(gradient: CHCl3  5% MeOH in CHCl3) to yield amide 16 as a white solid (24 mg, 73%): Rf = 
0.3 (10% MeOH in CHCl3); solubility issues prevented an optical rotation measurement; 
max(film)/cm–1 3342 br m (O–H, N–H), 2915 s, 2849 s, 2409 w, 1625 m (C=O), 1468 m, 1072 
m, 1005 w, 849 w, 718 m; H(300 MHz, 2:1 CDCl3:CD3OD) 0.84 (6H, t, J 6.7, 2 × CH2CH3), 
1.18–1.32 (68H, stack, alkyl chain), 1.45–1.69 (8H, stack, CH2 of cyclitol, alkyl chain), 2.12 
(2H, app t, J 7.5, H-2), 3.48–3.59 (3H, stack), 3.63–3.77 (4H, stack), 3.92–3.97 (1H, m), 4.10–
4.18 (1H, m), 7.23 (1H, d, J 8.7, NH), OHs not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.3 
(CH3), 22.4 (CH2), 23.1 (CH2), 25.6 (CH2), 26.3 (CH2), 26.4 (CH2), [29.8, 29.9, 30.0, 30.1, (CH2, 
significant resonance overlap)], 32.3 (CH2), 32.9 (CH2), 36.9 (CH2), 50.6 (CH, C-2), 68.7 (CH2, 
C-1), 69.5 (CH, C-4′), 71.4 (CH, C-2′), 72.7 (CH, C-3′), 72.7 (CH, C-4), 75.3 (CH, C-3), 78.9 




(CH, C-1′), 174.7 (C, C=O); m/z (TOF ES+) 849.1 ([M + Na]+, 100%);%); HRMS m/z (TOF 
ES+) 848.7313 [M + Na]+, C50H99NO7Na requires 848.7319. 
Data were in agreement with those reported in the literature.138 
 
(Z, Z, 2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-2-Eicosa-11, 14-dienoylamino-1-O-[2′, 3′, 4′-
trihydroxycyclohexyl]-1, 3, 4-octadecantriol (168) 
 
Preparation of (Z,Z)-Eicosa-11, 14-dienoic acid-2, 5-dioxo-1-pyrrolidinyl ester (215): EDCI.HCl 
(35 mg, 0.18 mmol), N-hydroxysuccinimide (23 mg, 0.20 mmol) and DMAP (5 mg, 0.04 mmol) 
were added to a solution of (Z,Z)-eicosa-11, 14-dienoic acid (50 mg, 0.16 mmol) in CH2Cl2 (1 
mL).  The solution was stirred in a sealed tube at 40 °C and the progress of the reaction 
monitored by TLC (40% Et2O in petroleum ether b.p. 40–60 °C). After 12 h, the reaction 
mixture was poured into H2O (5 mL) and extracted with Et2O (3 × 10 mL).  The combined 
organic layers were washed with brine (15 mL), dried with Na2SO4, filtered and the solution 
was concentrated under reduced pressure. The crude mixture was plugged quickly through a 
silica column (20% EtOAc in hexanes) and the NHS ester 215 used directly in the next step 
[Rf = 0.2 (40% Et2O in petroleum ether b. p. 40–60 °C)]. TFA (2 mL) was added to ether 213 
(30 mg, 0.041 mmol).  After stirring for 15 min, the TFA was removed by bubbling argon 
through the mixture.  Residual TFA was removed under reduced pressure.  This procedure 
was repeated if necessary until all of the protecting groups had been removed as evidenced 




by TLC.  The crude aminopolyol 214 was isolated, presumably as its TFA salt, as a yellow 
solid [Rf = 0.3 (30% MeOH in CHCl3)] and used without further purification in the next step:  
NHS ester 215 (20 mg, 0.041 mmol) and Et3N (10 L, 0.072 mmol) were added to a solution 
of aminopolyol 214 in dry THF (2 mL). After stirring the reaction mixture for 12 h, the solvent 
was removed under reduced pressure. The crude mixture was purified by column 
chromatography (gradient: CHCl3  5% MeOH in CHCl3) to yield amide 168 as a white solid 
(15 mg, 48%): Rf = 0.3 (10% MeOH in CHCl3); m.p. 97–99 °C; solubility issues prevented an 
optical rotation measurement; max(film)/cm–1 3371 br w (O–H, N–H), 3010 w, 2917 s, 2850 s, 
2466 w, 1626 s (C=O), 1545 w, 1454 m, 1401 w, 1368 w, 1341 w, 1322 w, 1286 w, 1260 w, 
1072 s, 1009 m, 950 m, 904 w, 884 w, 814 w, 851 w, 720 s, 693 m; H(400 MHz, 2:1 
CDCl3:CD3OD) 0.75–0.84 (6H, stack, 2 × CH2CH3), 1.16–1.25 (44H, stack), 1.51–1.65 (6H, 
stack), 1.97 (4H, app q, J 6.8, 2 × CH2CH2CH=CH), 2.12 (2H, app t, J 7.6, H-2′′), 2.69 (2H, 
app t, J 6.4, CH=CHCH2CH=CH), 3.44–3.56 (3H, stack, 3 × CHO), 3.58–3.73 (4H, stack, 4 × 
CHO), 3.90–3.94 (1H, m, CHO), 4.06–4.12 (1H, m, H-2), 5.21–5.34 (4H, stack, 2 × CH=CH), 
7.08 (1H, d, J 8.8, NH), OHs not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.2 (CH3), 22.3 
(CH2), 23.0 (CH2), 25.5 (CH2), 25.9 (CH2, CH=CHCH2CH=CH), 26.2 (CH2), [27.49, 27.53 (CH2, 
CH2CH2CH=CH), [29.7, 29.8, 29.9, 30.0, 30.1, (CH2, significant resonance overlap)], 31.8 
(CH2), 32.2 (CH2), 33.0 (CH2) 36.9 (CH2, C-2′′), 50.4 (CH, C-2), 68.7 (CH2, C-1), [69.4, 71.3, 
72.5, 72.6, 75.4, 78.8 (CH, CHO)], [128.2, 128.3, 130.4, 130.5 (CH,CH=CH)], 174.5 (C, C=O); 
m/z (TOF ES+) 761.8 ([M + H]+, 100%); HRMS m/z (TOF ES+) 761.6148 [M + Na]+, 










 (2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-3, 4-Di-O-acetyl-2-hexacosanoylamino-1-O-[2′, 3′, 4′-tri-O-
acetyl-trihydroxycyclohexyl]-1, 3, 4-octadecanetriol (216) 
 
Ac2O (8 L, 0.51 mmol) was added dropwise over 20 s to a solution of pentaol 16 (18 mg, 
0.017 mmol) in pyridine (1 mL). The reaction mixture was stirred at rt for 14 h, after which time, 
the volatiles were removed under reduced pressure. The residue was diluted with CH2Cl2 (15 
mL), washed sequentially with H2O (8 mL), NaHCO3 solution (10 mL) and brine (5 mL), and 
then dried over Na2SO4. The mixture was filtered and the filtrate was concentrated under 
reduced pressure. The crude product was purified by flash chromatography (25% EtOAc in 
hexanes) to yield penta-acetate 216 as an off white amorphous solid (19 mg, 87%): Rf = 0.3 
(25% EtOAc in hexanes); []D20  = +41.6 (c = 1.0, CHCl3); max(film)/ cm–1 3369 vw br (N–H), 
2919 s, 2851 s, 1743 s (ester C=O), 1638 w (amide C=O), 1468 w, 1372 m, 1231 s, 1060 w; 
H(300 MHz) 0.87 (6H, app t, J 6.8, 2 × CH2CH3), 1.12–1.28 (68H, stack, alkyl chain), 1.49–
1.64 (5H, stack, alkyl chain, CH2 of cyclitol), 1.67–1.76 (3H, stack, alkyl chain, CH2 of cyclitol), 
1.94 (3H, s, C(O)CH3), 1.95 (3H, s, C(O)CH3), 1.99 (3H, s, C(O)CH3), 2.020 (3H, s, C(O)CH3), 
2.023 (3H, s, C(O)CH3), 2.16 (2H, app t, J 7.6, H-2′′), 3.37–3.44 (2H, stack, H-1), 3.63−3.68 
(1H, m, H-1′ or H-4′), 4.21 (1H, ddd, J 9.4, 5.6, 2.8, H-2), 4.83 (1H, app td, J 10.0, 3.0, H-4), 
5.08 (1H, dd, J 9.5, 2.6, H-2′ or H-3′), 5.15 (1H, dd, J 9.6, 3.0, H-3′ or H-2′), 5.19 (1H, dd, J 
9.5, 2.5, H-3), 5.24−5.29 (1H, m, H-4′ or H-1′), 6.16 (1H, d, J 9.2, NH); C(100 MHz) 14.1 (CH3, 
2 × CH2CH3), [20.8, 20.9, 21.1 (CH3, C(O)CH3, resonance overlap)], 22.7 (CH2), 23.1 (CH2), 
25.6 (CH2), 25.8 (CH2), 27.6 (CH2), [29.4, 29.7, 31.9 (CH2, significant resonance overlap)], 
36.8 (CH2, C-2′′), 48.2 (CH, C-2), 68.0 (CH2, C-1), 69.4 (CH, C-1′ or C-4′ and C-2′ or C-3′, 
resonance overlap), 71.1 (CH, C-3 and C-3′ or C-2′, resonance overlap), 73.4 (CH, C-4), 76.4 




(CH, C-4′ or C-1′), 169.83 (C, acetyl C=O), 170.02 (C, acetyl C=O), 170.2 (C, acetyl C=O), 
170.6 (C, acetyl C=O), 171.1 (C, acetyl C=O), 172.9 (C, amide C=O); m/z (TOF ES+) 1058.7 
([M + Na]+, 100%); HRMS m/z (TOF ES+) 1058.7420 [M + Na]+, C60H109NO12Na requires 
1058.7425. 
 
(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-3, 4-Di-O-acetyl-2-hexacosathioylamino-1-O-[2′, 3′, 4′-tri-
O-acetyl-trihydroxycyclohexyl]-1, 3, 4-octadecantriol (217) 
 
Lawesson′s reagent (8 mg, 0.02 mmol) was added to a solution of amide 216 (16 mg, 0.015 
mmol) in toluene (1 mL) at rt. The reaction mixture was stirred at 80 °C for 4 h and then the 
solvent was removed under reduced pressure.  The residue was diluted with CH2Cl2 (10 mL), 
washed sequentially with H2O (5 mL), NaHCO3 solution (10 mL) and brine (5 mL), and then 
dried over Na2SO4.  The solution was filtered and the filtrate was concentrated under reduced 
pressure.  The crude product was purified by flash chromatography (25% EtOAc in hexanes) 
to yield thioamide 217 as an off-white low melting point solid (14 mg, 93%): Rf = 0.3 (20% 
EtOAc in hexanes); []D20 = +34.4 (c = 1.0, CHCl3); max(film)/cm–1 2922 vs, 2852 s, 1744 vs 
(C=O), 1536 w, 1463 w, 1370 m, 1227 vs (C=S), 1058 m, 1023 m, 950 w, 832 vw, 720 w; 
H(300 MHz) 0.88 (6H, app t, J 6.8, 2 × CH2CH3), 1.20–1.28 (68H, stack, alkyl chain), 1.57–
1.81 (8H, stack, alkyl chain, CH2 of cyclitol), 2.02 (3H, s, C(O)CH3), 2.03 (3H, s, C(O)CH3), 
2.06 (3H, s, C(O)CH3), 2.09 (3H, s, C(O)CH3), 2.11 (3H, s, C(O)CH3), 2.69 (2H, m, J 7.4, 2.5, 
H-2 ′′), 3.54 (1H, app d, J 9.3, H-1A), 3.66 (1H, dd, J 10.0, 3.1, H-1B), 3.71−3.75 (1H, m, H-1′ 
or H-4′), 4.83 (1H, app td, J 10.1, 3.0, H-4), 5.04 (1H, app tt, J 8.9, 2.9, H-2), 5.16 (1H, dd, J 
9.3, 2.5, H-2′ or H-3′), 5.23 (1H, dd, J 9.3, 2.5, H-3′ or H-2′), 5.29−5.34 (1H, m, H-4′ or H-1′), 




5.40 (1H, dd, J 8.7, 2.7, H-3), 8.20−8.27 (1H, m, NH); C(100 MHz) 14.1 (CH3, 2 × CH2CH3), 
[20.8, 20.9, 21.1 (CH3, COCH3, resonance overlap)], 22.7 (CH2), 23.2 (CH2), 25.5 (CH2), 25.8 
(CH2), 28.2 (CH2), 28.9 (CH2), [29.3, 29.4, 29.6, 29.7 (CH2, significant resonance overlap)], 
29.7 (CH2), 31.9 (CH2), 47.3 (CH2, C-2′′), 54.1 (CH, C-2), 66.4 (CH2, C-1), 69.3 (CH, C-1′ or 
C-4′ and C-2′ or C-3′, resonance overlap), 70.8 (CH, C-3 and C-3′ or C-2′, resonance overlap), 
73.4 (CH, C-4), 76.4 (CH, C-4′ or C-1′), 169.95 (C, acetyl C=O), 170.00 (C, acetyl C=O), 
170.01 (C, acetyl C=O), 170.5 (C, acetyl C=O), 171.3 (C, acetyl C=O), 206.4 (C, C=S); m/z 
(TOF ES+) 1053.8 ([M + H]+, 100%); HRMS m/z (TOF ES+) 1052.7820 [M + H]+, C60H110NO11S 
requires 1052.7800. 
 
(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-2-Hexacosathioylamino-1-O-[2′, 3′, 4′-
trihydroxycyclohexyl]-1, 3, 4-octadecanetriol (167) 
 
NaOMe (0.2 mL of a 1.0 M solution in MeOH, 0.2 mmol) was added to a solution of thioamide 
217 (14 mg, 0.014 mmol) in MeOH (2.5 mL).  After 2 h, the reaction mixture was neutralised 
by the addition of acidic ion-exchange resin [Dowex H CR-S, pre-washed with MeOH (100 
mL) and CHCl3 (50 mL)].  The solution was filtered and the resin washed with MeOH (25 mL) 
and CHCl3–MeOH (25 mL, 9:1).  The filtrate was concentrated under reduced pressure.  
Purification of the residue by column chromatography (gradient: CHCl3  5% MeOH in CHCl3) 
provided thioamide 167 as a pale white solid (8 mg, 74%): Rf = 0.3 (10% MeOH in CHCl3); 
solubility issues prevented an optical rotation measurement; max(film)/cm–1 3377 br w (O–H), 
2917 s, 2850 s, 2498 br w, 1648 w, 1467 m, 1377 w, 1260 m (C=S), 1071 m, 1017 m, 974 w, 
800 s, 720 s, 663 s; H(300 MHz, 2:1 CDCl3:CD3OD) 0.86 (6H, app t, J 6.7, 2 × CH2CH3), 
1.20–1.32 (69H, stack, alkyl chain), 1.55–1.75 (7H, stack, CH2 of cyclitol, alkyl chain), 2.64 




(2H, app t, J 7.6, H-2′′), 3.62–3.82 (6H, stack), 3.85 (1H, dd, J 9.8, 3.1), 4.01–4.04 (1H, m), 
4.82–4.87 (1H, m), 8.95 (1H, d, J 8.3, NH), OHs not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 
14.3 (CH3), 22.4 (CH2), 23.1 (CH2), 25.6 (CH2), 26.3 (CH2), 26.4 (CH2), [29.8, 29.9, 30.0, 30.1 
(CH2, significant resonance overlap)], 32.3 (CH2), 32.9 (CH2), 36.9 (CH2), 56.5 (CH, C-2), 67.2 
(CH2, C-1), 69.6 (CH, C-4′), 71.5 (CH, C-2′), 72.6 (CH, C-3′), 72.7 (CH, C-4), 74.2 (CH, C-3), 
78.8 (CH, C-1′), 205.6 (C, C=S); m/z (TOF ES+) 842.7 ([M + H]+, 50%), 539.3 (100); HRMS 
m/z (TOF ES+) 842.7291 [M + H]+, C50H100NO6S requires 842.7271. 
 
11-(4′-Fluorophenyl)undec-10-ynoic acid (220) 
 
A solution of 4-fluoroiodobenzene (833 mg, 2.73 mmol) and undec-10-ynoic acid (500 mg, 
3.76 mmol) in Et3N (6 mL) was degassed by bubbling argon through the solution for 10 min 
while sonicating. Pd(PPh3)2Cl2 (153 mg, 0.218 mmol) was added and the mixture was stirred.  
After 10 min, CuI (282 mg, 1.48 mmol) was added and the resulting mixture was heated under 
argon overnight at 50 °C.  The reaction mixture was then cooled to rt before filtering through 
a pad of Celite to remove the insoluble ammonium salt generated in the reaction, rinsing with 
Et2O (25 mL). The filtrate was concentrated under reduced pressure and the residue was 
purified by flash chromatography (10% MeOH in CHCl3) to afford alkyne 220 as an off white 
solid (595 mg, 79 %): Rf  = 0.6 (10% MeOH in CHCl3); m.p. 64–65 oC; max(film)/cm–1 3675 w 
(O–H), 2926 m, 2917 br m, 2867 w, 2850 m, 1705 vs (C=O), 1600 w, 1505 s, 1467 s, 1451 w, 
1427 m, 1410 m, 1345 w, 1327 m, 1288 w, 1264 w, 1252 m, 1217 vs, 1191 m, 1158 m, 1092 
m, 1064 w, 1029 w, 1012 w, 921 m, 835 vs, 825 s, 814 m, 786 w, 746 w, 717 m, 676 w, 657 
w; H(400 MHz) 1.29–1.39 (6H, stack, alkyl chain), 1.40–1.48 (2H, m, alkyl chain), 1.54–1.69 
(4H, stack, alkyl chain), 2.32–2.40 (4H, stack, H-2, H-9), 6.93–7.01 (2H, m, Ar), 7.32–7.39 
(2H, m, Ar), OH not observed; C(100 MHz) 19.3 (CH2), 24.7 (CH2), [29.7, 29.8, 28.9, 29.0, 




29.1 (CH2, alkyl chain)], 34.1 (CH2), [79.5, 90.0 (C, C-10, C-11)], 115.4 (CH, d, J, 20.0, C-3′), 
120.1 (C, Ar C-1′), 133.3 (CH, d, J 10.0, C-2′), 162.1 (C, d, J 250.0, C-4′), 180.0 (C, C=O); F 
(282 MHz) −112.4 (tt, J 8.7, 5.4); m/z (TOF ES+) 299.1 ([M + Na]+, 100%); HRMS m/z (TOF 
ES+) 299.1417 [M + Na]+, C17H21FO2Na requires 299.1423. 
Data were in agreement with those reported in the literature.187 
 
11-(4′-Fluorophenyl)undecanoic acid (221) 
 
A flask containing a solution of alkyne 220 (200 mg, 0.724 mmol) in MeOH (25 mL) was purged 
with H2 for 10 min. Pd/C (8 mg, 10% Pd) was added and the mixture was stirred under a flow 
of H2 gas.  After 12 h, the suspension was filtered through Celite, which was washed with 
MeOH (40 mL). The filtrate was concentrated under reduced pressure and the residue was 
purified by column chromatography (gradient: hexanes  30% EtOAc in hexanes) to afford 
acid 221 as a white solid (0.19 g, 95%): Rf = 0.4 (5% MeOH in CHCl3); m.p. 91–95 oC; 
max(film)/cm–1 3675 w (O–H), 2926 br m, 2914 m, 2867 w, 2850 m, 1694 s (C=O), 1605 w, 
1507 s, 1470 m, 1459 w, 1428 m, 1405 m, 1348 w, 1325 w, 1286 w, 1265 m, 1240 s, 1217 
vs, 1191 m, 1158 m, 1092 m, 1064 s, 1029 w, 1012 w, 919 m, 835 vs, 825 s, 817 s, 786 w, 
750 m, 721 m, 678 w; H(300 MHz) 1.24–1.35 (12H, stack, alkyl chain), 1.53–1.66 (4H, stack, 
alkyl chain), 2.35 (2H, t, J 7.5, H-2), 2.56 (2H, t, J 7.7, H-11), 6.92–6.98 (2H, m, Ar), 7.09–7.14 
(2H, m, Ar), OH not observed; C(100 MHz) [24.7, 29.1, 29.19, 29.24, 29.41, 29.46, 29.50 
(CH2, alkyl chain)], 31.6 (CH2), 34.0 (CH2), 35.2 (CH2), 114.9 (CH, d, J 20.8, C-3′), 129.7 (CH, 
d, J 7.6, C-2′), 138.5 (C, d, J 2.0, C-1′), 161.1 (C, d, J 240.0, C-4′), 180.1 (C, C=O); F (282 
MHz) −118.3 (tt, J 8.8, 5.6); m/z (TOF ES+) 303.2 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 
303.1745 [M + Na]+, C17H25FO2Na requires 303.1736. 




Data were in agreement with those reported in the literature.187 
(2S, 3S, 4R, 1′S, 2′S, 3′S, 4′S)-2-[11′′-(4′′′-Fluorophenyl)undecanoylamino-1-O-[2′, 3′, 4′- 
trihydroxycyclohexyl]-1, 3, 4-octadecantriol (169) 
 
TFA (2 mL) was added to ether 213 (30 mg, 0.041 mmol).  The mixture was stirred for 15 min 
before removing the TFA by bubbling argon through the mixture. Any residual TFA was 
removed under reduced pressure. This procedure was repeated if necessary until all of the 
protecting groups had been removed as evidenced by TLC.  The crude aminopolyol 214 was 
obtained, presumably as its TFA salt, as a yellow solid [Rf = 0.3 (30% MeOH in CHCl3)] and 
used without further purification. (COCl)2 (2 mL) was added to acid 221 (11 mg, 0.041 mmol) 
and the resulting solution was heated at 70 °C for 2 h, after which time, the solution was cooled 
to rt, and the residual (COCl)2 removed under a stream of dry argon. The residual volatiles 
were removed under reduced pressure. The resulting crude acyl chloride was dissolved in 
THF (0.5 mL) and added with vigorous stirring, to a solution of the crude aminopolyol 214 in 
THF/NaOAc (8 M) (1:1, 2 mL).  Vigorous stirring was maintained for 2 h, after which time the 
reaction mixture was left to stand and the layers were separated.  The aqueous layer was 
extracted with THF (3 × 2.0 mL) and the organic layers were combined and concentrated 




under reduced pressure.  The crude mixture was purified by column chromatography 
(gradient: CHCl3  5% MeOH in CHCl3) to yield amide 169 as a white solid (17 mg, 54%): Rf 
= 0.5 (10% MeOH in CHCl3); solubility issues prevented an optical rotation measurement; 
max(film)/cm–1 3332 br w (O–H), 2922 s, 2852 m, 1648 m (C=O), 1541 m, 1593 s, 1464 m, 
1253 m, 1221 m, 1079 s, 802 m, 765 m, 679 w; H(300 MHz, 2:1 CDCl3:CD3OD) 0.85 (3H, t, 
J 6.7, CH2CH3), 1.19–1.38 (37H, stack), 1.50–1.70 (9H, stack), 2.16 (2H, app t, J 7.5), 2.53 
(2H, app t, J 8.6), 3.48–3.78 (7H, stack), 3.92–3.99 (1H, m), 4.10–4.18 (1H, m), 6.86–6.96 
(2H, m, Ar), 7.04–7.14 (2H, m, Ar), 7.22 (1H, d, J 8.6, NH), OHs not observed; C(100 MHz, 
2:1 CDCl3:CD3OD) 14.2 (CH3, CH2CH3), 22.3 (CH2), 22.9 (CH2), 25.4 (CH2), 26.1 (CH2), [29.4, 
29.5, 29.6, 29.7, 29.8, 29.9, 30.0 (CH2, alkyl chain, resonance overlap)], 31.9 (CH2), 32.2 
(CH2), 35.3 (CH2), 36.8 (CH2), 50.3 (CH, C-2), 68.7 (CH2, C-1), [69.3, 71.2, 72.5, 72.6, 75.3, 
78.8 (CH, CH-O, C-3, C-4, C-1′, C-2′, C-3′, C-4′)], 115.1 (CH, d, J 20.9, C-3′′′), 130.0 (CH, d, 
J 3.2, C-2′′′), 138.8 (C, d, J 3.2, C-1′′) 161.5 (C, d, J 241.2, C-4′′′) ,174.4 (C, C=O); F (282 
MHz) −115.0 (tt, J 8.8, 5.5); m/z (TOF ES+) 710.5 ([M]+, 100%); HRMS m/z (TOF ES+) 
710.5382 [M]+, C41H73NFO7 requires 710.5371. 
 
 (2S, 3S)-1-O-Benzyl-2,3-O-isopropylidene-1,2,3,4-butanetetraol (235) 
 
NaH (123 mg of a 60% dispersion in mineral oil, 3.08 mmol,) was added to a solution of (+)-
2,3-O-isopropylidene-L-threitol (500 mg, 3.08 mmol) in THF (20 mL) at 0 °C. After 1 h, a 
solution of BnBr (527 mg, 3.08 mmol) in THF (5 mL) was added. The reaction mixture was 
warmed to rt and stirred for 16 h. The mixture was diluted with Et2O (50 mL) and washed with 
NH4Cl solution (50 mL). The aqueous layer was extracted with Et2O (3 x 20 mL). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. 




The crude product was purified by column chromatography (10% EtOAc in hexanes → 20% 
EtOAc in hexanes) to afford benzyl ether 235 as a pale yellow oil (0.77 g, 76%). Rf = 0.2 (20% 
EtOAc in hexanes); []D21 = +7.6 (c = 1.0, CHCl3) lit.188 []D20  = +9.1 (c = 1.0, CHCl3); 
max(film)/cm–1 3448 br m (O–H), 2986 m, 2931 m, 2868 m, 1454 m, 1370 s, 1249 s, 1213 s, 
1167 m, 1076 vs, 1048 vs, 989 m, 902 m, 845 s, 737 s, 698 s, 606 w; H(400 MHz) 1.35 (3H, 
s, C(CH3)A(CH3)B), 1.36 (3H, s, C(CH3)A(CH3)B), 2.51 (1H, br s, OH), 3.50 (1H, dd, J 9.9, 5.5, 
H-1A), 3.57–3.64 (2H, stack, H-1B, H-4A), 3.69 (1H, app. dt, J 11.5, 3.8, H-4B), 3.87 (1H, app. 
dt, J 8.4, 4.4, H-3), 3.99 (1H, app. dt, J 8.3, 5.3, H-2), 4.52 (2H, s, PhCH2), 7.19–7.31 (5H, 
stack, Ar CH); C(100 MHz) 26.8 [CH3, C(CH3)A(CH3)B], 26.9 [CH3, C(CH3)A(CH3)B], 62.3 (CH2, 
C-4), 70.3 (CH2, C-1), 73.6 (CH2, PhCH2), 76.4 (CH, C-2), 79.5 (CH, C-3), 109.3 (C, C(CH3)2), 
[127.6, 127.7, 128.4 (CH, Ar CH)], 137.5 (C, Ar C); m/z (TOF ES+) 275.1 ([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.188 
 
(2S, 3S, 4R, 2′S, 3′S)-1-O-[4′-O-Benzyl-2′,3′-O-isopropylidene-2′,3′,4′-trihydroxybutyl]-2-
toluenesulfonamido-3, 4-O-isopropylidene-1, 3, 4-octadecanetriol (236) 
 
NaH (32 mg of a 60% dispersion in mineral oil, 0.8 mmol,) was added to a solution of benzyl 
ether 235 (200 mg, 0.793 mmol) in DMF (1 mL) at 0 °C. After stirring for 1 h, a solution of 
aziridine 193 (325 mg, 0.658 mmol) in DMF (1.5 mL) was added.  After 20 min at 0 °C, the 
reaction mixture was warmed to rt and stirred for a further 15 h. The reaction mixture was then 
quenched with H2O (25 mL) and extracted with EtOAc (5 × 30 mL). The combined organic 
fractions were washed with brine (70 mL), dried over Na2SO4, filtered and the filtrate was 
concentrated under reduced pressure. The residue was purified by column chromatography 




(10% EtOAc in hexanes) to yield ether 236 as a colourless oil (314 mg, 64%): Rf = 0.3 (20% 
EtOAc in hexanes); []D21 = +6.0 (c = 1.0, CHCl3); max(film)/cm–1 3270 vw br (N–H), 2985 m, 
2924 s, 2854 m, 1598 w, 1455 m, 1379 m, 1369 m, 1336 m, 1246 m, 1218 m, 1162 s, 1089 
s, 848 w, 814 m, 736 w, 697 m, 666 m; H(400 MHz) 0.88 (3H, t, J 6.8, CH2CH3), 1.23–1.28 
(23H, stack, alkyl chain), 1.29 (3H, s, C(CH3)A(CH3)B), 1.36 (3H, s, C(CH3)A(CH3)B), 1.38 (3H, 
s, C(CH3)C(CH3)D), 1.41 (3H, s, C(CH3)C(CH3)D), 1.43–1.58 (3H, stack, alkyl chain), 2.41 (3H, 
s, Ar CH3), 3.08 (1H, dd, J 9.8, 2.9, H-1A), 3.23 (1H, dd, J 10.4, 4.7, H-1′A), 3.46–3.56 (3H, 
stack, H-2, H-1′B, H-4′A), 3.57–3.65 (2H, stack, H-1B, H-4′B), 3.87 (1H, app. dt, J 8.2, 4.6, H-
2′), 3.93–4.05 (3H, stack, H-3, H-4, H-3′), 4.56 (1H, A of AB, J 12.2, PhCHAHB), 4.61 (1H, B of 
AB, J 12.2, PhCHAHB), 5.31 (1H, d, J 9.7, N-H), 7.26–7.38 (7H, stack, Ar CH), 7.74–7.77 (2H, 
m, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 21.5 (CH3, Ar CH3), 22.7 (CH2, alkyl chain), 25.8 
[(CH3, C(CH3)A(CH3)B], 26.4 (CH2, alkyl chain), 27.0 (CH3, C(CH3)C(CH3)D), C(CH3)C(CH3)D, 
resonance overlap], 28.0 (CH3, C(CH3)A(CH3)B), [29.0, 29.4, 29.5, 29.7, 31.9  (CH2, alkyl chain, 
resonance overlap)], 53.1 (CH, C-2), 69.5 (CH2, C-1), 70.7 (CH2, C-4′), 71.7 (CH2, C-1′), 73.6 
(CH2, PhCH2), [75.8, 77.2 (CH, C-3 or C-4 or C-3′)], 77.6 (CH, C-2′), 77.7 (CH, C-3 or C-4 or 
C-3′), 107.7 (C, C(CH3)2 phyto), 109.4 (C, C(CH3)2 thr), [127.1, 127.8, 128.4, 129.6 (CH, Ar 
CH, resonance overlap)], [137.7, 138.5, 143.5 (C, Ar C)]; m/z (TOF ES+) 768.4 ([M + Na]+, 
100%); m/z (TOF ES ) 744.5 ([M H], 100%); HRMS m/z (TOF ES–) 744.4506 ([M H]), 












(2S, 3S, 4R, 2′S, 3′S)-1-O-[4′-O-Benzyl-2′,3′-O-isopropylidene-2′,3′,4′-trihydroxybutyl]-2-
[(N-tert-butoxycarbonyl)amino]-3, 4-O-isopropylidene-1, 3, 4-octadecanetriol (238) 
 
Boc2O (150 mg, 0.687 mmol) and DMAP (25 mg, 10 weight %) were added to a solution of 
sulfonamide 236 (250 mg, 0.335 mmol) in CH2Cl2 (10 mL). The solution was stirred for 4 h 
and then the solvent was removed under reduced pressure to provide the crude product 237, 
which was used directly in the next reaction without further purification: anhydrous MeOH (5 
mL) was added to the flask containing carbamate 237 (283 mg, 0.335 mmol, based on 100% 
conversion).  Mg powder (50 mg, 2.01 mmol) was added and the reaction mixture was 
sonicated in an ultrasound bath.  After 30 min, the mixture was poured into hydrochloric acid 
(10 mL, 1.0 M) and extracted with Et2O (3 × 20 mL).  The combined organic phases were 
washed sequentially with NaHCO3 solution (20 mL) and brine (20 mL), dried with Na2SO4 and 
filtered. The solvent was removed under reduced pressure and the residue purified by flash 
column chromatography (10% EtOAc in hexanes) to give Boc amide 238 as a colourless oil 
(150 mg, 65% over two steps): Rf = 0.5 (20% EtOAc in hexanes); []D21 = +18.8 (c = 1.0, 
CHCl3); max(film)/cm–1 3307 vw br (N–H), 2983 m, 2924 vs, 2854 s, 1717 s (C=O), 1499 m, 
1455 m, 1367 s, 1247 s, 1218 s, 1169 vs, 1086 s, 1046 s, 852 m, 737 m, 697 m; H(400 MHz) 
0.87 (3H, t, J 6.8, CH2CH3), 1.23–1.29 (23H, stack, alkyl chain), 1.30 (3H, s, C(CH3)A(CH3)B), 




1.39 (3H, s, C(CH3)A(CH3)B), 1.41–1.42 (6H, stack, C(CH3)C(CH3)D), 1.43 (9H, s, C(CH3)3), 
1.49–1.55 (3H, stack, alkyl chain), 3.56 (1H, dd, J 9.7, 2.5, H-1A), 3.58–3.63 (4H, stack, H-1′A, 
H-1′B, H-4′A, H-4′B), 3.71 (1H, dd, J 9.7, 3.5, H-1B), 3.75–3.84 (1H, m, H-2), 3.92–4.00 (2H, 
stack, H-3,H-2′), 4.02–4.10 (2H, stack, H-4, H-3′), 4.57 (1H, A of AB, J 12.1, PhCHAHB), 4.61 
(1H, B of AB, J 12.1, PhCHAHB), 4.82 (1H, d, J 9.7, N-H), 7.26–7.37 (5H, stack, Ar CH); C(100 
MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.8 (CH3, C(CH3)A(CH3)B), 26.6 (CH2, alkyl 
chain), 27.0 (CH3, C(CH3)C(CH3)D, resonance overlap), 28.1 (CH3, C(CH3)A(CH3)B), 28.3 (CH3, 
C(CH3)3), [28.8, 29.3, 29.5, 29.7, 31.9  (CH2, alkyl chain, resonance overlap)], 49.7 (CH, C-2), 
70.6 (CH2, C-4′), 71.6 (CH2, C-1, C-1′, resonance overlap), 73.5 (CH2, PhCH2), [76.1, 77.2, 
77.4, 77.9 (CH, C-3, C-4, C-2′, C-3′)], 79.4 (C, C(CH3)3), 107.8 (C, C(CH3)2 phyto), 109.5 (C, 
C(CH3)2 thr), [127.1, 128.4, (CH, Ar CH, resonance overlap)], 137.9 (C, Ar C), 155.0 (C, C=O); 
m/z (TOF ES+) 714.5 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 714.4922 [M + Na]+, 
C40H69NO8Na requires 714.4921. 
 
(2S, 3S, 4R, 2′S, 3′S)-2-[(N-tert-Butoxycarbonyl)amino]-1-O-[2′,3′-O-isopropylidene-
2′,3′,4′-trihydroxybutyl]-3, 4-O-isopropylidene-1, 3, 4-octadecanetriol (239) 
 
A flask containing a solution of benzyl ether 238 (120 mg, 0.173 mmol) in MeOH (10 mL) was 
purged with H2 gas for 10 min.  Pd/C (1 mg, 0.05 equiv) was then added and the mixture was 
stirred under a flow of H2 for 4 h, after which time, the mixture was filtered through Celite, 
washing sequentially with MeOH (40 mL) and CHCl3 (40 mL). The filtrate was concentrated 
under reduced pressure and the residue was purified by column chromatography (20% EtOAc 
in hexanes) to afford alcohol 239 as a colourless oil (82 mg, 79%): Rf = 0.2 (20% EtOAc in 
hexanes); []D21 = +9.2 (c = 1.0, CHCl3); max(film)/cm–1 3356 br m (O–H, N–H), 2983 m, 2923 




vs, 2854 s, 1714 s (C=O), 1521 m, 1456 m, 1379 s, 1367 vs, 1246 vs, 1218 vs, 1167 vs, 1078 
vs, 1045 vs, 1026 vs, 989 m, 847 s, 779 w, 721 w, 697 w; H(400 MHz) 0.85 (3H, t, J 6.8, 
CH2CH3), 1.20–1.29 (23H, stack, alkyl chain), 1.30 (3H, s, C(CH3)A(CH3)B), 1.38–1.43 (18H, 
stack, C(CH3)A(CH3)B, C(CH3)C(CH3)D,), 1.48–1.57 (3H, stack, alkyl chain), 2.54 (1H, br s, OH), 
3.56–3.78 (6H, stack, H-1A, H-1B, H-1′A, H-1′B, H-4′A, H-4′B), 3.79–3.89 (1H, m, H-2), 3.90–4.02 
(3H, stack, H-3,H-2′, H-3′), 4.06–4.11 (1H, m, H-4), 4.79 (1H, d, J 9.7, N-H); C(100 MHz) 14.1 
(CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.7 (CH3, C(CH3)A(CH3)B), 26.6 (CH2, alkyl chain), 
[27.0, 28.0 (CH3, C(CH3)A(CH3)B, C(CH3)C(CH3)D, resonance overlap)], 28.3 (CH3, C(CH3)3), 
[28.7, 29.3, 29.5, 29.6, 31.9  (CH2, alkyl chain, resonance overlap)], 49.4 (CH, C-2), 62.3 (CH2, 
C-4′), 71.3 (CH2, C-1), 71.8 (CH2, C-1′), [76.4, 76.6, (CH, C-3 or C-2′ or C-3′)], 77.9 (CH, C-4), 
79.0 (CH, C-3 or C-2′ or C-3′), 79.6 (C, C(CH3)3), 107.9 (C, C(CH3)2 phyto), 109.2 (C, C(CH3)2 
thr), 155.1 (C, C=O); m/z (TOF ES+) 624.4 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 
















 (2S, 3S, 4R, 2′S, 3′S)-2-Hexacosanoylamino-1-O-(2′, 3′, 4′-trihydroxybutyl)-1, 3, 4-
octadecanetriol (14)  
 
TFA (2 mL) was added to alcohol 239 (30 mg, 0.050 mmol).  After stirring for 1 h, the TFA was 
removed by bubbling argon through the mixture.  Residual TFA was removed under reduced 
pressure. This procedure was repeated if necessary until all of the protecting groups had been 
removed as evidenced by TLC.  The crude aminopolyol was isolated presumably as its TFA 
salt and used without further purification in the next step: NHS ester 189 (30 mg, 0.06 mmol) 
and Et3N (20 L, 1.0 mmol) were added to a solution of aminopolyol 240 in dry THF (2 mL). 
After 12 h, the solvent was removed under reduced pressure. The residue was purified by 
column chromatography (gradient: CHCl3  10% MeOH in CHCl3) to yield ThrCer 14 as a 
white solid (24 mg, 62%): Rf = 0.3 (8% MeOH in CHCl3); m.p. 106–111 °C, lit.111 107–109 °C; 
solubility issues prevented an optical rotation measurement; max(film)/cm–1 3393 br s (O–H, 
N–H), 2917 vs, 2849 vs, 1741 m, 1632 s (C=O), 1568 m, 1463 s, 1364 m, 1258 m, 1022 s, 
968 w, 720 m; H(400 MHz, 2:1 CDCl3:CD3OD) 0.84 (6H, t, J 6.7, 2 × CH2CH3), 1.20–1.30 
(68H, stack, alkyl chain), 1.47–1.65 (4H, stack, alkyl chain), 2.17 (2H, app. t, J 7.6, H-2′′), 
3.48–3.65 (8H, stack, CH-OH), 3.70 (1H, dd, J 9.8, 4.5, H-1B), 3.73– 3.77 (1H, m), 4.16 (1H, 
dd, J 9.0, 4.3, H-2) exchangeable protons not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.3 




(CH3, CH2CH3), [23.0, 26.3, 29.7, 29.9, 30.06, 30.09, 30.2, 32.3, 33.0 (CH2, alkyl chain, 
resonance overlap)], 36.8 (CH2, C-2′′), 50.4 (CH, C-2), 63.8 (CH2, C-4′), 70.7 (CH), 71.0 (CH2, 
C-1), 72.5 (CH), 72.9 (CH), 73.4 (CH2, C-1′), 75.2 (CH), 175.0 (C, C=O); m/z (TOF ES+) 822.7 
([M + Na]+, 50%), 480.4 (100); HRMS m/z (TOF ES+) 822.7159 [M + Na]+, C 48H97NO7Na 
requires 822.7163. 
Data were in agreement with those reported in the literature.111 
 
(2S, 3S)-4-O-Benzyl-2,3-O-isopropylidene-1-O-tosyl-1,2,3,4-butanetetraol (244) 
 
Et3N (1.11 mL, 7.93 mmol) and DMAP (20 mg, 0.16 mmol) were added to a solution of benzyl 
ether 235 (1.00 g, 3.96 mmol) in CH2Cl2 (20 mL). The reaction mixture was cooled to 0 °C and 
a solution of TsCl (0.76 g, 4.00 mmol) in CH2Cl2 (10 mL) was added. The reaction mixture was 
warmed to rt. After 6 h, the reaction was quenched by adding H2O (30 mL). Additional CH2Cl2 
(20 mL) was added and the phases were separated. The combined organic phases were 
washed with brine (1 × 30 mL), dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography (10%EtOAc in 
hexanes) to provide tosylate 244 as a colourless oil (1.44 g, 89%): Rf = 0.5 (10% EtOAc in 
hexanes); []D21 =  –13.6 (c = 1.0, CHCl3), [lit.189 []D26 =  –9.3 (c = 2.5, CHCl3); max(film)/cm–
1 2987 w, 2869 w, 1598 w, 1496 w, 1454 m, 1362 s, 1307 w, 1292 w, 1248 m, 1213 m, 1189 
s, 1175 vs, 1093 vs, 1028 m, 1019 m, 977 s, 907 m, 886 m, 848 m, 813 s, 785 s, 739 s, 698 
s, 676 m, 663 s; H(400 MHz) 1.34 (3H, s, C(CH3)A(CH3)B), 1.37 (3H, s, C(CH3)A(CH3)B), 2.43 
(3H, s, Ar CH3), 3.53 (1H, dd, J 10.1, 4.9, H-1A), 3.61 (1H, dd, J 10.1, 4.8, H-1B), 3.96–4.11 
(3H, stack, H-2, H-3, H-4A), 4.21 (1H, dd, J 10.3, 3.3, H-4B), 4.54 (2H, s, PhCH2), 7.27–7.38 




(7H, stack, Ar CH), 7.75–7.79 (2H, m, Ar CH); C(100 MHz) 21.7 (CH3, Ar CH3), 69.3 (CH2, C-
4), 70.1 (CH2, C-1), 73.6 (CH2, PhCH2), [76.27, 76.29 (CH, C-2, C-3)], 110.2 (C, C(CH3)2), 
[127.7, 127.8, 128.0, 128.5, 129.9 (CH, Ar CH)], [132.8, 137.7, 144.96 (C, Ar C)]; m/z (TOF 
ES+) 429.1 ([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.190 
 
(2S, 3S)-4-Azido-1-O-benzyl-2,3-O-isopropylidene-1,2,3-butanetriol (245) 
 
NaN3 (160 mg, 2.46 mmol) was added to a solution of tosylate 244 (500 mg, 1.23 mmol) in 
DMF (15 mL). The solution was stirred for 6 h at 100 °C after which time, it was cooled to rt 
and H2O (60 mL) was added. The phases were separated and the aqueous layer was 
extracted with EtOAc (5 × 50 mL). The combined organic layers were washed with brine (1 × 
200 mL), dried with Na2SO4, filtered, and the filtrate evaporated under reduced pressure. The 
crude mixture was purified by column chromatography (10% EtOAc in hexanes) to yield azide 
245 as a yellow oil (242 mg, 71%): Rf = 0.7 (25% EtOAc in hexanes); []D24 = –56.8 (c = 1.0, 
CHCl3); max(film)/cm–1 2933 w, 2863 w, 2099 vs (N3), 1454 m, 1371 s, 1246 s, 1216 s, 1167 
s, 1087 vs, 1028 m, 990 m, 901 m, 845 s, 804 w, 737 s, 698 s; H(400 MHz) 1.43 (3H, s, 
C(CH3)A(CH3)B), 1.47 (3H, s, C(CH3)A(CH3)B), 3.30 (1H, dd, J 13.3, 5.0, H-4A), 3.53–3.59 (2H, 
stack, H-1A, H-4B), 3.66 (1H, dd, J 10.0, 4.8, H-1B), 4.00–4.10 (2H, stack, H-2, H-3), 4.57 (2H, 
s, PhCH2), 7.27–7.38 (5H, stack, Ar CH); C(100 MHz) 26.9 [CH3, C(CH3)A(CH3)B], 27.0 [CH3, 
C(CH3)A(CH3)B], 52.1 (CH2, C-4), 70.2 (CH2, C-1), 73.7 (CH2, PhCH2), [76.6, 78.0 (CH, C-2, 
C-3)], 110.0 (C, C(CH3)2), [127.7, 127.8, 128.5, (CH, Ar CH)], 137.7 (C, Ar C); m/z (TOF ES+) 
300.1 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 300.1320 [M + Na]+, C14H19N3O3Na requires 
300.1324. 




(2S, 3S)- 4-Amino-1-O-benzyl-2,3-O-isopropylidene-1,2,3-butanetriol (246) 
 
A flask containing a solution of azide 245 (100 mg, 0.360 mmol) in MeOH (10 mL) was purged 
with H2 gas for 10 min.  Pd/C (2 mg, 0.05 equiv.) was then added and the mixture was stirred 
under a flow of H2. After 1.5 h, the mixture was filtered through Celite, washing sequentially 
with MeOH (40 mL) and CHCl3 (40 mL).  The filtrate was concentrated under reduced pressure 
and the residue was purified by column chromatography (30% EtOAc in hexanes) to afford 
amine 246 as a colourless oil (61 mg, 67%): Rf = 0.2 (10% MeOH in CHCl3); solubility issues 
prevented an optical rotation measurement; max(film)/cm–1 3366 br vs (N–H), 1639 s, 1496 m, 
1455m, 1373m, 1215 m, 1165m, 1091 m; H(400 MHz) 1.40 (3H, s, C(CH3)A(CH3)B), 1.41 (3H, 
s, C(CH3)A(CH3)B), 2.82 (1H, dd, J 13.2, 6.3, H-4A), 2.93 (1H, dd, J 13.2, 3.0, H-4B), 3.55 (1H, 
dd, J 10.1, 4.9, H-1A), 3.63 (1H, dd, J 10.1, 5.3, H-1B), 3.85 (1H, ddd, J 8.1, 6.3, 3.0, H-3),  
3.95 (1H, app. dt, J 8.1, 5.1, H-2), 4.56 (1H, A of AB, J 12.2, PhCHAHB), 4.59 (1H, B of AB, J 
12.2, PhCHAHB), 7.26–7.37 (5H, stack, Ar CH); C(100 MHz) 27.0 [CH3, C(CH3)A(CH3)B], 27.2 
[CH3, C(CH3)A(CH3)B], 44.1 (CH2, C-4), 70.8 (CH2, C-1), 73.6 (CH2, PhCH2), 77.3 (CH, C-2), 
80.5 (CH, C-3), 109.2 (C, C(CH3)2), [127.70, 127.74, 128.4, (CH, Ar CH)], 137.7 (C, Ar C); m/z 
(TOF ES+) 252.2 ([M + H]+, 100%). 









(2S, 3S, 4R, 2′S, 3′S)-1-N-[4′-O-Benzyl-2′,3′-O-isopropylidene-2′, 3′, 4′-
trihydroxybutanyl]-3, 4-O-isopropylidene-2-[ortho-nitrobenzenesulfonamido]-1-
aminooctadecane-3, 4-diol (249) 
 
A solution of amine 246 (30 mg, 0.119 mmol) and aziridine 192 (63 mg, 0.120) in CH3CN (2 
mL) were heated under reflux in a sealed vial for 3 h. The solvent was then evaporated under 
reduced pressure and the crude product purified by column chromatography (20% EtOAc in 
hexanes) to yield amine 249 as a yellow oil (61 mg, 65%): Rf = 0.2 (EtOAc in hexanes); []D20 
= +49.6 (c = 1.0, CHCl3); max(film)/cm–1 3317 br w (N–H), 2986 m, 2924 s, 2854 s, 1542 s, 
1455 m, 1411 m, 1367 s, 1245 m, 1216 s, 1168 s, 1070 s, 853 m, 783 m, 737 s, 698 s, 668 
m, 655 m; H(400 MHz) 0.88 (3H, t, J 6.8, CH2CH3), 1.22–1.30 (23H, stack, alkyl chain), 1.28 
(3H, s, C(CH3)A(CH3)B), 1.37 (6H, s, C(CH3)C(CH3)D), 1.38 (3H, s, C(CH3)A(CH3)B), 1.46–1.57 
(2H, stack, alkyl chain), 1.58–1.67 (1H, m, alkyl chain), 2.27–2.39 (2H, stack, H-1A, H-1′A), 
2.67 (1H, dd, J 12.3, 3.8, H-1′B), 2.91 (1H, dd, J 12.8, 3.6, H-1B), 3.51 (1H, dd, J 10.2, 4.8, H-
4′A), 3.58 (1H, dd, J 10.2, 5.1, H-4′B), 3.65 (1H, app. dt, J 6.9, 3.5, H-2), 3.77–3.84 (1H, m, H-
3), 3.99–4.05 (2H, stack, H-2′, H-3′), 4.10–4.16 (1H, m, H-4), 4.56–4.59 (2H, stack, PhCH2), 
7.28–7.39 (5H, stack, Ar CH), 7.57–7.77 (3H, stack, Ar CH), 8.10–8.14 (1H, m, Ar CH) NHs 
not observed; C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.4 [CH3, C(CH3)A(CH3)B], 26.5 
(CH2), 27.0 [CH3, C(CH3)C(CH3)D], 27.1 [CH3, C(CH3)C(CH3)D], 27.7 [CH3, C(CH3)A(CH3)B], 
[29.4, 29.5, 29.6, 29.7, 31.9  (CH2, alkyl chain, resonance overlap)], 49.6 (CH2, C-1), 51.3 
(CH2, C-1′), 53.8 (CH, C-2), 70.5 (CH2, C-4′), 73.6 (CH2, PhCH2), [77.2, 77.6, 77.7, 77.9 (CH, 
C-3, C-4, C-2′, C-3′)], 107.9 (C, C(CH3)2 phyto), 109.0 (C, C(CH3)2 thr), [125.4, 127.8, 128.5, 
130.4, 132.9, 133.4 (CH, Ar CH, resonance overlap)], [135.5, 138.0, 147.7 (C, Ar C)]; m/z 




(TOF ES+) 776.5 ([M + H]+, 100%); HRMS m/z (TOF ES+) 776.4521 [M + H]+, C41H66N3O9S 
requires 776.4520. 
 
(2S, 3S, 4R, 2′S, 3′S)-2-Amino-1-N-[4′-O-benzyl-2′, 3′-O-isopropylidene-2′, 3′, 4′-
trihydroxybutyl]-3, 4-O-isopropylidene-1-aminooctadecane-3, 4-diol (250) 
 
Thiophenol (15 L, 0.14 mmol) and Cs2CO3 (34 mg, 0.105 mmol) were added to a solution of 
nosyl amide 192 (27 mg, 0.035 mmol) in CH3CN (2 mL). After stirring at room temperature for 
24 h, NaHCO3 solution (20 mL) was added. The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried with 
Na2SO4, filtered and the solvent was evaporated under reduced pressure. The residue was 
purified by column chromatography (30% EtOAc in hexanes) to give amine 250 as a colourless 
oil (18 mg, 86%): Rf = 0.2 (10% MeOH in CHCl3); []D21 = +3.6 (c = 0.6, CHCl3); max(film)/cm–
1 3305 vw br (N–H), 2985 w, 2923 s, 2853 s, 1590 w, 1454 m, 1378 s, 1368 s, 1242 m, 1215 
s, 1166 s, 1073 s, 1028 m, 870 m, 847 m, 798 m, 753 vs, 696 s, 665 m; H(400 MHz) 0.88 
(3H, t, J 6.8, CH2CH3), 1.22–1.30 (23H, stack, alkyl chain), 1.31 (3H, s, C(CH3)A(CH3)B), 1.40 
(6H, s, C(CH3)A(CH3)B, C(CH3)C(CH3)D, resonance overlap), 1.41 (3H, s C(CH3)C(CH3)D), 1.46–
1.55 (3H, stack, alkyl chain), 2.55 (1H, app. td, J 8.9, 3.1, H-1A), 2.78–2.85 (2H, stack, H-1′A, 
H-1′B), 2.88–2.95 (2H, stack, H-1B, H-2), 3.57 (1H, dd, J 10.2, 4.2, H-4′A), 3.63 (1H, dd, J 10.2, 
4.9, H-4′B), 3.75–3.81 (1H, m, H-3), 3.96–4.03 (2H, stack, H-2′, H-3′), 4.10–4.16 (1H, m, H-4), 
4.56 (1H, A of AB, J 12.2, PhCHAHB), 4.60 (1H, B of AB, J 12.2, PhCHAHB), 7.27–7.35 (5H, 
stack, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.9 (CH3, 
C(CH3)A(CH3)B), 26.2 (CH2, alkyl chain), [27.0, 27.2, 28.3 (CH3, C(CH3)A(CH3)B, 
C(CH3)C(CH3)D)], [29.4, 29.6, 29.7, 31.9  (CH2, alkyl chain, resonance overlap)], 49.9 (CH, C-




2), 52.0 (CH2, C-1 or C-1′), 54.1 (CH2, C-1′ or C-1 ), 70.7 (CH2, C-4′), 73.6 (CH2, PhCH2), [77.9, 
78.0, 78.2, 80.7 (CH, C-3, C-4, C-2′, C-3′)], 107.9 (C, C(CH3)2 phyto), 109.3 (C, C(CH3)2 thr), 
[127.7, 128.4 (CH, Ar CH, resonance overlap)], 137.9 (C, Ar C); m/z (TOF ES+) 591.5 ([M + 
H]+, 100%); HRMS m/z (TOF ES+) 591.4735 [M + H]+, C35H63N2O5 requires 591.4737. 
 
(2R, 3S)-4-O-Benzyl-2,3-O-isopropylidene-2,3,4-trihydroxybutyl ethanethioate (253) 
 
A suspension of Cs2CO3 (320 mg, 0.984 mmol) and thioacetic acid (144 L, 1.97 mmol) in 
DMF (5 mL) was stirred in absence of light until all of the Cs2CO3 had dissolved.  A solution of 
tosylate 244 (200 mg, 0.492 mmol) in DMF (1 mL) was then added. After 20 h, the reaction 
mixture was diluted with H2O (20 mL) and extracted with EtOAc (5 × 20 mL). The combined 
organic extracts were washed with brine (75 mL), dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure. The crude product was purified by column 
chromatography to yield thioester 253 as a colourless oil (148 mg, 97%): Rf = 0.6 (20% EtOac 
in hexanes); []D21 = +31.6 (c = 1.0, CHCl3); max(film)/cm–1 1691 vs (C=O), 1496 w, 1454 m, 
1379 m, 1369 m, 1238 m, 1213 m, 1164 m, 1132 s, 1093 vs, 1023 m, 954 m, 912 m, 871 m, 
828 m, 737 vs, 698 vs; H(400 MHz) 1.40 (3H, s, C(CH3)A(CH3)B), 1.43 (3H, s, C(CH3)A(CH3)B), 
2.33 (3H, s, C(O)CH3), 3.06 (1H, dd, J 14.0, 6.3, H-1A), 3.26 (1H, dd, J 14.0, 4.3, H-1B), 3.58–
3.65 (2H, stack, H-4A, H-4B), 3.91 (1H, app. dt, J 8.0, 4.7, H-3), 4.00 (1H, ddd, J 8.0, 6.3, 4.3, 
H-2), 4.60 (2H, s, PhCH2), 7.26–7.37 (5H, stack, Ar CH); C(100 MHz) 26.98 (CH3, 
C(CH3)A(CH3)B), 27.01 (CH3, C(CH3)A(CH3)B), 30.4 (CH3, C(O)CH3), 31.3 (CH2, C-1), 70.1 
(CH2, C-4), 73.5 (CH2, PhCH2), 76.6 (CH, C-2), 79.1 (CH, C-3), 109.5 (C, C(CH3)2), [127.6, 
128.3, (CH, Ar CH, resonance overlap)], 137.8 (C, Ar C), 195.0 (C, C=O); m/z (TOF ES+) 




333.1 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 333.1139 [M + Na]+, C16H22O4SNa requires 
333.1136. 
 
(2S, 3S, 4R, 2′R, 3′S)-1-S-[4′-O-Benzyl-2′, 3′-O-isopropylidene-2′,3′,4′-trihydroxybutyl]-3, 
4-O-isopropylidene-1-mercapto-2-toluenesulfonamido-3, 4-octadecanediol (255) 
 
NaOMe (0.5 mL of a 1.0 M soln. in MeOH) was added to a solution of thioacetate 253 (75 mg, 
0.24 mmol) and aziridine 193 (120 mg, 0.24 mmol) in THF (5 mL). After 6 h, the reaction 
mixture was neutralised by the addition of acidic ion-exchange resin [Dowex H CR-S, pre-
washed sequentially with MeOH (100 mL) and CHCl3 (50 mL)]. The solution was filtered 
through Celite and the solvent evaporated under reduced pressure. The crude mixture was 
purified by flash column chromatography to give thioether 255 as a colourless oil (125 mg, 
68%): Rf = 0.4 (20% EtOAc I hexanes); []D20 = +21.2 (c = 1.0, CHCl3); max(film)/cm–1 3263 w 
br (N–H), 2985 m, 2923 s, 2854 m, 1598 w, 1496 w, 1454 m, 1379 m, 1369 m, 1335 m, 1242 
m, 1216 m, 1159 vs, 1092 vs, 1061 s, 927 m, 864 m, 814 m, 736 m, 698 vs; H(400 MHz) 0.88 
(3H, t, J 6.8, CH2CH3), 1.21–1.28 (23H, stack, alkyl chain), 1.28 (3H, s, C(CH3)A(CH3)B), 1.36 
(3H, s, C(CH3)A(CH3)B), 1.42 (6H, s, C(CH3)C(CH3)D), 1.45–1.50 (3H, stack, alkyl chain), 2.41 
(3H, s, Ar CH3), 2.51 (1H, dd, J 14.3, 3.4, H-1A), 2.58 (1H, dd, J 14.2, 4.1, H-1′A), 2.65 (1H, dd, 
J 14.2, 5.5, H-1′B), 2.92 (1H, dd, J 14.3, 4.4, H-1B), 3.52–3.68 (3H, stack, H-4′A, H-4′B, H-2), 
3.87–3.97 (2H, stack, H-2′, H-3′), 4.03–4.15 (2H, stack, H-3,H-4), 4.56 (2H, app. s, PhCH2), 
5.65 (1H, d, J 9.5, NH), 7.26–7.37 (7H, stack, Ar CH), 7.73–7.77 (2H, m, Ar CH); C(100 MHz) 
14.1 (CH3, CH2CH3), 21.6 (CH3, Ar CH3), 22.7 (CH2, alkyl chain), 25.7 (CH3, C(CH3)A(CH3)B), 
26.4 (CH2, alkyl chain), 27.1, (CH3, C(CH3)C(CH3)D), 27.8 [CH3, C(CH3)A(CH3)B],  [29.2, 29.4, 




29.5, 29.7, 31.9  (CH2, alkyl chain, resonance overlap)], 31.9 (CH2, C-1′), 36.2 (CH2, C-1), 52.6 
(CH, C-2), 70.1 (CH2, C-4′), 73.6 (CH2, PhCH2), [77.1, 77.6 (CH, C-3, C-4)], [78.4, 78.7 (CH, 
C-2′, C-3′)], 107.9 (C, C(CH3)2 phyto), 109.6 (C, C(CH3)2 thr), [127.2, 127.7, 127.8, 128.5, 
129.7 (CH, Ar CH)], [137.8, 138.3, 143.6 (C, Ar C)]; m/z (TOF ES+) 784.4 ([M + Na]+, 100%); 
HRMS m/z (TOF ES+) 784.4259 [M + Na]+, C42H67NO7S2Na requires 784.4257. 
 
(2S, 3S, 4R, 2′R, 3′S)-1-S-[4′-O-Benzyl-2′, 3′-O-isopropylidene-2′,3′,4′-trihydroxybutyl]- 2-
[(N-tert-butoxycarbonyl)amino]-3, 4-O-isopropylidene-1-mercapto-3, 4-octadecanediol 
(256) 
 
Boc2O (0.236 mg, 0.18 mmol) and DMAP (10 mg, 10 weight %) were added to a solution of 
sulfonamide 255 (90 mg, 0.12 mmol) in CH2Cl2 (2 mL). The solution was stirred for 4 h and 
then the solvent was removed under reduced pressure to provide the crude product 255a, 
which was used directly in the next reaction without further purification:  anhydrous MeOH (2 
mL) was added to the flask containing the intermediate carbamate 255a. Mg powder (17 mg, 
0.71 mmol) was added and the reaction mixture was sonicated in an ultrasound bath. After 30 
min, the mixture was poured into hydrochloric acid (10 mL, 1.0 M) and extracted with Et2O (3 
× 20 mL).  The combined organic phases were washed sequentially with NaHCO3 solution (20 
mL) and brine (20 mL), dried with Na2SO4 and filtered. The solvent was removed under 
pressure and the residue purified by flash column chromatography (20% EtOAc in hexanes) 
to give Boc amide 256 as a colourless oil (58 mg, 70% from 255): Rf = 0.6 (20% EtOAc in 
hexanes); []D21 = +10.0 (c = 1.0, CHCl3); max(film)/cm–1 3342 br w (N–H), 2982 m, 2923 s, 
2853 s, 1715 s (C=O), 1497 m, 1454 m, 1378 m, 1366 s, 1298 m, 1243 s, 1216 s, 1164 vs, 
1090 s, 1073 s, 1041 s, 1018 s, 869 s, 800 m, 750 s, 735 s, 697 s, 665 m; H(400 MHz) 0.88 




(3H, t, J 6.8, CH2CH3), 1.23–1.29 (23H, stack, alkyl chain), 1.31 (3H, s, C(CH3)A(CH3)B), 1.40 
(3H, s, C(CH3)A(CH3)B), 1.41 (3H, s, C(CH3)C(CH3)D), 1.43 (12H, s, C(CH3)C(CH3)D, C(CH3)3, 
resonance overlap), 1.49–1.56 (3H, stack, alkyl chain), 2.77–2.85 (3H, stack, H-1A, H-1′A, H-
1′B), 2.93 (1H, dd, J 13.9, 3.4, H-1B), 3.60–3.65 (2H, stack, H-4′), 3.85–3.93 (1H, m, H-2), 
3.95–4.05 (3H, stack, H-3, H-2′, H-3′), 4.07–4.13 (1H, m, H-4), 4.58 (2H, app. s, PhCH2), 4.88 
(1H, d, J 9.5, NH), 7.25–7.37 (5H, stack, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, 
alkyl chain), 25.7 [CH3, C(CH3)A(CH3)B], 26.6 (CH2, alkyl chain), 27.1 [CH3, C(CH3)C(CH3)D], 
27.2 [CH3, C(CH3)C(CH3)D], 27.9 [CH3, C(CH3)A(CH3)B], 28.4 [CH3, C(CH3)3], [29.1, 29.4, 29.6, 
29.7, 31.9  (CH2, alkyl chain, resonance overlap)], 35.6 (CH2, C-1′), 36.3 (CH2, C-1), 49.5 (CH, 
C-2), 70.5 (CH2, C-4′),  73.6 (CH2, PhCH2), [77.8, 77.9, 78.5, 79.3 (CH, C-3, C-4, C-2′, C-3′)], 
79.6 (C, C(CH3)3), 108.0 (C, C(CH3)2 phyto), 109.5 (C, C(CH3)2 thr), [127.1, 128.4, (CH, Ar 
CH, resonance overlap)], 137.9 (C, Ar C), 155.1 (C, C=O); m/z (TOF ES+) 730.5 ([M + Na]+, 
100%); HRMS m/z (TOF ES+) 730.4691 [M + Na]+, C40H69NO7SNa requires 730.4692. 
 
(2S, 3S, 4R, 2′R, 3′S)-1-S-[4′-O-Benzyl-2′,3′,4′-trihydroxybutyl]-2-(hexacosanoyl)amino-
1-mercapto-3, 4-octadecanediol (258) 
 
TFA (2 mL) was added to Boc amide 256 (52 mg, 0.073 mmol).  After 1 h, the TFA was 
removed by bubbling argon through the mixture.  Residual TFA was removed under reduced 
pressure. The crude aminopolyol 257 was isolated presumably as its TFA salt and used 
without further purification in the next step:  NHS ester 189 (54 mg, 0.15 mmol) and Et3N (30 
L, 0.22 mmol) were added to a solution of aminopolyol 257 (assuming 100% conversion in 
the first step) in dry THF (2 mL). After 12 h, the solvent was removed under reduced pressure. 
The crude mixture was purified by column chromatography (gradient: CHCl3  5% MeOH in 




CHCl3) to yield amide 258 as a white solid (31 mg, 47% over two steps): Rf = 0.5 (10% MeOH 
in CHCl3); solubility issues prevented an optical rotation measurement; max(film)/cm–1 3301 br 
m (O–H, N–H), 2917 vs, 2849 vs, 1639 m (C=O), 1531 m, 1467 m, 1454 m, 1366 w, 1250 w, 
1172 w, 1055 m, 1028 m, 906 w, 719 s, 696 s; H(400 MHz, 2:1 CDCl3:CD3OD) 0.84 (6H, t, J 
6.8, 2 × CH2CH3), 1.17–1.34 (68H, stack, alkyl chain), 1.46–1.69 (4H, stack, alkyl chain), 2.17 
(2H, app. td, J 7.3, 2.4, H-2′′) 2.61–2.73 (3H, stack, H-1A, H-1′A, H-1′B), 2.90 (1H, dd J 13.9, 
3.7, H-1B), 3.38–3.48 (2H, stack, H-3, H-4), 3.54 (1H, dd, J 9.9, 6.1, H-4′A), 3.58 (1H, dd, J 9.9, 
4.9, H-4′B), 3.72 (1H, ddd, J 8.8, 5.6, 3.2, H-2′), 3.78 (1H, ddd, J 6.1, 4.9, 3.2, H-3′), 4.20 (1H, 
app. dt, J 9.3, 3.4, H-2), 4.51 (1H, A of AB, J 11.9, PhCHACHB), 4.54 (1H, B of AB, J 11.9, 
PhCHACHB), 7.22–7.32 (5H, stack, Ar CH), exchangeable protons not observed; C(100 MHz, 
2:1 CDCl3:CD3OD) 14.3 (CH3, CH2CH3), [23.0, 26.1, 26.2, 29.67, 29.74, 29.9, 30.0, 32.2, 33.0 
(CH2, alkyl chain, resonance overlap)], 33.4 (CH2, C-1), 33.5 (CH2, alkyl chain), 36.0 (CH2, C-
1′), 36.9 (CH2, C-2′′), 51.1 (CH, C-2), [71.4, 71.5 (CH, C-2′, C-3′), 72.2 (CH2, C-4′), 72.4 (CH, 
C-3), 73.8 (CH2, PhCH2), 76.4 (CH, C-4), [128.1, 128.2, 128.7, (CH, Ar CH)], 175.3 (C, C=O), 
Ar C not observed; m/z (TOF ES+) 928.75 ([M + Na]+, 90%), 929.74 (100); HRMS m/z (TOF 
ES+) 928.7405 [M + Na]+, C55H103NO6SNa requires 928.7404. 
 
(2R, 3S)-4-O-Benzyl-1-iodo-2, 3-O-isopropylidene-2, 3, 4-butanetriol (265) 
 
Imidazole (227 mg, 3.33 mmol), Ph3P (457 mg, 1.74 mmol) and a solution of I2 (442 mg, 1.74 
mmol) in THF (1 mL) were added sequentially to a solution of alcohol 235 (400 mg, 1.59 mmol) 
in dry THF (10 mL) at 0 °C. After 2 h, the reaction mixture was quenched with H2O (20 mL) 
and extracted with Et2O (3 × 20 mL). The combined organic layers were washed with brine (1 
× 40 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. 




The residue was purified by column chromatography (10% Et2O in hexanes) to afford iodide 
265  as a colourless oil (564 mg, 96%): Rf = 0.8 (25% EtOAc in hexanes); []D24 = –4.0 (c = 
1.0, CHCl3), lit.192 []D26 = –8.6 (c = 2.5, CHCl3); max(film)/cm–1 3029 w, 2986 w, 2933 w, 2863 
w, 1496 w, 1453 m, 1379 s, 1370 s, 1321 w, 1236 s, 1210 s, 1170 s, 1090 vs, 1072 vs, 1028 
s, 1007 s, 908 m, 885 m, 860 s, 818 m, 779 w, 735 vs, 697 vs; H(400 MHz) 1.42 (3H, s, 
C(CH3)A(CH3)B), 1.47 (3H, s, C(CH3)A(CH3)B), 3.28 (1H, dd, J 10.6, 5.3, H-1A), 3.35 (1H, dd, J 
10.6, 5.1, H-1B), 3.61–3.69 (2H, stack, H-4), 3.87 (1H, app. dt, J 7.4, 5.2, H-2), 3.97 (1H, app. 
dt, J 7.4, 5.1, H-3), 4.59 (2H, app. s, PhCH2), 7.27–7.39 (5H, stack, Ar CH); C(100 MHz) 6.4 
(CH2, C-1), [27.3, 27.4 (CH3, C(CH3)A(CH3)B], 70.5 (CH2, C-4), 73.6 (CH2, PhCH2), 77.7 (CH, 
C-2), 80.1 (CH, C-3), 109.8 (C, C(CH3)2), [127.7, 127.8, 128.5, (CH, Ar CH)], 137.8 (C, Ar C); 
m/z (TOF ES+) 385.0 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 385.0273 [M + Na]+, 
C14H19IO3Na requires 385.0277. 
Data were in agreement with those reported in the literature.192 
 
(2S, 3S)-1-O-Benzyl-2, 3-O-isopropylidene-4-[2′-trimethylsilyl-1′,3′-dithian-2′-yl]-2, 3, 4-
butanetriol (266) and (2S, 3S)-1-O-benzyl-2, 3-O-isopropylidene-4-(1′,3′-dithian-2′-yl)-2, 
3, 4-butanetriol (267) 
                              
n-BuLi (1.0 mL, 2.5 M in THF, 2.48 mmol) was added to a solution of 2-trimethylsilyl-1, 3-
dithiane (0.31 mL, 2.48 mmol) in THF (3 mL) and HMPA (0.3 mL) at –30 °C. The solution was 
stirred for 1 h at –30 °C before adding a solution of iodide 265 (225 mg, 0.621 mmol) in THF 
(3 mL) and HMPA (0.3 mL). The resulting mixture was warmed to rt. After 14 h, the solution 
was neutralised with NH4Cl solution (40 mL) and extracted with Et2O (3 × 50 mL). The 




combined organic phases were washed with brine (50 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(20% EtOAc in hexanes) to yield, in order of elution, silyl dithiane 266 as a colourless oil (184 
mg, 69%): Rf = 0.7 (20% Et2O in hexane); []D20 = –13.2 (c = 1.0, CHCl3); max(film)/cm–1 2984 
m, 2900 m, 1637 w, 1497 w, 1454 m, 1422 m, 1369 m, 1245 s, 1215 m, 1167 m, 1072 s, 1028 
m, 987 m, 906 m, 876 s, 841 vs, 733 s, 715 s, 697 vs; H(400 MHz) 0.21 (9H, s, Si(CH3)3), 
1.35 (3H, s, C(CH3)A(CH3)B), 1.41 (3H, s, C(CH3)A(CH3)B), 1.73–1.80 (2H, stack, H-5′A, H-5′B), 
2.14–2.21 (2H, stack, H-4′A or H-6′A, H-4A), 2.32–2.38 (1H, m, H-4′A  or H-6′A), 2.70–2.83 (2H, 
stack, H-4′B  or H-6′B,  H-4B), 2.86–2.96 (1H, m, H-4′B or H-6′B), 3.59 (1H, dd, J 9.8, 5.8, H-1A), 
3.73 (1H, dd, J 9.8, 5.2, H-1B), 3.87 (1H, app. dt, J 8.5, 5.5, H-2), 4.08 (1H, app. t, J 8.3, H-3), 
4.55 (1H, d, J 11.8, A of AB, PhCHAHB), 4.62 (1H, d, J, 11.8, B of AB, PhCHAHB), 7.25–7.39 
(5H, stack, Ar CH); C(100 MHz) –2.9 [CH3, Si(CH3)3], [22.5, 23.1 (CH2, C-4′, C-6′)], 24.9 (CH2, 
C-5′), 26.7 [CH3, C(CH3)A(CH3)B], 27.2 [CH3, C(CH3)A(CH3)2], 37.7 (C, C-2′), 40.1 (CH2, C-4), 
71.1 (CH2, C-1), 73.7 (CH2, PhCH2), 77.4 (CH, C-3), 79.3 (CH, C-2), 109.2 (C, C(CH3)2), 
[127.8, 127.9, 128.4 (CH, Ar CH)], 137.9 (C, Ar C); m/z (TOF ES+) 449.2 ([M + Na]+, 100%); 
HRMS m/z (TOF ES+) 449.1619 [M + Na]+, C21H34O3S2SiNa requires 449.1616, followed by 
dithiane 267 as a colourless oil (56 mg, 25%): Rf = 0.5 (20% Et2O in hexane); []D20 = –7.6 (c 
= 1.0., CHCl3); lit.154 (R,R enantiomer) []D25 = +14.5 (c = 0.97, CHCl3); max(film)/cm–1 2985 
m, 2932 m, 2900 m, 1496 w, 1453 m, 1422 m, 1369 s, 1242 s, 1213 s, 1162 m, 1091 vs, 1069 
vs, 1028 s, 1012 s, 907 m, 895 m, 867 m, 844 s, 798 m, 741 vs, 697 vs, 667 m; H(400 MHz) 
1.40 (3H, s, C(CH3)A(CH3)B), 1.41 (3H, s, C(CH3)A(CH3)B), 1.80–1.92 (1H, m, H-5′A), 1.98–2.02 
(2H, stack, H-4), 2.05–2.13 (1H, m, H-5′B), 2.76–2.89 (4H, stack, H-4′A, H-4′B, H-6′A, H-6′), 3.53 
(1H, dd, J 10.1, 4.8, H-1A), 3.60 (1H, dd, J 10.1, 5.6, H-1B), 3.86 (1H, app. dt, J 7.9, 5.2, H-2), 
4.09–4.15 (1H, m, H-3), 4.19–4.23 (1H, m, H-2′), 4.55 (1H, d, J 12.2, A of AB, PhCHAHB), 4.61 
(1H, d, J 12.2, B of AB, PhCHAHB), 7.25–7.37 (5H, stack, Ar CH); C(100 MHz) 25.8 (CH2, C-
5′), 27.0 (CH3, C(CH3)A(CH3)B), 27.2 (CH3, C(CH3)A(CH3)B), [29.7, 30.1 (CH2, C-4′, C-6′), 39.6 
(CH2, C-4), 43.7 (CH, C-2′), 70.4 (CH2, C-1), 73.5 (CH2, PhCH2), 75.2 (CH, C-3), 79.8 (CH, C-




4), 109.4 (C, C(CH3)2), [127.7, 128.4 (CH, Ar CH, resonance overlap)], 137.9 (C, Ar C); m/z 
(TOF ES+) 377.1 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 377.1222 [M + Na]+, 
C18H26O3S2Na requires 377.1221. 
 
(2S, 3S)-1-O-Benzyl-2, 3-O-isopropylidene-4-(1′,3′-dithian-2′-yl)-2, 3, 4-butanetriol (267) 
 
TBAF (0.3 mL, 1.0 M in THF, 0.3 mmol) was added to a solution of silyl dithiane 266 (182 mg, 
0.138 mmol) in THF (2 mL). After 14 h, the reaction mixture was concentrated under reduced 
pressure. The residue was dissolved in EtOAc (30 mL). The resulting solution was washed 
sequentially with H2O (3 × 20 mL) and brine (1 × 20 mL), then dried with Na2SO4, filtered and 
the filtrate was concentrated under reduced pressure. The residue was purified by column 
chromatography to yield dithiane 266 as a colourless oil (76 mg, quant.). 
Data in agreement with those obtained for the same compound prepared from 265. 
 
 
 (2S, 3S, 4R)-3, 4-O-Isopropylidene-2-toluenesulfonamido-1-[2′-trimethylsilyl-1′, 3′-
dithian-2′-yl)]-1, 3, 4-octadecanetriol (269) 
 
n-BuLi (0.33 mL, 2.5 M in hexanes, 0.81 mmol) was added to a solution of 2-trimethylsilyl-1,3-
dithiane (156 mg, 0.81 mmol) in anhydrous THF (2.5 mL) at –23 °C. The solution was stirred 
for 1 h while maintaining the temperature at –23 °C. A solution of aziridine 193 (200 mg, 0.405 




mmol) in THF (2.5 mL) was then added and the resulting mixture was warmed to rt. After 
stirring overnight, the solution was neutralised with NH4Cl solution (40 mL) and the mixture 
extracted with Et2O (3 × 50 mL). The combined organic phases were washed with brine (50 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by column chromatography (20% EtOAc in hexanes) to yield silyl dithiane 269 as a 
colourless oil (155 mg, 56%): Rf = 0.6 (20% EtOAc in hexanes); []D21 = –16.8 (c = 1.0, CHCl3); 
max(film)/cm–1 3304 br w (N–H), 2923 vs, 2854 s, 1599 w, 1452 m, 1379 m, 1339 m, 1248 s, 
1216 m, 1155 vs, 1094 m, 1057 s, 954 w, 844 vs, 814 m, 758 w, 713 w, 663 m; H(400 MHz) 
0.21 (9H, s, Si(CH3)3), 0.88 (3H, t, J 6.8, CH2CH3), 1.22 (3H, s, C(CH3)A(CH3)B), 1.23–1.33 
(23H, stack, alkyl chain, resonance overlap), 1.36 (3H, s, C(CH3)A(CH3)B), 1.37–1.46 (3H, 
stack, alkyl chain), 1.79–1.90 (1H, m, dithiane CH), 1.97–2.05 (1H, m, dithiane CH), 2.35–
2.45 (4H, stack, H-1A, Ar CH3), 2.53– 2.60 (2H, stack, dithiane), 2.78 (1H, dd, J 15.8, 9.2, H-
1B), 3.01 (1H, ddd, J 14.0, 11.0, 2.8, dithiane CH), 3.10 (1H, ddd, J 14.0, 11.2, 2.9, dithiane 
CH), 3.44–3.50 (1H, m, H-4), 3.67–3.73 (1H, m, H-2), 4.41 (1H, app. t, J 6.3, H-3), 5.77 (1H, 
d, J 4.1, NH), 7.29 (2H, AA′ of AA′BB′, J 8.2, Ar CH), 7.78 (2H, BB′ of AA′BB′, J 8.2, Ar CH); 
C(100 MHz) –2.5 [CH3, Si(CH3)3], 14.1 (CH3, CH2CH3), 21.5 (CH3, Ar CH3), 22.7 (CH2, alkyl 
chain), [24.1, 24.87, 24.92 (CH2, 3 × dithiane CH2)], 25.2 [CH3, C(CH3)A(CH3)B], 26.3 (CH2, 
alkyl chain), 27.2 [CH3, C(CH3)A(CH3)B], [29.4, 29.56, 29.62, 29.7, 31.9 (CH2, alkyl chain, 
resonance overlap)], 36.3 (C, C-2′), 39.2 (CH2, C-1), 54.7 (CH, C-2), 76.98 (CH, C-3), 77.2 
(CH, C-4), 107.4 (C, C(CH3)2), [127.0, 129.5 (CH, Ar CH)], [139.4, 143.3 (C, Ar C)]; m/z (TOF 









(2S, 3S, 4R)-1-(1′,3′-Dithian-2′-yl)-3, 4-O-isopropylidene-2-toluenesulfonamido-3, 4-
octadecanediol (270) 
 
TBAF (1.0 mL, 1.0 M in THF, 1.0 mmol) was added to a solution of silyl dithiane 269 (155 mg, 
0.226 mmol) in THF (3.5 mL). After 4 h, the reaction mixture was concentrated under reduced 
pressure. The residue was dissolved in EtOAc (30 mL) and washed sequentially with H2O (3 
× 20 mL) and brine (1 × 20 mL), then dried with Na2SO4, filtered and the filtrate concentrated 
under reduced pressure. The residue was purified by column chromatography to yield dithiane 
270 as a colourless oil (120 mg, 87%): Rf = 0.3 (20% EtOAc in hexanes); []D21 = –49.6 (c = 
1.0, CHCl3); max(film)/cm–1 3244 br w (N–H), 2908 vs, 2852 s, 1599 w, 1461 m, 1433 m, 1378 
m, 1332 m, 1258 w, 1216 m, 1156 s, 1093 m, 1044 s, 976 w, 953 m, 859 w, 815 m, 773 w, 
663 m; H(400 MHz) 0.87 (3H, t, J 6.8, CH2CH3), 1.20–1.35 (23H, stack, alkyl chain, 
C(CH3)A(CH3)B, resonance overlap), 1.39 (3H, s, C(CH3)A(CH3)B), 1.41–1.54 (2H, stack, alkyl 
chain), 1.58–1.67 (1H, m, alkyl chain), 1.70–1.84 (2H, stack, dithiane, H-1A), 1.88–2.05 (2H, 
stack, dithiane, H-1B), 2.37–2.46 (4H, stack, dithiane.  Ar CH3), 2.62– 2.80 (3H, stack, 
dithiane), 3.59 (1H, app. t, J 9.3, H-2), 3.73 (1H, dd, J 11.5, 2.4, H-2′), 4.04–4.13 (2H, stack, 
H-3,H-4), 5.08 (1H, d, J 9.2, NH), 7.30 (2H, AA′ of AA′BB′, J 8.2, Ar CH), 7.80 (2H, BB′ of 
AA′BB′, J 8.2, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 21.5 (CH3, Ar CH3), 22.7 (CH2, alkyl 
chain), 24.9 [CH3, C(CH3)A(CH3)B], 25.8 (CH2, dithiane), 26.2 [CH3, C(CH3)A(CH3)B], 26.8 (CH2, 
alkyl chain), [28.7, 29.4, 29.5, 29.6, 29.7 (CH2, alkyl chain, dithane CH2, resonance overlap)], 
30.4 (CH2, dithiane CH2), 31.9 (CH2, alkyl chain), 37.7 (CH2, C-1), 43.6 (CH, C-2′),  52.1 (CH, 
C-2), [77.2, 80.2 (CH, C-3, C-4)], 108.1 (C, C(CH3)2), [127.3, 129.7 (CH, Ar CH)], [138.2, 143.3 
(C, Ar C)];  m/z (TOF ES+) 636.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 636.3192 [M + 
Na]+, C32H55NO4S3Na requires 636.3191. 
 




5.4. Chapter 4 
 
13-Trimethylsilyl-12-tridecynoic acid (304) 
 
nBuLi (4.97 mL, 12.4 mmol, 2.5 M solution in hexanes) was added to a solution of 
(trimethylsilyl)acetylene (1.56 mL, 11.3 mmol) in THF (10 mL) at –78 °C. After 30 min, a 
solution of 11-bromoundecanoic acid (1.00 g, 3.77 mmol) in dry THF (6 mL) and anhydrous 
HMPA (4 mL) was added via syringe over 10 min at –78 °C. The reaction mixture was stirred 
for 2 h at –78 °C, then at rt for12 h. The reaction was then quenched with NH4Cl solution (50 
mL) and extracted with Et2O (3 × 50 mL). The combined organic extracts were washed with 
brine (100 mL), dried using Na2SO4, filtered, and the filtrate concentrated under reduced 
pressure. The residue was purified by flash column chromatography (20% EtOAc/hexane) to 
give silyl alkyne 304 as a colourless oil (0.892 g, 88%): Rf = 0.4 (20% EtOAc in hexanes); 
max(film)/cm–1 OH not observed, 2927 s, 2855 m, 2174 m (alkynyl C≡C), 1708 vs (C=O), 1412 
m, 1283 m, 1248 s, 1028 w, 931 w, 839 vs, 759 s, 721 w, 698 m; H(400 MHz) 0.01 (9H, s, 
Si(CH3)3), 1.11–1.25 (12H, stack, alkyl chain), 1.32–1.40 (2H, m, H-3), 1.45–1.53 (2H, m, H-
10), 2.06 (2H, t, J 7.2, H-2), 2.20 (2H, t, J 7.5, H-11) OH not observed; C(100 MHz) 0.16 (CH3, 
Si(CH3)3), 19.8 (CH2, C-11), 24.7 (CH2, C-10), [28.6, 28.8, 29.0, 29.2, 29.3, 29.4 (CH2, alkyl 
chain, resonance overlap)], 34.0 (CH2, C-2), 84.2 (C, C-12), 107.7 (C, C-13), 180.1 (C, C-1); 
m/z (TOF ES+) 305.2 ([M + Na]+, 30%), 337.2 (100); HRMS m/z (TOF ES+) 305.1910 [M + 









Tridec-12-ynoic acid (301) 
 
TBAF (6.0 mL of a 1.0 M solution in THF, 6.0 mmol) was added to a solution of silyl alkyne 
304 (816 mg, 2.89 mmol) in THF (20 mL). After 14 h, the solution was concentrated under 
reduced pressure and the residue was dissolved in EtOAc (50 mL). The organic layer was 
washed sequentially with H2O (3 × 40 mL) and brine (1 × 50 mL), then dried with Na2SO4, 
filtered and the filtrate was concentrated under reduced pressure. The residue was purified by 
column chromatography to yield alkyne 301 as a white, low-melting point, amorphous solid 
(504 mg, 84%): Rf = 0.3 (20% EtOAc in hexanes); max(film)/cm–1 3287 m (alkynyl C–H), 3037 
br m (O–H), 2916 vs, 2848 vs, 2115 vw (alkynyl C≡C), 1697 vs (C=O), 1471 s, 1452 s, 1432 
s, 1409 s, 1346 m, 1324 m, 1300 s, 1272 s, 1258 s, 1243 s, 1215 s, 1190 m, 1122 w, 1107 w, 
1067 w, 1053 w, 899 s, 720 m, 731 m, 682 s, 666 vs, 649 s, 628 vs; H(400 MHz) 1.19–1.35 
(12H, stack, alkyl chain), 1.41–1.49 (2H, stack, alkyl chain), 1.52–1.62 (2H, stack, H-10), 1.87 
(1H, t, J 2.7, H-13), 2.11 (2H, td, J 7.1, 2.7, H-11), 2.28 (2H, t, J 7.5, H-2), OH not observed; 
C(100 MHz) 18.4 (CH2, C-11), 24.6 (CH2, C-10), [28.5, 28.7, 29.0, 29.2, 29.3, 29.4 (CH2, alkyl 
chain, resonance overlap)], 34.0 (CH2, C-2), 68.0 (CH, C-13), 84.8 (C, C-12), 180.1 (C, C-1); 
m/z (TOF ES+) 211.2 ([M + H]+, 70%), 193.2 (100, [M–OH]+); HRMS m/z (TOF ES+) 211.1697 











Methyl tridec-12-ynoate (305) 
 
Concentrated H2SO4 (6 drops) was added to a suspension of acid 301 (864 mg, 4.11 mmol) 
in MeOH (40 mL). After 14 h, at rt the reaction mixture was neutralised by the addition of solid 
NaHCO3. The mixture was then filtered through Celite, washing with MeOH (30 mL) and then 
CH2Cl2 (40 mL). The filtrate was concentrated under reduced pressure and the crude mixture 
purified by flash column chromatography (5% EtOAc in hexanes) to give methyl ester 305 as 
a colourless oil (842 mg, 91%): Rf = 0.7 (10% EtOAc in hexanes); max(film)/cm–1 3297 w 
(alkynyl C–H), 2930 s, 2856 m, 2117 vw (alkynyl C≡C) 1736 vs (C=O), 1435 m, 1361 w, 1238 
m, 1195 s, 1170 s, 1100 m, 1017 w, 863 w, 724 w, 628 s; H(400 MHz) 1.25–1.32 (12H, 
stack,alkyl chain), 1.33–1.40 (2H, stack, alkyl chain), 1.45–1.54 (2H, m, H-10), 1.55–1.64 (2H, 
m, H-3), 1.91 (1H, t, J 2.6, H-13), 2.15 (2H, td, J 7.1, 2.6, H-11), 2.28 (1H, t, J 7.5, H-2), 3.64 
(3H, s, OCH3); C(100 MHz) 18.4 (CH2, C-11), [24.9, 28.4, 28.7, 28.9, 29.1 (CH2, alkyl chain, 
resonance overlap)], 34.1 (CH2, C-1), 51.4 (CH3, OCH3), 68.1 (CH, C-13), 84.7 (C-12), 174.3 
(C, C=O); m/z (TOF ES+) 225.2 ([M + H]+, 30%), 193.2 ([M – OMe + H]+, 100%) ; HRMS m/z 












Methyl 13-(3′-benzoylphenyl)-tridec-12-ynoate (307) 
 
A solution of 3-bromo benzophenone (277 mg, 1.06 mmol) and methyl ester 305 (670 mg, 
3.18 mmol) in Et2NH (40 mL) was degassed using argon under sonication for 15 min. 
[Pd(Ph3P)2Cl2] (148 mg, 0.212 mmol) and CuI (20 mg, 0.106 mmol) were added and the 
reaction mixture was heated at reflux for 4 h. The solution was then filtered through Celite, 
washing with CH2Cl2 (50 mL). The filtrate was evaporated under pressure and the residue 
purified by column chromatography (5% EtOAc in hexanes) to yield alkyne 307 as a colourless 
oil (273 mg, 66%): Rf = 0.4 (20% EtOAc in hexanes);max(film)/cm–1 2926 vs, 2854 s, 1737 vs 
(C=O, ester), 1661 vs (C=O, ketone), 1596 w, 1575 w, 1447 m ,1435 m, 1363 w, 1318 m, 
1287 s, 1234 s, 1196 m, 1171 s, 1075 m, 1075 m, 943 w, 907 w, 816 w, 786 w, 718 vs, 697 
s; H(400 MHz) 1.24–1.32 (10H, stack, alkyl chain), 1.39–1.52 (2H, stack, alkyl chain), 1.54–
1.64 (4H, stack, alkyl chain), 2.28 (2H, t, J 7.6, H-11), 2.38 (2H, t, J 7.1, H-2), 3.64 (3H, s, 
CH3), 7.39 (1H, app. t, J 7.8, Ar CH), 7.45–7.50 (2H, stack, Ar CH), 7.56–7.60 (2H, stack, Ar 
CH), 7.67 (1H, app. dt, J 7.8 1.4, Ar CH) 7.76–7.77 (1H, m, Ar CH), 7.78–7.79 (2H, stack, Ar 
CH); C(100 MHz) 19.4 (CH2, C-11), [24.9, 28.6, 28.8, 28.9, 29.1, 29.2, 29.39, 29.42 (CH2, 
alkyl chain)], 34.1 (CH2, C-2), 51.4 (CH3, OCH3), 79.7 (C, C-13), 91.8 (C, C-12), 124.5 (C, Ar 
C), [128.2, 128.3, 128.8, 130.0, 132.5, 133.0, 135.2 (CH, Ar CH), [137.3, 137.7 (C, Ar C)], 
177.3 (C, ester C=O), 196.1 (C, ketone C=O); m/z (TOF ES+) 427.2 ([M + Na]+, 100%); HRMS 









Methyl 13-(3′-benzoylphenyl)-tridecanoate (309) 
 
A flask containing a solution of alkyne 307 (200 mg, 0.49 mmol) in MeOH (15 mL) was purged 
with H2 gas for 10 min.  Pd/C (5 mg, 0.1 equiv) was then added and the mixture was stirred 
under a flow of H2 for 15 min, after which time, the mixture was filtered through Celite, washing 
with MeOH (40 mL) and then CH2Cl2 (40 mL). The filtrate was concentrated under reduced 
pressure and the residue was purified by column chromatography (10% EtOAc in hexanes) to 
afford ester 309 as a white, low-melting point, amoprhous solid (170 mg, 85%): Rf = 0.7 (20% 
EtOAc in hexanes); max(film)/cm–1 2924 vs, 2853 vs, 1737 vs (C=O, ester), 1659 vs (C=O, 
ketone), 1598 m, 1581 w, 1447 s, 1435 s, 1361 w, 1316 s, 1278 vs, 1203 s, 1172 s, 1104 w, 
1000 w, 977 w, 907 w, 838 w, 781 m, 709 vs, 719 vs; H(400 MHz) 1.22–1.37 (16H, stack, 
alkyl chain), 1.56–1.67 (4H, stack, H-3, H-12), 2.30 (2H, t, J 7.6, H-2), 2.66 (2H, t, J 7.7, H-
13), 3.66 (3H, s, OCH3), 7.35–7.42 (2H, stack, Ar CH), 7.45–7.50 (2H, stack, Ar CH), 7.56–
7.61 (2H, stack, Ar CH), 7.62–7.64 (1H, m, Ar CH), 7.78–7.82 (2H, stack, Ar CH); C(100 MHz) 
25.0 (CH2, C-3), [29.2, 29.3, 29.5, 29.6 (CH2, alkyl chain, resonance overlap)], 31.4 (CH2, C-
12), 34.1 (CH2, C-2), 35.8 (CH2, C-13), 51.4 (CH3, OCH3), [127.6, 128.1, 128.2, 129.9, 130.1, 
132.3, 132.6 (CH, Ar CH)], [137.6, 137.8, 143.2 (C, Ar C)], 174.3 (C, ester C=O), 197.0 (C, 
ketone C=O); m/z (TOF ES+) 431.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 431.2563 [M + 










13-(3′-benzoylphenyl)-tridecanoic acid (294) 
 
1 M NaOH (0.36 mL, 0.36 mmol) was added to a solution of ester 309 (100 mg, 0.24 mmol) 
in THF (0.36 mL) and MeOH (0.36 mL). After 2 h at rt the organic solvents were removed and 
the solution acidified with 1 M HCl (5 mL). The aqueous layer was extracted with EtOAc (3 × 
30 mL). The combined organic layers were washed with brine (1 × 50 mL), dried with Na2SO4, 
filtered and the filtrate was concentrated under reduced pressure. The residue was purified by 
column chromatography to yield carboxylic acid 294 as a white amorphous solid (89 mg, 91%): 
Rf = 0.3 (20% EtOAc in hexanes); m.p. 68–70 °C; max(film)/cm–1 3059 br m (O–H), 2919 vs, 
2848 vs,1689 vs (C=O), 1655 vs (C=O), 1600 m, 1581 w, 1480 w, 1460 m, 1434 s, 1409 m, 
1343 w, 1322 m, 1305 s, 1279 vs, 1259 s, 1234 s, 1206 s, 1189 m, 1164 w, 1135 w, 1115 w, 
1076 w, 1025 w, 988 m, 970 m, 927 s, 908 s, 837 s, 807 m, 759 w, 726 vs, 707 vs, 687 vs; 
H(400 MHz) 1.23–1.36 (16H, stack, alkyl chain), 1.58–1.68 (4H, stack, H-3, H-12), 2.34 (2H, 
t, J 7.5, H-2), 2.67 (2H, t, J 7.7, H-13), 7.35–7.43 (2H, stack, Ar CH), 7.45–7.51 (2H, stack, Ar 
CH), 7.56–7.61 (2H, stack, Ar CH), 7.62–7.64 (1H, m, Ar CH), 7.79–7.82 (2H, stack, Ar CH) 
OH not observed; C(100 MHz) [24.7, 29.1, 29.3, 29.4, 29.5, 29.6, 31.4 (CH2, alkyl chain, 
resonance overlap)], 34.0 (CH2, C-2), 35.8 (CH2, C-13), [127.6, 128.1, 128.2, 129.9, 130.1, 
132.3, 132.6 (CH, Ar CH)], [137.6, 137.8, 143.2 (C, Ar C)], 179.6 (C, acid C=O), 197.1 (C, 
ketone C=O); m/z (TOF ES+) 417.2 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 417.2408 [M + 









Succinimidyl 13-(3′-benzoylphenyl)-tridecanoate (310) 
 
EDCI.HCl (62 mg, 0.32 mmol),  N-hydroxysuccinimide (30 mg, 0.26 mmol) and DMAP (2 mg, 
cat.) were added to a solution of acid 294 (85 mg, 0.22 mmol) in CH2Cl2 (2 mL). The reaction 
mixture was heated at 40 °C for 12 h and then poured into H2O (20 mL). The mixture was 
extracted with Et2O (3 × 20 mL). The combined organic fractions were washed with brine (20 
mL), dried over Na2SO4, and filtered. The solvent was removed under reduced pressure to 
give  NHS ester 310 (100 g, 94%) as an  amorphous solid; Rf = 0.5 (40% EtOAc in hexanes); 
m.p. 66–68 °C; max(film)/cm–1 2924 s, 2853 m, 1814 m, 1784 m, 1727 vs (C=O), 1657 s (C=O), 
1598 w, 1580 w, 1447 m, 1431 m, 1365 m, 1316 m, 1279 s, 1213 vs, 1134 w, 1086 vs, 994 
w, 814 w, 783 w, 721 s, 709 m; H(400 MHz) 1.22–1.35 (14H, stack, alkyl chain), 1.35–1.41 
(2H, stack, H-4), 1.58–1.66 (2H, m, H-12), 1.68–1.75 (2H, m, H-3), 2.57 (2H, t, J 7.5, H-2), 
2.65 (2H, app. t, J 7.7, H-13), 2.77–2.81 (4H, stack, NHS CH2), 7.35–7.42 (2H, stack, Ar CH), 
7.45–7.50 (2H, stack, Ar CH), 7.56–7.61 (2H, stack, Ar CH), 7.62–7.64 (1H, m, Ar CH), 7.78–
7.82 (2H, stack, Ar CH); C(100 MHz) 24.6 (CH2, C-3), 25.6 (CH2, NHS CH2), [28.8, 29.1, 29.2, 
29.3, 29.4, 29.5 (CH2, alkyl chain, resonance overlap)], 30.9 (CH2, C-2), 31.4 (CH2, C-12), 
35.8 (CH2, C-13), [127.6, 128.1, 128.2, 129.9, 130.0, 132.3, 132.6 (CH, Ar CH)], [137.6, 137.8, 
143.2 (C, Ar C)], 168.7 (C, ester C=O), 169.3 (C, NHS C=O), 196.9 (C, ketone C=O); m/z 











NaH (95 mg of a 60% dispersion in mineral oil, 2.39 mmol,) was added to a solution of 1-
bromo-undecan-1-ol (500 mg, 1.99 mmol) in THF (10 mL) at 0 °C. After 1 h, a solution of BnBr 
(410 mg, 2.39 mmol) in THF (5 mL) was added. The reaction mixture was warmed to rt and 
stirred for 16 h. The mixture was diluted with Et2O (20 mL) and washed with NH4Cl solution 
(25 mL). The aqueous layer was extracted with Et2O (3 x 20 mL). The combined organic 
extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified by column chromatography (5% EtOAc in hexanes) to afford benzyl 
ether 312 as a pale yellow oil (678 mg, quant.): Rf = 0.7 (5% EtOAc in hexanes); max(film)/cm–
1 2924 vs, 2852 s, 1719 m, 1453 m, 1361 w, 1273 s, 1204 w, 1099 s, 1072 m, 1027 w, 735 m, 
712 s, 697 s; H(400 MHz) 1.18–1.38 (14H, stack, alkyl chain), 1.50–1.60 (2H, m, H-2 or H-
10), 1.72–1.83 (2H, m, H-10 or H-2), 3.30–3.41 (4H, stack, H-1, H-11), 4.43 (2H, s, PhCH2), 
7.18–7.28 (5H, stack, Ar CH); C(100 MHz) [26.2, 28.2, 28.8, 29.4, 29.46, 29.53, 29.8 (CH2, 
alkyl chain, resonance overlap)], 32.8 (CH2, C-2 or C-10), 34.0 (CH2, C-1), 70.5 (CH2, C-11), 
72.9 (CH2, PhCH2), [127.5, 127.6, 128.3 (CH, Ar CH)], 138.7 (C, Ar C); m/z (TOF ES+) 363.1 














nBuLi (0.64 mL, 1.61 mmol, 2.5 M solution in hexanes) was added to a solution of 
(trimethylsilyl)acetylene (0.23 mL, 1.61 mmol) in THF (4 mL) at –78 °C. After 30 min, the 
solution was warmed to –30 °C and a solution of bromide 312 (500 mg, 1.46 mmol) in dry THF 
(4 mL) and anhydrous HMPA (1 mL) was added via syringe over 5 min. After 15 min the 
reaction mixture was warmed to 0 °C for 5h and then to rt for an additional 12 h. The reaction 
was then quenched with NH4Cl solution (20 mL) and extracted with Et2O (3 × 30 mL). The 
combined organic extracts were washed with brine (50 mL), dried using Na2SO4, filtered, and 
the filtrate concentrated under reduced pressure to yield an inseparable mixture of silyl alkyne 
TMS-313 and alkyne 313, which was directly used without further purification. Assuming full 
conversion of the starting material, TBAF (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) was 
added to a solution of the mixture (482 mg) in THF (10 mL). After 14 h, the solution was 
concentrated under reduced pressure and the residue was dissolved in EtOAc (20 mL). The 
organic layer was washed sequentially with H2O (3 × 15 mL) and brine (1 × 15 mL), then dried 
with Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue 
was purified by column chromatography to yield alkyne 313 as a colour oil (504 mg, 83% over 
two steps): Rf = 0.7 (5% EtOAc in hexanes); max(film)/cm–1 3309 m (alkyne C–H), 2924 vs, 
2852 vs, 2123 vw (alkyne C≡C), 1454 m, 1362 m, 1204 w, 1099 vs, 1028 m, 734 s, 696 s; 
H(400 MHz) 1.11–1.15 (10H, stack, alkyl chain), 1.19–1.28 (4H, stack, alkyl chain), 1.33–1.41 
(2H, m, H-10), 1.43–1.50 (2H, m, H-2), 1.79 (1H, t, J 2.7, H-13), 2.03 (2H, td, J 7.1, 2.7, H-
11), 3.31 (2H, t, J 6.7, H-1), 4.35 (2H, s, PhCH2), 7.10–7.16 (1H, m, Ar CH), 7.18–7.21 (4H, 
stack, Ar CH); C(100 MHz) 18.4 (CH2, C-11), 26.2 (CH2), 28.5 (CH2, C-10), [28.8, 29.1, 29.49, 




29.55, 29.6 (CH2, alkyl chain, resonance overlap)], 29.9 (CH2, C-2), 68.1 (CH, C-13), 70.5 
(CH2, C-1), 72.9 (CH2, PhCH2), 84.8 (C, C-12), [127.5, 127.6, 128.3 (CH, Ar CH)], 138.8 (C, 
Ar C); m/z (TOF ES+) 309.2 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 309.2192 [M + Na]+, 




N-Bromo succinimide (0.55 g, 3.06 mmol) and benzoyl peroxide (62 mg, 0.26 mmol) were 
added to a solution of 3-methylbenzophenone (500 mg, 2.55 mmol) in benzene (15 mL). After 
12 h at reflux the reaction was concentrated under reduced pressure and the resulting residue 
was diluted with EtOAc (30 mL). The mixture was washed with H2O (3 × 20 mL), brine (20 
mL), dried (Na2SO4), filtered and the filtrate was concentrated under reduced pressure the 
resulting residue was used direcly without further purification in the next step: CaCO3 (1.28 g, 
12.8 mmol) was added to a solution of the crude bromide 319 (assuming 100% conversion in 
the first step) in dioxane:water (1:1, 20 mL). After 14 h at reflux, the reaction was cooled to rt 
and quenched with 2M HCl (25 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were washed with water (75 mL) brine (75 mL), dried using Na2SO4, filtered 
and the filtrate was concentrated under reduced pressure. The residue was purified using flash 
column chromatography (20% EtOAc in hexanes) to yield alcohol 298 as a colourless oil (411 
mg, 76%, over two steps): Rf = 0.1 (20% EtOAc in hexanes); max(film)/cm–1 3388 br m (O-H), 
1650 vs (C=O), 1596 s, 1577 m, 1447 m, 1362 w, 1314 s, 1281 vs, 1205 s, 1179 m, 1132 m, 
1024 m, 1000 m, 965 m, 929 w, 904 w, 836 w, 816 w, 781 m, 720 vs, 709 vs, 696 vs; H(400 
MHz) 3.09 (1H, br s, OH), 4.69 (2H, s, CH2OH), 7.39–7.47 (3H, stack, Ar CH), 7.53–7.59 (2H, 
stack, Ar CH), 7.62–7.65 (1H, m, Ar CH), 7.72–7.76 (3H, stack, Ar CH); C(100 MHz) 64.4 




(CH2, CH2OH), [128.1, 128.2, 128.3, 129.1, 130.0, 130.1, 132.5 (CH, Ar CH)], [137.3, 137.6, 
141.3 (C, Ar C)], 196.9 (C, C=O); m/z (TOF ES+) 212.1 ([M]+, 30%), 77.0 (100,Ph+). 
Data were in agreement with those reported in the literature.193 
11-O-[3′-Benzoylphenylmethoxy]undecanoic acid (296) 
 
NaH (113 mg of a 60% dispersion in mineral oil, 2.82 mmol) was added to a solution of alcohol 
298 (200 mg, 0.94 mmol) in DMF (10 mL) at 0 °C. After stirring for 1 h, a solution of 11-bromo 
undecanoic acid (166 mg, 0.63 mmol) in DMF (5 mL) was added.  After 20 min at 0 °C, the 
reaction mixture was warmed to rt and stirred for a further 15 h. The reaction was then 
quenched with 2M HCl (25 mL) and extracted with EtOAc (5 × 30 mL). The combined organic 
layers were washed with water (75 mL) brine (75 mL), dried using Na2SO4, filtered and the 
filtrate was concentrated under reduced pressure. The residue was purified using flash column 
chromatography (20% EtOAc in hexanes) to yield ether 296 as a colourless oil (234 mg, 83%.): 
Rf = 0.4 (40% EtOAc in hexanes);max(film)/cm–1 3303 vbr s (O–H), 2927 vs, 2855 s, 1706 vs 
(C=O), 1658 vs (C=O), 1599 m, 1448 w, 1282 s, 1208 m, 1100 m, 715 vs; H(400 MHz) 1.22–
1.38 (12H, stack, alkyl chain), 1.57–1.66 (4H, stack, alkyl chain), 2.33 (2H, t, J 7.5, H-2), 3.49 
(2H, t, J 6.6, H-11), 4.56 (2H, s, CH2Ar), 7.43–7.50 (3H, stack, Ar CH), 7.56–7.61 (2H, stack, 
Ar CH), 7.68–7.72 (1H, m, Ar CH), 7.76–7.81 (3H, stack, Ar CH); C(100 MHz) [24.7, 26.2, 
29.0, 29.2, 29.35, 29.43, 29.5, 29.7 (CH2, alkyl chain)], 34.1 (CH2, C-2), 70.8 (CH2, C-11), 72.3 
(CH2, Ar CH2), [128.29, 128.34, 129.1, 129.3, 130.1, 131.1, 132.5 (CH, Ar CH)], [137.6, 137.7, 
139.1 (C, Ar C)], 179.9 (C, acid C=O), 196.8 (C, ketone C=O); m/z (TOF ES+) 419.2 ([M + 
Na]+, 100%); HRMS m/z (TOF ES+) 419.2202 [M + Na]+, C25H32O4Na requires 419.2198. 
 
 






EDCI.HCl (47 mg, 0.24 mmol) and N-hydroxysuccinimide (31 mg, 0.27 mmol) were added to 
a solution of carboxylic acid 296 (88 mg, 0.22 mmol) in CH2Cl2 (3 mL). After 12 h at 40 °C, the 
mixture was poured into H2O (20 mL) and extracted with Et2O (60 mL). The organic layer was 
washed with brine (20 mL), dried over Na2SO4, and filtered. The solvent was removed under 
reduced pressure to give NHS ester 320 as a glassy non-amorphous solid(95 mg, 90%): Rf = 
0.5 (40% EtOAc in hexanes); max(film)/cm–1 2928 m, 2854 m, 1813 m, 1784 m, 1737 vs (C=O), 
1658 s (C=O), 1598 w, 1447 w, 1362 m, 1317 m, 1282 m, 1250 w, 1205 s, 1179 m, 1131 m, 
1103 m, 1067 s, 994 w, 970 w, 815 w, 783 w, 721 m, 712 m; H(400 MHz) 1.24–1.40 (12H, 
stack, alkyl chain), 1.57–1.64 (2H, stack, alkyl chain), 1.68–1.76 (2H, stack, alkyl chain), 2.58 
(2H, t, J 7.5, H-2), 2.79 (4H, stack, NHS), 3.48 (2H, t, J 6.6, H-11), 4.56 (2H, s, CH2Ar), 7.43–
7.51 (3H, stack, Ar CH), 7.55–7.61 (2H, stack, Ar CH), 7.67–7.71 (1H, m, Ar CH), 7.75–7.81 
(3H, stack, Ar CH); C(100 MHz) [24.6, 25.6, 26.2, 28.7, 29.0, 29.3, 29.4, 29.7, 30.9 (CH2, alkyl 
chain, resonance overlap)], 34.1 (CH2, C-2), 70.8 (CH2, C-11), 72.3 (CH2, Ar CH2), [128.29, 
128.34, 129.0, 129.3, 130.1, 131.6, 132.4 (CH, Ar CH)], [137.6, 137.7, 139.2 (C, Ar C)], 168.7 
(C, ester C=O )169.2 (C, NHS C=O), 196.7 (C, benzophenone C=O); m/z (TOF ES+) 516.2 










(2S, 3S, 4R)-2-[(N-tert-Butoxycarbony)amino]-1, 3, 4-octadecanetriol (322) 
 
Et3N (2.2 mL, 15.7 mmol) and Boc2O (3.02 g, 13.2 mmol) were added sequentially to a solution 
of phytosphingosine 179 (4.0 g, 12.5 mmol) in THF (100 mL). The solution was stirred 
vigorously for 14 h after which time the reaction mixture was concentrated under reduced 
pressure. Recrystallisation of the residue from EtOAc (100 mL) yielded carbamate 322 as 
white crystals (5.49 g, 96%): Rf = 0.2 (5% MeOH in CHCl3); m.p. 80–82 °C (lit.52 86–88 °C); 
solubility issues prevented an optical rotation measurement; max(film)/cm–1  3306 br m (O–H, 
N–H), 2953 w, 2918 s, 2851 s, 1669 vs C=O, 1545 s, 1468 m, 1392 w, 1356 m, 1304 m, 1253 
m, 1170 s, 1107 w, 1060 s, 1043 s, 1028 s, 927 w, 872 w, 783 w, 720 m; H(400 MHz) 0.84 
(3H, t, J 6.8, CH2CH3), 1.20–1.30 (24H, stack, alkyl chain), 1.41 (9H, s, C(CH3)3), 1.47–1.56 
(1H, m, alkyl chain), 1.60–1.69 (1H, m, alkyl chain), 3.49–3.57 (2H, stack, H-3,H-4), 3.63–3.69 
(1H, m, H-1A), 3.70–3.78 (2H, stack, H-1B, H-2); C(100 MHz) 14.5 (CH3, CH2CH3), [23.2, 26.5 
(CH2, alkyl chain)], 28.8 [CH3, C(CH3)3], [29.9, 30.3, 32.5, 33.3 (CH2, alkyl chain, resonance 
overlap)], 53.1 (CH, C-2), 62.0 (CH2, C-1), [73.1, 76.3 (CH, C-3, C-4)], 80.3 (C, C(CH3)3), 157.1 
(C, C=O); m/z (TOF ES+) 440.3 ([M + Na]+, 100%). 













TBDPSCl (3.71 mL, 14.3 mmol) was added to a solution of carbamate 322 (5.00 g, 11.9 mmol) 
in pyrdine (50 mL). After 12 h, the reaction mixure was concentrated under reduced pressure. 
The residue was dissolved with EtOAc (100 mL) and the resulting solution sequentially 
washed with H2O (3 × 50 mL) and brine (1 × 50 mL), and dried using Na2SO4. The solution 
was filtered and concentrated under reduced pressure and the residue was purified by flash 
column chromatography (20% EtOAc in hexanes) to provide pure silyl ether 323 as  colourless 
oil (7.2 g, 92%): Rf = 0.7 (30% EtOAc in hexanes); D21  = +12.8 (c = 1.0, CHCl3), lit.194 D25  
= +13.6 (c = 0.3, CHCl3);; max(film)/cm–1 3424 br w (O–H, N–H), 2924 s, 2854 s, 1690 m 
(C=O), 1501 m, 1467 m, 1427 m, 1391 m, 1366 m, 1323 w, 1246 w, 1168 s, 1113 s, 1064 s, 
857 w, 822 w, 779 w, 739 w, 700 vs, 608 s; H(400 MHz) 0.88 (3H, t, J 6.9, CH2CH3), 1.09 
(9H, s, SiC(CH3)3), 1.23–1.33 (25H, stack, alkyl chain), 1.43 (9H, s, OC(CH3)3), 1.66–1.75 (1H, 
stack, alkyl chain), 2.51 (1H, br d, J 5.3, OH), 3.05 (1H, br d, J 6.9, OH),  3.60–3.69 (2H, stack, 
H-3,H-4), 3.79–3.89 (2H, stack, H-1A, H-2),  3.98 (1H, app. d, J 9.0, H-1B), 5.16 (1H, d, J 8.2, 
NH), 7.36–7.48 (6H, stack, Ar CH), 7.62–7.70 (4H, stack, Ar CH); C(100 MHz) 14.1 (CH3, 
CH2CH3), 19.2 (C, SiC(CH3)3), 22.7 (CH2, alkyl chain), 26.0 (CH2, alkyl chain), 26.9 (CH3, 
SiC(CH3)3), 28.4 (CH3, C(CH3)3), [29.4, 29.67, 29.73, 31.9, 33.1 (CH2, alkyl chain, resonance 
overlap)], 52.1 (CH, C-2), 64.1 (CH2, C-1), [73.5, 75.7 (CH, C-4, C-3)], 79.7 (C, OC(CH3)3), 




[127.9, 130.0 (CH, Ar)], [132.4, 132.6 (C, Ar)], [135.5, 135.6 (CH, Ar)], 155.7 (C, C=O); m/z 
(TOF ES+) 678.5 ([M + Na]+, 100%). 
Data were in agreement with those reported in the literature.194 
 
 (2S, 3S, 4R)-2-[(N-tert-butoxycarbonyl)amino]-1-O-tert-Butyldiphenylsilyloxy-3, 4-O-
isopropylidene-1, 3, 4-octadecanetriol (324) 
 
Concentrated H2SO4 (4 drops) was added to a solution of silyl ether 323 (4.80 g, 7.33 mmol) 
in dry acetone (50 mL) at 0 °C.  After 20 h the reaction mixture was quenched by the addition 
of solid NaHCO3 and then concentrated under reduced pressure. The residue was partitioned 
between EtOAc (35 mL) and H2O (30 mL). The layers were separated and the aqueous phase 
was extracted with EtOAc (3 × 20 mL).  The combined organic layers were washed with brine 
(20 mL), then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure. 
The crude product was purified by column chromatography (5% EtOAc in hexanes) to give 
acetonide 324 as a colourless oil (4.32 g, 84%): Rf = 0.7 (10% EtOAc in hexanes); D21  = 
+18.0 (c = 1.0, CHCl3), max(film)/cm–1 3425 br w (N–H), 2925 s, 2854 s, 1720 s, 1707 s (C=O), 
1496 m, 1466 m, 1428 m, 1390 m, 1378 m, 1366 s, 1247 m, 1218 m, 1167 s, 1109 s, 1045 s, 
1027 m, 955 w, 866 w, 822 m, 780 w, 739 m, 700 vs, 615 w; H(400 MHz) 0.89 (3H, t, J 6.8, 
CH2CH3), 1.07 (9H, s, SiC(CH3)3), 1.22–1.32 (23H, stack, alkyl chain), 1.35–1.37 (6H, stack, 
C(CH3)A(CH3)B), 1.46 (9H, s, OC(CH3)3), 1.50–1.56 (3H, stack, alkyl chain), 3.70–3.85 (2H, 
stack, H-2, H-1A), 3.92 (1H, dd, J 9.9, 2.8, H-1B), 4.10–4.16 (1H, m, H-4), 4.20 (1H, dd, J 9.1, 
5.6, H-3), 4.80 (1H, d, J 9.9, NH), 7.35–7.45 (6H, stack, Ar CH), 7.64–7.73 (4H, stack, Ar CH); 




C(100 MHz) 14.1 (CH3, CH2CH3), 19.3 (C, SiC(CH3)3), 22.7 (CH2, alkyl chain), 25.9 (CH3, 
C(CH3)A(CH3)B), 26.3 (CH2, alkyl chain), 26.8 (CH3, SiC(CH3)3), 28.2 (CH3, C(CH3)A(CH3)B), 
28.4 (CH3, C(CH3)3), [29.1, 29.3, 29.5, 29.7, 31.9 (CH2, alkyl chain, resonance overlap)], 51.0 
(CH, C-2), 63.9 (CH2, C-1), 75.9 (CH, C-4), 77.9 (CH, C-3), 79.4 (C, OC(CH3)3), 107.8 (C, 
C(CH3)2), [127.6, 127.7, 129.66, 129.68 (CH, Ar)], [133.3, 133.5 (C, Ar)], [135.5, 135.6 (CH, 
Ar)], 155.1 (C, C=O); m/z (TOF ES+) 718.5 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 
718.4844 [M + Na]+, C42H69NO5SiNa requires 718.4843. 
 
(2S, 3S, 4R)-2-[(N-tert-Butoxycarbonyl)amino]-3, 4-O-isopropylidene-1, 3, 4 
octadecanetriol (325) 
 
TBAF (8.6 mL, 1.0 M in THF, 8.6 mmol) was added to a solution of acetonide 324 (5.00 g, 
7.18 mmol) in THF (50 mL). After 14 h, the reaction mixture was concentrated under reduced 
pressure. The residue was dissolved in EtOAc (100 mL). The resulting solution was washed 
sequentially with H2O (3 × 50 mL) and brine (1 × 50 mL), dried with Na2SO4, filtered and the 
filtrate was concentrated under reduced pressure. The residue was purified by column 
chromatography to yield alcohol 325 as a white amorphous solid (2.79 g, 85%): Rf = 0.1 (20% 
EtOAc in hexanes); D21  = +6.0 (c = 1.0, CHCl3), lit. D21  = +6.0 (c = 1.0, CHCl3);  
max(film)/cm–1 3347 br m (O–H, N–H), 2984 w, 2918 vs, 2850 s, 1683 vs (C=O), 1665 m, 1529 
vs, 1467 m, 1390 w, 1366 s, 1310 w, 1275 w, 1246 s, 1220 s, 1167 vs, 1065 s, 1041 s, 1018 
s, 997 m, 919 w, 903 w, 867 w, 796 w, 781 w, 763 w, 745 w, 720 m, 678 m; H(400 MHz) 0.88 
(3H, t, J 6.8, CH2CH3), 1.23–1.30 (22H, stack, alkyl chain), 1.33 (3H, s, C(CH3)A(CH3)B), 1.44 




(9H, s, OC(CH3)3), 1.45 (3H, s, C(CH3)A(CH3)B), 1.52–1.65 (4H, stack, alkyl chain), 2.30 (1H, 
br s, OH), 3.66–3.73 (1H, m, H-1A), 3.73–3.81 (1H, m, H-2), 3.81–3.87 (1H, m, H-1B), 4.08 
(1H, app. t, J 6.2, H-3), 4.17 (1H, dd, J 12.1, 6.9, H-4), 4.95 (1H, d, J 8.8, NH); C(100 MHz) 
14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.3 (CH3, C(CH3)A(CH3)B), 26.7 (CH2, alkyl 
chain), 27.6 (CH3, C(CH3)A(CH3)B), 28.3 (CH3, OC(CH3)3), [29.3, 29.5, 29.6, 29.7, 31.9 (CH2, 
alkyl chain, resonance overlap)], 51.1 (CH, C-2), 63.8 (CH2, C-1), 77.8 (CH, C-4), 78.2 (CH, 
C-3), 79.7 (C, OC(CH3)3), 108.1 (C, C(CH3)2), 155.4 (C, C=O); m/z (TOF ES+) 480.4 ([M + 
Na]+, 100%). 
Data were in agreement with those reported in the literature.195 
 
1, 2, 3, 4, 6-Penta-O-trimethylsilyl-α-D-galactopyranoside (330) 
 
HMDS (50 mL, 0.24 mol) and TMSCl (25 mL, 0.20 mol) were added sequentially to a solution 
of D-galactose (5.0 g, 55.5 mmol) in pyridine (100 mL). The solution was heated at 75 ºC for 
1 h under an Ar atmosphere and then cooled to rt. The mixture was poured into ice-H2O (250 
mL) and extracted with hexane (3 × 150 mL). The combined organic extracts were washed 
with H2O (3 × 150 mL), dried (MgSO4) and concentrated under reduced pressure to afford per-
silylated galactose 330 as a viscous, colourless oil (15.0 g, 91%, -anomer only): Rf = 0.2 (4% 
EtOAc in hexanes); []D22 = +32.0 (c = 1.0, CHCl3), lit.52 []D20 = +67.9 (c = 0.5, CHCl3); 
max(film)/cm–1 2956 m, 2901 w, 1459 w, 1402 w, 1383 w, 1248 s, 1154 m, 1103 m, 1071 s, 
1051 m, 968 m, 892 m, 865 s, 832 vs, 747 s, 682 m; H(400 MHz) 0.10 (9H, s, Si(CH3)3), 0.11 
(9H, s, Si(CH3)3), 0.13 (9H, s, Si(CH3)3), 0.14 (18H, s, Si(CH3)3), 3.53 (1H, dd, J 9.6, 5.6, H-
6A), 3.63 (1H, dd, 9.6, 7.9, H-6B), 3.81–3.83 (2H, stack, incl. H-2), 3.88–3.92 (2H, stack, incl. 
H-5), 5.05 (1H, d, J 2.2, H-1); C(100 MHz) [–0.5, 0.2, 0.3, 0.5, 0.6, CH3, Si(CH3)3], 61.2, (CH2, 




C-6), 67.0 (CH), 70.5 (CH), 71.1 (CH), 72.3 (CH), 94.6 (CH, C-1); m/z (TOF ES+) 563.25 ([M 
+ Na]+, 100%). 
Data were in agreement with those reported in the literature.52 
 
(2S, 3S, 4R)-2-[N-tert-Butoxycarbonylamino]-1-O--D-galactopyranosyl-3,4-O-
isopropylidene-1, 3, 4-octadecanetriol (331) and (2S, 3S, 4R)-2-[N-tert-
butoxycarbonylamino]-1-O--D-galactopyranosyl-1, 3, 4-octadecantriol (332) 
                            
TMSI (1.87 mL, 13.1 mmol) was added to a solution of per-silylated galactose 330 (7.1 g, 13.1 
mmol) in CH2Cl2 (50 mL) at 0 °C. The reaction mixture was stirred under an Ar atmosphere 
for 1 h before the solvent was removed under reduced pressure. The residue was dissolved 
in anhydrous toluene (20 mL) and the solvent was removed under reduced pressure to remove 
any traces if HI. The resulting glycosyl iodide intermediate 95 was dissolved in CH2Cl2 (20 mL) 
and kept under an Ar atmosphere. Activated 4 Å molecular sieves (2.20 g) were added to a 
separate flask containing n-Bu4NI (8.45 g, 26.2 mmol), i-Pr2NEt (3.5 mL, 20.1 mmol) and 
alcohol 325 (2.00 g, 4.37 mmol) in CH2Cl2 (30 mL). After 30 min, the solution of glycosyl iodide 
95 in CH2Cl2 was added to the solution containing the alcohol and the resulting mixture was 
stirred overnight. The solution was filtered through Celite and after removal of the solvent 
under reduced pressure, Et2O (50 mL) and H2O (50 mL) were added and the phases were 
separated. The organic phase was dried (Na2SO4) and then concentrated under reduced 
pressure. CHCl3:MeOH:2 M HCl (40 mL total volume, 10:10:3) was added to the resulting 
residue. After stirring for 20 min, CHCl3 (17.5 mL) and H2O (7.5 mL) were added at which point 




the mixture separated into two phases. The top phase was isolated and concentrated under 
reduced pressure. Purification of the residue by flash column chromatography (1% MeOH in 
CHCl3 → 10% MeOH in CHCl3) afforded, in order of elution, glycoside 331 as a colourless 
syrup (1.30 g, 48%, -anomer only): Rf = 0.3 (10% MeOH in CHCl3); solubility issues 
prevented an optical rotation measurement; max(film)/cm–1 3352 br m (O–H, N–H), 2923 s, 
2853 s, 1686 s (C=O), 1526 w, 1458 w, 1367 s, 1248 s, 1220 s, 1161 s, 1043 vs, 1023 vs, 
974 w, 867 w, 770 w; H(400 MHz, 2:1 CDCl3:CD3OD) 0.84 (3H, t, J 6.8, CH2CH3), 1.20–1.28 
(23H, stack, alkyl chain), 1.29 (3H, s, C(CH3)A(CH3)B), 1.38 (3H, s, C(CH3)A(CH3)B), 1.40 (9H, 
s, OC(CH3)3), 1.45–1.51 (3H, stack, alkyl chain), 3.68–3.81 (8H, stack, incl. H-2, H-1A, H-1B, 
H-2′, H-6′A, H-6′B), 3.92–3.94 (1H, m, sugar CH), 4.03–4.11 (2H, stack, H-3, H-4), 4.89 (1H, d, 
J 2.7, H-1′), exchangeable protons not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.5 (CH3, 
CH2CH3), 23.2 (CH2, alkyl chain), 26.1 (CH3, C(CH3)A(CH3)B), 26.9 (CH2, alkyl chain), 28.6 
(CH3, C(CH3)A(CH3)B), 28.8 (CH3, OC(CH3)3), [29.9, 30.1, 30.2, 32.4 (CH2, alkyl chain, 
resonance overlap)], 50.6 (CH, C-2), 62.5 (CH2, C-1), 69.1 (CH2, C-6′), [69.9, 70.4, 70.9, (CH, 
C-2′, C-3′, C-4′, C-5′, resonance overlap)], 76.0 (CH, C-4), 78.7 (CH, C-3), 80.1 (C, OC(CH3)3), 
100.2 (CH, C-1′), 108.7 1 (C, C(CH3)2), 156.4 (C, C=O); m/z (TOF ES+) 642.4 ([M + Na]+, 
100%); HRMS m/z (TOF ES+) 642.4196 [M + Na]+, C32H61NO10Na requires 642.4193 and then 
glycoside 332 as a white foam (0.71 g, 28%, -anomer only): Rf = 0.1 (10% MeOH in CHCl3); 
solubility issues prevented an optical rotation measurement; max(film)/cm–1 3334  br s (O–H, 
N–H), 2917 s, 2849 s, 1692 s, 1679 s (C=O), 1526 s, 1464 m, 1392 m, 1366 m, 1316 m, 1296 
m, 1246 s, 1169 s, 1134 s, 1081 s, 1039 vs, 1001 s, 978 m, 937 w, 882 w, 823 w, 785 w, 764 
w, 719 w; H(400 MHz, 2:1 CDCl3:CD3OD) 0.84 (3H, t, J 6.8, CH2CH3), 1.20–1.30 (24H, stack, 
alkyl chain), 1.41 (9H, s, OC(CH3)3), 1.47–1.57 (1H, m, alkyl chain), 1.60–1.69 (1H, m, alkyl 
chain), 3.48–3.57 (2H, stack, H-3, H-4), 3.63 (1H, dd, J 11.9, 6.0, H-6′A), 3.67–3.81 (5H, stack, 
incl. H-1A, H-1B, H-2′), 3.82–3.88 (2H, stack, H-2, H-6′B), 3.90–3.93 (1H, m, sugar CH), 4.87 
(1H, d, J 3.6, H-1′); C(100 MHz, 2:1 CDCl3:CD3OD) 14.5 (CH3, CH2CH3), [23.2, 26.5 (CH2, 
alkyl chain)], 28.8 (CH3, OC(CH3)3), [29.9, 30.3, 32.5, 33.1 (CH2, alkyl chain, resonance 




overlap)], 51.8 (CH, C-2), 62.4 (CH2, C-6′), 68.3 (CH2, C-1), [69.5, 70.4, 70.9, 71.3 (CH, C-2′, 
C-3′, C-4′, C-5′)], [72.6, 75.7 (CH, C-3, C-4)], 80.3 (C, OC(CH3)3), 100.3 (CH, C-1′), 156.9 (C, 
C=O); m/z (TOF ES+) 602.4 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 602.3882 [M + Na]+, 
C29H57NO10Na requires 602.3880. 
 
(2S, 3S, 4R)-2-[11′′-O-(3′′′-Benzoylphenylmethoxy)-undecanoylamino]-1-O--D-
galactopyranosyl-1, 3, 4-octadecanetriol (333)  
 
TFA (2 mL) was added to a flask containing glycoside 332 (30 mg, 0.052 mmol). After 30 min, 
the solvent was removed under reduced pressure. The residue was dissolved in THF (2 mL) 
followed by addition Et3N (30 L, 0.215 mmol) and NHS ester 320 (31 mg, 0.062 mmol). After 
14 h at 50 °C, the reaction mixture was concentrated under reduced pressure and purified by 
flash column chromatography (1% MeOH in CHCl3 →10% MeOH in CHCl3) to afford amide 
333 as a colourless syrup (21 mg, 48%):  Rf = 0.1 (10% MeOH in CHCl3); solubility issues 
prevented an optical rotation measurement; max(film)/cm–1 3350 br m (O–H, N–H), 2923 m, 
2851 m, 1672  vs br (C=O), 1449 m, 1399 w, 1360 w, 1317 w, 1283 w, 1243 w, 1200 vs, 1180 




s, 1129 vs, 1072 m, 1034 m, 976 w, 833 m, 799 m, 719 m; H(400 MHz, 2:1 CDCl3:CD3OD) 
0.84 (3H, t, J 6.7, CH2CH3), 1.2–1.33 (38H, stack, alkyl chain), 1.50–1.67 (5H, stack, alkyl 
chain), 1.71–1.78 (1H, m, alkyl chain), 2.17 (2H, app. t, J 7.7, H-2′′), 3.48 (2H, t, J 6.6, H-11′′), 
3.51–3.55 (2H, stack, H-3, H-4), 3.66 (1H, dd, J 10.7, 4.4, H-1A), 3.68–3.80 (4H, stack), 3.85 
(1H, dd, J 10.7, 4.7, H-1B), 3.90 (1H, app. d, J 3.0), 4.14–4.19 (1H, m, H-2), 4.31 (1H, t, J 
6.67), 4.55 (2H, s, ArCH2), 4.87 (1H, d, J 3.7, H-1′), 7.45–7.51 (3H, Ar CH), 7.56–7.63 (2H, 
stack, Ar CH), 7.66–7.69 (1H, m, Ar CH), 7.71–7.78 (3H, stack, Ar CH), exchangeable protons 
not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.3 (CH3, CH2CH3), [23.1, 26.3, 29.7, 29.8, 
29.9, 30.07, 30.13, 31.5, 32.3, 32.9 (CH2, alkyl chain, resonance overlap)], 36.9 (CH2, C-2′′), 
50.8 (CH, C-2), 62.3 (CH2, C-6′), 67.8 (CH2, C-1), [69.4, 70.3, 70.7, 71.1 (CH, C-2′, C-3′, C-4′, 
C-5′)], 71.3 (CH2, C-11′′), 72.5 (CH, C-3 or C-4), 72.7 (CH2, ArCH2), 75.1 (CH, C-4 or C-3)], 
100.1 (CH, C-1′), [128.8, 128.95, 129.00, 129.8, 130.5, 131.4, 133.2 (CH, Ar CH)], 175.0 (C, 
C=O), ketone C=O or Ar C not observed; m/z (TOF ES+) 880.5 ([M + Na]+, 100%); HRMS m/z 
















(2S, 3S, 4R)-2-[13′′-(3′′′-Benzoylphenyl)tridecanoylamino]-1-O--D-galactopyranosyl-1, 
3, 4-octadecanetriol (334)  
 
TFA (2 mL) was added to a flask containing glycoside 332 (30 mg, 0.052 mmol). After 30 min,  
the solvent was removed under reduced pressure. The residue was dissolved in pyridine:H2O 
(2 mL, 9:1) and then NHS ester 310 (32 mg, 0.063 mmol) was added. After 14 h at 60 °C, the 
reaction mixture was co-evaporated with toluene under reduced pressure and purified by flash 
column chromatography (1% MeOH in CHCl3 →10% MeOH in CHCl3) to afford amide 334 (22 
mg, 50%) as a glassy foam: Rf = 0.1 (10% MeOH in CHCl3); solubility issues prevented an 
optical rotation measurement; max(film)/cm–1 3355 br m (O–H, N–H), 2917 vs, 2849 s, 1731 
w, 1657 m (C=O), 1638 m, 1465 m, 1348 w, 1316 w, 1280 m, 1207 w, 1153 m, 1061 m, 1029 
m, 799 w, 719 m, 644 w, 612 w; H(400 MHz, 2:1 CDCl3:CD3OD) 0.84 (3H, t, J 6.8, CH2CH3), 
1.20–1.35 (40H, stack, alkyl chain), 1.50–1.67 (6H, stack, alkyl chain), 2.17 (2H, app. t, J 7.7, 
H-2′′), 2.65 (2H, app. t, J 7.7, H-13′′), 3.49–3.54 (2H, stack, H-3, H-4), 3.62–3.79 (6H, stack, 
incl. H-1A, H-2′, H-6′A, H-6′B), 3.84 (1H, dd, J 10.7, 4.6, H-1B), 3.90 (1H, app. d, J 3.0), 4.13–
4.20 (1H, m, H-2), 4.87 (1H, d, J 3.7, H-1′), 7.35–7.43 (2H, Ar CH), 7.45–7.50 (2H, stack, Ar 




CH), 7.53–7.61 (3H, stack, Ar CH), 7.73–7.77 (2H, stack, Ar CH), exchangeable protons not 
observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.3 (CH3, CH2CH3), [23.1, 26.3, 29.7, 29.8, 29.86, 
29.89, 30.07, 30.13, 31.8, 32.3, (CH2, alkyl chain, resonance overlap)], 32.9 (CH2, C-13′′), 36.9 
(CH2, C-2′′), 50.9 (CH, C-2), 62.3 (CH2, C-6′), 67.8 (CH2, C-1), [69.4, 70.2, 70.7, 71.3 (CH, C-
2′, C-3′, C-4′, C-5′)], [72.4, 75.1 (CH, C-3, C-4)], 100.2 (CH, C-1′), [128.1, 128.7, 128.8, 130.4, 
130.5, 133.1, 133.4 (CH, Ar CH)], [137.9, 138.1, 143.8 (C, Ar C)], 175.0 (C, C=O), ketone C=O 
not observed; m/z (TOF ES+) 878.6 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 878.5762 [M 
+ Na]+, C50H81NO10Na requires 878.5758. 
 
(2S, 3S, 4R)-1-Azido-3, 4-O-isopropylidene-2-(ortho-nitrobenzenesulfonamido)-3, 4-
octadecanediol (348) 
 
NaN3 (20 mg, 0.31 mmol) was added to a solution of nosyl aziridine 192 (100 mg, 0.21 mmol) 
in CH3CN:H2O (3 mL; 9:1). After 2 h heating at reflux, the reaction flask was cooled to rt and 
the CH3CN was removed under reduced pressure. The residue was dissolved in EtOAc (40 
mL) and the mixture was washed sequentially with H2O (3 × 30 mL), brine (30 mL), dried using 
Na2SO4, filtered and the filtrate concentrated under reduced pressure. The residue was 
purified by flash column chromatography (10% EtOAc in hexanes) to give azide 348 as a 
yellow oil (78 mg, 72%): Rf = 0.7 (20% EtOAc in hexanes); []D21 = +80.0 (c = 1.0, CHCl3), 
lit.130 []D = +11 (c = 1.0, CHCl3); max(film)/cm–1 3336 w br (N–H), 2923 s, 2853 s, 2104 s (N3), 
1541 vs, 1442 m, 1421 m, 1354 s, 1300 m, 1251 m, 1217 m, 1167 s, 1123 m, 1059 s, 958 w, 
854 m, 783 m, 740 m, 731 m, 700 w, 655 m; H(400 MHz) 0.88 (3H, t, J 6.8, CH2CH3), 1.22–
1.30 (22H, stack, alkyl chain, resonance overlap), 1.33 (3H, s, C(CH3)A(CH3)B), 1.40 (3H, s, 
C(CH3)A(CH3)B), 1.47–1.67 (4H, stack, alkyl chain), 3.28 (1H, dd, J 12.7, 3.0, H-1A), 3.58 (1H, 




dd, J 12.7, 4.5, H-1B), 3.78–3.84 (1H, m, H-2), 4.04 (1H, dd, J 7.9, 5.7, H-3), 4.18 (1H, ddd, J 
9.5, 5.7, 3.6, H-4), 5.73 (1H, d, J 9.8, N-H), 7.73–7.80 (2H, stack, Ar CH), 7.91–7.98 (1H, m, 
Ar CH), 8.13–8.20 (1H, m, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 
25.4 [CH3, C(CH3)A(CH3)B], 26.5 (CH2, alkyl chain), 27.7 (CH3, C(CH3)A(CH3)B), [29.2, 29.3, 
29.47, 29.52, 29.6, 29.7, 31.9 (CH2, alkyl chain, resonance overlap)], 52.6 (CH, C-1), 53.8 
(CH, C-2), 76.5 (CH, C-3), 77.4 (CH, C-4), 108.3 (C, C(CH3)2), [125.8, 130.1, 133.2, 133.7 
(CH, Ar CH)], [135.5, 147.6 (C, Ar C)]; m/z (TOF ES+) 590.3 ([M + Na]+, 100%). 
 
Data were in agreement with those reported in the literature.130 
 
(2S, 3S, 4R)-2-Amino-1-azido-3, 4-O-isopropylidene-3, 4-octadecanediol (349) 
 
Thiophenol (19 L, 0.18 mmol) and Cs2CO3 (45 mg, 0.14 mmol) were added sequentially to a 
solution of azide 348 (26 mg, 0.046 mmol) in anhydrous CH3CN (1 mL). After 16 h, the reaction 
was quenched by the addition of NaHCO3 solution (20 mL). The phases were partitioned and 
the aqueous phase was extracted with CH2Cl2 (3 × 30 mL). The combined organic fractions 
were dried with Na2SO4, filtered and the filtrate was concentrated under reduced pressure. 
The residue was purified by flash column chromatography (20% EtOAc in hexanes) to afford 
amine 349 as a colourless oil (14 mg, 83%): Rf = 0.3 (EtOAc in hexanes); []D21 = + 20.0 (c = 
1.0, CHCl3), lit.130 []D = + 19.0 (c = 1.0, CHCl3); max(film)/cm–1 3369 w (N–H), 2923 vs, 2853 
s, 2102 s (N3), 1678 w, 1461 m, 1379 m, 1369 m, 1246 m, 1218 m, 1167 m, 1059 s, 871 m, 
799 m, 722 m; H(400 MHz) 0.88 (3H, t, J 6.8, CH2CH3), 1.24–1.28 (21H, stack, alkyl chain), 
1.33 (3H, s, C(CH3)A(CH3)B), 1.41 (3H, s, C(CH3)A(CH3)B), 1.44–1.58 (5H, stack, alkyl chain), 
2.98 (1H, ddd, J 9.1, 6.4, 3.0, H-2), 3.44 (1H, dd, J 12.2, 6.4, H-1A), 3.57 (1H, dd, J 12.2, 3.0, 




H-1B), 3.84 (1H, dd, J 9.1, 5.6, H-3), 4.16 (1H, ddd, J 9.1, 5.6, 3.6, H-4), NH not observed; 
C(100 MHz) ) 14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.8 [CH3, C(CH3)A(CH3)B, 26.2 
(CH2, alkyl chain), 28.2 [CH3, C(CH3)A(CH3)B], [29.3, 29.6, 29.7, 29.8, 31.9 (CH2, alkyl chain, 
resonance overlap)], 50.4 (CH, C-2), 56.6 (CH2, C-1), 77.7 (CH, C-4), 79.0 (CH, C-3), 108.1 
(C, C(CH3)2); m/z (TOF ES+) 405.3 ([M + Na]+, 30%), 383.3 ([M + H]+, 50%), 325.3 (100%). 
 
Data were in agreement with those reported in the literature.130 
 
(2S, 3S, 4R)-1-Azido-2-[13′-(3′′-benzoylphenyl)tridecanoylamino] -3, 4-O-
isopropylidene-3, 4-octadecanediol (350) 
 
Et3N (100 L, 0.66 mmol) and NHS ester 310 (115 mg, 0.242 mmol) were added to a flask 
containing amine 349 (84 mg, 0.22 mmol) in THF (2 mL), After  heating at 50 °C for 14 h, the 
reaction mixture was concentrated under reduced pressure and the residue purified by flash 
column chromatography (10% EtOAc in hexanes) to afford amide 350 as a colourless oil (125 
mg, 76%):  Rf = 0.4 (20% EtOAc in hexanes); []D21 = +17.6 (c = 1.0, CHCl3); max(film)/cm–1 
3303 w (N–H), 2914 vs, 2848 s, 2118 s (N3), 1645 vs (C=O), 1598 w, 1579 m, 1547 s, 1469 
s, 1441 m, 1416 m, 1380 m, 1350 m, 1309 m, 1279 s, 1255 s, 1217 m, 1165 m, 1129 w, 1073 
s, 1062 s, 1015 w, 998 w, 986 w, 972 w, 909 w, 864 m, 838 w, 809 w, 784 m, 709 vs, 702 vs, 
691 s, 633 m, 606 w; H(400 MHz) 0.88 (3H, t, J 6.8, CH2CH3), 1.22–1.28 (40H, stack, alkyl 
chain), 1.33 (3H, s, C(CH3)A(CH3)B), 1.42 (3H, s, C(CH3)A(CH3)B), 1.45–1.55 (2H, stack, alkyl 
chain), 1.57–1.67 (4H, stack, alkyl chain), 2.16 (2H, app. td, J 7.6, 4.1, H-2′), 2.66 (2H, app. t, 
J 7.8, H-13′), 3.47 (1H, dd, J 12.4, 3.0, H-1A), 3.65 (1H, dd, J 12.4, 4.1, H-1B), 4.03 (1H, dd, J 




8.7, 5.6, H-3), 4.07–4.13 (1H, m, H-4), 4.22 (1H, m, H-2), 5.69 (1H, d, J 9.3, NH), 7.34–7.42 
(2H, stack, Ar CH), 7.45–7.50 (2H, stack, Ar CH), 7.55–7.61 (2H, stack, Ar CH), 7.61–7.64 
(1H, m, Ar CH), 7.78–7.82 (2H, stack, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, 
alkyl chain), 25.6 (CH3, C(CH3)A(CH3)B), [25.7, 26.5 (CH2, alkyl chain)], 27.9 (CH3, 
C(CH3)A(CH3)B), [29.1, 29.2, 29.3, 29.4, 29.45, 29.49, 29.54, 29.6, 29.7, 31.4, 31.9, (CH2, alkyl 
chain, resonance overlap)], 35.8 (CH, C-13′), 36.8 (CH2, C-2′), 48.0 (CH, C-2) 53.0 (CH2, C-
1), 76.2 (CH, C-3), 77.6 (CH, C-4), 108.3 (C, C(CH3)2), [127.6, 128.1, 128.2, 129.8, 130.0, 
132.6, 133.7 (CH, Ar CH)], [137.5, 137.8, 143.2 (C, Ar C)], 172.5 (C, amide C=O), 197.1 (C, 
ketone C=O); m/z (TOF ES+) 781.6 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 781.5610 [M + 
Na]+, C47H74 N4 O4Na requires 781.5608  
 
(2S, 3S, 4R)-1-Azido-2-[13′-(3′′-benzoylphenyl)tridecanoylamino]-3, 4-octadecanediol 
(342) 
 
TFA (5 drops) and H2O (2 drops) were added to a solution of amide 350 (120 mg, 0.16 mmol) 
in CH2Cl2 (2 mL). After 12 h, the solvent was removed under reduced pressure. EtOAc (40 
mL) was added to the residue and the solution was washed with NaHCO3 solution (3 × 25 
mL), dried with Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The 
residue was purified by column chromatography (30% EtOAc in hexanes) to yield diol 342 as 
an off-white amorphous solid (63 mg, 56%): Rf = 0.1 (30% EtOAc in hexanes); solubility issues 
prevented an optical rotation measurement; max(film)/cm–1 3274 br s (O–H, N–H), 2921 vs, 
2852 vs, 2100 vs (N3), 1660 s (C=O), 1642 vs (C=O), 1598 w, 1581 s, 1533 m, 1466 m, 1447 
m, 1316 m, 1279 vs, 1207 w, 1178 w, 1149 w, 1098 w, 1047 w, 960 w, 812 w, 779 m, 718 vs, 




709 vs;  H(400 MHz) ) 0.87 (3H, t, J 6.8, CH2CH3), 1.22–1.35 (40H, stack, alkyl chain), 1.38–
1.55 (2H, stack, alkyl chain), 1.57–1.70 (4H, stack, alkyl chain), 2.20 (2H, app. dd, J 8.1, 7.0, 
H-2′), 2.46 (1H, br s, OH), 2.66 (2H, app. t, J 7.7, H-13′), 3.42 (1H, br s, OH), 3.56–3.63 (3H, 
stack, H-1A, H-3, H-4), 3.77 (1H, dd, J 12.6, 5.7, H-1B), 4.12–4.18 (1H, m, H-2), 6.18 (1H, d, J 
8.3, NH), 7.35–7.42 (2H, stack, Ar CH), 7.45–7.50 (2H, stack, Ar CH), 7.56–7.61 (2H, stack, 
Ar CH), 7.61–7.64 (1H, m, Ar CH), 7.78–7.82 (2H, stack, Ar CH);  C(100 MHz) 14.1 (CH3, 
CH2CH3), [22.7, 25.6, 28.8, 29.25, 29.33, 29.4, 29.5, 29.57, 29.65, 29.7, 31.4, 31.9, 33.0 (CH2, 
alkyl chain, resonance overlap)], 35.8 (CH, C-13′), 36.8 (CH2, C-2′), 50.7 (CH, C-2), 51.4 (CH2, 
C-1), [73.0, 75.1 (CH, C-3, C-4)], [127.7, 128.1, 128.3, 129.9, 130.1, 132.4, 132.7 (CH, Ar 
CH)], [137.5, 137.8, 143.2 (C, Ar C)], 174.0 (C, amide C=O), 197.2 (C, ketone C=O); m/z (TOF 






Freshly prepared solutions of CuSO4 solution (12 L of 0.5 M solution, 0.006 mmol) and 
sodium ascorbate solution (20 L of 1.0 M solution, 0.0020 mmol) were added to a solution of 
diol 342 (27 mg, 0.0375 mmol) and 4-pentynol (4 mg, 0.045 mmol) in H2O:THF (2 mL, 2:1). 
After heating the reaction mixture at 80 °C for 5 h, the solvent was evaporated under reduced 
pressure and the residue was purified by flash column chromatography (1% MeOH in CHCl3 
→ 10% MeOH in CHCl3) to afford triazole 351 as a white solid (27 mg, 90%): Rf = 0.5 (10% 
MeOH in CHCl3); m.p. 143–147 °C; solubility issues prevented an optical rotation 




measurement; max(film)/cm–1 3337 br w (O-H, N–H), 2918 vs, 2848 s, 1657 m (C=O), 1632 s 
(C=O), 1579 w, 1464 m, 1309 w, 1279 m, 1208 w, 1149 w, 1072 m, 1028 w, 971 w, 909 w, 
720 m; H(400 MHz, 2:1 CDCl3:CD3OD) 0.83 (3H, t, J 6.8, CH2CH3), 1.17–1.32 (40H, stack, 
alkyl chain), 1.36–1.45 (3H, stack, alkyl chain), 1.46–1.65 (3H, stack, alkyl chain),1.78–1.86 
(2H, stack, H-2′′), 1.99–2.04 (2H, stack, H-2′′′), 2.63 (2H, app. t, J 7.7, H-13′′′), 2.71 (2H, app. 
t, J 7.4, H-1′′), 3.40–3.49 (2H, stack, H-3, H-4), 3.53 (2H, app.t, J 6.3, H-3′′), 4.40 (1H, app. dt, 
J 8.4, 4.7, H-2), 4.48–4.59 (2H, stack, H-1), 7.32–7.40 (2H, stack, Ar CH), 7.42–7.49 (3H, 
stack, Ar CH), 7.52–7.59 (3H, stack, Ar CH), 7.72–7.76 (2H, stack, Ar CH) exchangeable 
protons not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.2 (CH3, CH2CH3), 21.8 (CH2, C-1′′), 
[22.8 25.8, 26.0, 29.4, 29.5, 29.66, 29.68, 29.8, 29.9, 31.6 (CH2, alkyl chain, resonance 
overlap)], [32.0, 32.1, 32.8 (CH2, alkyl chain including C-2′′)], 36.0 (CH2, C-13′′′), 36.5 (CH2, C-
2′′′), 49.8 (CH2, C-1), 51.2 (CH, C-2), 61.1 (CH2, C-3′′), [72.3, 75.0 (CH, C-3, C-4)], 122.9 (CH, 
Ar CH, triazole), [127.8, 128.4, 128.5, 130.1, 130.3, 132.8, 133.1 (CH, Ar CH)], [143.4, 143.5, 
147.7 (C, Ar C)], 174.9 (C, amide C=O), triazole C and ketone C=O not observed; m/z (TOF 
ES+) 825.6 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 825.5868 [M + Na]+, C49H78N4O5Na 
requires 825.5870. 
 
(3S, 4S, 5R)-4, 5-O-Isopropylidene-2-(ortho-nitrobenzenesulfonamido)-1-
nonadecanenitrile-4, 5-diol (352) 
 
NaCN (14 mg, 0.29 mmol) was added to a solution of nosyl aziridine 192 (100 mg, 0.19 mmol) 
in CH3CN:H2O (2 mL; 9:1). After heating at reflux for 3 h, the flask was cooled to rt and the 
CH3CN was removed under reduced pressure. EtOAc (40 mL) was added and the solution 
was washed sequentially with H2O (3 × 25 mL) and brine (30 mL), dried using Na2SO4, filtered 




and the filtrate concentrated under reduced pressure. The residue was purified by flash 
column chromatography (10% EtOAc in hexanes) to give nitrile 352 as a yellow oil (72 mg, 
64%): Rf = 0.6 (20% EtOAc in hexanes); []D21 = + 42.8 (c = 1.0, CHCl3), lit.130 []D = + 9.3 (c 
= 1.0, CHCl3); max(film)/cm–1 3352 w br (N–H), 2989 w, 2922 vs, 2852 s, 2244 w (CN), 1597 
w, 1534 vs, 1469 m, 1443 m, 1427 s, 1396 m, 1346 vs, 1247 m, 1219 m, 1168 vs, 1115 m, 
1052 s, 932 w, 857 m, 824 m, 787 s, 739 s, 730 m, 686 m, 654 s; H(400 MHz)  0.88 (3H, t, J 
6.8, CH2CH3), 1.22–1.30 (24H, stack, alkyl chain, resonance overlap), 1.33 (3H, s, 
C(CH3)A(CH3)B), 1.41 (3H, s, C(CH3)A(CH3)B), 1.43–1.51 (2H, stack, alkyl chain), 2.63 (1H, dd, 
J 17.1, 4.0, H-2A), 2.73 (1H, dd, J 17.1, 5.7, H-2B) 3.91–3.98 (1H, m, H-3), 4.13 (1H, app. t, J 
6.4, H-4), 4.19 (1H, ddd, J 9.3, 5.9, 3.2, H-5), 5.78–5.84 (1H, m, NH), 7.75–7.80 (2H, stack, 
Ar CH), 7.90–7.96 (1H, m, Ar CH), 8.15–8.20 (1H, m, Ar CH); C(100 MHz) 14.1 (CH3, 
CH2CH3), 21.9 (CH2, C-2), 22.7 (CH2, alkyl chain), 25.1 (CH3, C(CH3)A(CH3)B), 26.6 (CH2, alkyl 
chain), 27.4 [CH3, C(CH3)A(CH3)B], [29.2, 29.4, 29.45, 29.51, 29.6, 29.7, 31.9 (CH2, alkyl chain, 
resonance overlap)], 51.2 (CH, C-3), 77.1 (CH, C-5), 77.8 (CH, C-4), 108.7 (C, C(CH3)2), 116.4 
(C, C-1), [125.8, 130.2, 133.3, 134.1 (CH, Ar CH)], [135.0, 147.7 (C, Ar C)]; m/z (TOF ES+) 
574.3 ([M + Na]+, 100%). 
 
Data were in agreement with those reported in the literature.130 
 
(3S, 4S, 5R)-2-Amino-4, 5-O-Isopropylidene-1-nonadecanenitrile-4, 5-diol (353) 
 
Thiophenol (27 L, 0.26 mmol) and Cs2CO3 (64 mg, 0.20 mmol) were added sequentially to a 
solution of nitrile 353 (36 mg, 0.065 mmol) in CH3CN (2 mL). After 16 h, the reaction was 
quenched by addition of NaHCO3 solution (20 mL). The mixture was extracted with CH2Cl2 (3 
× 30 mL). The combined organic layers were dried with Na2SO4, filtered and the filtrate 




concentrated under reduced pressure. The residue was purified by flash column 
chromatography (20% EtOAc in hexanes) to afford amine 353 as a colourless oil (22 mg, 
92%): Rf = 0.2 (20% EtOAc in hexanes); []D21 = +11.2 (c = 1.0, CHCl3); max(film)/cm–1 3387 
vw (NH2) 2922 vs, 2852 s, 2249 w (CN), 1620 w, 1465 m, 1370 m, 1246 m, 1218 s, 1166 m, 
1069 m, 871 m, 797 w, 766 w; H(400 MHz) 0.88 (3H, t, J 6.8, CH2CH3), 1.24–1.30 (21H, 
stack, alkyl chain), 1.33 (3H, s, C(CH3)A(CH3)B), 1.40 (3H, s, C(CH3)A(CH3)B),  1.42–1.60 (5H, 
stack, alkyl chain), 2.52 (1H, dd, J  16.7, 7.4, H-2A), 2.72 (1H, dd, J 16.7, 3.5, H-2B), 3.14 (1H, 
ddd, J 8.8, 7.4, 3.5, H-3), 3.82 (1H, dd, J 8.8, 5.7, H-4), 4.17 (1H, ddd, J 10.6, 5.7, 2.5, H-5), 
NH2 not observed; C(100 MHz) 14.1 (CH3, CH2CH3), 22.7 (CH2, C-2), 25.4 (CH2, alkyl chain), 
25.7 (CH3, C(CH3)A(CH3)B), 26.3 (CH2, alkyl chain), 28.1 (CH3, C(CH3)A(CH3)B), [29.4, 29.66, 
29.68, 31.9 (CH2, alkyl chain, resonance overlap)], 48.0 (CH, C-3), 77.6 (CH, C-5), 80.1 (CH, 
C-4), 108.1 (C, C(CH3)2), 118.2 (C, C-1); m/z (TOF ES+) 367.3 ([M + H]+, 100%); HRMS m/z 
(TOF ES+) 367.3319 [M + H]+, C22H43N2O2 requires 367.3325. 
 
(4S, 5S, 6R)-5, 6-O-Isopropylidene-4-(ortho-nitrobenzenesulfonamido)-1-trimethylsilyl-
eicos-1-yne-5, 6-diol (354)  
 
nBuLi (0.35 mL, 0.88 mmol, 2.5 M solution in hexanes) was added to a solution of 
(trimethylsilyl)acetylene (0.12 mL, 0.88 mmol) in THF:HMPA (1.5 mL, 10:1) at –78 °C. After 
30 min, a solution of Ns-aziridine 192 (155 mg, 0.30 mmol) in THF:HMPA (0.5 mL, 10:1) was 
added via syringe at –78 °C. The reaction mixture was stirred for 2 h at –78 °C, then at rt for12 




h. The reaction was then quenched with NH4Cl solution (20 mL) and extracted with Et2O (3 × 
30 mL). The combined organic extracts were washed with brine (50 mL), dried using Na2SO4, 
filtered, and the filtrate concentrated under reduced pressure. The residue was purified by 
flash column chromatography (10% EtOAc/hexane) to give in order of elution silyl alkyne 354 
as a colourless oil (0.086 g, 46%): Rf = 0.6 (20% EtOAc in hexanes); []D21 = +136.0 (c = 1.0, 
CHCl3); max(film)/cm–1 3324 w (N–H), 2924 vs, 2854 s, 2175 w (C≡C), 1542 vs, 1442 m, 1420 
s, 1355 vs, 1249 s, 1218 m, 1173 vs, 1123 m, 1059 m, 844 vs, 784 m, 759 m, 740 m, 699 m, 
655 m; H(400 MHz) 0.08 (9H, s, Si(CH3)3), 0.87 (3H, t, J 6.8, CH2CH3), 1.22–1.30 (23H, stack, 
alkyl chain, resonance overlap), 1.33 (3H, s, C(CH3)A(CH3)B), 1.39 (3H, s, C(CH3)A(CH3)B), 
1.50–1.65 (2H, stack, alkyl chain), 1.67–1.77 (1H, m, alkyl chain), 2.22 (1H, dd, J 17.2, 4.5, 
H-3A), 2.62 (1H, dd, J 17.2, 3.2, H-3B) 3.81–3.89 (1H, m, H-4), 4.10 (1H, dd, J 9.1, 5.4, H-5), 
4.19 (1H, ddd, J 10.4, 5.4, 3.1, H-6), 5.96 (1H, d, J 10.1, NH), 7.73–7.79 (2H, stack, Ar CH), 
7.93–7.98 (1H, m, Ar CH), 8.13–8.18 (1H, m, Ar CH); C(100 MHz) –0.2 (CH3, Si(CH3)3), 14.1 
(CH3, CH2CH3), 22.7 (CH2, alkyl chain), 23.0 (CH2, C-3), 25.6 [CH3, C(CH3)A(CH3)B], 26.3 (CH2, 
alkyl chain), 28.0 [CH3, C(CH3)A(CH3)B], [29.3, 29.48, 29.58, 29.64, 29.67, 31.9 (CH2, alkyl 
chain, resonance overlap)], 51.9 (CH, C-4), 76.4 (CH, C-5), 77.6 (CH, C-6), 89.1 (C, C-2), 99.9 
(C, C-1) 108.0 (C, C(CH3)2), [125.8, 130.1, 133.4, 133.6 (CH, Ar CH)], [135.9, 147.6 (C, Ar 
C)]; m/z (TOF ES+) 645.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 645.3372 [M + Na]+, 
C32H54N2O6SiNa requires 645.337, followed by alkyne 355 as a colourless oil (0.039 g, 25%): 
Rf = 0.5 (20% EtOAc in hexanes); []D21 =  +89.2 (c = 1.0, CHCl3); max(film)/cm–1 3311 w (N–
H), 2923 vs, 2853 s, 1541 vs, 1460 m, 1442 m, 1421 m, 1353 vs, 1302 w, 1245 m, 1216 m, 
1169 vs, 1124 m, 1056 s, 945 w, 854 m, 783 m, 755 vs, 741 vs, 699 m, 655 s; H(400 MHz) 
0.87 (3H, t, J 6.8, CH2CH3), 1.24–1.30 (23H, stack, alkyl chain, resonance overlap), 1.33 (3H, 
s, C(CH3)A(CH3)B), 1.40 (3H, s, C(CH3)A(CH3)B), 1.48–1.62 (2H, stack, alkyl chain), 1.63–1.72 
(1H, m, alkyl chain), 1.82 (1H, app. t, J 2.6, H-1), 2.25 (1H, ddd, J 17.2, 4.1, 2.6, H-3A), 2.57 
(1H, ddd, J 17.2, 4.2, 2.6, H-3B), 3.84 (1H, app. ddt, J 9.8, 8.1, 4.2, H-4), 4.13 (1H, dd, J 8.1, 
5.7, H-5), 4.15–4.22 (1H, m, H-6), 5.86 (1H, d, J 9.8, NH), 7.72–7.79 (2H, stack, Ar CH), 7.93–




7.98 (1H, m, Ar CH), 8.14–8.20 (1H, m, Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 21.8 (CH2, 
C-3), 22.7 (CH2, alkyl chain), 25.5 [CH3, C(CH3)A(CH3)B], 26.5 (CH2, alkyl chain), 27.8 [CH3, 
C(CH3)A(CH3)B), [29.2, 29.4, 29.5, 29.6, 29.7, 31.9 (CH2, alkyl chain, resonance overlap)], 52.5 
(CH, C-4), 71.9 (CH, C-1), 77.1 (CH, C-5), 77.6 (CH, C-6), 78.4 (C, C-2), 108.2 (C, C(CH3)2), 
[125.8, 130.3, 133.3, 133.6 (CH, Ar CH)], [135.8, 147.6 (C, Ar C)]; m/z (TOF ES+) 573.3 ([M 
+ Na]+, 100%); HRMS m/z (TOF ES+) 573.2977 [M + Na]+, C29H46N2O6SNa requires 573.2974. 
 
(4S, 5S, 6R)-5, 6-O-Isopropylidene-4-(ortho-nitrobenzenesulfonamido)-eicos-1-yne-5, 6-
diol (355) 
 
TBAF (0.3 mL of a 1.0 M solution in THF, 0.3 mmol) was added to a solution of silyl alkyne 
354 (86 mg, 0.14 mmol) in THF (2 mL). After 14 h, the reaction mixture was concentrated 
under reduced pressure. The residue was dissolved in EtOAc (30 mL). The solution was 
washed sequentially with H2O (3 × 20 mL) and brine (1 × 20 mL). The combined organic layers 
were dried with Na2SO4, filtered and the filtrate was concentrated under reduced pressure. 
The residue was purified by flash column chromatography to yield alkyne 355 as a colourless 
oil (76 mg, quant.). 










(4S, 5S, 6R)- 4-Amino-5, 6-O-isopropylidene-eicos-1-yne-5, 6-diol (356) 
 
Thiophenol (76 L, 0.74 mmol) and Cs2CO3 (181 mg, 0.556 mmol) were sequentially added 
to a solution of alkyne 355 (101 mg, 0.185 mmol) in anhydrous CH3CN (2 mL). After 16 h, the 
reaction was quenched by addition of NaHCO3 solution (20 mL). The mixture was extracted 
with CH2Cl2 (3 × 30 mL). The combined organic fractions were dried with Na2SO4, filtered and 
the filtrate was concentrated under reduced pressure. The residue was purified by flash 
column chromatography (1% MeOH in CHCl3 → 10% MeOH in CHCl3) to afford amine 356 as 
a colourless oil (52 g, 77%): Rf = 0.3 (20% EtOAc in hexanes);  []D21 = +20.0 (c = 1.0, CHCl3); 
max(film)/cm–1 3311 m (alkynyl C–H), 3291 vw (N–H) 2923 vs, 2853 vs, 1463 m, 1378 m, 1369 
m, 1245 m, 1218 s, 1165 w, 1070 w,  869 w, 722 w; H(400 MHz) 0.87 (3H, t, J 6.8, CH2CH3), 
1.23–1.29 (23H, stack, alkyl chain, resonance overlap), 1.32 (3H, s, C(CH3)A(CH3)B), 1.40 (3H, 
s, C(CH3)A(CH3)B), 1.45–1.60 (3H, stack, alkyl chain), 2.03 (1H, app. t, J 2.6, H-1), 2.34 (1H, 
ddd, J 16.8, 7.5, 2.6, H-3A), 2.58 (1H, app. dt, J 16.8, 3.0, H-3B), 2.96 (1H, ddd, J 9.0, 7.5, 3.4, 
H-4), 3.83 (1H, dd, J 9.0, 5.6, H-5), 4.11–4.16 (1H, m, H-6), NH2 not observed; C(100 MHz) 
14.1 (CH3, CH2CH3), 22.7 (CH2, alkyl chain), 25.8 (CH2, C-3), 25.9 (CH3, C(CH3)A(CH3)B), 26.2 
(CH2, alkyl chain), 28.3 (CH3, C(CH3)A(CH3)B), [29.4, 29.6, 29.7, 29.8, 31.9 (CH2, alkyl chain, 
resonance overlap)], 49.2 (CH, C-4), 70.7 (CH, C-1), 77.9 (CH, C-6), 80.3 (CH, C-5), 81.3 (C, 
C-2), 107.8 (C, C(CH3)2); m/z (TOF ES+) 388.3 ([M + Na]+, 100%); HRMS m/z (TOF ES+) 








(4S, 5S, 6R)-4-[13′-(3′′-benzoylphenyl)tridecanoylamino]-5, 6-O-isopropylidene-eicos-1-
yne-5, 6-diol (357) 
 
NHS ester 310 (61 mg, 0.12 mmol) was added to a solution of amine 356 (45 mg, 0.12 mmol) 
in pyridine:H2O (9:1, 3 mL). After heating at 50 °C for 14 h, the reaction mixture was 
concentrated under reduced pressure and the residue was purified by flash column 
chromatography (10% EtOAc in hexanes) to afford amide 357 as a colourless oil (55 mg, 
60%): Rf = 0.4 (20% EtOAc in hexanes); []D21 = +15.6 (c = 1.0, CHCl3); max(film)/cm–1 3303 
m (alkynyl C–H), 3254 w (N–H), 2915 vs, 2848 s, 1649 s (C=O), 1598 w, 1543 m, 1468 m, 
1380 w, 1310 w, 1277m, 1247 w, 1222 w, 1177w, 1070 w, 864 w, 773 w, 720 w; H(400 MHz) 
0.87 (3H, t, J 6.8, CH2CH3), 1.22–1.33 (40H, stack, alkyl chain), 1.34 (3H, s, C(CH3)A(CH3)B), 
1.42 (3H, s, C(CH3)A(CH3)B), 1.45–1.56 (2H, stack, alkyl chain), 1.58–1.66 (4H, stack, alkyl 
chain), 1.99 (1H, app. t, J 2.6, H-1), 2.17 (2H, m, H-2′), 2.50 (ddd, J 16.9, 4.0, 2.8, H-3A), 2.60 
(ddd, J 16.9, 5.0, 2.6, H-3B), 2.66 (2H, app. t, J 7.7, H-13′),  4.07– 4.12 (2H, stack, H-5, H-6), 
4.18–4.26 (1H, m, H-4), 5.63 (1H, d, J 9.5, NH), 7.34–7.42 (2H, stack, Ar CH), 7.45–7.50 (2H, 
stack, Ar CH), 7.55–7.61 (2H, stack, Ar CH), 7.61–7.64 (1H, m, Ar CH), 7.78–7.82 (2H, stack, 
Ar CH); C(100 MHz) 14.1 (CH3, CH2CH3), 21.9 (CH2, C-3), 22.6 (CH2, alkyl chain), 25.6 (CH3, 
C(CH3)A(CH3)B), [25.7, 26.6 (CH2, alkyl chain)], 27.8 (CH3, C(CH3)A(CH3)B), [29.1, 29.3, 29.4, 
29.5, 29.6, 29.7, 31.4, 31.9, (CH2, alkyl chain, resonance overlap)], 35.8 (CH, C-13′), 36.9 
(CH2, C-2′), 46.3 (CH, C-4), 70.7 (CH, C-1), [77.3, 77.7 (CH, C-5, C-6)], 80.3 (C, C-2), 108.1 
(C, C(CH3)2), [127.6, 128.1, 128.2, 129.9, 130.1, 132.3, 132.6 (CH, Ar CH, resonance 
overlap)], [137.6, 137.8, 143.2 (C, Ar C)], 172.5 (C, amide C=O), 197.0 (C, ketone C=O); m/z 




(TOF ES+) 742.6 ([M + H]+, 100%); HRMS m/z (TOF ES+) 742.5772 [M + H]+, C49H76N O4 
requires 742.5774. 
 
(4S, 5S, 6R)-4-[13′-(3′′-benzoylphenyl)tridecanoylamino]-eicos-1-yne-5, 6-diol (344) 
 
TFA (6 drops) was added to a solution of amide 357 (50 mg, 0.067 mmol) in CH2Cl2 (2 mL). 
After 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved 
in EtOAc (40 mL) and the solution was washed with NaHCO3 solution (3 × 25 mL), then dried 
with Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The crude 
product was purified by column chromatography (30% EtOAc in hexanes) to yield diol 344 as 
a white amorphous solid (38 mg, 85%): Rf = 0.1 (30% EtOAc in hexanes); solubility issues 
prevented an optical rotation measurement; max(film)/cm–1 3304 br m (O–H, alkynyl C–H), 
2921 vs, 2851 vs, 1641 vs (C=O), 1598 w, 1537 m, 1465 m, 1316 m, 1279 s, 1206 w, 1139 
w, 1068 w, 1026 w, 719 s; H(400 MHz) 0.87 (3H, t, J 6.8, CH2CH3), 1.22–1.35 (41H, stack, 
alkyl chain), 1.58–1.69 (5H, stack, alkyl chain), 2.03 (1H, app. t, J 2.6, H-1), 2.20 (2H, app. dd, 
J 8.0, 7.1, H-2′), 2.56 (1H, ddd, J 17.1, 4.7, 2.6, H-3A), 2.66 (2H, app. t, J 7.7, H-13′), 2.73 (1H, 
ddd, J 17.1, 6.4, 2.6, H-3B), 3.60–3.65 (2H, stack, H-5, H-6), 4.11–4.18 (1H, m, H-4), 6.11 (1H, 
d, J 8.5, NH), 7.35–7.42 (2H, stack, Ar CH), 7.45–7.50 (2H, stack, Ar CH), 7.56–7.61 (2H, 
stack, Ar CH), 7.61–7.64 (1H, m, Ar CH), 7.78–7.82 (2H, stack, Ar CH) OHs not observed; 
C(100 MHz) 14.1 (CH3, CH2CH3), 20.0 (CH2, C-3), [22.7, 25.7, 25.9, 29.2, 29.4, 29.5, 29.6, 
29.65, 29.72, 31.4, 31.9, 33.0 (CH2, alkyl chain, resonance overlap)], 35.8 (CH2, C-13′), 36.8 
(CH2, C-2′), 49.8 (CH, C-4), 70.9 (CH, C-1), [73.2, 75.6 (CH, C-5, C-6)], 81.3 (C, C-2), [127.6, 
128.1, 128.2, 129.9, 130.1, 132.3, 132.6 (CH, Ar CH, resonance overlap)], [137.6, 137.8, 




143.2 (C, Ar C)], 173.8 (C, amide C=O), 197.1 (C, ketone C=O); m/z (TOF ES+) 724.5 ([M + 





Freshly prepared CuSO4 solution (8 L of a 0.5 M solution, 0.004 mmol) and sodium ascorbate 
solution (63 L of  1.0 M solution, 0.016 mmol) were added to a solution of diol 344 (28 g, 
0.040 mmol) and 3-azidopropan-1-ol (6 mg, 0.06 mmol) in H2O:THF (1.5 mL, 2:1) After heating 
at 80 °C for 5 h, the solvent was evaporated under reduced pressure. The residue was purified 
by flash column chromatography (1% MeOH in CHCl3 → 10% MeOH in CHCl3) to afford 
triazole 358 as a white solid (25 mg, 78%): Rf = 0.5 (10% MeOH in CHCl3); m.p. 144–147 °C;  
solubility issues prevented an optical rotation measurement; max(film)/cm–1 3236 br m (O–H, 
N–H), 2918 s, 2849 s, 1656 m (C=O), 1633 s (C=O), 1560 m, 1468 m, 1339 w, 1278 m, 1066 
s, 720 m; H(400 MHz, 2:1 CDCl3:CD3OD) 0.84 (3H, t, J 6.9, CH2CH3), 1.19–1.33 (42H, stack, 
alkyl chain), 1.36–1.70 (4H, stack, alkyl chain), 2.00–2.08 (4H, stack, H-2′′, H-2′′′), 2.64 (2H, 
app. t, J 7.7, H-13′′′), 2.85 (1H, dd, J 15.1, 10.2, H-1A), 3.05 (1H, dd, J 15.1, 3.4, H-1B) 3.39–
3.53 (4H, stack, H-3, H-4, H-3′′), 4.26–4.32 (1H, m, H-2), 4.41 (2H, t, J 6.9, H-1′′), 7.34–7.42 
(2H, stack, Ar CH), 7.43–7.49 (2H, stack, Ar CH), 7.53–7.61 (4H, stack, Ar CH), 7.73–7.77 
(2H, stack, Ar CH), exchangeable protons not observed; C(100 MHz, 2:1 CDCl3:CD3OD) 14.3 
(CH3, CH2CH3), 23.0 (CH2, alkyl chain), 25.8 (CH2, C-1), 26.2 (CH2,alkyl chain), [29.6, 29.7, 
29.8, 29.9, 30.0, 30.1, 31.8, 32.3 (CH2, alkyl chain, resonance overlap)], 32.9 (CH2, C-2′′), 33.2 
(CH2, alkyl chain), 36.1 (CH2,C-13′′′), 36.8 (CH2, C-2′′′), 47.4 (CH2, C-1′′), 51.3 (CH, C-2), 58.3 




(CH2, C-3′′), [72.5, 76.7 (CH, C-3, C-4)], 123.5 (CH, Ar CH, triazole), [128.0, 128.6, 128.7, 
130.3, 130.4, 133.0, 133.3 (CH, Ar CH)], [137.8, 138.0, 143.7 (C, Ar C)], 174.9 (C, amide 
C=O), triazole C and ketone C=O not observed; m/z (TOF ES+) 803.6 ([M + H]+, 100%); HRMS 
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